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“Penso nisto, não como quem pensa, mas como quem respira. 
E olho para as flores e sorrio... 
Não sei se elas me compreendem 
Nem se eu as compreendo a elas, 
Mas sei que a verdade está nelas e em mim 
E na nossa comum divindade 
De nos deixarmos ir e viver pela Terra…” 
 
 
 “Mas as coisas não têm nome nem personalidade: 
Existem, e o céu é grande e a terra larga, 
E o nosso coração do tamanho de um punho fechado... 
  
Bendito seja eu por tudo quanto não sei. 
Gozo tudo isso como quem sabe que há o sol.” 
 
 
 
 
Alberto Caeiro, “O guardador de rebanhos”  
(Fernando Pessoa) 
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ABSTRACT 
 
Two major circumstances have accentuated the quest for new antibacterial agents and 
alternative therapies in the last decades. Primarily, because microbes, due to their incredible 
adaptability, seem to have at least equal chances for survival as scientists and pharmaceutical 
industries develop methods to kill them (Berdy, 2012). Multidrug-resistant (MDR) bacteria are 
responsible for a large number of nosocomial but also community-acquired infections and are 
spreading all over the globe (González-Lamothe et al., 2009). Additionally, the limitation of our 
current arsenal of effective antibiotics accompanied by the lack of new antimicrobial alternatives 
are prompting the beginning of the “post-antibiotic era”, which threats all the achievements of 
modern medicine.  
The use of plants as therapies in traditional medicine is as old as mankind. 
Ethnopharmacologists, botanists, microbiologists, phytochemists and other natural product 
researchers have also been searching plants hoping to find new, strong and viable antibiotics. 
However, it can be rapidly established that this effort of finding individual active antibiotics in 
plants has been pointless, since the spectrum of activity of purified components is often non-
specific (thus toxic) or very narrow, and for sure weaker than compounds from other sources such 
as fungi and bacteria (Tegos et al., 2002). However, plants can still fight most of their infections 
successfully, which proves that plant defense mechanisms are still not well understood. 
Plants do not produce single strong antibacterial compounds as their main defense mechanism, 
but hundreds of structurally different chemicals with a wide range of activity (González-Lamothe 
et al., 2009). Some of them are antimicrobial and act synergistically between each other to 
produce an enhanced effect against the pathogen. Others are non-antimicrobials, but can improve 
solubility, absorption and stability of the active compounds. At last but not least, some 
phytochemicals have been associated with an antibiotic adjuvant activity, especially due to the 
inhibition of the resistance mechanisms from plant pathogens.  
The present thesis has the main purpose of finding phytochemicals with such an adjuvant or 
regulatory activity that could be used in cotherapy with antibiotics to promote the effective 
treatment of Staphylococcus aureus, including multi-drug resistant strains, such as methicillin-
resistant S. aureus (MRSA). Finding antibiotic coadjuvants capable to inhibit the bacterial 
resistance mechanisms would be a valuable mid-term solution, until new classes of antibiotics are 
discovered. 
Firstly, four methods detecting antibiotic potentiation were optimized and compared, in terms 
of efficacy and simplicity. In this task, ten phytochemicals (five alkaloids and five flavonoids) 
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were combined with five antibiotics (ampicillin, oxacillin, ciprofloxacin, erythromycin and 
tetracycline) against S. aureus strains. The alkaloids reserpine, quinine, pyrrolidine and the 
flavonoids quercetin and morin at subinhibitory concentrations were found to reduce the minimal 
inhibitory concentrations (MIC) of ciprofloxacin, erythromycin and tetracycline by several times. 
A modified and optimized disk diffusion method was highlighted as the simplest and easiest 
method to perform and detect antibiotic potentiation. However, it is recommended to use this 
method together with at least other, the microdilution checkerboard, in order to overcome the 
limitations of each method and obtain conclusions more trustable. 
Additionally, since many reports have shown that staphylococcal infections were associated 
with biofilm formation, which can be much more difficult to eradicate, biofilm control and 
prevention abilities of reserpine, quinine, pyrrolidine, quercetin and morin were evaluated. The 
phytochemicals were also studied for their ability to avoid bacterial adaptation to ciprofloxacin, 
when exposed for long periods to it, and to inhibit NorA efflux pumps [by measuring the 
accumulation of ethidium bromide (EtBr) in the NorA overexpressing SA1199B strain]. Morin, 
pyrrolidine and quercetin (0.5 g l-1) had significant effects in biofilm prevention and/or control 
when applied alone and combined with antibiotics. Synergy was found especially in combinations 
with ciprofloxacin against biofilms of SA1199B. This strain growing with subinhibitory 
concentrations of ciprofloxacin for 15 days developed increased tolerance to this antibiotic. 
However, this was successfully reversed by quinine (0.1 g l-1) and morin (0.5 g l-1). Besides 
reserpine (0.1 g l-1), quercetin (0.5 g l-1) also showed significant NorA efflux pump inhibition. 
Cytotoxicity on lung fibroblast cell lines was evaluated as well.  
Further, 29 plants from different families were assessed for their antibacterial activity, and also 
as adjuvants in antibiotic therapy, against S. aureus and MRSA strains. The methanolic extracts 
of Eucalyptus globulus, Castanea sativa, Agrimonia eupatoria and Fraxinus excelsior showed 
antibacterial activity with MIC values of 0.125-0.5, 0.5-1.0, 1.0-2.0, and 2.0-4.0 g l-1, respectively. 
Non-antibacterial plants were assessed in combination with the five antibiotics by the modified 
disk diffusion method. Methanolic extracts of Cytisus striatus, Acacia dealbata, Prunus spp. 
plants, Centaurea nigra, Eupatorium cannabium and Buxus sempervirens showed a potentiating 
effect mostly of ciprofloxacin, erythromycin and tetracycline. C. striatus (0.5 g l-1) and B. 
sempervirens (1 g l-1) were highlighted for their antibiotic-potentiating activities and selected for 
further studies for the identification and elucidation of the active compounds. 
 Cytisus striatus leaves methanolic extract showed to selectively potentiate ciprofloxacin and 
erythromycin by 4 to 8-times against MRSA strains belonging to clonal complex CC8, including 
the common ST239 found in Asia and USA300 originated in North America. To look for 
secondary metabolites that could act as antibiotic adjuvants in this plant, a Nuclear Magnetic 
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Resonance (NMR)-based metabolomics approach was used. Luteolin was found to have 
antibacterial activity (with MIC between 30 and 120 mg l-1) and three other phytochemicals, 
genistein, 2’-hydroxygenistein and apigenin, were found to be potentially implicated in 
antibacterial-potentiation. Daidzein, also found in the plant, showed 4-fold potentiation of 
ciprofloxacin against S. aureus SA1199B. This study reveals the high synergy between 
metabolites from this plant, showing a great potential for their application in clinical therapy of 
MRSA infection. Additionally, it was observed that both genistein and daidzein (60 mg l-1) were 
able to increase accumulation of EtBr in SA1199B cells, showing a NorA efflux pump inhibition. 
Genistein showed the same activity on MRSA strains. Daidzein showed the best eradication of 
biofilms when exposed for 1 h [reduction of the number of colony-forming units (CFU) cm-2 of 
62%] and 24 h (CFU cm-2 reduction of 63%) on SA1199B cells.  
To understand the mode of action of isoflavonoids and to study their structure-activity 
relationship (SAR), 22 isoflavonoids were assessed as antibiotic adjuvants. Three isoflavonoids 
showed antibacterial activity – neobavaisoflavone (MIC = 20 mg l-1), corylifol A (MIC = 0.06 - 
20 mg l-1) and orobol (MIC = 60 - 120 mg l-1). Genistein, tectorigenin and biochanin A were 
highlighted for reducing the MIC of ciprofloxacin and erythromycin by 2-8 times against MRSA. 
The hydroxyl group in position 5 seems to be correlated with the activity of the three isoflavonoids 
since the same compounds lacking this group did not show antibiotic-potentiation. The inhibition 
of topoisomerases or of other processes in the cell such as transport could explain the activity 
obtained by these compounds. The possible inhibition of Erm methyltransferases by these 
isoflavonoids, which could explain the potentiation observed with erythromycin on ST239 MRSA 
strains, was not confirmed. In total, seven isoflavonoids demonstrated potentiation of 
ciprofloxacin against the NorA overexpresser SA1199B strain: genistein, biochanin A, 
tectorigenin, daidzein calycosin, irigenin and irisflorentin. A NorA efflux pump inhibitory activity 
of the isoflavonoids was tested by EtBr accumulation in the presence of these compounds. The 
results support that NorA inhibition is a possible mechanism for this coadjuvant activity by the 
seven isoflavonoids. Additionally, the effect of the isoflavonoids was assessed on biofilms and, 
besides daidzein, irisflorentin was also highlighted for promoting 83% of CFU cm-2 reduction 
within 1 h of exposure, and 54% within 24 h of exposure.  
Buxus sempervirens methanolic extract was also studied for its high ability to increase the 
efficacy of several antibiotics, even for β-lactams. This extract was applied against biofilms of S. 
aureus strains, being able to cause 88% reduction of 24 h-old biofilms of S. aureus CECT 976 
within 1 h of exposure. Further phytochemical investigation of B. sempervirens active fraction 
allowed to identify betulinic acid as a major component together with oleanane and ursane type 
terpenoids. Studies with this and other five similar terpenoids allowed to highlight oleanolic acid 
and ursolic acid, with MICs of 62.5 and 15.6 mg l-1, respectively, against S. aureus CECT 976 
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and synergy when combined with tetracycline and/or erythromycin by checkerboard technique. 
Additionally, oleanolic acid at ½ MIC, MIC and 2 × MIC promoted biofilm reductions of 70, 81 
and 85%, respectively. 
In conclusion, this study allowed to assess the potential of 29 plant extracts from different 
species and 41 commercial phytochemicals to be used in co-therapies against S. aureus and 
MRSA and decrease bacterial resistance to antibiotics. The concept of restoring and enhancing 
the therapeutic value of antimicrobials is a formidable challenge. This thesis greatly contributed 
to highlight the richness and superiority of plants as therapeutic sources of valuable compounds. 
Understanding their complex defense systems can provide new insights that could be used in our 
own fight against human pathogens. 
 
 
 
Keywords: multidrug resistance, Staphylococcus aureus, MRSA, biofilm, phytochemicals, 
metabolomics, resistance-modifying agents, antibiotic potentiation 
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RESUMO 
 
Nas últimas décadas, dois fatores principais têm despoletado a procura por novos agentes 
antibacterianos e terapias clínicas alternativas. Primeiro, o facto dos microrganismos, devido à 
sua capacidade incrível de adaptação, terem tantas hipóteses de sobreviver como têm os cientistas 
de os matar (Berdy, 2012). As bactérias multirresistentes são responsáveis por uma enorme 
quantidade de doenças a nível hospitalar e da comunidade, e estão a disseminar-se pelo mundo 
todo. Adicionalmente, a limitação do nosso arsenal de antibióticos eficazes, acompanhada pela 
falta de novas alternativas terapêuticas, desencadearam o início da chamada “era pós-
antibióticos”, que revela ser uma ameaça a todas as conquistas e descobertas trazidas pela era 
moderna da medicina. 
As plantas são usadas como terapia na medicina tradicional desde os princípios da 
humanidade. Inúmeros etnofarmacólogos, botânicos, microbiologistas, fitoquímicos e outros 
investigadores na área dos produtos naturais têm procurado incessantemente por novas plantas e 
compostos, com a esperança de encontrar antibióticos novos, viáveis e eficazes. No entanto, todo 
este esforço para encontrar antibióticos ativos em plantas tem-se mostrado ineficaz, uma vez que 
a maioria dos compostos isolados de plantas apresenta espetros de atividade não-específicos 
(sendo, portanto, tóxicos) e é, no geral, menos eficaz e potente comparando com compostos de 
outras proveniências, como por exemplo de bactérias e fungos. As plantas sobrevivem, contudo, 
à maioria das infeções, o que reforça a ideia de que os seus mecanismos de defesa não são, de 
todo, compreendidos.  
É importante realçar que as plantas não produzem antibióticos individuais e potentes como 
mecanismo de defesa principal, produzindo ao revés centenas de compostos estruturalmente 
diferentes que apresentam uma gama de atividade ilimitada. Alguns compostos têm mostrado 
atividades antimicrobianas e parecem atuar de forma sinérgica entre eles de forma a produzir um 
efeito global mais intenso e eficaz. Outros compostos não-antimicrobianos aparentam ter uma 
função mais reguladora, promovendo o aumento da solubilidade, absorção e estabilidade química 
dos compostos mais ativos. Por último, outros compostos têm sido associados a uma atividade 
antibacteriana adjuvante, principalmente por serem capazes de inibir ativamente alguns 
mecanismos de resistência por parte de organismos patogénicos.  
A presente dissertação teve como principal objetivo encontrar fitoquímicos que apresentem 
uma atividade adjuvante na defesa antibacteriana ou uma atividade reguladora/auxiliar, que 
possam ser usados em coterapia com antibióticos comerciais de forma a promover o tratamento 
eficaz de Staphylococcus aureus, inclusive de estirpes multirresistentes, como é o caso de S. 
aureus resistente à meticilina (MRSA). Estes compostos adjuvantes capazes de inibir os 
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mecanismos de resistência das bactérias podem ser considerados como uma solução 
intermediária, até que novas classes de antibióticos sejam descobertas. 
Inicialmente, pretendeu-se otimizar quatro métodos distintos para a deteção de atividades 
potenciadoras dos antibióticos, e compará-los em termos de eficácia e simplicidade. Para este 
efeito, 10 fitoquímicos foram combinados com cinco antibióticos (ampicilina, oxacilina, 
ciprofloxacina, eritromicina e tetraciclina) para o tratamento de S. aureus. Três alcalóides 
(reserpina, quinina e pirrolidina) e dois flavonóides (morina e quercetina) destacaram-se dos 
restantes fitoquímicos e reduziram a concentração mínima inibitória (MIC) da ciprofloxacina, 
eritromicina e tetraciclina. O método de difusão em disco, como se encontra otimizado e descrito 
nesta dissertação, foi considerado o mais fácil e simples para detetar a potenciação de antibióticos 
promovido por extratos de plantas. No entanto, o uso conjunto deste método com pelo menos 
outro, particularmente o do checkerboard, permite ultrapassar as limitações de cada método e 
obter conclusões mais fiáveis.  
Adicionalmente, uma vez que a maioria das infeções desenvolvidas por Staphylococcus aureus 
encontra-se associada à formação de biofilmes, as melhores combinações entre fitoquímicos e 
antibióticos foram testadas em biofilmes de S. aureus, que são à partida mais resistentes ao 
tratamento que células suspensas. Averiguou-se de igual forma se os fitoquímicos seriam eficazes 
em prevenir o desenvolvimento/aumento de tolerância das estirpes bacterianas à ciprofloxacina e 
em inibir bombas de efluxo dos antibióticos (medindo para este efeito a acumulação de brometo 
de etídio na estirpe SA1199B, que sobre-expressa a bomba de efluxo NorA). A morina, pirrolidina 
e quercetina (0.5 g l-1), aplicadas em concentrações sub-inibitórias, mostraram ter um efeito 
positivo na prevenção da formação de biofilmes e na remoção ou inativação de biofilmes 
previamente formados, quer quando aplicadas individualmente, quer em combinação com os 
antibióticos. A combinação de alguns fitoquímicos com a ciprofloxacina foi considerada sinérgica 
na remoção ou controlo dos biofilmes produzidos pela estirpe de S. aureus SA1199B. Esta estirpe 
desenvolveu uma tolerância acrescida a este antibiótico ao ser incubada em concentrações sub-
inibitórias do mesmo por 15 dias. No entanto, este processo foi revertido em parte na presença da 
quinina (0.1 g l-1) e morina (0.5 g l-1). Adicionalmente, a reserpina (0.1 g l-1) e a quercetina (0.5 g 
l-1) demonstraram serem capazes de inibir a bomba de efluxo NorA. A citotoxicidade destes 
fitoquímicos foi também avaliada em linhas celulares de fibroblastos.  
Após esta etapa inicial, 29 plantas de diversas famílias foram selecionadas e testadas quanto à 
sua atividade antibacteriana e como adjuvantes de terapia antibiótica no tratamento de S. aureus 
e MRSA. Os extratos metanólicos das folhas de Eucalyptus globulus, Castanea sativa, Agrimonia 
eupatoria e Fraxinus excelsior apresentaram atividade antibacteriana, com MICs de 0.125-0.5, 
0.5-1.0, 1.0-2.0, e 2.0-4.0 g l-1, respetivamente. Adicionalmente, os extratos metanólicos das 
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folhas de Cytisus striatus, Acacia dealbata, três plantas de espécie Prunus, Centaurea nigra, 
Eupatorium cannabium e Buxus sempervirens demonstraram uma atividade de potenciação 
quando combinadas com os antibióticos, especialmente com a ciprofloxacina, eritromicina e 
tetraciclina. Destas plantas, duas destacaram-se pelas suas atividades potenciadoras, C. striatus 
(0.5 g l-1) e B. sempervirens (1 g l-1), e foram selecionadas para serem estudadas em mais 
pormenor, para a identificação e elucidação dos compostos ativos presentes nas mesmas. 
O extrato metanólico das folhas de C. striatus potenciou 4 a 8 vezes a atividade da 
ciprofloxacina e eritromicina no tratamento de estirpes MRSA pertencentes ao complexo clonal 
CC8 (ST239 e USA300, provenientes da Ásia e América do Norte, respetivamente). De forma a 
identificar os metabolitos secundários da planta responsáveis por esta atividade, foi realizado um 
estudo metabolómico acoplado à técnica de Ressonância Magnética Nuclear (NMR). A luteolina 
foi isolada desta planta e apresenta atividade antibacteriana, com MICs compreendidas entre 30 
e 120 mg l-1, e outros três compostos, genisteina, 2’-hidroxigenisteina e apigenina, foram 
associados a uma atividade potenciadora antibacteriana. Outro isoflavonóide também isolado 
desta planta, a daidzeina, foi eficaz em potenciar a ciprofloxacina no tratamento de S. aureus 
SA1199B. Este estudo revelou e identificou com sucesso relações de sinergismo entre vários 
metabolitos desta planta, mostrando o potencial para aplicação deste tipo de sistemas em infeções 
provocadas por MRSA. Adicionalmente, observou-se que quer a genisteina como a daidzeina (60 
mg l-1) aumentaram a acumulação de brometo de etídio em células SA1199B, podendo estar desta 
forma a causar inibição das bombas de efluxo NorA. A genisteina apresentou a mesma atividade 
nas estirpes MRSA. A daidzeina exibiu a melhor erradicação do biofilme formado por SA1199B, 
quando exposta por 1 hora (remoção de biofilme de 62%) e por 24 horas (remoção de biofilme 
de 63%). 
De forma a entender o modo de ação dos isoflavonóides e estudar a relação atividade-estrutura 
(SAR) dos mesmos, 22 isoflavonóides foram testados como potenciadores de antibióticos. Três 
isoflavonóides demonstraram possuir atividade antibacteriana: neobavaisoflavona (MIC = 20 mg 
l-1), corilifol A (MIC = 0.06 - 20 mg l-1) e orobol (MIC = 60 - 120 mg l-1). A genisteina, 
tectorigenina e biochanina A potenciaram 2-8 vezes a atividade da ciprofloxacina e eritromicina 
no tratamento de MRSA. O grupo hidróxilo na posição 5 da estrutura dos isoflavonóides parece 
estar relacionado com esta atividade, uma vez que isoflavonóides idênticos, mas sem o referido 
grupo hidróxilo, não demonstraram atividade potenciadora. A inibição de topoisomerases e outros 
processos celulares, como o transporte, poderia explicar a potenciação de ambos os antibióticos 
observada. Adicionalmente, a inibição de Erm metiltransferases pelos isoflavonóides foi também 
testada, o que poderia explicar a potenciação da eritromicina em estirpes ST239. No entanto, o 
resultado foi negativo. Para além dos isoflavonóides previamente referidos, calicosina, irigenina 
e irisflorentina potenciaram de igual forma a atividade da ciprofloxacina quando aplicados à 
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estirpe SA1199B. Através da medição da acumulação de brometo de etídio nestas células, foi 
possível confirmar que estes isoflavonóides inibem esta bomba de efluxo NorA, explicando deste 
modo a atividade potenciadora da ciprofloxacina. Paralelamente, a eficácia destes isoflavonóides 
no controlo de biofilmes foi testada, sendo de destacar a irisflorentina, para além da daidzeina, 
que apresenta percentagens de remoção do número de CFU cm-2 de 83% após 1 hora de exposição, 
e de 54% após 24 horas de exposição. 
O extrato metanólico de Buxus sempervirens foi igualmente investigado por ter promovido a 
atividade de vários antibióticos, incluindo β-lactâmicos. Desta forma, este extrato foi testado em 
biofilmes de S. aureus, promovendo uma redução de 88% de biofilmes da estirpe CECT 976 
quando exposto por 1 hora. Um composto maioritário, o ácido betunílico, foi idendificado na 
fração ativa do extrato de B. sempervirens, assim como terpenóides do tipo oleanane e ursane. O 
ácido betulínico e outros cinco terpenóides estruturalmente semelhantes foram testados, 
realçando-se o ácido oleanólico e o ácido ursólico por apresentarem atividade antibacteriana (MIC 
de 62.5 e 15.6 mg l-1, respetivamente, em S. aureus CECT 976) e sinergia quando combinados 
com a tetraciclina e/ou eritromicina pelo método checkerboard. Adicionalmente, o ácido 
oleanólico promoveu reduções de biofilme de 70, 81 e 85% quando aplicado a ½ MIC, MIC e 2 
× MIC, respetivamente.  
Como conclusão principal, poderá dizer-se que este estudo permitiu avaliar o potencial de 29 
extratos de plantas de espécies diferentes e 41 fitoquímicos comerciais para serem aplicados em 
coterapia com os antibióticos, de forma a promover um tratamento mais eficaz de infeções de S. 
aureus e MRSA e diminuir a resistência bacteriana aos antibióticos. É de realçar que o conceito 
de restaurar o valor terapêutico dos antibióticos apresenta um potencial enorme. Esta dissertação 
contribui desta forma para engrandecer o potencial das plantas como fonte de grande diversidade 
de compostos medicinais e terapêuticos. O estudo destes sistemas de defesa complexos das 
plantas pode ser uma mais-valia na nossa própria luta contra agentes patogénicos humanos. 
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1. WORK OUTLINE 
 
 
 
  
his chapter aims to describe the context and background of this thesis, 
the main purposes and the motivations to develop this work. 
Furthermore, it serves as a guideline to the overall work, describing the main 
elements constituting this thesis and their organization along the five main 
chapters. 
 
 
Chapter 
1 
  
  
 
CHAPTER 1. WORK OUTLINE 2016 
 
 
3 
 BACKGROUND AND PROJECT PRESENTATION 
The development of antibiotic-resistant microbes is the consequence of decades of constant 
selective pressure from human applications of antibiotics, via underuse, overuse, and misuse. The 
worldwide spread of MDR bacteria is increasingly drawing the attention of global surveillance 
authorities and media, being undoubtedly rated as a major threat in the 21st century. Each year 
over 13 million deaths in the world are attributed to the emergence of new infectious diseases or 
to the re-emergence of old pathogens with new resistance determinants (Kourtesi et al., 2013). 
This situation affects everyone, independent of age, gender or country in which they live, and 
threatens to undermine all recent notable achievements of modern medicine. The harsh prediction 
for a close future is that the treatment of certain types of severe bacterial infections will 
experiment a therapeutic dead end. There is a rising clamor for new medicines to combat 
infectious diseases and lethal pathogens resistant to existing treatments, but few promising 
therapies are in the biopharmaceutical R&D pipeline. The situation raises fear of a “post-
antibiotic” age of super-resistant superbugs, a prediction each day made more real.  
Natural products, mainly, though not exclusively of microbial origin, have become one of the 
most important sources of lead antimicrobials for the pharmaceutical industry (Clardy et al., 2006; 
Piddock et al., 2010). Since the beginning of mankind, plants were undoubtedly the most 
important source of therapeutic remedies with an enormous range of applications. The earliest 
records of natural products were depicted from Mesopotamia (2600 B.C.) and included oils 
from cypress (Cupressus sempervirens) and myrrh (Commiphora species), which are still used 
today to treat coughs, colds and inflammation (Dias et al., 2012). Plants have been the source of 
numerous drugs of clinical application as, for example, glucoside inhibitors of sodium/potassium 
ATPase, which are used to treat cardiac arrhythmias and certain kinds of heart failure, and the 
antimalarial drugs quinine and artemisinin (Lewis, 2013). Plants have been also studied with the 
expectation of finding novel leads for antibiotics. However, though resistant to many 
microorganisms, plants have not yielded promising antimicrobial leads so far. A likely 
explanation for this is that plants use a combination of strategies to deal with infections rather 
than individual metabolites.  
Plants produce an array of structurally diverse secondary metabolites that seem to be involved 
in defense mechanisms against a wide range of microorganisms including fungi, yeasts and 
bacteria (Gibbons et al., 2004; Siebra et al., 2016). However, when isolated, these antimicrobial 
metabolites exhibit only weak or moderate activities. In fact, their MICs are typically in the range 
of 100-1000 mg l-1, that is, several orders of magnitude weaker than those of typical antibiotics 
produced by bacteria and fungi (MICs of 0.01-10 mg l-1) (Tegos et al., 2002), and accounts for 
the absence of plant-derived antimicrobials in clinical applications (Cowan, 1999). It is thus clear 
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that if plants have a highly efficient defensive system to deal with microbial threats. This 
capability makes it of interest for further studies, as there might be lesson to learn that can be lead 
to treat human infectious diseases. Millions of years of evolution have resulted in plant defense 
systems that are not easily violated by the development of microbial resistance. Plants have 
different levels of defense against microorganisms: constitutive chemical defense, direct 
inducible chemical defense (phytoanticipins) and gene-level inducible chemical defense 
(phytoalexins). These most likely complement each other. The defense strategy involves not only 
various secondary metabolites, but also other very diverse molecules ranging from proteins to 
H2O2 and oxygen radicals. This could explain why the classical approach consisting in bioassay 
guided fractionation to find antibiotics from plants has not yet resulted in any lead for antibiotics 
as this approach fails to reveal interactions between compounds, such as synergism, and the 
isolated single compounds might not be very active in in vitro tests (Tegos et al., 2002). 
Synergistic interactions between various metabolites could enhance the activity of weakly 
antimicrobial agents that are not in contact either due to location or in time in normal 
circumstances, but are released or produced when needed in the site of an infection. The defense 
strategies may thus involve the synergistic activity of two or more compounds, which could act 
via different mechanisms and/or targets (Lila and Raskin, 2005). A great number of plant 
metabolites have been reported to inhibit several MDR efflux pumps for Gram-positive bacteria 
(Cushnie and Lamb, 2005; Gibbons et al., 2004; Gibbons et al., 2003a; Jin et al., 2011; Kang et 
al., 2011; Marquez, 2005; Miller et al., 2001; Stavri et al., 2007), implicated in bacterial resistance 
to several antibiotic classes, or to inhibit protein-binding proteins (PBP) 2a (Shimizu et al., 2001; 
Shiota et al., 2004), among others. Synergy could also be due to physico-chemical interactions 
such as the opening of membranes or an increase in the solubility of the active antimicrobial 
compounds.  
The fact that the only 50 years of use of antibiotics has already led to wide spread resistance, 
shows that more sophisticated systems are required to effectively treat infectious diseases. 
Improving the clinical performance of various antibiotics by employing active molecules capable 
of restoring antibiotic susceptibility in MDR pathogens represents a novel and promising 
approach to deal with multidrug resistance. These molecules have been termed resistance-
modifying agents (RMAs). The design of such combinations is a promising alternative taking into 
account the scarcity of new antibacterials available and active. The effort to discover plant EPIs 
has been delayed by the fact that, until now, this process consisted mostly on bioassay-guided 
isolations, which can be time-consuming and laborious (Fiamegos et al., 2011). However, new 
perspectives and methodologies such multivariate data analysis coupled to metabolomics studies 
have been promising and open new and exciting perspectives in the field. 
 
CHAPTER 1. WORK OUTLINE 2016 
 
 
5 
 MAIN OBJECTIVES 
Plants offer an untapped source of such adjuvant compounds, which represents an increasingly 
active research topic for the design of modified or combination therapeutics. The goal of this 
thesis was to test whether it was possible to take advantage of the plant’s powerful defense system, 
presumably based on complex synergistic interactions, to potentiate the activity of antimicrobial 
activity of known antibiotics. The purpose is to reverse drug resistance on Staphylococcus aureus, 
which is an important cause of serious, invasive and life threatening infections worldwide and 
remains a leading cause of community and nosocomial bacteraemia (Lawes et al., 2012). 
Firstly, it was aimed to evaluate, compare and optimize the best method to detect antibiotic 
potentiation against S. aureus strains, including efflux pump overexpressing and methicillin-
resistant S. aureus (MRSA) strains. Thus, four methods (checkerboard, etest, disk diffusion 
method, time-kill assay) were assessed to detect potentiation of antibiotics promoted by 
phytochemicals. The ten phytochemicals chosen for this part of the study belonged to two classes, 
alkaloids and flavonoids. One of the tested compounds is reserpine, that is recognized as an EPI. 
The antibiotics chosen (ampicillin and oxacillin - β-lactam, ciprofloxacin – fluoroquinolone, 
erythromycin – macrolide, and tetracycline) have more limited application nowadays due to 
increased bacterial tolerance. 
Since several of the tested phytochemicals were effective antibiotic potentiators and 
considering that staphylococcal infections are mostly associated with biofilm formation, 
combinations of selected phytochemicals with antibiotics were tested on the prevention and 
control of S. aureus biofilms. The phytochemicals were also studied for their ability to avoid 
antibiotic adaptation within long exposure times and to inhibit antibiotic efflux pumps. 
Cytotoxicity of lung fibroblast cell lines was evaluated as well. 
After the selection and optimization of the methods to detect antibiotic potentiation, the ability 
of a considerable range of plants belonging to different families was screened for their 
antibacterial activity and antibiotic-potentiating ability with the five antibiotics. From this initial 
screening with 29 plant methanolic extracts, two plants were highlighted and selected for further 
phytochemical elucidation, for showing interesting antibiotic-potentiating activities: Cytisus 
striatus and Buxus sempervirens.  
Cytisus striatus, commonly known as Portuguese broom, is particularly abundant in the Iberian 
Peninsula. As mentioned before, the classical bioassay guided fractionation is rarely efficient 
when synergistic interactions are responsible for a given bioactivity. While antimicrobial 
compounds may be identified, detecting synergistic interactions would imply testing an almost 
infinite number of combinations. A metabolomics approach seemed to be promising. The starting 
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point was evaluating the antibiotic-potentiating activity of different types of extracts of this plant 
and then submit them to NMR-metabolomics to identify the signals related to that activity. The 
next step was to isolate and identify the compounds responsible for these signals and to test them 
for potentiating antimicrobial activity. In particular, MRSA strains belonging to CC8, including 
ST239 and USA300 strains, were used. 
In view of the promising results obtained with isoflavonoids as antibiotic potentiators, twenty-
two isoflavonoids were evaluated for their antibacterial and synergistic effects with ciprofloxacin 
and erythromycin against S. aureus strains. The most studied phytoalexins from Fabaceae plants 
are isoflavonoids (Jeandet et al., 2013). The aim was to understand the structure-activity 
relationship of isoflavonoids as antibiotic adjuvants. The effect of the isoflavonoids was also 
evaluated on the accumulation of EtBr in S. aureus using both fluorometric and flow cytometry 
methods, looking for MDR efflux pumps inhibition. Likewise, the hypothesis of inhibition of Erm 
methyltransferases by the isoflavonoids was assessed. Additionally, the effect of the isoflavonoids 
on the eradication of S. aureus biofilms was evaluated, either when applied alone or in 
combination with antibiotics. 
Buxus sempervirens was also selected for its potentiating activity and applied against S. aureus 
biofilms. It was intended to proceed with phytochemical investigation of B. sempervirens and to 
identify the main metabolites responsible for the activity. The triterpenoid found in this plant was 
assessed, along with other five similar triterpenoids, regarding its antibacterial, antibiotic-
potentiation and biofilm eradication activities (within 1 and 24 h of exposure).  
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 THESIS ORGANIZATION 
This thesis is organized in five chapters comprised by: work outline (Chapter 1), literature 
review (Chapter 2), materials and methods (Chapter 3), results and discussion (Chapter 4) and 
concluding remarks (Chapter 5). A brief introduction to each chapter is made in FIGURE 1.1. 
 
 
FIGURE 1.1 | Scheme of the organization of this thesis according to each chapter. 
 
Chapter 1 describes the main objectives, context and motivations for the development of this 
work and serves as a guideline to the overall work presented in the further chapters.  
In Chapter 2 a review of the literature is provided. Plant secondary metabolites 
(phytochemicals) have already demonstrated their potential as antibacterials when used alone and 
as synergists or potentiators of other antibacterial agents. Phytochemicals frequently act through 
different mechanisms than conventional antibiotics and could, therefore be of use in the treatment 
of resistant bacteria. The therapeutic utility of these products, however, remains to be clinically 
proven. The aim of this chapter is to review the advances in in vitro and in vivo studies on the 
potential chemotherapeutic value of phytochemical products and plant extracts as RMAs to 
restore the efficacy of antibiotics against resistant pathogenic bacteria. The mode of action of 
RMAs on the potentiation of antibiotics is also described. Important chemical and biological 
concepts and explanations are given. 
Chapter 1
• Work Outline. describes the main objectives and motivations of this thesis
Chapter 2
• Literature Review. reviews important concepts, recent studies and discoveries on the field
Chapter 3
•Materials and methods. describes the material and methodology applied in this thesis
Chapter 4
•Results and discussion. describes and discuss all the results obtained in this thesis
Chapter 5
• Concluding remarks. describes the main conclusions and proposes future research
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In Chapter 3, the materials and methods used to perform all the experimental work are fully 
described. The material of biological and chemical sources tested in this thesis is characterized 
and some important technical or mechanistic details are described. A detailed chronological 
description of the project is given by tasks according to FIGURE 1.2. In Chapter 4, the results are 
showed, analysed and discussed. The organization of this chapter is done with the same logic 
sequence comprised by these 6 tasks. Important remarks and conclusions after each step of this 
work are also performed. 
 
 
FIGURE 1.2 | Sequence of the six main experimental tasks developed in this project. 
 
Briefly, in Task 1, four methods to measure antibiotic potentiation are optimized using 
combinations between ten phytochemicals and five antibiotics against ten S. aureus strains, 
including 3 MRSA strains. Comparison between methods is performed and the best method is 
selected. In Task 2, the best phytochemical-antibiotic combinations previously obtained were then 
applied against biofilms and other mechanistic details concerning the mode of action of the 
phytochemicals are revealed. In Task 3, 29 plant methanolic extracts were screened for 
antibacterial and antibiotic potentiation activities against S. aureus strains. Cytisus striatus was 
selected for further phytochemical characterization and elucidation using a NMR-based 
metabolomics study (Task 4). Isolated compounds form this plant were characterized for their 
biological activities. Isoflavonoids proved to be important compounds of this plant; thus, 22 
Task 1
• Evaluation of the best method to assess antibiotic potentiation by phytochemicals against 
Staphylococcus aureus
Task 2
• Combinatorial approaches with selected phytochemicals to increase antibiotic efficacy 
against Staphylococcus aureus biofilms
Task 3
• Reexamining plants with a new look into their defense systems: the search for antibiotic 
adjuvants to promote effective treatment of drug-resistant Staphylococcus aureus
Task 4
• The potential of Cytisus striatus for antibiotic-potentiating activity: isolation and 
identification of antibiotic adjuvants from this plant
Task 5
• Evaluation of the structure-activity relationship of isoflavonoids as antibiotic adjuvants in 
clinical therapy
Task 6
• The potential of Buxus sempervirens for antibiotic-potentiating activity: isolation and 
identification of antibiotic adjuvants from this plant
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different isoflavonoids were also evaluated for antibacterial and antibiotic-potentiation activities 
and as efflux pump inhibitors; a structure-activity relationship (SAR) study was performed, and 
finally their activity against biofilms was assessed (Task 5). In Task 6, Buxus sempervirens was 
also selected among the 29 plants for further investigation and tested for biofilm control. Further 
fractionation of this plant methanolic extract allowed to identify one major triterpenoid as 
bioactive compound. The antibacterial and antibiotic-potentiating activities of this and other five 
similar triterpenoids was assessed. The most promising triterpenoid was selected for further 
studies against biofilms. 
Finally, Chapter 5 presents an overview of all the developed work, with emphasis on the main 
conclusions obtained within this project. Perspectives and suggestions for further research are 
also identified and described. 
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2. LITERATURE REVIEW 
 
 
 
his chapter provides a review of important aspects that constitute the 
background of this thesis. First, the current concern about the 
emergency of MDR pathogens accompanied by the lack of effective 
antibacterial options is analysed, and so are the possible strategies to address 
this problem. Further, an insight to the rich variety of interesting secondary 
metabolites from plants and on their biological role against microorganisms is 
performed. Several studies have provided clear evidence that plant-derived 
products can be used to improve the therapeutic efficacy of antibiotics. A 
special emphasis will be performed on non-antimicrobial compounds, which 
are able to act synergistically with antimicrobials in order to promote effective 
defense. The biotechnological values of these antibiotic adjuvants as potential 
candidates in cotherapies with antibiotics for the fight against MDR bacteria 
is highlighted. Several mechanisms have been proposed to explain the mode 
of action of these compounds and are discussed in this section. This chapter 
therefore reviews data on the combinatorial interaction of plant-derived 
products as RMAs with antibiotics for the treatment of infectious diseases. 
Additionally, in vivo and toxicity data, when available, are mentioned.  
Chapter 
2 
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 THE BEGINNING OF THE “POST-ANTIBIOTIC ERA” 
Antibiotics have proven to be powerful drugs for the control of infectious diseases and remain 
one of the most significant discoveries in modern medicine. Their extensive and unrestricted use 
has, however, imposed a selective pressure upon bacteria, leading to the development of 
antimicrobial resistance (Čižman, 2003; Oluwatuyi et al., 2004; Russell, 2003; Schelz et al., 2010; 
Stewart, 2002). The capacity of bacteria to acquire and transmit genetic determinants of resistance 
is a conserved evolution strategy and has exacerbated the worldwide resistance problem. 
Antibiotic resistance is recognized by the World Health Organization (WHO) as the greatest threat 
in the treatment of infectious diseases (Conly, 2004; Nascimento et al., 2000; Oluwatuyi et al., 
2004; Walker and Levy, 2001; Wright, 2005). 
In order to control the occurrence and spread of resistant strains, the WHO has promoted a 
complex action plan, based on the slogan “No action today, no cure tomorrow” that includes 
strategic actions for mitigation, prevention and control (WHO, 2011). The plan is based on the 
accomplishment of several objectives: the prudent use of antibacterial drugs (with the correct drug 
at the right dosage and for the appropriate duration) across all relevant sectors; enhanced infection 
control and environmental hygienic practices to reduce the transmission of resistant strains and 
the strengthening of surveillance systems to monitor antibiotic use and resistant bacteria in human 
and animal health, including the food chain; and the encouragement to the discovery of new active 
agents (Conly, 2004; Dötsch et al., 2009; Pandra et al., 2010; WHO, 2011). However, this 
campaign was not enough to prevent the beginning of the “post-antibiotic era”, as it was stated 
by WHO in the beginning of 2014. Among several studies, a recent study in the United States 
estimated an annual inappropriate antibiotic prescription up to 30%, supporting the need for 
establishing a goal for outpatient antibiotic stewardship (Fleming-Dutra et al., 2016). 
Additionally, 44% of outpatient antibiotic prescriptions are written to treat patients with acute 
respiratory conditions, where half of these prescriptions are unnecessary (The Pew Charitable 
Trusts, 2016). 
The quest for new antimicrobials to overcome resistance problems has long been a top research 
priority for the pharmaceutical industry (Alekshun and Levy, 2007; Oluwatuyi et al., 2004; Schelz 
et al., 2010). However, as shown in FIGURE 2.1, in the past thirty years only two novel classes 
of antibiotics have entered the market, the oxazolidinones and the cyclic lipopeptides, both of 
which are used against Gram-positive bacterial infections (WHO, 2011). No new anti-Gram-
negative drugs have been developed.  
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FIGURE 2.1 | History of antibacterial drug approval and introduction in the market. MLS: 
Macrolides/Lincosamides/Streptogramins antibiotics. Figure adapted from Powers (2004). 
 
The low rate of emergence of new drug classes since the 1960s is evident when one examines 
the history of the Food and Drug Administration (FDA) approval for antibacterial agents shown 
by FIGURE 2.2, in which most of these approved drugs (75%) are from two classes, β-lactams 
and quinolones, and the success of most of these has been compromised due to the emergence of 
resistance (Alekshun and Levy, 2007; Chan et al., 2011; Gibbons, 2008). Only six new antibiotics 
have been approved over the last six years (Ventola, 2015). 
 
FIGURE 2.2 | Number of new antibacterial agents approved by FDA from 1980 to 2014.  
Data obtained from Ventola (2015). 
 
All other similar efforts to find a new antibiotic failed, which indicates that there is an 
extremely low probability of discovering a new drug (Lewis, 2013). A successful antibiotic must 
satisfy a perplexing number of demands: it should be able to cross bacterial cell membranes at 
high rates, avoid bacterial efflux pumps, not be a target for bacterial modifying or hydrolyzing 
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enzymes, reach its target at a sufficiently high concentration, have a broad spectrum of 
antibacterial activity, have little or no toxicity and minimal side effects in humans (Hughes, 2003). 
There is no perfect antibiotic, and even if such antibiotic is discovered, it would be essential to 
restrict its use to very specific situations. Anti-infective therapies are difficult to develop, and 
clinical trials are complex and costly. As of March 2016, only 37 new antibiotics were in 
development, and just 13 in Phase III clinical trials - way less than some 500 oncology therapies 
in the pipeline (The Pew Charitable Trusts, 2016). In addition to serious scientific and clinical 
challenges, there are difficult financial issues to overcome since effective antimicrobial treatments 
face tight policies that limit use to prevent resistance. Increasingly, more rigorous clinical trials 
and safety checks have been required before a drug is introduced to the market. Despite this 
legislation is aimed to protect the consumer; certain antimicrobials prescribed today would most 
likely not meet such standards (Gill et al., 2015). Government incentives to fill the gap are likely 
to help over time. For example, the new drugs Dalvance® and Oritavancin® (approved by the FDA 
in 2014), which are both administered intravenously to combat skin infections caused by Gram-
positive bacteria including MRSA, are a result of the American Generating Antibiotics Incentives 
Now (GAIN) incentive (Gill et al., 2015). Recently, a new antibiotic was discovered, teixobactin, 
produced by a hitherto undescribed soil microorganism (provisionally named Eleftheria terrae) 
(Ling et al., 2015). Teixobactin has activity against Gram-positive organisms (such as MRSA and 
Streptococcus pneumoniae) and mycobacteria (such as Mycobacterium tuberculosis) and a novel 
mode of action inhibiting peptidoglycan biosynthesis (Piddock, 2015). However, clinical trials 
and full toxicology tests of this compound still need to be carried out. 
 
 GLOBAL EPIDEMIC PROPORTIONS OF MDR BACTERIA 
Resistance of pathogenic microorganisms to individual antibiotics is a great problem by itself. 
However, the emergence of MDR strains represents an increasing complication in the treatment 
of bacterial infections (Dötsch et al., 2009; Guz et al., 2000; Schelz et al., 2010). The number of 
hospital-acquired infections (HAI) has been growing exponentially worldwide since 1980s, 
especially due to the emergence and widespread of MDR bacteria. Approximately 50% of HAI 
worldwide are caused by MDR microorganisms (Hoffman, 2001). HAI are among the major 
causes of death and increased morbidity among hospitalized patients with a minimum of 175,000 
deaths every year in industrialized countries (Cotter et al., 2011; Joshi et al., 2010; Rutala and 
Weber, 2001; Zollfrank et al., 2012). Several investigations showed that over 60% of worldwide 
HAI have been linked to the attachment of different pathogens on medical implants and devices, 
such as venous and urinary catheters, arthroprostheses, fracture-fixation devices, heart valves, 
among others (Costerton et al., 2005; Cozad and Jones, 2003; Griffith et al., 2000; Otter et al., 
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2011; Pinto et al., 2011; Weber et al., 2010). As a direct consequence, the replacement of implants, 
which involves significant costs and suffering for patients, often remains the only efficient therapy 
(Wach et al., 2008). Additionally, it has been demonstrated that the increased incidence of HAI 
is related to cross-infections from patient to patient or hospital staff to patient and to the presence 
of pathogenic microorganisms that are selected and maintained within the hospital environment 
(Burts et al., 2009; Madigan et al., 2004; Madkour et al., 2009; Rutala and Weber, 2001; Sexton 
et al., 2011; Talon, 1999). 
Traditional antibiotics are increasingly suffering from the emergence of MDR bacteria, which 
made it imperative to search for alternative treatments (Fiamegos et al., 2011). Among the most 
problematic MDR bacteria are vancomycin-resistant enterococci (VRE), MRSA, vancomycin-
resistant S. aureus (VRSA) and bacteria producing extended-spectrum β-lactamases (ESβL) such 
as Pseudomonas aeruginosa, Helicobacter pylori, Acinetobacter baumannii, Escherichia coli and 
Klebsiella pneumonia (Alekshun and Levy, 2007; Gibbons et al., 2003b; Zahin et al., 2010). Other 
important MDR pathogens include Legionella pneumophila, penicillin-resistant S. pneumonia 
(PRSP), and Shigella and Salmonella species (Conly, 2004; Spížek et al., 2010). Additionally, 
tuberculosis caused by M. tuberculosis, continues to be a major problem, with estimated 2 million 
deaths worldwide each year (WHO, 2015). The reemergence of tuberculosis is partially associated 
with the development of mycobacterial resistance against two of the most important tuberculosis 
drugs, rifampicin and isoniazid, without any new drug being commercialized since 1964 (Spížek 
et al., 2010; WHO, 2015).  
 
  A focus on Staphylococcus aureus 
Staphylococcus aureus is notorious for its ability to become resistant to antibiotics. Around 
90 – 95% of S. aureus strains worldwide are resistant to penicillin and, in most of Asian countries, 
70 – 80% are also methicillin resistant (Hemaiswarya et al., 2008). The emergence of antibiotic 
resistance in S. aureus can be visualised as a series of waves as shown in FIGURE 2.3.  
Infections that are caused by antibiotic-resistant strains of S. aureus have reached epidemic 
proportions globally. MRSA merits special attention since it is responsible for a high-level of 
HAIs (Gibbons, 2008; Gould et al., 2010; Oluwatuyi et al., 2004; Pinho et al., 2001; Smith et al., 
2007a; Stapleton et al., 2004). In fact, few agents can treat infections caused by this bacterium 
since many MRSA strains are resistant not only to almost all kinds of β-lactams but also to 
macrolides, quinolones and even to aminoglycosides (Gould et al., 2010; Shibata et al., 2005).  
The first MRSA clinical isolates were ST250 and members of CC8 and circulated in Europe 
before the 1970s but had largely disappeared by the 1980s (Chambers and DeLeo, 2010). 
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However, other highly successful clones emerged, including the ST247 Iberian or Epidemic 
MRSA (EMRSA)-5 clone. MRSA strains have generally been found to be members of a subset 
of S. aureus CCs, including CC1, CC5, CC8, CC22, CC30 and CC45. Between 2005 and 2011, 
overall rates of invasive MRSA dropped 31%; the largest declines (around 54%) were observed 
in HAIs (Ventola, 2015). However, during the past decade, rates of community-associated (CA)-
MRSA infections have increased rapidly among the general population, being associated with 
fulminant and lethal infections and worse clinical outcomes (Chambers and DeLeo, 2010). 
 
 
FIGURE 2.3 | Timeline of the emergence of antibiotic resistance in Staphylococcus aureus. 
Wave 1: began shortly after the introduction of penicillin into clinical practice in the 
1940s. The first resistant strains from phage type 80/81 were penicillin-resistant and 
Panton-Valentine leukocidin (PVL)-positive; Wave 2: began almost immediately 
following the introduction of methicillin into clinical practice with the isolation of 
MRSA-I, which contained staphylococcal chromosome cassette (SCC) mecl; Wave 3: 
began in the mid to late 1970s with the emergence of MRSA-II and MRSA-III, containing 
SCCmecll and SCCmeclll, respectively. The increase in vancomycin use for the treatment 
of MRSA infections led to the emergence of vancomycin-intermediate S. aureus (VISA) 
strains; Wave 4: began in the mid to late 1990s and marks the emergence of CA-MRSA 
strains [containing SCCmecIV (MRSA-IV) and various virulence factors]. VRSA strains, 
first identified in 2002, have been isolated exclusively in health care settings. To date, 
eight SCCmec allotypes, designated SCCmecI–SCCmecVIII have been described, along 
with numerous subtypes. Figure adapted from Chambers and DeLeo (2010). 
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 AN INSIGHT INTO THE MECHANISMS OF BACTERIAL RESISTANCE TO 
ANTIBIOTICS 
The term ‘antibiotic resistome’ was been proposed for the collection of all antibiotic resistance 
genes in microorganisms, including those from pathogenic and non-pathogenic bacteria (Wright, 
2007). This resistome has suffered several alterations over time, mainly in the last years with the 
introduction of new resistance genes.  
Bacteria evolve rapidly causing the failure of antimicrobial treatments, not only by mutation 
and rapid multiplication, but also by transfer of genetic material, which can result in strains with 
beneficial changes (Thomas and Nielsen, 2005; Gilbert et al., 2002; Simões et al., 2008). The 
horizontal gene transfer (FIGURE 2.4), is the process of exchange and acquisition of new genetic 
material and may occur via three main mechanisms: transduction (from one bacterium to another 
by a bacteriophage), transformation (by uptake from the external environment) or conjugation (by 
direct contact between two bacterial cells). It contributes to the rapid horizontal dissemination of 
resistance determinants. The localization of resistance determinants on mobile elements, such as 
genomic islands, transposons, plasmids, or phages, greatly enhances their dispersion (McCallum 
et al., 2010). Although most frequent in bacteria, this transfer also occurs naturally in viruses, 
plants, insects, and even between bacteria and fungi (Cruz and Davies, 2000). 
 
 
 
 
FIGURE 2.4 | Scheme explaining the main horizontal dissemination mechanisms of 
resistance determinants in bacteria: conjugation, transformation and transduction. 
Figure adapted from von Wintersdorff et al. (2016). 
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The major biochemical mechanisms of bacterial resistance to antimicrobials are demonstrated 
in FIGURE 2.5 and include drug inactivation, target modification, alteration in the accessibility 
to the target through drug efflux and decreased uptake (Brehm-Stecher and Johnson, 2003; Dantas 
et al., 2008; Kumar and Schweizer, 2005; Russell, 2003; Wright, 2005). All of these mechanisms 
require new genetic programming by the cell in response to the presence of antibiotics (Wright, 
2005). 
 
FIGURE 2.5 | Main mechanisms explaining the resistance of bacterial cells to antibiotics. 
Active drug efflux systems from the cell via membrane-associated pumping proteins 
that effectively remove toxic compounds from cells; mutations resulting in altered cell 
permeability; enzymatic degradation of antimicrobials by the synthesis of modifying- 
or inactivating-enzymes that selectively target and destroy these compounds; 
alteration/ modification of the target site, e.g., through mutation of key binding 
elements such as ribosomal RNA. 
 
There is an amazing diversity of antibiotic resistance mechanisms within each of these four 
categories and a single bacterial strain may possess several types of resistance mechanisms. 
Resistance becomes a clinical problem when the frequency of the resistant variant threatens the 
effectiveness of empirical drug therapy. The selection of resistant determinants in the patient is 
determined by the level of exposure of the pathogen population to an antibiotic, as well as by the 
pharmacokinetic and pharmacodynamic properties of the antibiotic (Andersson and Hughes, 
2010). Relevant examples of bacterial resistance mechanisms are briefly described in this section. 
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  Inactivation of antibiotics 
Enzymatic degradation or modification of antimicrobials is an important mechanism of 
bacterial resistance (Pandra et al., 2010; Wagner and Ulrich-Merzenich, 2009). There are several 
strategies of antibiotic inactivation. Hydrolysis, group transfer, and redox enzymes are involved 
in this type of resistance. β-lactam antibiotics are the largest antibiotic family used in medicine. 
However, their use is readily compromised partly because of the production of β-lactamases, such 
as TEM, leading to clavulanate resistance, or SHV-1 (Demanèche et al., 2008; Yap et al., 2014). 
The resistance to β-lactams by the overproduction of β-lactamases that partially hydrolyze 
methicillin and related penicillins is probably the most widespread example of antibiotic 
inactivation involving enzymes (Shibata et al., 2003). Several generations of drugs with enhanced 
activity have been developed to counter antibiotic resistance to β-lactamases such as 3rd and 4th 
generation cephalosporins, carbapenems or quinolones (Bax et al., 2000; Hoffman, 2001; WHO, 
2011). Some of them, e.g. the isoxazolyl penicillins, imipenem and meropenem, are more resistant 
to enzymatic inactivation (Chopra et al., 1997). However, ESBLs have been reported to confer 
resistance to newer generations of cephalosporins in E. coli, Enterobacter and Klebsiella species 
(Hoffman, 2001). Enzymes such as active-site serine carbapenemases, plasmid-encoded class C 
cephalosporinases and acquired metallo-β-lactamases have also emerged (Miller et al., 2001; 
WHO, 2011). KPC, OXA-48, VIM and IMP-1 carbapenemases producers are currently the most 
widespread types of carbapenemase in Enterobacteriaceae. More recently, a new type of 
carbapenemase was reported - New Delhi metallo-β lactamase-1 (NDM-1) (Hughes, 2003). 
NDM-1 producers are becoming highly prevalent and some cases have been identified all over 
the world (Nordmann et al., 2011).  
 
  Target modification 
Modification of target sites is a common mechanism of resistance and may occur for diverse 
classes of antibiotics which include tetracyclines, β-lactams and glycopeptides (Chopra et al., 
1997). In the case of β-lactam antibiotics, their targets are the penicillin binding proteins (PBPs), 
which are important cell-wall structural enzymes present in almost all bacteria (Hoffman, 2001). 
Resistance to β-lactam antibiotics can be acquired by the acquisition and expression of the mecA 
gene which codes for an altered transpeptidase additional to PBP (PBP2a) (Chopra et al., 1997; 
Lambert, 2005; Shibata et al., 2003; Shimizu et al., 2001). PBP2a confers resistance to β-lactam 
antibiotics due to its low affinity for penicillins (Pinho et al., 2001). Alterations in PBPs are known 
to be responsible for specific resistances namely in MRSA and PRSP (Barker, 1999).  
Other important examples of bacterial resistance mediated by modification of the targets of 
antibiotics are presented in TABLE 2.1.  
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TABLE 2.1 | Examples of antibiotic resistance mediated by target modification 
Antibiotic class Target Resistance mechanism Examples of bacteria 
Quinolones DNA gyrase or topoiso-
merase IV, (inhibition of 
DNA synthesis) 
Chromosomal mutations in both 
target enzymes which promotes 
lower affinity for quinolones 
Gram-positive bacteria, 
particularly S. aureus 
and S. pneumoniae 
Glycopeptides 
(e.g. vancomycin, 
teicoplanin) 
Peptidyl-d-alanyl-d-
alanine (d-Ala-d-Ala) 
termini of peptidoglycan 
precursors (inhibition of 
cell wall synthesis) 
Biosynthesis of peptidoglycan 
with altered glycopeptide 
recognition sites 
VRSA, S. aureus, 
glycopeptide-
intermediate S. aureus 
Acquisition of vanA and vanB, 
which encode for enzymes that 
produce a modified peptidogly-
can precursor terminating in d-
Ala-d-Lac 
VRE, such as E. 
faecium and E. faecalis 
Macrolides, 
lincosamides and 
streptogramin B 
 
50S ribosomal subunit 
(block protein synthesis) 
 
Post-transcriptional modification 
of the 23S rRNA component of 
the 50S ribosomal subunit 
involving methylation or 
demethylation of key adenine 
bases in the peptidyl transferase 
functional domain 
Wide range of Gram-
positive and Gram-
negative bacteria 
Oxazolidinones 
(e.g. linezolid) 
50S ribosomal subunit 
(inhibition of formation of 
the initiation complex and 
interference with 
translocation of peptidyl-
tRNA from A to P site) 
Mutations in the 23S rRNA 
resulting in decreased affinity for 
binding; most mutations involve 
G to U substitutions in the 
peptidyl transferase region of 23S 
rRNA 
Several 
microorganisms 
including enterococci 
Aminoglycosides 16S rRNA in the smaller 
subunit of the bacterial 
ribosome, perturbing 
decoding of the mRNA 
Mutations in the 16S rRNA gene 
 
Mycobacterium 
smegmatis, M. 
tuberculosis and M. 
abscessus 
Polymyxin B and 
Polymyxin E (e.g. 
colistin) 
 
Lipopolysaccharide (LPS) 
component of the outer 
membrane 
Modification of the phosphate 
esters linked to the digluco-
samine components of the lipid A 
region by addition of 4-
aminoarabinose groups to the 
phosphate esters 
Gram-negative bacteria 
Data obtained from (Barker, 1999; Hoffman, 2001; Lambert, 2005; Wright, 2003) 
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  Alteration in the accessibility to the target by overexpression of efflux pumps  
The overexpression of efflux pumps, which extrude antibiotics from the bacterial cell, is one 
of the most important mechanisms of microbial resistance to antimicrobials and can be observed 
in many clinically relevant pathogens (Gibbons and Udo, 2000; Stermitz et al., 2000a; Stermitz 
et al., 2000b). Although some are drug-specific, many efflux systems may transport a range of 
products with different structures and classes, contributing significantly to multidrug resistance 
(Kumar and Schweizer, 2005; Piddock, 2006). Indeed, the poly-specificity of efflux transporters 
can drive the acquisition of additional mechanisms of antibiotic resistance such as mutation of 
antibiotic targets or secretion of enzymes that degrade antibiotics (e.g. β-lactamases) (Pagès and 
Amaral, 2009). The overexpression of these pumps and synergy with other drug resistance 
mechanisms hampers effective antimicrobial treatment (Bhardwaj and Mohanty, 2012). 
Antibiotic efflux transporters have been classified into five main families based primarily on 
amino acid sequence homology. These are the major facilitator superfamily (MFS), the resistance-
nodulation-division (RND) family, the small multi-drug resistance (SMR) family, the ATP 
binding cassette (ABC) family and the multiple antibiotic and toxin extrusion (MATE) family 
(Lynch, 2006; Stavri et al., 2007). The efflux of drugs from Gram-positive bacteria is mainly 
mediated by a single cytoplasmic membrane-located transporter of the MFS, SMR or ABC 
families (Stavri et al., 2007; Tegos et al., 2008). Among Gram-negative bacteria, multidrug efflux 
pumps belonging to RND and SMR are common (Nikaido, 1998). The analysis of antibiotic efflux 
transporters has been already extensively reviewed (Lynch, 2006; Stavri et al., 2007). It is, 
however, interesting to highlight some important MDR efflux pumps, such as the protein NorA 
of S. aureus (significant for several fluoroquinolones, monocationic dyes and disinfectants), 
which is probably the most intensively studied pump in pathogenic Gram-positive bacteria and 
may be responsible for at least 10% of antibiotic resistance in MRSA (Kaatz et al., 2003; Sibanda 
and Okoh, 2007); TetK (mediates tetracycline efflux) and MsrA (for macrolides) in S. aureus; 
QacA, responsible for the export of several antimicrobial compounds and for acriflavine and EtBr 
resistance, the Bmr in Bacillus subtilis, the TetA(B) protein, among Gram-negative bacteria, also 
for tetracyclines and is also one of the most extensively studied members of the MFS (Borges-
Walmsley et al., 2003; Gibbons et al., 2003a; Guay et al., 1994; Guz et al., 2000; Oluwatuyi et 
al., 2004; Sibanda and Okoh, 2007; Stavri et al., 2007). The ABC transporter LmrA from 
Lactococcus lactis has also been intensively studied (Infed et al., 2011). The AcrAB-TolC, which 
is the main efflux transporter in Enterobacteriaceae for diverse products (e.g. tetracyclines, 
fluoroquinolones, chloramphenicol), and the MexAB-OprM in P. aeruginosa, causing resistance 
to β-lactams, quinolones, tetracyclines and trimethoprim, are examples of the RND family 
(Lynch, 2006; Marquez, 2005; Sibanda, 2007; Stavri et al., 2007; Tegos et al., 2008).  
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  Alteration in the accessibility to the target by reduced membrane permeability 
The outer membrane (OM) of Gram-negative bacteria serves as a selective permeation barrier 
for many external hydrophobic solutes due to its high LPS, content and it forms specific contacts 
with integral outer membrane proteins (OMPs), such as porins (e.g., OmpF in E. coli and OprD 
in P. aeruginosa), which act as entry and exit points for antibiotics and other organic chemicals 
(Alekshun and Levy, 2007; Hemaiswarya et al., 2008; Nikaido, 2003; Nikaido and Vaara, 1985; 
Vaara, 1992). Changes in OMPs copy number, size and selectivity, promoted by the loss or 
modification of certain OMPs as a consequence of decreased expression, point mutations or 
insertion sequences in the encoding genes, or the production of modified OMPs with reduced 
permeability to antibiotics (Drawz and Bonomo, 2010; Hoffman, 2001), can alter the rate of 
diffusion and uptake of antibiotics (Pandra et al., 2010). Thus, porin mutations confer resistance 
to several antibiotics such as β-lactams, carbapenems, fluoroquinolones, tetracyclines, 
sulfonamides and chloramphenicol (Drawz and Bonomo, 2010; Hoffman, 2001). 
 
  Increased bacterial resistance by other mechanisms  
 By overexpression of the drug target  
The overexpression of the drug target is also responsible for an increasing bacterial resistance. 
However, this may not be so simple. Palmer and Kishony (2014) interestingly found that target 
overexpression in E. coli has conflicting effects on drug resistance: it can increase, remain 
unchanged, decrease or even change non-monotonically. This highly depends on the properties 
of drug mechanism. 
 
 By stress-induced modifications 
Some changes in the cell presumably have something to do with stress because they are 
affected by this stress locus (Levy, 2002). Stress derived from nutrient starvation, hypoxia, 
membrane damage, low pH, increased osmotic pressure, extreme temperature shifts, ribosome 
disruption or antimicrobial exposure, elicit a variety of specific and highly regulated adaptive 
responses that not only protect bacteria from the offending stress, but also manifest changes in 
the cell that impact innate antimicrobial susceptibility. This occurs indirectly, as a result of stress-
induced growth cessation, since antimicrobials typically act on growing cells, or directly as a 
result of the stress-dependent recruitment of resistance determinants (e.g. antimicrobial efflux), 
changes to antimicrobial targets, generation of resistance mutations, promotion of resistant 
growth modes (biofilms) (Poole, 2012), etc. 
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  Increased bacterial tolerance due to formation of biofilms 
Chronic infections in which biofilms have been demonstrated to be involved are many and 
include periodontitis, cystic fibrosis pneumonia, and numerous infections associated with 
indwelling devices such as catheters, heart valves, and prostheses (Stewart, 2002). Also, biofilms 
constitute a major threat in the clinical environment by acting as reservoirs of multidrug resistant 
pathogenic bacteria. 
A biofilm is a functional consortia of bacteria populations adherent to a surface and to each 
other and/or embedded within extracellular polymers matrices (glycocalyx), concentrated 
products of their own metabolism and ions and nutrients from the environment (Gilbert et al., 
1997; Smith, 2005; StepanoviĆ et al., 2007; Toté et al., 2008). This adaptation as adherent 
populations allow bacteria to survive within hostile environments and unfavorable conditions 
(including predation, antimicrobials presence and host immune responses) (Olson et al., 2002; 
Verstraeten et al., 2008).  
A central tenet of biofilm formation is its dynamic nature. Most current models depict biofilm 
formation as a linear process that begins when free-floating bacterial cells attach to a surface 
(Shen et al., 2011). Then, it is believed to occur in a sequential process that includes initial 
reversible/irreversible adhesion to a solid surface and/or other microbes previously attached to 
the surface, cell–cell communication, formation of microcolonies on the surface, extracellular 
polymeric substances (EPS) production and, finally, differentiation of microcolonies into 
exopolymeric-encased, mature biofilms (FIGURE 2.6) (Costerton et al., 1999; Simões et al., 
2010). EPS participate in the formation of microbial aggregates and are responsible for binding 
cells and other particulate materials together - cohesion - and to the surface – adhesion (Simões, 
2005). Genetic analysis of biofilm formation has led to the proposal that extracellular signals and 
quorum-sensing (QS) regulatory systems are essential (Kjelleberg and Molin, 2002). 
The rapid reversal of resistance upon dispersion from a biofilm suggests that this is an adaptive 
resistance mechanism rather than a genetic alteration (Stewart, 2002). Cells in the biofilm can 
return to a planktonic lifestyle by two possible ways. In order to colonize new areas or in response 
to environmental cues, such as starvation, a programmed set of events leads to hydrolysis of the 
extracellular polymeric matrix and conversion of a subpopulation of cells into motile planktonic 
cells, which can rapidly multiply and leave the sessile communities (Costerton et al., 1999). Also, 
biofilm dispersal can occur as a consequence of physical detachment or mechanical breakage of 
biofilms due to flow or shear stresses (Landini et al., 2010).  
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FIGURE 2.6 | Schematic representation of the steps involved in the formation of a biofilm. 
Planktonic cells can form cell-to-surface and cell-to-cell contacts resulting in the 
formation of microcolonies. Quorum-sensing leads to the formation of differentiated, 
thick and mature biofilm structures. Cells in the biofilm can return to a planktonic 
lifestyle. Figure adapted from O'Toole et al. (2000). 
 
It is well known that bacteria in biofilms can be hundreds of times more resistant to antibiotics 
compared with planktonic cells. The microorganisms generate physiological changes when cells 
attach to a surface by expressing a biofilm phenotype that can confer resistance face to stress 
environmental conditions such as nutrient limitation, heat and cold shocks, changes in pH and to 
chemical agents. Biofilm resistance involves multiple mechanisms (Inoue et al., 2008). One 
obvious difference between planktonic cells and biofilms is the presence of a polymeric matrix 
enveloping the community that retards diffusion of antimicrobials into the biofilm (Brooun et al., 
2000; Costerton et al., 1999; Fux et al., 2005).  
Many studies have investigated the formation of biofilms as an explanation for microbial 
resistance (Mah and O'Toole, 2001; Smith, 2005; Stewart, 1996; Xu et al., 2000). FIGURE 2.7 
represents some hypotheses explaining the higher resistance to antibiotics in biofilms. Antibiotics 
have been shown to penetrate biofilms readily in some cases and poorly in others, depending on 
the particular agent and biofilm (Costerton et al., 1999). However, given that, in many cases, 
biofilms consist of stacks of cells with aqueous channels flowing in between, only impenetrability 
seems unlikely (Smith, 2005). Because of the special structure of biofilms, there are gradients of 
nutrients and oxygen and, for this reason, cells can be in distinct growth states. Consequently, 
cells in different layers of the biofilm will be affected differently by different types of 
antimicrobials depending on their mechanism of action (Fernández et al., 2011). For example, 
penicillins, which target cell-wall synthesis, kill only growing bacteria (Stewart and William 
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Costerton, 2001). Other theories include a reduced susceptibility of biofilm microorganisms 
compared to their freely suspended counterparts (Stewart, 1996); and the existence of persister 
cells, a small population of cells with a highly protected phenotype (Brooun et al., 2000; Lai et 
al., 2009; Stewart, 2002).  
 
 
FIGURE 2.7 | Hypothesized explanations for the increased antibiotic resistance of biofilms.  
(A) the antibiotic (black points) penetrates slowly or incompletely the biofilm; (B) an 
adaptive stress response is expressed by some cells (marked cells); (C) a concentration 
gradient of a metabolic substrate or product leads to zones of slow non-growing bacteria 
(shaded cells); (D) a small fraction of cells differentiates into a highly protected persister 
state (dark cells). 
 
 HOW TO CIRCUMVENT BACTERIAL RESISTANCE TO ANTIBIOTICS? 
New classes of antibiotics and more effective antimicrobial agents are needed. High-
throughput methodologies combined with traditional molecular biology techniques have enabled 
the discovery of potential drug targets for new antibiotics and antibiotic potentiators. However, 
translating these targets from identification to actual drug compounds requires a significant 
amount of additional work and financial investment (Lu and Collins, 2009). A potential source of 
bioactive compounds is also the reinvestigation of metabolites previously assumed to be inactive, 
which represent ~60% of known metabolites (Berdy, 2012). For example, Naftifine®, an FDA-
approved antifungal drug, was found to be a lead compound for potent Benzofuran-Derived 
Diapophytoene Desaturase (CrtN) inhibitors and to attenuate the virulence of a variety of clinical 
S. aureus, including MRSA, in mouse infection models (Chen et al., 2016). The total number of 
marketed drugs used in human therapy is estimated to be ~3500 compounds, representing less 
than 0.01% of all known chemical compounds (Berdy, 2012). Several additional approaches to 
antibiotic discovery have been pursued, including targeting virulence factors, antimicrobial 
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peptides, host-directed therapies, probiotics and phage therapy (Gill et al., 2015; Lewis, 2013). 
Also, the use of vaccines, monoclonal antibodies, immuno-regulatory cytokines and 
hematopoiesis-stimulating factors may have utility in the control of antibiotic resistant infections 
(Chopra et al., 1997). 
Recently, multidrug therapy has gained a wider acceptance in the fight of multidrug resistant 
microbial strains. The use of drug combinations rather than single drugs provides better clinical 
outcomes, as the use of single agents is highly associated with occurrence of resistance (Kyaw et 
al., 2012). So, antimicrobial combinations are employed in order to prevent the emergence of 
resistant strains or to increase activity, in cases of mixed infections, or to reduce the toxicity of a 
substance without compromising the antimicrobial action. For example, it has become clear that 
a multidrug approach must be used to treat tuberculosis (e.g. isoniazid, rifampicin, pyrazinamide 
and ethambutol), to have a realistic chance of success (Lewis, 2013). Other effective synergistic 
pairing is trimethoprim and sulfamethoxazole, which have a great impact on folate metabolism 
(Brown and Wright, 2016). 
Cases of synergy (where the combined effect of two drugs is greater than the sum of individual 
activities) between a broad range of antibiotics have been reported. In some cases, combining 
established antimicrobials has extended the useful life of an antibiotic. These combinatorial 
activities may be due to multi-target effects, or also to improved solubility, resorption rate or 
enhanced bioavailability (Wagner and Ulrich-Merzenich, 2009; Zimmermann et al., 2007). Other 
important potential strategy to help combat the resistance problem involves the discovery and 
development of new active agents capable of partly or completely suppressing bacterial resistance 
mechanisms (Malléa et al., 2003). This reversal of multidrug resistance represents a promising 
approach to mitigate the spread of resistance. Many strategies for avoiding, inhibiting, or 
bypassing resistance mechanisms in pathogens have been attempted (Davies and Davies, 2010). 
The development of RMAs, anti-resistance drugs or antibiotic adjuvants represents an attractive 
strategy to mitigate the spread of bacterial drug resistance since it could facilitate the recycling of 
well-established antibiotics that are often cheaper and less toxic than new candidate 
antimicrobials (Schelz et al., 2010; Sibanda, 2007).  
Such non-conventional antibiotic treatments have shown promising results in preclinical 
studies but few of them have succeeded in demonstrating significant clinical outcomes (Chatterjee 
et al., 2016). Other possibilities of non-conventional antibiotic treatments include the use of 
compounds that inhibit quorum-sensing, target pathogen virulence, prevent biofilm formation or 
the adherence to the host tissues (Chatterjee et al., 2016), etc. FIGURE 2.8 exemplifies situations 
of synergy or potentiation between antibiotics and other bioactive compounds (Kalan and Wright, 
2011; Wagner and Ulrich-Merzenich, 2009; Zimmermann et al., 2007).  
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FIGURE 2.8 | Possible mechanisms of action of antibiotic adjuvants to improve therapy. 
(A) multi-target effect; (B) serial or orthogonal inhibition of vital physiological 
pathways; (C) inhibition of resistance enzymes, of compounds that block antibiotic 
efflux or that decrease the uptake into the cell; (D) dispersal of a biofilm to 
planktonically growing cells, resulting in increased susceptibility to antibiotics; (E) 
enhancement of the permeability of cell for antibiotics; (F) quorum-sensing inhibition, 
which may affect the behavior of the cells, such as pathogenicity, expression of 
resistance mechanisms, biofilm formation, etc. 
 
An antibiotic potentiating compound may work by any of a variety of different mechanisms: 
it may or not affect the same molecular target or pathway (e.g., metabolic pathway, biosynthetic 
pathway) as the antibiotic(s) whose activity it potentiates; it may inhibit the metabolism of the 
antibiotic; it may be an inhibitor (e.g., a competitive or non-competitive inhibitor) of an enzyme 
that degrades the antibiotic; it may alter the mechanism of the antibiotic, e.g., may increase the 
metabolism to a more active form, shift the profile of metabolites; it may alter distribution, 
absorption, or excretion of the antibiotic in a way that effectively increases its activity in the body 
(Zechini and Versace, 2009), etc.  
The inhibition of resistance mechanisms of bacteria to antibiotics has been an important topic 
and some current examples were made available. Bacterial enzymes that degrade or modify 
antibiotics are important targets for drug action since their inhibition protects the antibiotic from 
degradation (Chopra et al., 1997). The co-administration of β-lactamase inhibitors is an important 
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strategy for restoring the activity of β-lactam antibiotics enabling the antibiotic to more effectively 
interact with the PBPs (Drawz and Bonomo, 2010). Inhibitors of β-lactamases have long been 
known and their administration with antibiotics has been associated with considerable success, 
proving to be one of the most effective antibiotic combinations (Hemaiswarya et al., 2008; Miller 
et al., 2001). Penicillins, cephalosporins and carbapenems antibiotics with higher stability to 
hydrolysis were developed to circumvent the inactivating activity of these enzymes (Ulrich-
Merzenich et al., 2010). An important example of such inhibitors is clavulanic acid, which binds 
with high affinity to many bacterial β-lactamases thus protecting antibiotics from destruction and 
is available commercially in combination with amoxicillin as Augmentin® and Ticarcillin 
(Timentin®) (Chopra et al., 1997; Miller et al., 2001; Sullivan et al., 2001). Interestingly, 
clavulanic acid is produced by Streptomyces clavuligerus, which also produces several β-lactam 
antibiotics. Other inhibitors of β-lactamases are sulbactam, marketed in combination with 
ampicillin (as Unasyn®), and tazobactam, marketed in combination with piperacillin (as 
Tazocin®) (Chopra et al., 1997; Drawz and Bonomo, 2010; Sullivan et al., 2001).  
To inhibit cephalosporinase and other enzymatic activities, a possibility is to facilitate the 
diffusion of antibiotics through the bacterial envelope in order to increase their intracellular 
concentration. Some compounds, e.g., polycationic cyclic lipopeptides and cationic antimicrobial 
peptides, which are amphiphilic in nature, targeting membranes thus increasing their 
permeability, have been assayed in combination with usual antibiotics to combat resistant clinical 
strains (Bolla et al., 2011). Many other compounds have also been reported to affect membrane 
permeability on a diverse range of microorganisms (Helander et al., 1998), mainly due to the 
perturbation of the lipid fraction of the cell membrane and, owing to their lipophilic character, 
increasing membrane permeability (Trombetta et al., 2005). Such permeabilizers, as they have 
been termed, can non-specifically enhance the permeability of bacterial cells to exogenous 
products, including antimicrobial agents and may therefore potentiate the antibacterial potential 
of antibiotics that interact with intracellular targets (Simões et al., 2009).  
It is also of great interest to find co-therapeutic agents that inhibit PBP 2as. Some agents have 
already demonstrated the potential to either inhibit the modified targets or exhibit a synergy by 
blocking one or more of the other targets in the metabolic pathway, thus causing cell death 
(Hemaiswarya et al., 2008). A number of β-lactam antibiotics, including modified cephalosporins, 
carbapenems and trinem have been designed with enhanced activity against PBP2a (Hemaiswarya 
et al., 2008). Newer glycopeptide antibiotics have activity against vancomycin and teicoplanin-
resistant Gram-positive bacteria, which express modified peptidoglycan structures refractory to 
the binding of the older glycopeptides (Chopra et al., 1997). 
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Since most bacteria can acquire MDR efflux pumps, the inhibition of these systems is a 
promising strategy for potentiating antibiotic effectiveness (Wagner and Ulrich-Merzenich, 
2009). Recent studies suggest that efflux systems may be a first response to the antimicrobial 
making possible for the cell to survive and acquire other, more stable resistance mechanisms that 
will then provide a high-level resistance phenotype (Costa et al., 2013). EPIs would allow the 
enhancement of antibiotic uptake to overcome drug efflux (Kalan and Wright, 2011), and restore 
the antibacterial treatment by decreasing the intrinsic bacterial resistance to antibiotics, reversing 
the acquired resistance associated with efflux pumps overexpression, and reducing the frequency 
of the emergence of resistant mutant strains (Bhardwaj and Mohanty, 2012; Zechini and Versace, 
2009). Also, an effective EPI would allow to decrease the antibiotic doses required for bacterial 
inhibition (Lechner et al., 2008; Mahamoud et al., 2007; Marquez, 2005; Smith et al., 2007b). 
Substantial efforts are needed to develop new, safe and effective bacterial EPIs that could be used 
in antimicrobial therapy (Lomovskaya et al., 2001; Marquez, 2005). Several ways of targeting 
efflux pumps are: alteration of pump gene expression, inhibition of membrane assembly of pump 
component, blocking OM exit duct, and collapsing the energy driven source (Bolla et al., 2011).  
The process of discovery, testing and commercialization of drugs is rather slow (Bhardwaj and 
Mohanty, 2012). Despite that, a large number of MDR inhibitors have been discovered and 
patented (Gill et al., 2015) in last two decades. Structural and genetic studies have contributed to 
a better understanding of the transport mechanisms of the efflux pumps, and these include the 
identification of amino acid regions for rational design of drugs capable of evading efflux (Li and 
Nikaido, 2009). Globomycin from Streptomyces hagronensis blocks the functional assembly of 
some components of efflux pump, such as AcrA; carbonyl cyanide m-chlorophenylhydrazone and 
potassium cyanide affect the energy level of the bacterial membrane (Pagès and Amaral, 2009); 
Phe-Arg-β-naphthylamine resulted in a up to 2,000-fold reduction in the MICs of antibacterials 
known to be substrates of the Campylobacter CmeABC pump, and the frequency of emergence 
of erythromycin-resistant mutants in C. jejuni reduced more than 1,000 fold (Martinez and Lin, 
2006). 
A strategy already proposed to mitigate efflux-mediated resistance is the synthesis of analogs 
of macrolides, quinolones and tetracyclines that are not recognized by efflux pumps (Chopra et 
al., 1997). For example, the activities of tigecycline against various pathogens are at least partly 
attributable to being an inferior substrate for specific Tet transporters (Li and Nikaido, 2009). 
Research has also been conducted to engineer fluoroquinolones to avoid efflux via NorA pumps, 
such as garenoxacin (a dual topoisomerase IV and DNA gyrase inhibitor) and the lead stage 
compound DX-619 (an inhibitor of type II topoisomerase) (Gill et al., 2015). Nevertheless, very 
few bacterial EPIs had entered into a clinical trial phase (Li and Nikaido, 2009). 
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  Current methods to assess in vitro synergy 
Antibiotic combination therapy has become increasingly important in clinical area not only as 
an attempt to cover a broad spectrum of pathogens when the cause of the infection is unknown, 
but also to prevent and fight against drug-resistant infections (Odds, 2003; Sopirala et al., 2010). 
The accurate detection of clinically relevant antibiotic synergy based upon the results of in vitro 
testing has been a goal of researchers for some time (White et al., 1996). A number of methods 
used to detect in vitro synergy between antibiotics have been described (FIGURE 2.9). 
 
A – Checkerboard B - Time-kill assay 
 
 
C – Etest D - Disk diffusion method 
 
 
FIGURE 2.9 | Main methods to detect in vitro synergy between antibacterial compounds. 
 (A) checkerboard microdilution method: the pattern of microtiter wells is formed by 
multiple two-fold dilutions of the two antibacterial compounds (drugs A and B), in 
concentrations that typically range from 0 to twice the anticipated MIC (or higher if 
antagonism is suspected) (Hemaiswarya et al., 2008; Kontoyiannis and Lewis, 2003); 
(B) time-kill assay to detect synergy between compounds; samples from the flask with 
the inoculum and the antimicrobials are taken along 24 h and colony counts of 
surviving bacteria over time are determined; (C) two Etest strips with antibiotics 
placed on the agar surface inoculated with the bacterium at a 90° angle with the 
intersection at the respective MICs; (D) possible results for the combination of two 
antimicrobials obtained with the double-disk diffusion test. 
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The microdilution checkerboard has been one of the most popular methods for the 
measurement of antibiotic synergy (Rand et al., 1996). In order to assess the effect of a given 
antimicrobial combination, each well of the checkerboard array contains a unique combination of 
the two drugs being tested (Kontoyiannis and Lewis, 2003). The time-kill assay is useful to study 
the dynamics of synergy between two antimicrobial agents by determining the number of viable 
bacteria remaining over time after exposure to each individual agent and the various combinations 
(Garcia and Isenberg, 2007).  
Agar medium methods such as the Etest and the disk diffusion test have been applied, 
demonstrating good results in detecting synergy effects. Etest consists of a non-porous plastic 
strip containing a continuous gradient of antimicrobial concentrations covering 15 two-fold 
dilutions. For testing in vitro combinations, Etest strips of the two antimicrobials are placed on 
the agar at a 90° angle with the intersection at the respective MICs for the organism (Sueke et al., 
2010). After incubation overnight, an elliptical zone of growth inhibition is formed and the MICs 
of the antimicrobial agents can be visualised (Garcia and Isenberg, 2007). Disk susceptibility 
testing methods remain the most commonly used techniques in clinical microbiology laboratories 
(Galani et al., 2008; Skov et al., 2003). Disk diffusion tests easily assess net antimicrobial 
activities of combinations for which commercially prepared disks are available (e.g. amoxicillin-
clavulanate, trimethoprim-sulfamethoxazole). For other combinations, double-disk diffusion 
techniques have been revised to qualitatively determine drug interactions. 
The conclusions of synergy/ indifference/ antagonism derived by each method may be unclear 
since there are several definitions to what constitutes synergy and numerous experimental 
techniques for synergy detection (Lambert et al., 2003). Typically, synergy indicates that the 
compounds in the mixture act via different mechanisms and/or targets (Lila and Raskin, 2005). 
In these cases, where both compounds have antimicrobial activity, it is only necessary to 
determine whether the combination is beneficial or not. However, some compounds, the so-called 
antibiotic adjuvants or RMAs, which possess weak or inexistent antibacterial activities by 
themselves, have been reported to potentiate antibacterial compounds against pathogens (Gill et 
al., 2015; Kalan and Wright, 2011). Further in this thesis, optimized methods to detect and 
characterize potentiation will be described. The adjuvant approach offers advantages such as the 
potential to decrease the therapeutic concentration of antibiotic that is needed, which can be 
beneficial in terms of emergence of resistance and toxicity issues, to extend the effective lifespan 
drugs, and to minimize barriers to be accepted into clinical setting for being already familiar 
compounds (Brown and Wright, 2016). However, the combination approach also presents 
challenges. It may not totally avoid resistance emergence in long term, as it is for any 
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antimicrobial therapy. Moreover, the potential for unexpected drug–drug interactions, side effects 
and toxicity issues that might arise from drug promiscuity must also be examined thoroughly. 
 
 SEARCHING FOR THERAPEUTIC ALTERNATIVES IN THE ‘PREY’ AND 
NOT IN THE ‘PREDATOR’  
Selection for antibiotic resistance in bacteria provides one of the most well-documented 
examples of an evolutionary response to natural selection (Walker and Levy, 2001). Similar 
resistance development has also been observed in viruses, fungi, plants and insects towards 
antiviral drugs, antifungals, herbicides and insecticides, respectively, creating increasing medical 
and economic problems (Maisnier-Patin and Andersson, 2004). Even before the beginning of the 
clinical use of antibiotics more than 60 years ago, resistant organisms had been isolated, which 
proves that this is not a recent problem (Levy, 2002). Indeed, antibiotic resistant genes have been 
characterized in coliforms from glacial water and ice in the Arctic estimated at 2000 years old 
(Barker, 1999).  
Co-evolution between predator and prey has millions of years of experience to offer. Bacteria 
and fungi are the leading sources of therapeutic antimicrobials (Cowan, 1999). If one is indeed 
taking advantage of the natural weapons that microorganisms have been producing to fight with 
their ‘enemies’ for millions of years, perhaps one could expect that by co-evolution, resistance to 
these compounds would appear also naturally. The question then is, does the environmental 
resistome intersect with the resistome of clinical pathogens or are they distinct? Wright (2010) 
extensively reviewed connections that show a clearly link between resistance in the environment 
with the clinic: the CTX-M extended spectrum β-lactamase appears to have come from 
chromosomal genes of environmental genus Kluyvera; the qnrA gene associated with 
fluoroquinolone resistance has an environmental reservoir in the aquatic bacterium Shewanella 
algae; the gene cluster that confers resistance to vancomycin (a glycopeptide antibiotic) in 
Enterococci and Staphylococci have been identified in environmental Bacilli, in glycopeptide-
producing bacteria, and in non-producing environmental strains (Wright, 2010). Additionally, 
culturable bacteria in soil were found to encode enzymes that degrade or inactivate antibiotics 
(Allen et al., 2010). Dantas et al. (2008) isolated hundreds of soil bacteria with intrinsic multidrug 
resistance phenotypes with the capacity to grow on antibiotics as a sole carbon source. In one soil 
species, over 400 actinomycetes cultured from forest, agricultural and urban soils were found to 
have highly varied resistance profiles and some of them even exhibited resistotypes that had not 
been seen before (D'Costa et al., 2006). Forsberg et al. (2012) describes MDR soil bacteria 
containing resistance cassettes against five classes of antibiotics (β-lactams, aminoglycosides, 
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amphenicols, sulfonamides, and tetracyclines) that have perfect nucleotide identity to genes from 
diverse human pathogens. Handelsman group identified and characterized several new antibiotic 
resistance genes from soil bacteria encoding for aminoglycoside acetyltransferases, tetracycline 
efflux (Riesenfeld et al., 2004), β-lactamases (Donato et al., 2010), fenicol efflux proteins (Lang 
et al., 2010), etc. Even in subsurface, bacterial antibiotic resistance was found to be common by 
Brown and Balkwill (2008): higher frequencies of resistance and multiple resistance bacteria to 
nalidixic acid, mupirocin or ampicillin were found.  
The examples of resistance genes shared between environmental microbes and human 
pathogens raise questions regarding the clinical impact of environmental resistance. 
Microorganisms rapidly acquire resistance, which probably forces their competitors to produce 
inhibitors for such mechanisms. For example, plants have been extensively reported to be able to 
produce drug-resistance inhibitors in order to ensure the delivery of the antimicrobial compounds. 
These interesting compounds may have direct application on clinical setting. The chemical 
diversity between plants and microorganisms represents then a formidable possibility to identify 
MDR inhibitors from natural sources.  
 
 PLANTS DEFENSE SYSTEMS AS POTENTIAL SOURCES OF THERAPEUTIC 
STRATEGIES 
In their ecosystem, plants are continuously exposed to a wide range of environmental stresses 
and hostile conditions. Stress factors affecting plant fitness include environmental (abiotic) 
factors, such as nutrient deficiency, hypoxia/anoxia, drought, salinity, adverse temperature 
fluctuations, high light intensity, and also those derived from anthropogenic activities, such as 
pesticides, pollutants and increased UV radiation (Iriti and Faoro, 2009; Suzuki et al., 2014). 
Besides, several living (biotic) factors are also stress-inducing factors, including bacteria, fungi, 
viruses, nematodes, insects and herbivore pests (Rausher, 2001).  
Plants have faced most of their attackers for more than 350 million years. This allowed plants 
to co-evolved with their natural enemies in a reciprocal evolutionary interaction and to learn how 
to resist to their attacks. Although lacking mobile defender cells and a somatic adaptive immune 
system comparable to animals (Dangl and Jones, 2001), plants have the ability to recognize 
pathogen signals or elicitors and activate immune responses, such as the reinforcement of the cell 
wall, biosynthesis of lytic enzymes and production of secondary metabolites and pathogenesis 
related proteins (War et al., 2012).  
Owing to their sessile lifestyle and this evolutionary arms race, plants have evolved a stunning 
broad array of structural, chemical defenses, formerly referred to as secondary metabolites, 
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designed to fight their invaders and protect themselves from damage. These compounds can be 
either constitutive, stored as inactive forms, known as phytoanticipins, or inducible in response 
to pathogen attack, known as phytoalexins (Fürstenberg-Hägg et al., 2013).  
Phytoanticipins give the plant a characteristic odor (such as terpenoids), distinctive 
pigmentation (e.g., quinones and tannins) or their flavor (e.g., the terpenoid capsaicin from chili 
peppers) (Aiyegoro and Okoh, 2009; Simões et al., 2009; Zahin et al., 2010). Some 
phytoanticipins are found at the plant surface while others are present in vacuoles or organelles 
and released through a hydrolyzing enzyme after pathogen challenge (González-Lamothe et al., 
2009).  
Phytoalexins (including terpenoids, glycosteroids, and polyphenols) are small molecules 
(molecular weight < 500 g mol-1) which are both synthesized and accumulated in plant after 
recognition of elicitors derived from the exposure to attackers (Hemaiswarya et al., 2008). There 
are four major pathways for synthesis of secondary metabolites: (1) shikimic acid pathway, (2) 
malonic acid pathway, (3) mevalonic acid pathway and (4) non-mevalonate pathway (Azmir et 
al., 2013). Polyphenolic compounds from plants show a huge structural diversity, including 
chlorogenic acids, hydrolyzable tannins, and flavonoids (flavonols, flavanones, flavan-3-ols, 
anthocyanidins, isoflavones, and flavones) (Marín et al., 2015). Other common classes of 
phytochemicals include alkaloids, lactones, diterpenes, triterpenes, glycosteroids and 
naphthoquinones (Cowan, 1999; Hemaiswarya et al., 2008; Lewis and Ausubel, 2006; Zahin et 
al., 2010).  
Plant extracts have been utilized in the name of human health for centuries particularly in Asia 
to accelerate wound healing and to treat common infectious diseases. Such traditional medicines 
are still utilized in the routine treatment of various diseases. Examples include the use of bear-
berry (Arctostaphylos uva-ursi) and cranberry juice (Vaccinium macrocarpon) to treat urinary 
tract infections, or essential oils of Tea Tree (Melaleuca alternifolia) as active ingredients in many 
topical formulations to treat cutaneous infections and also of Hydrastis canadensis and Echinacea 
species to “treat” tuberculosis infections (Gibbons, 2008; Nikaido, 1998; Schelz et al., 2010). 
Also, Hydrastis canadensis is used to combat inflammation and infection. Its antibacterial activity 
in vitro has been attributed to its alkaloids, the most abundant of which is berberine (Ettefagh et 
al., 2011).  
Numerous clinical studies have proved the therapeutic value of molecules of plant origin on 
the human organism (Betoni et al., 2006; Gibbons, 2004; Schelz et al., 2010). Indeed, secondary 
metabolites are an important source of anticancer, antioxidant, antidiabetic, immunosuppressive, 
antifungal, anti-inflammatory, antimalarial, anti-oomycete, antibacterial, antifever, antidiabetic, 
insecticidal, nematicidal, and antiviral agents (Akram et al., 2014; da Silva et al., 2005; Dehghan 
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et al., 2016). In total, higher plant-derived products represent approximately 25% of drugs in 
current clinical use (Phillipson, 2007).  
Due to their curative potential, plant extracts have been investigated for the development of 
novel drugs to control bacterial infections (Dickson et al., 2006; Jayaraman et al., 2010; Sibanda 
and Okoh, 2008). Of the more than 350000 species of higher plants currently recognized, only 5-
10% have been investigated, and only ~15% phytochemically (Cragg and Newman, 2013), and 
considering that each plant species may contain 500-800 different secondary metabolites, the 
potential for the discovery of new therapeutic products in this largely untapped resource is 
considerable (Coutinho et al., 2010a; Miller, 2011; Schelz et al., 2010; Sibanda and Okoh, 2007).  
Additionally, due to the current increase in awareness of the population of antibiotic resistance 
problems, the use of herbal medicinal products and supplements has increased tremendously over 
the past three decades with not less than 80% of people worldwide relying on them for some part 
of primary healthcare (Ekor, 2013). Indeed, in 2013, the global retail sale of herbal and botanical 
dietary supplements amounted to more than $6.032 billion in the United States, according to 
HerbalGram - the journal of the nonprofit American Botanical Council. 
 
  Synergistic interactions between plant phytochemicals 
The therapeutic value of synergistic interactions has been known since antiquity, and many 
different cultural healing systems (such as Ayurveda and traditional Chinese herbal medicine) 
have relied on this principle and in the belief that combination therapy may enhance efficacy (van 
Vuuren and Viljoen, 2011). These synergistic interactions explain the efficacy of apparently low 
doses of active constituents in an herbal product (Aiyegoro and Okoh, 2009). This concept is 
based in the idea that an extract of a plant offers advantages over a single isolated ingredient. In 
fact, of the many medicines that have higher-plant origins, very few show strong antimicrobial 
activity. Phytochemical products usually produce MICs in the range of 100 to 1000 mg l-1 in in 
vitro susceptibility tests (Simões et al., 2009), much weaker than compounds produced by bacteria 
and fungi (MICs between 0.1 to 10 mg l-1). Still, some products produced by plants can fight 
infections successfully (Sibanda and Okoh, 2007). In fact, the relative rarity of infectious diseases 
in wild plants is an indication of the effectiveness of their innate defense mechanisms 
(Hemaiswarya et al., 2008; Lewis and Ausubel, 2006). Hence, those phytochemicals are believed 
to work synergistically between each other, thus playing a role against infection in the plants 
defense system (Hemaiswarya et al., 2008; Sibanda, 2007; Tegos et al., 2002). Interaction with 
different targets by the different defensive components of the extract can promote synergistic 
effects and enhance the defensive system of plants. For example, in tomato, alkaloids, phenolics, 
CHAPTER 2. LITERATURE REVIEW 2016 
 
 
37 
proteinase inhibitors and oxidative enzymes act synergistically, affecting the insect during 
ingestion, digestion and metabolism; in Nicotiana attenuata, trypsin proteinase inhibitors and 
nicotine expression contributed synergistically to the defensive response against Spodoptera 
exigua (Hub.) (Lepidoptera, Noctuidae) (War et al., 2012).  
Some phytochemicals have been reported to inhibit important bacterial enzymes, thus having 
an interesting application in cotherapies with antibiotics. Myricetin, a flavonol found in many 
vegetables, herbs, berries and fruits, inhibited DNA B helicase in E. coli, which plays a central 
role during DNA replication initiation and elongation (Griep et al., 2007; Hemaiswarya et al., 
2008). Moreover, myricetin inhibits a variety of DNA polymerases, RNA polymerases, reverse 
transcriptases and telomerases (Griep et al., 2007). This phytochemical also had a significant 
synergic activity against ESβL-producing K. pneumoniae in combination with cefoxitin, 
amoxicillin/clavulanate and ampicillin/sulbactam (Lin et al., 2005). Allicin is one of the most 
effective antimicrobial products isolated from garlic (Allium sativum) and was shown to potentiate 
the action of cefazolin and oxacillin against Staphylococcus spp., cefoperazone against P. 
aeruginosa (Cai et al., 2007), and vancomycin against VRE strains (Abascal and Yarnell, 2002). 
Allicin reportedly inhibits bacterial RNA synthesis (Hemaiswarya et al., 2008) and interacts with 
important thiol-containing microbial enzymes such as cysteine proteinases, acetate kinase, 
alcohol dehydrogenases, thioredoxin reductases and phosphotransacetyl-CoA synthetases (Ankri 
and Mirelman, 1999). 
Nevertheless, many of the phytochemicals that are synthesized in response to pathogen 
invasion are not even antimicrobial. Most of the functions of such phytochemical products in 
plants are still unknown (Simões et al., 2009). They might have a regulatory function, indirectly 
increasing the level of resistance of the plant (Tegos et al., 2002), or can be produced if the 
interaction between constituents of the extract results in increased solubility and, thereby, enhance 
the bioavailability of active substances. A special synergy effect can then occur when antibiotics 
are combined with an agent that antagonizes bacterial resistance mechanisms (Wagner and 
Ulrich-Merzenich, 2009). The utility of plant products as antimicrobial potentiators and virulence 
attenuators has been intensively studied (González-Lamothe et al., 2009), much of it in the 
antifungal field. Some examples include marked synergy between azole antifungals and a group 
of small molecules called citridones, produced by Penicillium sp. (Kalan and Wright, 2011). The 
activity of rhein, the principal antimicrobial from rhubarb was potentiated 100- to 2000-fold 
(depending on the bacterial species) by disabling the MDR efflux pumps (Tegos et al., 2002). The 
following sections will focus on combinatorial activities of plant extracts and products with 
antibiotics, mainly due to a resistance-modifying activity. 
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  In vitro antibiotic-potentiation by RMAs 
The strategy of resistance-modifying activity implies that an antimicrobial product should be 
co-administered with an inhibitor that deactivates the bacterial resistance mechanism thus 
increasing the effectiveness of the antimicrobial product (Shahverdi et al., 2007). These products 
could be of significant benefit for the treatment of MDR infections. There are diverse 
phytochemical products which have already demonstrated the potential to act as RMAs and 
potentiated the antimicrobial effects of antibiotics. TABLE 2.2 shows several examples of such 
compounds described in bibliography. The chemical structures of these compounds can be found 
in Appendix A1. 
 
TABLE 2.2 | Important examples of phytochemicals promoting antibiotic-potentiation 
due to a resistance-modifying activity 
Phytochemical  Plant source Antibiotic 
potentiated 
Mechanisms of action References 
Carnosic acid; 
Carnosol 
Rosmarinus 
officinalis 
Tetracycline 
Erythromycin 
MDR efflux pumps 
inhibition 
(Gibbons et al., 2003a; 
Oluwatuyi et al., 2004; 
Stavri et al., 2007) 
Reserpine Rauwolfia 
serpentina 
Fluoroquinolones 
Tetracycline 
MDR efflux pumps 
inhibition 
(Gibbons et al., 2003a; 
Gibbons and Udo, 2000; 
Markham et al., 1999; 
Marquez, 2005; Schmitz 
et al., 1998; Stavri et al., 
2007) 
Totarol 
Diterpene 416 
Chamaecypari
s nootkatensis 
Norfloxacin 
Tetracycline 
Erythromycin 
Methicillin 
NorA inhibition; 
Interference with PBP2a 
expression 
(Gibbons, 2005; 
Nicolson et al., 1999; 
Simões et al., 2009; 
Smith et al., 2007a) 
Berberine Berberis spp. Ampicillin 
Oxacillin 
Intercalation into DNA; 
Increase membrane 
permeability 
(Lewis and Ausubel, 
2006; Simões et al., 
2009; Stermitz et al., 
2000b; Yu et al., 2005) 
5*-methoxyhydno-carpin; 
pheophorbide a 
Berberis spp. Berberine 
Others (e.g. 
norfloxacin) 
NorA inhibition (Gibbons et al., 2003a; 
Guz et al., 2000; Stavri 
et al., 2007; Tegos et al., 
2002) 
Ferruginol 
5-Epipisiferol 
Chamaecypari
s lawsoniana 
 
Norfloxacin 
Erythromycin 
Oxacillin 
Tetracycline 
EtBr efflux inhibition (Sibanda and Okoh, 
2007; Smith et al., 
2007a) 
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Baicalein Scutellaria 
spp. 
Tetracycline 
β-lactams 
Gentamicin 
Ciprofloxacin 
Inhibition of PBP2a; 
Reaction with the 
peptidoglycan; 
NorA inhibition 
(Chan et al., 2011; 
Fujita et al., 2005; 
Wagner and Ulrich-
Merzenich, 2009) 
Catechin gallate; 
Epicatechin gallate; 
Epigallocatechin gallate 
Camellia 
sinensis 
β-lactams 
Norfloxacin 
Carbapenems 
Tetracycline 
β-lactamases inhibition; 
PBP2a synthesis 
inhibition; 
Reaction with 
peptidoglycan; 
EtBr efflux inhibition; 
TetK inhibition 
(Hu et al., 2002; 
Marquez, 2005; 
Roccaro et al., 2004; 
Shibata et al., 2005; 
Yam et al., 1998; Zhao 
et al., 2001) 
Methyl-1α-acetoxy-7α-
14α-dihydroxy-8,15-
isopimaradien-18-oate; 
Methyl-1α,14α-diacetoxy-
7α-hydroxy-8,15-
isopimaradien-18-oate 
Lycopus 
europaeus 
Tetracycline 
Erythromycin 
MDR efflux pumps 
inhibition 
(Gibbons et al., 2003b) 
Piperine Piper nigrum, 
Piper longum 
Ciprofloxacin EtBr efflux inhibition (Jin et al., 2011; Khan et 
al., 2006) 
2,6-dimethyl-4-phenyl-
pyridi-ne-3,5-dicar-
boxylic acid diethyl ester 
Jatropha 
elliptica 
Ciprofloxacin 
Norfloxacin 
NorA inhibition (Marquez et al., 2005; 
Sibanda and Okoh, 
2007) 
Ethil gallate Caesalpinia 
spinosa 
β-lactams Restriction of substrate 
diffusion for PBPs 
(Shibata et al., 2005) 
Cinnamaldehyde Cinnamomum 
zeylanicum 
Clindamycin CdeA inhibition (Shahverdi et al., 2007) 
Tellimagrandin I; 
Rugosin B 
Rosa canina L. β-lactams Inactivation of PBPs, 
particularly PBP2a 
(Shiota et al., 2000; 
Shiota et al., 2004) 
Corilagin Arctostaphylos 
uva-ursi 
β-lactams 
Cefmetazole 
Inhibition of PBP2a 
activity or production 
(Shimizu et al., 2001; 
Shiota et al., 2004) 
Silybin Silybum 
marianum 
Ampicillin 
Oxacillin 
MDR efflux pumps 
inhibition 
(Kang et al., 2011; 
Stermitz et al., 2000b) 
Polyacylated 
neohesperidoses 
Geranium 
caespitosum 
Berberine 
Ciprofloxacin 
Norfloxacin 
Rhein 
MDR efflux pumps 
inhibition 
(Stavri et al., 2007; 
Stermitz et al., 2003; 
Tegos et al., 2002) 
Chrysosplenol-D 
Chrysoplenetin 
Artemisia 
annua 
Artemisinin 
Berberine 
Norfloxacin 
MDR efflux pump 
inhibition 
(Stavri et al., 2007) 
Chalcone Dalea 
versicolor 
Berberine 
Erythromycin 
Tetracycline 
NorA inhibition (Belofsky et al., 2004; 
Stavri et al., 2007; 
Zdzisława, 2007) 
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4’,5’-O-dicaffeoyl-quinic 
acid 
Artemisia 
absinthium 
Berberine 
Fluroquinolones 
MFS family efflux 
systems inhibition 
(Fiamegos et al., 2011) 
Genistein; 
Orobol; 
Biochanin A 
Lupinus 
argenteus 
Berberine 
Norfloxacin 
MDR efflux pump 
inhibition 
(Morel et al., 2003) 
 
Rosmarinus officinalis L. (commonly referred to as rosemary) extracts act as a soft analgesic 
and antimicrobial agent in traditional use (Lo et al., 2002; Pintore et al., 2002). Extracts of 
rosemary provide a major source of antimicrobials including carnosic acid and carnosol (Frankel 
et al., 1996; Oluwatuyi et al., 2004). These compounds at 10 mg l-1 were found to potentiate the 
activity of tetracycline (2- and 4-fold, respectively) against a TetK possessing S. aureus strain and 
carnosic acid showed a 8-fold reduction in MIC of erythromycin against S. aureus strains 
expressing MsrA (Sibanda and Okoh, 2007). Additionally, carnosic acid was shown to inhibit 
EtBr (a substrate for several MDR pumps) efflux in a NorA expressing S. aureus strain with an 
IC50 of 50 mM (1/4 of the MIC for the strain) (Oluwatuyi et al., 2004; Sibanda and Okoh, 2007). 
However, this activity is likely to be related to the inhibition of efflux pump(s) other than NorA.  
The plant alkaloid reserpine produced by Rauwolfia serpentina was originally found to inhibit 
Bmr efflux pump (Guz et al., 2000; Stavri et al., 2007). Its EPI activity was also demonstrated 
against the NorA pump in S. aureus by reducing the MIC of norfloxacin at least 4-fold (Gibbons 
et al., 2003a; Markham et al., 1999). Reserpine reduced sparfloxacin, moxifloxacin and 
ciprofloxacin MICs up to 4-fold in several clinical isolates of S. aureus (Schmitz et al., 1998). 
Gibbons and Udo (2000) showed the same reduction for tetracycline in clinical isolates of MRSA 
with the TetK determinant. Reserpine also inhibited LmrA of L. lactis (Marquez, 2005). However, 
it was found that reserpine is toxic for humans at concentrations required for MDR pumps 
inhibition (Dickson et al., 2006; Markham et al., 1999). Moreover, bacterial resistance to this 
natural product was already observed (Hemaiswarya et al., 2008). 
Berberine, a hydrophobic alkaloid produced by Berberis species (Hemaiswarya et al., 2008), 
is known to increase membrane permeability and to intercalate into DNA (Lewis and Ausubel, 
2006). Yu et al. (2005) found an additive effect between berberine and ampicillin and a synergistic 
effect with oxacillin against MRSA. This product has the potential to restore the effectiveness of 
β-lactam antibiotics against MRSA (Stermitz et al., 2000b; Yu et al., 2005). However, berberine 
is rapidly extruded by multidrug efflux pumps (Stermitz et al., 2000a). It was observed that 
Berberis species also synthesize the 5’-methoxyhydnocarpin-D and pheophorbide a, which were 
identified as inhibitors of the NorA MDR efflux pump in S. aureus (Guz et al., 2000; Marquez, 
2005; Sibanda and Okoh, 2007; Stermitz et al., 2000b; Tegos et al., 2002). These MDR inhibitors 
facilitate the penetration of berberine into S. aureus by completely inhibiting its efflux from the 
CHAPTER 2. LITERATURE REVIEW 2016 
 
 
41 
cell (Gibbons et al., 2003a; Tegos et al., 2002; Wagner and Ulrich-Merzenich, 2009). This is an 
important example of synergy between components from the same plant. 5’-
methoxyhydnocarpin-D also had a synergistic effect with several other products exported by 
NorA, including norfloxacin (Stavri et al., 2007). An extract of Dalea versicolor, chalcone, 
reportedly enhanced the activity of berberine, erythromycin and tetracycline against S. aureus, 
also apparently due to NorA inhibition (Belofsky et al., 2004; Stavri et al., 2007; Zdzisława, 
2007). Chalcone increased the activity of berberine against B. cereus by 30-fold (Zdzisława, 
2007). This is also an interesting case where products with strong direct antimicrobial activity and 
those with MDR pump inhibitory action were found in the same plant (Belofsky et al., 2004). 
4’,5’-O-dicaffeoylquinic acid from Artemisia absinthium also potentiated berberine and 
fluroquinolones against a wide panel of Gram-positive human pathogenic and was characterized 
by Fiamegos et al. (2011) as an efflux pump inhibitor with the potential to target efflux systems 
especially of the MFS family. The flavones chrysosplenol-D and chrysoplenetin isolated from 
Artemisia annua potentiated the activity of the antimalarial artemisinin against Plasmodium 
falciparum in the presence of berberine and norfloxacin (Stavri et al., 2007), due to NorA 
inhibition. The isoflavones genistein, orobol and biochanin A, isolated from Lupinus argenteus, 
potentiated the antibacterial activity of α-linolenic acid, also from the same plant, and enhanced 
the antibacterial activity of berberine and norfloxacin against S. aureus cells, indicating that they 
may inhibit MDR pumps (Morel et al., 2003). 
Totarol, a diterpene isolated from immature cones of Chamaecyparis nootkatensis, reduced 
the MIC of tetracycline, norfloxacin and erythromycin for 4-, 4- and 8-fold, respectively, in 
MRSA strains (Smith et al., 2007b), suggesting that this product is a NorA EPI (Smith et al., 
2007b). Totarol also potentiated by 8-fold activity of methicillin against MRSA (Nicolson et al., 
1999). Despite the fact that the primary staphylococcal target for totarol is the respiratory chain, 
it was found that this synergic activity is due to the interference with PBP2a expression (Gibbons, 
2005; Nicolson et al., 1999). Other studies suggest that this product may affect the production of 
macromolecules, including DNA and peptidoglycan, causing cell membrane disruption (Nicolson 
et al., 1999; Simões et al., 2009; Smith et al., 2007b). Other diterpenes, especially diterpene 416 
(14-methylpodocarpa-8,11,13-trien-13-ol; 5), also potentiated methicillin, with a reduction on the 
MIC of more than 256-fold against MRSA, owing to a significant reduction in PBP2a expression 
(Nicolson et al., 1999). Two isopimarane diterpenes, methyl-1α-acetoxy-7α,14α-dihydroxy-8,15-
isopi-maradien-18-oate and methyl-1α,14α-diacetoxy-7α-hydroxy-8,15-isopimaradi-en-18-oate, 
isolated from an extract of Lycopus europaeus by Gibbons et al. (2003b) demonstrated a 2-fold 
potentiation of tetracycline and erythromycin against two strains of S. aureus possessing the TetK, 
MsrA and NorA efflux-mechanisms. 
CHAPTER 2. LITERATURE REVIEW 2016 
 
 
42 
Japanese green tea (Camellia sinensis) is consumed every day by billions of people worldwide 
for its antipyretic, antidotal, antidiarrheal and diuretic effects (Zhao et al., 2001). These benefits 
of green tea are not only due to the bacteriostatic and bactericidal activities of some constituents 
but also to the presence of several resistance-inhibitory products (Yam et al., 1998). Aqueous 
extracts of tea, especially catechin gallate, epicatechin gallate and epigallocatechin gallate, 
demonstrated the potential to reverse methicillin resistance in MRSA and penicillin resistance in 
β-lactamase-producing S. aureus, apparently by the prevention of PBP2a synthesis and the 
inhibition of β-lactamase secretion, respectively (Hu et al., 2002; Marquez et al., 2005; Roccaro 
et al., 2004; Yam et al., 1998). Moreover, in the presence of catechin gallate and epicatechin 
gallate the MIC of oxacillin was reduced from 256 and 512, respectively, to 1-4 mg l-1 against 
MRSA (Shibata et al., 2005). Epigallocatechin gallate had much lower activity than epicatechin 
gallate, although only differing by an extra hydroxyl group on the B-ring, causing a reduction in 
oxacillin MIC ranging between 4 and 64-fold (Smith et al., 2007a). Gibbons et al. (2004) showed 
that epicatechin gallate and epigallocatechin gallate caused a 4-fold potentiation of the activity of 
norfloxacin against a NorA over-expressing S. aureus strain. Another explanation for this synergy 
with β-lactams against MRSA is the possible interference of these products with the integrity of 
the cell wall through direct binding to peptidoglycan (Zhao et al., 2001). Additionally, 
epigallocatechin gallate was found to synergistically enhance the activity of carbapenems against 
MRSA (Hemaiswarya et al., 2008; Hu et al., 2002). It was also demonstrated that epicatechin 
gallate and epigallocatechin gallate are able to reverse tetracycline resistance in staphylococcal 
isolates expressing TetK and TetB efflux pumps, probably due to the inhibition of these pumps 
(Marquez, 2005; Roccaro et al., 2004).  
Baicalein, isolated from extracts of the leaves of Scutellaria baicalensis, which is one of the 
most popular herbs in China for the treatment of bacterial and viral infections (Chan et al., 2011), 
had a synergistic effect with tetracycline against MRSA with and without TetK-genes and in TetK 
overexpressing E. coli (Fujita et al., 2005). This flavone potentiated the effects of β-lactam 
antibiotics against MRSA (Wagner and Ulrich-Merzenich, 2009). Chan et al. (2011) also 
demonstrated synergy between baicalein and ciprofloxacin against MRSA strains and with 
gentamicin against VRE, apparently by the inhibition of the NorA efflux pump. The synergistic 
actions of this compound on MRSA may therefore involve several mechanisms of action such 
bacterial efflux pumps inhibition (others different from TetK), PBPs inhibition or cell wall 
disintegration by interference with the peptidoglycan structure (Chan et al., 2011; Wagner and 
Ulrich-Merzenich, 2009). Tellimagrandin I and rugosin B, obtained from the extract of petals of 
Rosa canina L. (rose red), markedly reduced the MIC of β-lactams against MRSA (Shiota et al., 
2000), possibly due to the inactivation of PBPs, especially of PBP2a (Shiota et al., 2004). Shimizu 
et al. (2001) found that corilagin from an extract of Arctostaphylos uva-ursi markedly reduced 
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the MIC of β-lactams, such as oxacillin and cefmetazole, by 100- to 2000-fold in MRSA, also 
possibly due to inhibition of PBP2a, its activity or its synthesis (Shimizu et al., 2001; Shiota et 
al., 2004). 
Piperine, the major plant alkaloid in black pepper (Piper nigrum) and long pepper (Piper 
longum) reduced the MIC of ciprofloxacin (Khan et al., 2006) and mupirocin (Mirza et al., 2011) 
against S. aureus, including MRSA, and decreased EtBr efflux (Jin et al., 2011). Smith et al. 
(2007a) isolated active compounds from the cones of Chamaecyparis lawsoniana and observed 
that ferruginol and 5-epipisiferol were effective in increasing the efficacy of tetracycline, 
norfloxacin, erythromycin and oxacillin against resistant S. aureus. It was demonstrated that 
ferruginol inhibited in 40% the efflux of EtBr, using a NorA expressing S. aureus strain (Smith 
et al., 2007a). The penta-substituted pyridine 2,6-dimethyl-4-phenylpyridine-3,5-dicarboxylic 
acid diethyl ester, isolated from an ethanol extract of rhizome of Jatropha elliptica (Marquez et 
al., 2005), increased by 4-fold the activity of ciprofloxacin and norfloxacin against NorA 
expressing S. aureus, suggesting an efflux pump inhibition (Marquez et al., 2005; Sibanda and 
Okoh, 2007). Cinnamaldehyde from Cinnamomum zeylanicum bark essential oil may inhibit 
CdeA efflux pump in Clostridium difficile (Shahverdi et al., 2007), and reduced the MIC of 
ampicillin, tetracycline, penicillin, erythromycin and novobiocin in E. coli N00 666 (Palaniappan 
and Holley, 2010). Garvey et al. (2011) extracted Levisticum officinale and identified falcarindiol, 
oleic acid and linoleic acid in the fractions displaying the greatest synergy with five antibiotics; 
possibly by an efflux inhibition of AcrAB–TolC. Geraniol, found in the essential oil 
of Helichrysum italicum, significantly increased the efficacy of β-lactams, quinolones, and 
chloramphenicol in E. coli, P. aeruginosa, Enterobacter aerogenes and A. baumannii (Lorenzi et 
al., 2009). The flavonolignan silybin obtained from Silybum marianum, which is one of the oldest 
known traditional European medicine and has mainly been used for liver disorders (Kitajima and 
Yamaguchi, 2009), reduced by more than 4-fold the MIC of ampicillin or oxacillin against 20 
clinical isolates of MRSA (Kang et al., 2011), possibly by a MDR pump inhibition (Park et al., 
2012; Stermitz et al., 2000b). Two poliacylated neohesperidosides from Geranium caespitosum 
increased the activity of ciprofloxacin and norfloxacin, also apparently due to MDR pump 
inhibition (Stavri et al., 2007; Stermitz et al., 2003; Tegos et al., 2002). 
 
  In vitro antibiotic-potentiation by membrane permeabilizers 
Another strategy to overcome resistance is to improve the delivery or enhance the accessibility 
of antibiotics to their sites of action. Many compounds have been reported to affect membrane 
permeability of a diverse range of microorganisms (Helander et al., 1998), mainly due to the 
perturbation of the lipid fraction of the cell membrane. Also, owing to their lipophilic character, 
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they can increase membrane permeability (Trombetta et al., 2005). Such permeabilizers can non-
specifically enhance the permeability of bacterial cells to exogenous products, including 
antimicrobial agents, and may therefore potentiate the antibacterial activity of antibiotics that 
interact with intracellular targets (Simões et al., 2009).  
Thymol and carvacrol, two main products of the essential oil of Thymus vulgaris, reportedly 
disintegrate the OM and thus increase membrane permeability and fluidity in Gram-negative 
bacteria, facilitating the penetration of antibiotics (Helander et al., 1998; Lambert et al., 2001; 
Schelz et al., 2010; Simões et al., 2009; Wagner and Ulrich-Merzenich, 2009). The combined 
application of both products resulted in a stronger antibacterial effect than if applied separately 
(Szczepaniak et al., 2011). Synergistic interactions have been reported between thymol and 
carvacrol with antibiotics against Sphingomonas paucimobilis and Klebsiella oxytoca (Zhang et 
al., 2011). These products increased the susceptibility of Salmonella enterica Typhimurium SGI-1 
to ampicillin, tetracycline, penicillin, bacitracin, erythromycin and novobiocin and the resistance 
of Streptococcus pyogenes with the macrolide-resistant gene ermB to erythromycin (Palaniappan 
and Holley, 2010). 
Ethyl gallate and other alkyl gallates purified from a dried pod of Caesalpinia spinosa, reduced 
the MIC of β-lactams against MRSA and methicillin-sensitive S. aureus (MSSA) strains (Shibata 
et al., 2005). The mechanism of action of these gallates is still unknown but, the possible 
perturbation on the membrane and the resulting restrictions on its components fluidity could 
difficult the diffusion of substrates for PBPs (Shibata et al., 2005).  
Gallic acid from berry extracts has proven to be an efficient permeabilizer for several 
Salmonella strains (Nohynek et al., 2006). Moreover, synergic interactions were observed with 
the combination of gallic acid with tetracycline against P. aeruginosa strains (Jayaraman et al., 
2010) and with streptomycin against E. coli and P. aeruginosa (Saavedra et al., 2010). The OM 
disintegrating activity of gallic acid was suggested to be based on the chelation of divalent cations 
from the OM. Additionally, the partial hydrophobicity of this product (Nohynek et al., 2006), 
decrease of negative surface charge, and occurrence of local rupture or pore formation in the cell 
membranes also allowed bacterial membrane destabilization (Borges et al., 2012). 
A putatively synergic effect has been reported for the antibacterial constituents of Humulus 
lupulus, xanthohumol and lupulon, and some antibiotics such as polymyxin B sulfate, tobramycin 
and ciprofloxacin, against Gram-positive and Gram-negative bacteria (Wagner and Ulrich-
Merzenich, 2009). The antimicrobial action of xanthohumol and lupulon was due to changes 
induced in the properties and permeability of the membrane (Natarajan et al., 2008). 
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  Plant extracts with resistance-modifying activity in vitro 
In addition to the synergistic effects observed for the previously described products, a large 
number of other in vitro studies have reported the capacity of plant extracts to potentiate the 
activity of antibiotics. Mechanistic studies into such synergistic effects is often complicated by 
the fact that plant extracts consist of complex mixtures of compounds, several of which can be 
involved in the final result (Wagner and Ulrich-Merzenich, 2009). The screening of these extracts 
is, however, expected to provide leads for the isolation of MDR inhibitors (Sibanda and Okoh, 
2008). Some examples are described in this section. 
Methanolic extracts of Punica granatum have shown synergistic activity by the broth dilution 
method and time-kill assays with chloramphenicol, gentamicin, ampicillin, tetracycline and 
oxacillin against strains of MRSA and MSSA (Braga et al., 2005). The extracts also demonstrated 
the potential to either inhibit the efflux pump NorA or to enhance the influx of the antibiotics 
(Braga et al., 2005). Aqueous crude extracts of Catha edulis at sub-MIC potentiated the action of 
tetracycline against Streptococcus sanguis TH-13 and Streptococcus oralis SH-2 (2- and 4-fold, 
respectively), and of penicillin-G against Fusobacterium nucleatum 9911 (4-fold) (Al-hebshi et 
al., 2006). Ethanol extracts of Eugenia uniflora L. and Eugenia jambolanum exhibited synergistic 
activity with gentamicin against E. coli (Coutinho et al., 2010b). Synergistic interactions were 
also observed between extracts of several Brazilian plants and eight antibiotics against S. aureus, 
indicating the presence of a range broad of inhibitors of protein synthesis, cell wall synthesis, 
nucleic acid synthesis and folic acid synthesis (Betoni et al., 2006). Methanolic extracts of 19 
Jordanian plants had significant synergistic interactions against MRSA and MSSA strains in 
combination with chloramphenicol, gentamicin, erythromycin and penicillin G (Darwish et al., 
2002). Ethanol extracts of the Chinese plants Isatis tinctoria, Scutellaria baicalensis and Rheum 
palmatum improved the activity of ciprofloxacin, penicillin, gentamicin and ceftriaxone against 
antibiotic resistant S. aureus strains (Yang et al., 2005). Dalea spinosa (smoke tree) extracts 
potentiated antibiotic activity against MRSA, due to MDR efflux pump inhibition (Belofsky et 
al., 2006; Simões et al., 2009). Coutinho et al. (2010a) demonstrated that an ethanol extract of 
Momordica charantia L. reduced the MIC for some aminoglycosides against MRSA. Extracts of 
Securinega virosa and Mezoneuron benthamianum exerted a potentiation activity against 
fluoroquinolone-, tetracycline- and erythromycin-resistant S. aureus strains (Stavri et al., 2007). 
Additionally, 4-fold potentiation of the activity of norfloxacin was observed with ethanol extracts 
of M. benthamianum and, in a less extension, with chloroform extracts of S. virosa (Dickson et 
al., 2006). Coutinho et al. (2009) reported that the ethanol extract of Turnera ulmifolia L. had a 
synergic effect with aminoglycosides. Acetone extracts of Garcinia kola seeds potentiated the 
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activity of tetracycline and chloramphenicol against E. coli and K. pneumonia and of amoxicillin 
and penicillin G against S. aureus (Sibanda and Okoh, 2008).  
Adwan and Mhanna (2008) demonstrated a significant reduction in the MIC of several 
antimicrobial agents with water extracts of Psidium guajava, Rosmarinus officinalis, Salvia 
fruticosa, Majorana syriaca, Ocimum basilucum, Syzygium aromaticum, Laurus nobilis and Rosa 
damascene against MRSA and MSSA. Ethanolic extracts of some Indian medicinal plants, Acorus 
calamus, Hemidesmus indicus, Holarrhena antidysenterica and Plumbago zeylanica, 
demonstrated synergistic activities when combined with tetracycline, chloramphenicol, 
ciprofloxacin, cefuroxime and ceftidizime against several MRSA strains (Aqil et al., 2006) and 
with tetracycline and ciprofloxacin against ESβL-producing MDR enteric bacteria (Ahmad and 
Aqil, 2007). Synergistic interactions of crude extracts from Camellia sinensis, Lawsonia inermis, 
Terminalia chebula and Terminalia belerica have been reported with tetracycline against MRSA 
and MSSA strains and with ampicillin for Camellia sinensis extract (Aqil et al., 2005). Extracts 
of Commiphora molmol, Centella asiatica, Daucus carota, Citrus aurantium and Glycyrrhiza 
glabra had a good activity against S. enterica serovar Typhimurium overexpressing the AcrAB-
TolC efflux protein (Stavri et al., 2007). Synergy was found between ethanolic extracts of Rhus 
coriaria (seed) and some antimicrobial drugs, including oxytetracycline HCl, penicillin G, 
cephalexin, sulfadimethoxine sodium and enrofloxacin against MDR P. aeruginosa strains, 
suggesting the presence of natural inhibitors, including EPIs (Adwan et al., 2010). The 
combinations of the methanol extract of the leaves of Helichrysum pedunculatum and 8 first-line 
antibiotics were investigated against several bacterial strains implicated in wound infections and 
60% of the interactions were synergic (Aiyegoro et al., 2009b). The combination of methanol 
extracts of Helichrysum longifolium with penicillin G sodium, amoxicillin, chloramphenicol, 
oxytetracycline, erythromycin and ciprofloxacin against several bacterial isolates of referenced, 
clinical and environmental strains resulted in 61.7% of synergy for all interactions (Aiyegoro et 
al., 2009a). Touani et al. (2014) found that the methanol extracts of Brassica oleacera var. butyris, 
Brassica oleacera var. Italica, capsicum frutescens var. facilulatum and Basilicum polystachyon 
showed synergistic effects [fractional inhibitory concentration (FIC) ≤ 0.5] with an average of 
75.3% of the tested antibiotics against MDR Gram-negative bacteria. Barreto et al. (2015) showed 
that the ethanol and hexane extracts of stem bark of Anadenanthera colubrine (Vell.) Brenan var. 
cebil enhanced the activity of neomycin and amikacin against S. aureus SA10 strain. Barreto et 
al. (2014) also showed a 10-fold reduction of the MIC of neomycin and amikacin when combined 
with the essential oil from Lippia origanoides H.B.K. against MRSA strain. 
Many examples of synergistic activities in which essential oils have been found to reduce the 
minimum effective dose of antibiotics in the treatment of infections are described by Yap et al. 
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(2014). Aumeeruddy-Elalfi et al. (2015) reported the synergy of the essential oils of Pimenta 
dioica, Psidia arguta and Piper betle when combined with gentamicin against E. coli and S. 
epidermis. Fankam et al. (2015) investigated the antibacterial and antibiotic-resistance modifying 
activities of the methanol extracts from Allanblackia gabonensis, Gladiolus quartinianus and 
Combretum molle against 29 Gram-negative bacteria including MDR phenotypes. Percentages of 
antibiotic-modulating effects ranging from 67 to 100% were observed against MDR bacteria 
when combining the leaves extract from C. molle (½ and ¼ MIC) with chloramphenicol, 
kanamycin, streptomycin and tetracycline (Fankam et al., 2015). Tankeo et al. (2015) found 
synergistic effects against a panel of Gram-negative bacteria, including MDR phenotypes 
expressing active efflux pumps, obtained with Beilschmedia acuta bark extract and tetracycline 
as well as with Polyscias fulva leaves extract at MIC/2 and tetracycline and kanamycin. Also, in 
wild mushrooms extracts, especially from Mycena rosea and Fistulina hepatica, interesting 
synergistic activities between the extracts and commercial antibiotics (penicillin, ampicillin, 
amoxicillin/clavulanic acid, cefoxitin, ciprofloxacin, cotrimoxazol, levofloxacin) against E. coli, 
ESβL E. coli and MRSA (Alves et al., 2014). 
 
  Plant extracts promoting the dispersal of a biofilm to planktonically growing 
cells or quorum-sensing inhibition 
Plant-based antimicrobial studies on planktonic microorganisms have been given extensive 
priority. The inhibition of biofilms, whether on independent or combined plant inhibitors, 
however, has been largely neglected (van Vuuren and Viljoen, 2011). Potential therapies for 
biofilm control include enzymes that dissolve the matrix polymers of the biofilm, chemical 
reactions that block biofilm matrix synthesis, and analogues of microbial signaling molecules that 
interfere with cell-to-cell communication, required for normal biofilm formation (Stewart and 
William Costerton, 2001). 
Many bacteria are known to regulate diverse physiological processes through a mechanism 
called quorum-sensing which is accomplished through the production, secretion and subsequent 
detection of extracellular signal molecules called autoinducers (AIs). When these molecules reach 
a particular threshold concentration, they are taken up by other microbes and trigger adaptive 
changes appropriate to the community of organisms (Cvitkovitch et al., 2003; Fernández et al., 
2011; Hammer and Bassler, 2003). QS has been found to regulate a number of physiological 
activities, including motility, conjugation, competence, sporulation, virulence and biofilm 
formation. Some of these quorum sensing molecules, such as the Pseudomonas quinolone signal 
(PQS) and the N-acyl homoserine lactones (AHL) from P. aeruginosa, possess antimicrobial 
activity at very high concentrations (Fernández et al., 2011). Consequently, QS pathways of 
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competing bacteria are potential targets for such nontoxic chemical defenses. Screening for 
natural products able to promote biofilm dispersal has led to the identification of inhibitors of 
AHL-based QS, such as bromoageliferin and oroidin (Landini et al., 2010). The aqueous extract 
of Moringa oleifera was found to inhibit violacein production, a QS-regulated behavior in 
Chromobacterium violaceum (Singh et al., 2009). In other study, the hexane, chloroform and 
methanol extracts of an Ayurveda spice, namely clove (Syzygium aromaticum), shown anti-QS 
activity by inhibiting the response of C. violaceum CV026 to exogenously supplied N-hexanoyl-
homoserine lactone, in turn preventing violacein production (Krishnan et al., 2012). Aqueous 
extracts of six plants, Conocarpus erectus, Chamaesyce hypericifolia, Callistemon viminalis, 
Bucida buceras, Tetrazygia bicolor and Quercus virginiana, caused the inhibition of QS genes 
and QS-controlled factors, with marginal effects on bacterial growth of P. aeruginosa (Adonizio 
et al., 2008). Also, common dietary fruit, herb and spice extracts showed a significant inhibition 
of QS (Vattem et al., 2007). 
 
  In vivo tests of phytochemicals 
Extracts from many plant species have been previously tested against hundreds of bacterial 
strains in vitro, and some of them have demonstrated antimicrobial activity. All these findings 
have provided good indications for the potential of plants to be applied in combination with 
antibiotics to treat infectious diseases. Unfortunately, much of the data acquired are only 
preliminary, having been derived from in vitro antimicrobial assays, potentiation assays and 
efflux studies; and the mechanisms of action often remain unexplained (Stavri et al., 2007). 
Further research should therefore focus on the use of preclinical animal infection models, 
followed when appropriate, by clinical trials, enabling the definition of pharmacokinetic and 
pharmacodynamic targets and the measurement of many other parameters at the site of infection, 
such as antimicrobial efficacy, appropriate doses and safety data (Hemaiswarya et al., 2008; 
Renneberg, 1993). It is also required enormous investigation to elucidate side-effects and 
strategies of extraction and preservation of these products (Mendonça-Filho, 2006).  
In this context, studies evaluating RMAs or phytochemicals-antibiotics therapies in vivo are 
few. To date, the efficacy of EPIs has been demonstrated in the therapy of malignancies in vitro 
and in vivo, as reviewed by Tegos et al. (2011). The only documented microbial EPI is currently 
MP-601,205, used for respiratory infections in patients with cystic fibrosis and ventilator-
associated pneumonia (Tegos et al., 2011). The activity of levofloxacin plus an efflux pump 
inhibitor (a low molecular weight dipeptide amide) was evaluated in an animal model of a P. 
aeruginosa infection caused by a strain overexpressing the MexAB–OprM MDR efflux system 
and demonstrated efficacy (Renau et al., 1999). The combination of piperine with mupirocin in a 
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dermal infection model of mice showed better in vivo efficacy when compared with the 
commercially available formulation of 2% mupirocin (Mirza et al., 2011). The combination of 
Japanese green tea extract with levofloxacin against enterohemorrhagic E. coli infection in a 
gnotobiotic mouse model produced an increased survival rate and the prevention of tissue damage 
(Isogai et al., 2001). Isbrucker et al. (2006) developed safety studies of epigallocatechin gallate 
and demonstrated that this product caused minor dermal irritation in rats and guinea pigs, but not 
rabbits, and was a moderate dermal sensitizing agent in the guinea pig maximization test. 
Moreover, the dietary administration of epigallocatechin gallate to rats for 13 weeks was not toxic 
at doses up to 500 mg kg-1 day-1 (Isbrucker et al., 2006) and to 40 volunteers for 4 weeks at 800 
mg day-1 only caused minor adverse effects (Doughari et al., 2009). Co-administration of EPIs 
with an antibiotic already progressed to human clinical trials (Guz et al., 2000; Lechner et al., 
2008).  
Other studies have focused on the in vivo antimicrobial activity of plant extracts or 
phytochemicals. For example, Chowdhury et al. (1991) demonstrated that allicin has promising 
in vivo antibacterial activity against Shigella flexneri when tested in the rabbit model of 
experimental shigellosis. Si et al. (2006) studied the antimicrobial activity of carvacrol, thymol 
and cinnamaldehyde against Salmonella in pig diets and reported that higher concentrations were 
needed to retain their antimicrobial activity when added to the diets. The effects of oolong tea 
polyphenols on dental caries in rats were tested and showing that total fissure caries lesions was 
significantly reduced by the addition of tea polyphenols to the diet or in the drinking water 
(Sakanaka et al., 1992). Tea catechins also inhibited the fluid accumulation induced by cholera 
toxin in sealed adult mice and reduced fluid accumulation by Vibrio cholerae O1 in intestinal 
loops of rabbits, suggesting that tea catechins may possess protective activity against V. cholerae 
O1 (Toda et al., 1992). P. aeruginosa lung infection of athymic rats was used to test subcutaneous 
administrations of ginseng, which seems to increase the resistance of the athymic rats to this 
bacteria (Song et al., 1997).  
 
 STUDYING PHYTOCHEMISTRY – IMPORTANT STEPS AND TECHNIQUES 
To study phytochemistry, several factors must be considered for the preparation and extraction 
of the plant material, followed by the separation, purification and identification of the different 
constituents of plants. A brief description of important methods is made in this section. 
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  Sample preparation and extraction 
Sample preparation is the crucial first step in the analysis of plants because it is necessary to 
extract the desired chemical components (Huie, 2002). Proper actions must be taken to assure that 
potential active constituents are not lost, distorted or destroyed (by the presence of water, for 
example), etc. Preparation of plant material usually includes the following steps: pre-washing, 
drying (or freeze drying) and grinding to obtain a homogenous sample and increase the contact 
of sample surface with the solvent system (Sasidharan et al., 2011). Then, extraction plays a 
significant and crucial role on the final result and outcome (Azmir et al., 2013). The most common 
factors affecting extraction processes are matrix properties of the plant part, solvent, temperature, 
pressure and time (Huie, 2002; Wang and Weller, 2006). The selection of the solvent system 
largely depends on the chemical properties of the target compounds. Different solvent systems 
are available to extract the bioactive compound from natural products: polar solvents such as 
methanol, ethanol or ethyl-acetate are more suitable for the extraction of hydrophilic compounds, 
while for more lipophilic compounds, dichloromethane or a mixture of dichloromethane/ 
methanol in ratio of 1:1 can be used (Sasidharan et al., 2011). Extraction of plant materials can 
be done by various extraction procedures and the suitability of the methods of extraction 
according to characteristics of the target compounds must be considered. Methods such as 
ultrasound, sonication, pulsed electric field, enzyme digestion, extrusion, ohmic heating, soxhlet, 
heating under reflux can be applied. More modern methods such as surfactant-mediated 
extraction, supercritical-fluid extraction, pressurized-liquid extraction, microwave-assisted 
extraction and solid-phase extraction possess certain advantages. These are, e.g. the reduction in 
organic solvent consumption and in sample degradation, elimination of additional sample clean-
up and concentration steps before chromatographic analysis, improvement in extraction 
efficiency, selectivity, and/ kinetics of extraction (Huie, 2002; Sasidharan et al., 2011). 
 
  Characterization of bioactive compounds 
After extraction, further separation, identification, and characterization of bioactive 
compounds is required. Metabolomics, one of the ‘omic’ sciences in systems biology, is the 
discipline where endogenous and exogenous metabolites are assessed, identified and quantified 
within a biologic system (Zhang et al., 2012). Nowadays, 1H NMR, Gas Chromatography–Mass 
Spectrometry (GC–MS) and Liquid Chromatography–Mass Spectrometry (LC–MS) are well-
established powerful analytical methods for generating metabolomics profiles (Patel et al., 2010). 
These techniques have their advantages and disadvantages. For instance, GC–MS requires sample 
derivatization, which lengthens the sample preparation time (O'Gorman et al., 2013). In general, 
LC–MS and GC–MS are more time-consuming concerning the sample preparation. On the other 
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hand, GC–MS and LC–MS yield a higher sensitivity than NMR and therefore may detect 
metabolites that are present in a concentration below the detection limit of 1H NMR (Scalbert et 
al., 2009). 1H NMR is non-destructive, non-biased, and easily quantifiable, permits the 
identification of novel compounds and needs no chemical derivatization (Wishart, 2008). 1H 
NMR may detect compounds that are too volatile for GC, while metabolites without proton 
(phosphoric acid) are not detected by 1H NMR.  
The technological developments in the field of NMR spectroscopy have enabled the 
identification and quantitative measurement of the many metabolites in a non-targeted and non-
destructive manner (Smolinska et al., 2012). NMR-based metabolomics are finding use in plant 
science in discovery-oriented natural products chemistry (Kim et al., 2010a). Activity guided 
fractionation, a common approach in natural products research, fails when several metabolites act 
synergistically. A metabolomics approach has proved to be very efficient in detecting synergistic 
compounds. Through the statistical analysis of NMR spectra of complex mixtures of metabolites, 
unique spectral features can be identified and correlated to a phenotype or biological property of 
interest (Larive et al., 2015), FIGURE 2.10. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.10 | Scheme of NMR-based metabolomics used to identify metabolites in 
complex mixtures and correlate them to a phenotype or biological property of interest. 
Multivariate data analysis (MVDA) methods aim to differentiate between classes in 
highly complex data sets, despite within class variability. 
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Also, multidimensional NMR experiments spectra [such as 2D-NMR technique: J-
resolved, 1H-1H correlation spectroscopy (COSY), 1H-13C heteronuclear multiple bond 
correlation (HMBC), and 1H-13C heteronuclear single quantum coherence (HSQC)] can aid in the 
process of assigning resonances, despite this strategy can be time-consuming (Kim et al., 2010a).  
When the identity of the metabolites in a sample is known (or suspected), resonance 
assignments can be facilitated using libraries or databases. Public and commercial databases, such 
as HMDB, LipidMaps and Metlin (Bartel et al., 2013) now contain experimental 1D 1H, 13C and 
2D 1H-13C spectra and extracted spectral parameters for over a thousand compounds and 
theoretical data for thousands more (Ellinger et al., 2013).  
 
  Multivariate Data Analysis (MVDA) in Metabolomics 
Usually, scientific phenomena cannot be interpreted by a single variable but by multi ones. To 
handle the obtained multivariates, specific methods are required for data reduction, 
multicomponent statistics and prediction (Berrueta et al., 2007). A characteristic of metabolomics 
is the large amount of data generated and an important part of any metabolomics study is the 
analysis of these data using multivariate statistics (Brennan, 2013).  
One approach to find meaning in metabolomics datasets involves MVDA methods that seek 
to capture not only changes of single metabolites between different groups, but also to utilize the 
dependency structures between the individual molecules. MVDA can be performed by 
unsupervised or supervised methods.  
The unsupervised methods seek discriminating factors between the independent variables with 
the aim to obtain a graphical representation as the result of maximization of variances. For 
example, principal component analysis (PCA), is an unsupervised linear mixture mode. PCA is 
arguably the most widely used multivariate analysis method for metabolic fingerprinting and in 
chemometrics in general. Principal component analysis is often used as a starting point for data 
analysis, especially in a hypothesis free, exploratory experimental setup and attempts to identify 
inherent grouping of samples as a result of the similarity of the metabolic composition by a 
smaller number of mutually decorrelated principal components (PCs) (Bartel et al., 2013; 
Brennan, 2013). So, principal component regression analyzes X in order to obtain components 
which can explain X in the best way. 
Supervised methods find the best fitting relationship between independent and dependent 
variables. Examples of supervised techniques is partial least-squares (PLS) and orthogonal 
projection to latent structures (OPLS) modeling (Brennan, 2013; Worley and Powers, 2013). PLS 
is a model for relating two data matrices of X and Y by a multivariate linear model. PLS regression 
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finds components of X which can predict Y in the best way. OPLS method is the improved form 
of PLS was first presented in 2002 and removes X changes that have no correlation with Y. Here 
the S-plot is proposed as a tool for visualization and interpretation of OPLS helping to identify 
statistically significant metabolites, based both on contributions to the model and their reliability 
(Sugimoto et al., 2012). 
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3. MATERIALS AND METHODS 
 
 
 
 
n this section, a description of all the biological and chemical materials 
used in this study is made, along with important observations 
necessary for their preparation. A protocol and a set of parameters adjusted 
for the identification of RMAs and other types of antibiotic adjuvants are 
defined. All the methods used in this thesis are described, highlighting crucial 
and important steps, appropriate conditions and a number of requirements that 
must be considered and fulfilled. A detailed chronological and methodological 
description of the project is given.  
3 
Chapter 
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 CRUCIAL STEPS AND PREPARATION OF MATERIAL BEFORE TESTING 
  General considerations 
Material from any source is appropriate for these protocols, but initial pretreatment and 
preparation may vary accordingly. The protocol as written is focused on plant extracts, plant-
isolated compounds or phytochemicals combined with commercial antibiotics. Any other natural 
extracts (from fungi, bacteria, algae, marine samples, etc.) and single isolated phytochemicals or 
synthetized compounds could be tested in combination with antibiotics as well. Also 
combinations with other antibacterial compounds that not commercial antibiotics can be 
performed. These protocols are also focused on S. aureus and MRSA clinical isolates but other 
aerobic bacteria can be tested as well. However, this requires optimization procedures and 
selection of appropriate conditions.  
When assessing the susceptibility of bacteria to antimicrobial products it is important to 
promote the uniform application of terminology to the methods used (Simões et al., 2009). 
According to the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the dilution 
methods (agar dilution or broth microdilution) are the designated reference methods for 
antimicrobial susceptibility testing (EUCAST, 2000). As with any test of antibiotic activity over 
time, it is of utmost importance specifications regarding inoculum size, growth phase and medium 
composition (Eliopoulos and Eliopoulos, 1988). So, to produce accurate and reproducible results 
for the test of antibiotics and antibiotic-adjuvant combinations, a number of requirements must 
be considered and fulfilled. If implemented rigorously according to the procedures described 
herein, these modifications allow the generation of reliable data that will be comparable between 
different laboratories. 
 
  Choice of bacteria growth medium 
The use of all methods of this protocol is limited to aerobic bacteria that grow well within 24 
h in the CLSI (2015b) and EUCAST (2000; 2003) recommended test Mueller–Hinton (MH) 
growth medium. Preparation of growth medium can be found later in Section 3.1.8. For other 
organisms, specific recommendations for medium composition and testing conditions can be 
found in the CLSI (2015b) guidelines. 
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  Preparation of bacterial inoculum  
Bacteria must be isolated to a pure culture. The standardization of the bacterial cell numbers 
used is of critical importance for obtaining accurate and reproducible results. Both inoculum size 
and growth phase may lead to false susceptible results. A fresh pure culture should be used for 
the preparation of the inoculum.  
Different methods for the preparation of the bacterial suspension can be used: direct colony 
suspension into liquid; growth method using either fresh or overnight cultures. In this thesis, 
preparation of the inoculum was carried out using the growth method using overnight cultures. 
The density of the cell suspension was assessed spectrophotometrically at 600 nm. Alternatively, 
a turbidity standard can be used as a visual yardstick. The McFarland 0.5 turbidity standard is 
equal to 1–2 × 108 CFU ml-1 (Wiegand et al., 2008). CLSI (2015b) has recommended a final 
inoculum size for susceptibility testing of aerobic bacteria in broth of 5 × 105 CFU ml-1. The final 
inoculum size was always confirmed by a colony count for interpretation of killing endpoints on 
the following day of each experiment. Preparation of saline tubes (0.9% wt vol-1 NaCl) for 
performing dilutions in preparation for colony counts will be further explained in Section 3.1.8. 
 
  Staphylococcus aureus strains 
In total, fifteen S. aureus strains were tested in this thesis. Their characteristics are shown in 
TABLE 3.1. As previously mentioned in Section 2.2.1, ST239 type MRSA strains are probably 
the most predominant clone of MRSA causing hospital-acquired infections (Abimanyu et al., 
2012). The CA-MRSA strain USA300 is the most predominant MRSA strain type causing 
infections outside the health care environment in the United States (David et al., 2013). This strain 
is PVL-positive, meaning that has been epidemiologically associated with severe skin infections 
and pneumonia (Chambers and DeLeo, 2010). 
Prior to use, each strain at -80ºC was transferred onto MH (Merck, Darmstadt, Germany) agar 
plate, grown overnight, and inoculated into MH broth at 37ºC and under agitation (150 rpm). 
There are several sets of controls that should be carried out. American Type Culture Collection 
(ATCC) or other national collections should be used to perform a better quality control. Thus, to 
be able to compare individual results and to validate the method, a quality control organism was 
always inserted for MIC characterization (S. aureus CECT 976 was used in this project).  
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TABLE 3.1 | Description of the fifteen Staphylococcus aureus strains used in this study 
according to their origin and genetic profiles 
 
S. aureus Origin Observations 
1 CECT 976 Laboratory strain 
Spanish Type Culture Collection; equivalent to ATCC 
13565; no antibiotic resistance; enterotoxin A gene 
2 SA1199B Laboratory strain 
Derived from a MSSA bloodstream isolate from a patient 
with endocarditis; NorA efflux pump overexpresser 
3 XU212 Laboratory strain TetK efflux pump overexpresser; MRSA 
4 RN4220 Laboratory strain MsrA efflux pump overexpresser (plasmid pU5054) 
5 MJMC001 CHTMAD, Portugal MRSA, isolated from a diabetic foot 
6 MJMC002 CHTMAD, Portugal MRSA, isolated from a diabetic foot 
7 MJMC003 CHTMAD, Portugal MSSA, isolated from a diabetic foot 
8 MJMC004 CHTMAD, Portugal MRSA, isolated from a diabetic foot 
9 MJMC009 CHTMAD, Portugal MSSA, isolated from a diabetic foot 
10 MJMC010 CHTMAD, Portugal MSSA, isolated from a diabetic foot 
11 M116 Indonesia ST239-MRSA 
12 RWW337 Malaysia ST239-MRSA 
13 RWW50 United States MLST ST8 
14 M82 Indonesia MSSA CC20 strain, Bovine lineage 
15 RN6390 Laboratory strain ALC132; no antibiotic resistance 
CHTMAD: Centro Hospitalar de Trás-os-Montes e Alto Douro (Vila Real, Portugal) 
 
  Preparation of antibiotics 
Five antibiotics were used in this thesis: ampicillin, oxacillin, ciprofloxacin, erythromycin and 
tetracycline. Description and characterization of these antibiotics regarding their mode of action 
and spectrum of activity can be found in TABLE 3.2.  
The antibiotics were obtained from Sigma-Aldrich (Sintra, Portugal). Powders were accurately 
weighed and dissolved in the appropriate solvents, following the manufacturer’s 
recommendations and CLSI (2015b) and EUCAST (2003) requirements, to yield the desired 
concentration, using sterile glassware. Stock solutions for all antimicrobials were always prepared 
as well as several range of intermediate concentrations of antibiotic, such as 0.1, 1, 10, 100 and 
1000 mg l-1. Aseptic precautions were followed when further dilutions were warranted. 
Sterilization was guaranteed by a membrane filtration (care should be taken to avoid the use of 
fiber pads owing to their absorbent nature) and samples before and after sterilization were 
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compared by assay to ensure that adsorption to the membrane had not occurred. Stock solutions 
were frozen as soon as possible after preparation. The stock was aliquoted in 1 ml volumes and 
frozen at -20ºC for periods up to six months. Stock solutions were used promptly on defrosting 
and not re-frozen. Standard strains of stock cultures were used to evaluate the antibiotic stock 
solutions. MICs were compared with CLSI (2015b) guidelines for a collection strain (for control), 
in order to be sure that the antibiotic was well prepared. 
 
TABLE 3.2 | General characterization of the five antibiotics tested along this study.  
Information of mechanisms of action and spectrum of activity are described 
and chemical structures represented 
Antibiotic Class Mechanism of action Spectrum Chemical structure 
Ampicillin β-lactam Inhibition of cell wall 
synthesis through 
binding to PBPs 
Gram-
positive and some 
Gram-negative 
bacteria 
H
N
O
N
S
O
CH3
CH3
HO
O
NH2
 
Oxacillin β-lactam Inhibition of cell wall 
synthesis mediated 
binding to PBPs 
Gram-
positive and some 
Gram-negative 
bacteria 
N
O
H
N
O
CH3
N
S
O
CH3
CH3
HO
O
 
Ciprofloxacin Quinolone Inhibition of 
topoisomerase II 
(DNA gyrase) and 
topoisomerase IV 
Gram-positive cocci 
(in urinary tract 
infections), some 
Gram-negative 
bacteria  
 
N N
F
OO
OH
NH
 
Erythromycin Macrolide Reversibly binding to 
the 50 S ribosomal 
subunit 
Gram-positive cocci 
(mainly staphylococci 
and streptococci) and 
bacilli, and to lesser-
extent gram-negative 
cocci; Mycoplasma, 
Legionella  
O
O
CH3
OHO
H3C
CH3
H3C OH
O
CH3
CH3
O
O
CH3
O
H3C
OH
HO
CH3
H3C
O
HO
CH3
H3C
H3C
 
Tetracycline 
 
Polyketide Reversibly binding to 
the bacterial 30S 
ribosomal subunit 
Several bacterial 
infections such as 
Rocky Mountain 
spotted fever, typhus 
fever, tick fevers, Q 
fever, rickettsialpox 
OH
OH
OOH
CH3
OH
NH2
O
OH
N
CH3H3C
O
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  Preparation of phytochemicals  
The phytochemicals selected and tested in this thesis are described in this section and their 
chemical structures are represented. 
 
 Alkaloids: caffeine, pyrrolidine, quinine, reserpine, theophylline – purchased from Sigma-
Aldrich (Sintra, Portugal) (FIGURE 3.1); 
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Caffeine Pyrrolidine Quinine Reserpine Theophylline 
FIGURE 3.1 | Chemical structures of the five alkaloids tested in this study. 
 
 Flavonoids: apigenin, (+)-catechin, chrysin, hesperidin, luteolin, morin, quercetin, rutin – 
purchased from Sigma-Aldrich (Sintra, Portugal) (TABLE 3.3); 
 
TABLE 3.3 | A summary of the chemical structures of the eight flavonoids tested in this study  
Flavonoids: 
 Substituents at carbon position: 
3 5 6 7 8 2′ 3′ 4′ 5′ 
 Apigenin1  OH - OH - - - OH - 
 Chrysin1  OH - OH - - - - - 
 Luteolin1  OH - OH - - OH OH - 
 Morin2 OH OH - OH - OH - OH - 
 Quercetin2 OH OH - OH - - OH OH - 
 Rutin2 O-rut OH - OH - - - OH OH 
 Hesperidin3  OH - O-rut - - OH OCH3 - 
 (+)-catechin4* OH OH - OH - - - OH OH 
 
1Flavone 2Flavonol 3Flavanone 4Flavan-3-ol *(+)-catechin 
O
O
2´
3´
4´
5´
5
6
7
8
6´
 
 
O
OH
O  
O
O  
O
OH  
 
 
 
O
O
O
O
6’ 
2 
2’ 
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O
OH
HO
OH
OH
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 Isoflavonoids: biochanin A, calycosin, calycosin-7-O-β-D-glucoside, corylifol A, 
daidzein, daidzin, genistein, genistin, glycitein, glycitin, formonenetin, 3’-
hydroxypuerarin, iridin, irigenin, irisflorentin, 3’-methoxypuerarin, neobavaisoflavone, 
ononin, orobol, puerarin, tectoridin and tectorigenin - purchased from Biopurify (Chengdu, 
China) (TABLE 3.4).  
 
TABLE 3.4 | A summary of the chemical structures of the twenty-two isoflavonoids 
tested in this study 
Isoflavonoids: 
 Substituents at carbon position:* 
3 5 6 7 8 2′ 3′ 4′ 5′ 
 Daidzein  - - OH - - - OH - 
 Daidzin  - - O-glc - - - OH - 
 Corylifol A(a)  - - OH - - - OH 2Xprenyl 
 Neobavaisoflavone(b)  - - OH - - prenyl OH - 
 Genistein  OH - OH - - - OH - 
 Genistin  OH - O-glc - - - OH - 
 Orobol  OH - OH - - OH OH - 
 Calycosin  - - OH - - OH OCH3 - 
 Calycosin-7-O-β-D-
glucoside 
 - - O-glc - - OH OCH3 - 
 Formononetin  - - OH - - - OCH3 - 
 Ononin  - - O-glc - - - OCH3 - 
 Biochanin A  OH - OH - - - OCH3 - 
 Tectorigenin  OH OCH3 OH - - - OH - 
 Tectoridin  OH OCH3 O-glc - - - OH - 
 Glycitein  - OCH3 OH - - - OH - 
 Glycitin  - OCH3 O-glc - - - OH - 
 Irigenin  OH OCH3 OH - - OH OCH3 OCH3 
 Iridin  OH OCH3 O-glc - - OH OCH3 OCH3 
 Puerarin  - - OH glc - - OH - 
 3'-Hydroxypuerarin  - - OH glc - OH OH - 
 3'-Methoxypuerarin  - - OH glc - OCH3 OH - 
 Irisflorentin(c)  OCH3 R3 R3 - OCH3 OCH3 OCH3 - 
(glc – glucose) 
*Structure of isoflavonoid 
 
(a) Corylifol A 
 
(b) Neobavaisoflavone 
 
(c) Irisflorentin 
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 Triterpenoids: betulinic acid, lupeol, betulin, hederagenin, ursolic acid and oleanolic acid 
- purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands) (FIGURE 3.2). 
O
CH3
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OH
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FIGURE 3.2 | Chemical structures of the six triterpenoids tested in this study. 
 
For susceptibility testing, all phytochemicals should ideally be prepared in the same solvent. 
For plant-derived compounds dimethyl sulfoxide (DMSO) is recommend since water solubility 
is usually low. Additionally, DMSO is not toxic for most bacteria under the concentration of 
approximately 5% v v-1. Therefore, all the phytochemicals tested in this study were dissolved in 
DMSO (Sigma-Aldrich, Sintra, Portugal). The phytochemicals were prepared at a certain initial 
concentration considering that only a volume ideally less than 5% v v-1 should be applied either 
on, depending on the method, broth or on agar medium (in Section 3.1.8 it is described how to 
add the phytochemicals in MH agar), so to ensure that the solvent is not promoting growth 
inhibition and thus interfering with the results. When testing one phytochemical for its 
antibacterial activity, at least one antibiotic was included in the same assay to ensure that the 
bacterial strains present the normal susceptibility profiles and are in the expected conditions. 
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  Collection and plant samples preparation  
Twenty-nine Portuguese medicinal, invasive and fruit plant species were mostly collected in 
the region of Trás-os-Montes and Beira Transmontana (Portugal) and characterized by the 
Botanical Garden from Vila Real (Portugal). All plants tested are described in TABLE 3.5. 
Information about the ethnopharmacological uses of these plants can be found in Appendix A2. 
 
TABLE 3.5 | Description of the twenty-nine species tested in this study 
 
Plant name Common name Family 
1. Acacia dealbata Mimosa Fabaceae 
2. Cytisus striatus  Giesta Fabaceae 
3. Genista tridentate Carqueja Fabaceae 
4. Prunus domestica Plum Rosaceae 
5. Prunus avium Wild cherry Rosaceae 
6. Prunus persica Peach tree Rosaceae 
7. Pyrus communis Pear tree Rosaceae 
8. Agrimonia eupatoria Church Steeples Rosaceae 
9. Eriobotrya japonica Loquat Rosaceae 
10. Crataegus monogyna Hawthorn Rosaceae 
11. Rubus idaeus Wild Raspberry Rosaceae 
12. Malus communis Apple tree Rosaceae 
13. Eupatorium cannabinum Hemp agrimony Asteraceae 
14. Centaurea nigra Black knapweed Asteraceae 
15. Physalis angulata Cutleaf Ground-cherry Solanaceae 
16. Cyphomandra betacea Tree tomato Solanaceae 
17. Nerium oleander Oleander Apocynaceae 
18. Trachelospermum jasminoides Star jasmine Apocynaceae 
19. Eucalyptus globulus Blue Gum Tree Myrtaceae 
20. Calluna vulgaris Calluna Ericaceae 
21. Ficus carica Fig tree Moraceae 
22. Castanea sativa Sweet chestnut Fagaceae 
23. Juglans regia Walnut Juglanduceae 
24. Diospyros kaki Japanese Persimmon Ebenaceae 
25. Vitis vinifera Grape Vine Vitaceae 
26. Fraxinus excelsior European ash Oleaceae 
27. Actinidia chinensis Chinese gooseberry Actinidiaceae 
28. Buxus sempervirens Common box Buxaceae 
29. Pteridium aquilinum Bracken Dennstaedtiaceae 
The leaves of all plants were used for the extraction, excepting for C. striatus, for which flowers and 
twigs were also separately extracted and tested. 
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The leaves of all plants as well as the flowers and twigs of Cytisus striatus were harvested, 
separated and immediately frozen in liquid N2 in order to avoid unwanted enzymatic reactions 
and stored at -20°C until analysis.  
 
  Reagent setup 
 Physiological saline solution [0.9% (wt/vol) NaCl] sterilized by autoclaving dispensed in 
15 ml polystyrene capped tubes: saline volumes for performing dilutions in preparation for colony 
counts were dispensed aseptically after autoclaving to minimize volumes inconsistencies that may 
occur during autoclaving of small volumes. The volume of saline needed for serial dilutions is 9 
ml. cap tubes tightly for storage to prevent evaporation. These tubes were stored at 4ºC. 
 Mueller-Hinton (MH) broth medium preparation: MH broth was prepared according to 
the manufacturer’s instructions, autoclaved and cooled to 2–8ºC before the addition of the cation 
solutions. Additional cation supplementation (Ca2+ and Mg2+ ions) may be made as indicated by 
CLSI (2015b) when testing several antibiotics and strains. The final concentration should be 20–
25 mg Ca2+ and 10–12.5 mg Mg2+ per liter (Wiegand et al., 2008), which reflects the divalent 
cation concentration in blood. The pH of each batch of MH broth was checked with a pH meter 
when the medium is prepared (between 7.2 and 7.4). 
 Preparation of MH agar: MH was added to a 1 l flask according to the manufacturer’s 
instruction with 12-15 g of agar and add 1 l of distilled water. The solution was autoclaved and 
cooled down until it could be poured into 90 mm Petri dishes to give a uniform depth of 
approximately 4 mm as previously refereed. The agar medium was allowed to set and to cool to 
room temperature and stored at 4ºC. 
 Preparation of MH agar with the phytochemical/plant extract to test: MH was added to 
a 1 l flask according to the manufacturer’s instruction with 12-15 g of agar and add 1 l of distilled 
water. Depending on the amount of plates necessary, other containers with other volumes can be 
used. One flask was prepared for each candidate as adjuvant to test. After autoclaving the MH 
broths and when the solution was cool enough, the adjuvant solutions were added as described in 
Section 3.1.6, yielding the final concentration desired (no more than 5% v v-1 of medium). Dried 
plant extracts prepared in DMSO were used in agar medium in the same way. The cooled 
supplemented medium was poured into 90 mm Petri dishes to give a uniform depth of 
approximately 4 mm. The agar medium was allowed to set and cool down to room temperature. 
These plates were usually prepared and used immediately to avoid drug deterioration on the 
medium. Unless, the plates were stored at 4ºC for a maximum period of 5 days. 
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  DESCRIPTION OF METHODOLOGY STEP-BY-STEP 
  Task 1. Evaluation of the best method to assess antibiotic potentiation by 
phytochemicals against Staphylococcus aureus 
 
Small description. In this section, a protocol and a set of parameters adjusted for the identification of 
RMAs and other types of antibiotic adjuvants are described. Checkerboard, time-kill 
assay, Etest and the disk diffusion methods were optimized and adjusted to provide 
such an analysis. Five alkaloids and five flavonoids were tested in combination with 
five antibiotics against S. aureus strains, including MRSA. A comparison of the 
results of potentiation given by these methods was evaluated to choose the best one. 
Bacterial strains. Three clinical MRSA (MJMC001, MJMC002, MJMC004) and three clinical MSSA 
(MJMC003, MJMC009, MJMC010), S. aureus SA1199B, RN4220, XU212 and 
CECT 976. Information of bacterial strains can be found in Section 3.1.4.  
Antibiotics.  
 
Ampicillin, ciprofloxacin, erythromycin, oxacillin and tetracycline. Preparation and 
specificities of the antibiotics are described in Section 3.1.5. Etest strips of antibiotics 
(AB Biodisk, Marcy L´Étoile, France) were obtained from Izasa (Oeiras, Portugal). 
Phytochemicals. Alkaloids: caffeine, pyrrolidine, quinine, reserpine and theophylline; flavonoids: (+)-
catechin, hesperidin, morin, quercetin and rutin. Preparation and specificities of the 
phytochemicals are described in Section 3.1.6. FIGURE 3.1 and TABLE 3.3 show 
the chemical structures of the alkaloids and flavonoids tested, respectively. 
 
 Experimental design 
The concept of restoring the utility of already known antimicrobials by employing RMAs 
seems to be a remarkable alternative, despite of some concerns of possible toxicity that might 
arise from drug promiscuity. The combination of bioactive compounds is expected to exert a 
synergistic outcome or to reduce possible adverse side effects. Also, the development of active 
compounds in conjugation with existing antibiotics could probably avoid the emergence of 
resistant variants that might otherwise arise during treatment (Gibbons et al., 2003a; Olajuyigbe 
and Afolayan, 2012). There are several evidences of non-antimicrobial molecules that enhanced 
the activity of antimicrobial agents (Gill et al., 2015; Kalan and Wright, 2011), usually for 
improving solubility, absorption, safety, stability, or bioavailability of the active principle or due 
to a resistance-modifying effect.  
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A number of conceptual and methodological gaps are barring the identification of RMAs for 
clinical implementation. The methods reported in bibliography are more suitable for multi-
antibacterial drugs therapy and not for the application of one antibacterial compound coupled with 
RMAs or antibiotic adjuvant. Also, most plant-related studies are still based on simple 
antibacterial tests against a range of bacteria, and the outcome is interpreted according to the 
simple classification of being antibacterial active or not. This classification as “antibacterial” is 
done even when plant extracts are tested at concentrations that exceed a lot the acceptable limits 
of clinical standards. It is important to highlight that researchers should continue investigating the 
synergistic capacity of plant extracts or other natural products, independently of the antimicrobial 
activity they might have. Thus, a more integrated approach is necessary to fully and deeply 
evaluate the defense features of each plant. A strategy to evaluate all interesting antibacterial 
activities shown by a plant extract or phytochemical is proposed as schematized in FIGURE 3.3.  
 
 
FIGURE 3.3 | Characterization of phytochemicals as antibacterials or antibiotic-adjuvants. 
(*) at doses that can be tolerated according to sound medical practice; (**) the 
definition of synergy or potentiation should be given according to the classification 
systems for each method that will be further explained in Section 3.2.1.7; (***) 
additional methods are required to assess the mode of action of the adjuvant and its 
interaction with the antibiotic. 
MIC determination 
Does the phytochemical have antibacterial activity? (*) 
Yes No 
Antibacterial 
compound 
Does the antibiotic has an increased effect in the presence of the phytochemical? (**) 
Yes No 
Synergy, 
possibly due to 
multi-target activity 
Indifference or 
antagonism 
Potentiation, due to: 
- Resistance inhibition, 
- Enhancing uptake, 
- Altering physiology 
- … (***) 
Indifference or 
antagonism 
Yes No 
Test combination antibiotic + compound 
 Checkerboard test 
 Time-kill assay 
 Etest 
 Disk diffusion method 
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The analysis explained in the left part of FIGURE 3.3 is generally made for compounds or 
extracts that have shown interesting antibacterial activity. The definition of being ‘antibacterial’ 
can be controversial. An antibacterial drug can be defined as anything that destroys bacteria or 
suppresses their growth or their ability to reproduce. However, the minimal concentration 
required for this activity is important if one consider a clinical application. It is known that 
antibacterial compounds from bacteria and fungi sources are orders of magnitude stronger (0.01-
10 mg l-1) than plant-derived antibacterials (100-1000 mg l-1) (Tegos et al., 2002). Plant-derived 
compounds have not been considered for clinical application, since they can be toxic and effective 
at concentrations higher than the dose-related toxicity. For more toxic drugs, clinical use is based 
on weighing the favorable and unfavorable effects at a particular dose. Antibacterial compounds 
can play synergistically between each other throughout a multi-target therapeutic effect. Here, the 
components can have either separate targets or separate sites on the same target to create a 
combination effect and increase the pharmacological action (Zimmermann et al., 2007). 
In the case that the compound/extract of interest has no antibacterial activity, the strategy is 
explained in the right part of the scheme (FIGURE 3.3). For detecting RMAs or antibiotic 
coadjuvants, it is expected to observe a high inactivation of resistant bacteria when the 
combination of antibiotic/plant compound is applied and only minor or no antibacterial activity 
of the phytochemical at doses that can be tolerated according to sound medical practice.  
For all the methods, determination of the ability of a candidate compound to potentiate the 
activity of an antibiotic agent includes comparison of cell growth or survival in test cells and 
control cells, wherein test cells are incubated in the presence of the antibiotic agent and candidate 
compound, while control cells are incubated only in the presence of the antibiotic agent under the 
initial conditions of bacterial inoculum, the same concentration of the antibiotic and the time of 
exposure. In such methods, a candidate compound is identified as a potentiating compound of the 
antibiotic agent if the growth or survival of cells in the presence of the antibiotic agent and the 
candidate compound is less than the growth of the cells in the presence of the antibiotic agent 
alone.  
Growth or survival can be assessed using cells growing in liquid or solid media. Any method 
known in the art can be used to determine inhibition of growth, proliferation and/or survival. 
Examples include measuring optical density in liquid culture, measuring colony formation, or 
measuring bacterial viability. Reproducibility of the results obtained may be tested by repeating 
the experiment and, in the case of a high-throughput assay, by incubating cells in more than one 
well of the assay plate e.g., in triplicate, with the same concentration of the same candidate 
compound. Additionally, since candidate compounds may be effective at varying concentrations 
depending on their mechanisms of action, varying concentrations of the candidate compound may 
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be added to different wells containing cells. In certain embodiments, the methods should involve 
the use of one or more negative or positive control compounds. A positive control compound may 
be any molecule, agent, moiety or drug that is known to potentiate the activity of the antibiotic 
under investigation. A negative control compound may be any molecule, agent, moiety or drug 
that is known to have no significant potentiating effect on the activity of the antibiotic agent. The 
solvent used for preparing the compounds could be used. Further comparison of the potentiating 
effect of the candidate compound to the potentiating effect (or lack thereof) of the positive (or 
negative) control compound is required (Cottarel et al., 2010).  
The term “synergy” might not be a valid way to characterize positive interactions 
intermediated by these agents with no antimicrobial activity. Synergy by definition means that 
two compounds are potentiating each other. In this case it would be better to only consider this as 
a potentiation. Several explanations of possible interactions between antibiotics and adjuvants 
were previously made in FIGURE 2.8 in Section 2.4. Methods used so far to evaluate 
combinations between one antibiotic and an antibiotic-adjuvant are based on the same outcome 
used to classify synergy between two antibacterial compounds. This section aims to describe 
optimization of methods for detection of antibiotic adjuvants. As previously mentioned, the 
protocols described in this section are adjusted to a step-by-step format and for testing the 
susceptibility to natural extracts and phytochemicals and follow the guidelines of the two 
established organizations and committees, CLSI (2015a; 2015b) and EUCAST (2000; 2003), in 
order to assure intra- and inter-laboratory reproducibility.  
 
 Antibacterial susceptibility testing 
The MIC of each agent was determined by microdilution techniques according to CLSI 
(2015a) guidelines. Bacteria (~106 CFU ml-1) were inoculated into MH broth and dispensed at 
200 μl well-1 in polystyrene sterile 96-well microtiter plates, along with 2-fold dilutions of the 
compounds to test. Two-fold dilution series with around 10–12 dilutions down from 512 mg l-1 
are conventionally used for most antibacterial agents for MIC determination. However, the 
concentration range will depend on the bacterial isolates to be tested and the antibacterial agent 
itself. MIC was defined as the lowest concentration of the antimicrobial compound that inhibited 
bacterial growth after 24 h of incubation at 37ºC. The bacterial growth was determined at 600 nm 
using a microplate reader (Spectramax M2e, Molecular Devices, Inc., Sunnyvale, CA, USA). At 
least three independent experiments were always performed for each compound. A drug-free 
control was included to evaluate the growth behavior of cells in normal condition. The solvents 
used for the preparation of the compounds were tested for their antimicrobial activity (as negative 
controls). The highest concentration of DMSO remaining after dilution (5% v v-1) caused no 
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inhibition of bacterial growth. Bacteria-free controls constituted by the drugs in fresh medium 
were always prepared, as well as sterility controls containing only the medium.  
 
 Checkerboard microdilution assay 
The checkerboard assay was performed in 96-well microtiter plates according to CLSI (2015a) 
guidelines with some modifications. First, final concentrations of user-defined panel 
configuration should be planed. If the phytochemical to be tested with the antibiotic has detectable 
MIC, concentrations ranging from, for example, 1/64 MIC to 4 × MIC should be included in order 
to observe the occurrence and magnitude of synergy or antagonism. For combinatorial testing, 
one compound is being diluted along the x axis of the checkerboard array while the other is diluted 
along the y axis, so each well has a different combinations of the compounds. An intermediate 
solution of the compounds to test should be prepared from the stock solution so that a certain 
volume (< 2.5% v v-1 of the well) of this solution is added to the wells of the microtiter plate in 
order to generate a final highest desired concentration. The other concentrations will be further 
produced in the microtiter plate by serial dilution. The volume added of both compounds should 
be ≤ 5% v v-1 for a final volume of the well of 200 µl. Nevertheless, it is necessary to be sure that 
the solvent is not promoting growth inhibition and interfering with the results.  
In the case that the phytochemical to be tested in combination with an antibiotic has no 
detectable MIC, an initial range of concentrations down from 256 or 512 mg l-1 of the 
phytochemical was applied. In order to optimize the method, depending on the number of 
adjuvants or antibiotics to test, the space of the checkerboard array can be adjusted and, for an 
initial screening, each adjuvant can be applied only at two or three concentrations. After initial 
screening, best combinations can be assessed for optimal concentrations. It is expected to find the 
minimal and optimal concentration of the adjuvant causing the highest MIC fold reduction of the 
antibiotic. 
After an overnight incubation into MH broth at 37ºC, bacterial cultures were adjusted in fresh 
broth to approximately 106 CFU ml-1. Bacterial suspensions were added to each well along with 
the antibiotics and phytochemicals (in a total volume of 200 μl) according to the panel 
configuration. Negative growth controls were performed in a separate microtiter plate by mixing 
sterile medium with the drugs. Readings were determined in a spectrometer at 600 nm. 
 
  Etest 
This method was performed according to the manufacturer's instructions. Each phytochemical 
was added to MH agar (after autoclaved and cooled) yielding the final concentration desired, 
CHAPTER 3. MATERIALS AND METHODS 2016 
 
 
72 
which was chosen according to the checkerboard results. Then, the medium was poured into 90 
mm Petri dishes to give a uniform depth of approximately 4 mm (~20 mL). The bacterial 
suspensions were adjusted to 0.5 McFarland standards and seeded over hardened MH agar Petri 
dishes using a sterilized cotton swab and allowed to set (for 10 to 15 min). Antibiotic Etest strips 
were applied in duplicate on the MH agar plates. As control, the antibiotic strips were applied on 
simple MH agar plates (without the phytochemical). Plates were incubated for 24 h at 37ºC. MICs 
were read on plates with the combination of the two agents and on antibiotic control plates. 
 
 Disk diffusion method 
This method was a modification from the Kirby-Bauer one and it was already applied in other 
studies (Saavedra et al., 2010). The bacterial inoculum and the MH agar plates were prepared in 
the same way of that described for Etest. Sterile blank disks (6 mm diameter; Oxoid, Madrid, 
Spain) were placed on the agar plate seeded with the respective bacteria. A volume of 15 µl of 
each antibiotic, prepared according to CLSI (2015b) guidelines (ampicillin – 10 μg disk-1; 
ciprofloxacin – 5 μg disk-1; erythromycin – 15 μg disk-1; tetracycline – 30 μg disk-1; oxacillin – 1 
μg disk-1), was added to blank disks. Disks of antibiotics on simple MH agar plates (without the 
phytochemicals) were used as positive controls (FIGURE 3.4). Disks impregnated with DMSO 
were used as negative controls. The plates were incubated at 37°C for 24 h. After incubation, each 
inhibition zone diameter (IZD) was recorded and analysed according to CLSI (2015b) guidelines.  
 
FIGURE 3.4 | Disk diffusion method for detection of potentiation of antibiotic activity. 
 The phytochemical is inserted in MH agar (≤ 5% v v-1). Inhibition zone diameters 
(IZDs) promoted by antibiotic disks are measured in plates with [IZD (a+p)] and 
without [IZD (a)] the phytochemical and compared. 
 
 Time-kill assay 
Time-kill studies were performed according to Roccaro et al. (2004) with some modifications. 
Overnight cultures were diluted with MH broth to a starting inoculum of 106 CFU ml-1. Each 
IZD (a) 
Antibiotic 
IZD (a+p) 
Antibiotic 
Phytochemical 
in the medium 
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antibiotic was tested at MIC, ½ × MIC and ¼ × MIC. The concentration of the phytochemicals 
was chosen according to the checkerboard results. The combinations were added to sterilized 50 
ml polystyrene capped tubes and inoculated with each isolate in a total volume of 10 ml. The 
antimicrobial combinations did not exceed 5% v v-1 of the final volume. Controls were performed 
with each compound separately. The tubes were incubated at 37ºC and 150 rpm for 24 h. CFU 
counts in MH agar were performed after 0, 4, 8 and 24 h of the beginning of the incubation.  
 
 Classification of the interaction between two antibacterial compounds or between 
one antibacterial compound and an adjuvant 
In the combination between two antibacterial drugs, there are four possible effects: 
 indifference (when the combination of antibacterial products promotes equal effects to 
these of the most active product);  
 additive effect (when the combination of antibacterial products is equal to that of the sum 
of the effects of the individual products);  
 synergy (when the combination of antibacterials exceeds the sum of the effects of the 
individual products);  
 antagonism (when the combination of antibacterial products promotes a reduced effect 
compared to the effect of the most efficient individual product) (Simões et al., 2009).  
Additive and synergistic effects may be experimentally characterized and quantified. Negative 
interactions (interferences) occur when certain components of the mixture inhibit full biological 
activity of pharmacologically-active compounds by reducing their stability or bioavailability or 
by enhancing their metabolism (Lila and Raskin, 2005).  
Generally, for checkerboard, if the two combined compounds are antibacterial, in order to 
assess the effect of any given antimicrobial combination, the fractional inhibitory concentration 
(FIC) index is usually determined. FIC index FICI = FIC(A) + FIC(B), where FIC(A) is the ratio 
between the MIC of drug A in combination and the MIC of drug A alone and FIC(B) is the ratio 
of the MIC of drug B in combination and the MIC of drug B alone (Sopirala et al., 2010). Synergy 
has generally been defined as requiring a 4-fold reduction in the MIC of both antimicrobial in 
combination, compared with each used alone, i.e. a FICI of 0.5 (Odds, 2003). For detecting 
antagonism, the > 4 rule have been widely accepted (Mackay et al., 2000; Rand et al., 1996). The 
definition of indifference or additivity has been debated for a long time and cannot always be 
distinguished.  
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For Etest, if the MIC of antibiotic is reduced by > 3-fold, the result is considered synergic; an 
increase ≥ 3-fold of the MIC is usually classified as antagonistic (Sopirala et al., 2010). Otherwise, 
FICI can also be determined as previously explained. 
For time-kill assays, a ≥ 2-log10 decrease and a ≥ 2-log10 increase in CFU ml-1 between the 
combination and its most active constituent at the designated sample time, is considered synergy 
and antagonism, respectively (Eliopoulos and Eliopoulos, 1988). Additivity/indifference is 
usually defined as any scenario not meeting the criteria for either synergy or antagonism. 
This classification derived by each method may be confusing since there are several definitions 
to what constitutes synergy and numerous experimental techniques for synergy detection 
(Lambert et al., 2003). For example, it is not surprising that with two different methods such as 
checkerboard and time-kill assay, results might vary as these techniques measure two different 
endpoints: inhibition of grow and killing (Bonapace et al., 2002). As the test results vary widely 
under different test conditions, the procedures have to be standardized for intra- and inter-
laboratory reproducibility.  
A new approach was established for interactions between compounds that have no 
antimicrobial activity but that can potentiate antimicrobials. Positive interactions that intensify 
the potency of a bioactive product are generally called potentiation. This approach is based on 
some synergistic definitions applied for combinations involving two antimicrobials using 
checkerboard (Mackay et al., 2000; Rand et al., 1996), Etest (Cantón et al., 2005; Lewis et al., 
2002; Sopirala et al., 2010), and time-kill assay (Eliopoulos and Eliopoulos, 1988; NCCLS/ CLSI, 
1999). In order to propose a classification scheme for the interactions obtained with disk-diffusion 
method, simple linear regressions were performed in order to define linear functions correlating 
the data from checkerboard and Etest (MIC fold reductions) to the IZDs obtained with the disk-
diffusion method (FIGURE 3.5). The Etest and checkerboard variables were linearized by 
logarithmic conversions. The population (n) used for this correlation included the combinations 
between the antibiotics with the phytochemicals tested, five alkaloids and five flavonoids (380 
combinations in total). The strength of the linear association between pairs of variables was 
determined by coefficients of determination (R-square). According to Nicodemo et al. (2004), a 
strong correlation was found between Etest and disk-diffusion method (R-square = 73.5%; P < 
0.05; n = 240) and between checkerboard and disk-diffusion method (R-square = 71.4%, P < 0.05; 
n = 380).  
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FIGURE 3.5 | Correlation between the disk-diffusion method results (IZD combination – 
IZD most active agent) and the MIC reductions given by checkerboard (A, C) and by 
Etest (B, D). Representations B and D allow to visualize a box between the lower 
quartile (e.g. the median of the first half of the data corresponding to the inferior limit 
of box) and the upper quartile (e.g. the median of the second half of the data 
corresponding to the superior limit of the box), the median of the data (represented by 
the line inside the box) and the data average (represented by a cross). Error lines show 
the lowest and highest values of the data. Data comprises 380 combinations between 
five antibiotics (ciprofloxacin, tetracycline, erythromycin, oxacillin and ampicillin) 
and the phytochemicals (five alkaloids – caffeine, pyrrolidine, quinine, reserpine, 
theophylline, - and five flavonoids – (+)-catechin, hesperidin, morin, quercetin, rutin). 
For Etest, the β-lactam antibiotics were not included.  
 
This analysis is valid for the antibiotics used in this study, where only ciprofloxacin, 
erythromycin and tetracycline were potentiated by the phytochemicals (4-8 times reduction). 
However, by using other antibiotics, results can differ. 
According to these correlations, TABLE 3.6 shows the scheme proposed for disk diffusion 
method to classify an interaction between the antibiotic and one adjuvant as negative, indifferent, 
additive or potentiation. For checkerboard, when the MIC of the phytochemical alone is not 
A 
B 
C 
D 
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detected in the range of tested concentrations, the double of the highest concentration tested for 
MIC determination can be used for FICI determination and if FICI value was ≤ 0.5 this interaction 
was determined to be potentiation (Sopirala et al., 2010).  
 
TABLE 3.6 | Characterization of the effect promoted by a phytochemical in the activity 
of one antibacterial agent. Indifferent effect is considered between the limits proposed 
for additive and negative interactions 
Interaction Checkerboard Etest Disk-diffusion Time-kill assay 
Potentiation MICa reduction > 
4-fold dilutions 
MICa reduction > 
3-fold dilutions 
(IZDa+p – IZDa) ≥ 
6 mm 
≥ 2 log10 decrease in 
CFU of the antibiotic 
Additive MICa reduction ≥ 
2-fold and < 4-
fold dilutions 
MICa reduction ≥ 
2-fold and < 3-
fold dilutions 
4 ≤ (IZDa+p – 
IZDa) < 6 mm 
log10 decrease ≥ 1 
and < 2 in CFU of 
the antibiotic 
Negative MICa increase > 
4-fold dilutions 
MICa increase   
3-fold dilutions 
(IZDa – IZDa+p) ≥ 
6 mm 
≥ 2-log10 increase in 
CFU of the antibiotic 
 
The classification of each combination was compared between methods. Agreement between 
methods was defined as all methods having the same interpretative category, minor disagreement 
as only one method displaying disagreement results and major disagreement was defined when 
two or more methods displayed disagreement results. 
 
 Statistical analysis 
For statistical analysis, the in vitro results were analysed by Student’s t test using the statistical 
program SPSS (Statistical Package for the Social Sciences) version 19.0 (IBM Corp., Armonk, 
NY, USA). Statistical calculations were based on a confidence level ≥ 95% (P < 0.05) which was 
considered statistically significant. Relatively to the simple linear regressions performed 
correlating the checkerboard and Etest data to the disk-diffusion results, the validation of these 
linear models was carried out by F-test. All P values reported were two-tailed and values lower 
than 0.05 were considered significant.  
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  Task 2. Combinatorial approaches with selected phytochemicals to increase 
antibiotic efficacy against Staphylococcus aureus biofilms 
 
Small description. Selected phytochemicals shown to potentiate antibiotics against planktonic S. 
aureus cells were tested on the prevention and control of S. aureus biofilms. 
The phytochemicals were also studied for their ability to avoid antibiotic 
adaptation and to inhibit NorA efflux pumps (by measuring EtBr 
accumulation) in SA1199B. Additionally, cytotoxicity of phytochemicals on 
lung fibroblast cell lines was assessed. 
Bacterial strains. S. aureus SA1199B, RN4220, XU212 and CECT 976. Information of 
bacterial strains can be found in Section 3.1.4. 
Antibiotics. 
 
Ciprofloxacin, erythromycin and tetracycline. Preparation and specificities of 
the antibiotics are described in Section 3.1.5. 
Phytochemicals. Morin, pyrrolidine, quercetin, quinine and reserpine. Preparation and 
specificities of the phytochemicals are described in Section 3.1.6. FIGURE 
3.1 and TABLE 3.3 show the chemical structures of the alkaloids and 
flavonoids tested, respectively. 
 
 
 Biofilm formation, prevention and control 
The MIC of antibiotics and phytochemicals were determined against planktonic cells 
according to CLSI (2015a) guidelines in the previous Section 3.2.1.2. Antibiotics were applied at 
MIC, 10 × MIC and 50 × MIC against biofilms. The phytochemicals were found to have no 
antimicrobial activity for the concentrations tested (up to 1500 mg l-1). Consequently, the 
concentrations applied correspond to the optimal concentrations previously found to potentiate 
the antibiotics against the tested bacteria in planktonic state: 100 mg l-1 for reserpine and quinine 
and 500 mg l-1 for pyrrolidine, quercetin and morin. 
Antibiotics and phytochemicals were tested individually and in combination in order to assess 
their ability to control biofilms and prevent their formation. Two exposure times were tested for 
the control of established biofilms (1 and 24 h). Overnight cultures adjusted to a cell density of 
106 cells ml-1 were added to sterile 96-well polystyrene microtiter plates (Orange Scientific, 
Braine-l'Alleud, Belgium) to form biofilms during 24 h at 37ºC and 150 rpm. Afterwards, the 
medium was removed and the biofilms were exposed to the antibiotics, phytochemicals and their 
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combinations (at 5% v v-1 of the well for a final volume of 200 µl), for 1 h at 37ºC and 150 rpm. 
The same protocol was performed for an exposure time of 24 h.  
In order to assess the combinations towards the prevention of biofilm formation, overnight cell 
suspensions were added to microtiter plates along with antibiotics, phytochemicals and their 
combinations (at 5 % v v-1 of the well). The plates were incubated for 24 h at 37ºC and 150 rpm. 
After incubation, biofilms were scraped and diluted in saline solution (0.85% NaCl). The numbers 
of CFU per unit of adhesion area (CFU cm-2) were assessed in MH agar for both biofilm control 
and prevention experiments.  
A phytochemical-antibiotic synergy assay was performed according to Monzón et al. (2001). 
The combination was considered synergic when the log10 reduction CFU cm-2 caused by the 
combination was significantly higher (P < 0.05) than the sum of reductions of individual 
treatments, and antagonistic when the log10 reduction in CFU cm-2 of the combination was 
significantly lower (P < 0.05) than that obtained with the more active compound. 
 
 Antibiotic adaptation assay 
The most promising phytochemical-antibiotic synergy results on biofilms were obtained with 
S. aureus SA1199B. Therefore, this strain was selected for an antibiotic adaptation assay aiming 
to understand if the phytochemicals were effective in reversing bacterial resistance or avoiding 
the development of resistance due to prolonged exposure. The antibiotic adaptation assay was 
performed with S. aureus SA1199B growing with increasing sub-inhibitory concentrations of 
ciprofloxacin for 15 days, according to FIGURE 3.6.  
 
FIGURE 3.6 | Administration of ciprofloxacin (CIP) with phytochemicals during 15 days 
to Staphylococcus aureus SA1199B to assess bacterial adaptation to this antibiotic. 
Bacterial cultures incubated with sub-inhibitory doses of ciprofloxacin increasing 
every 3 days (from 1/32 × MIC to 1/2 × MIC) for a total of 15 days. Bacterial 
susceptibility to ciprofloxacin was determined in the end of each cycle by disk 
diffusion method (CLSI, 2015b).  
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S. aureus SA1199B was grown overnight in MH broth at 37 °C, adjusted to a cell density of 
106 CFU ml-1 and incubated with ciprofloxacin at 1/32 × MIC (4 mg l-1, phase 1) for 24 h (37ºC 
and 150 rpm agitation) in the presence of each phytochemical. After 24 hours, the bacterium was 
refreshed: centrifugation was performed at 3999 g for 10 min, the supernatant discarded, the pellet 
was washed twice and resuspended in MH broth with the same concentrations of antibiotic and 
phytochemical. This procedure was repeated after 48 hours. In the 3rd day, after washing the 
cultures, the concentration of the antibiotic was increased to 1/16 × MIC (8 mg l-1, phase 2), and 
consecutively, for a total of 15 days, until a final concentration of 1/2 × MIC. The concentration 
of each phytochemical was maintained along the assay. Controls were performed in the absence 
of phytochemicals or ciprofloxacin and with DMSO (5% v v-1). Bacterial samples were taken 
every 3 days, washed as previously described and susceptibility profiles of bacterial populations 
to ciprofloxacin were evaluated by the disk diffusion method according to CLSI (2015b) 
guidelines. The final population grown in the presence of only ciprofloxacin [named SA1199B(r)] 
was recovered after the 15 days, washed and stocks were prepared for further experiments to 
assess efflux pump inhibition with EtBr. Triplicates of each combination were performed. 
 
 Disk diffusion method 
Bacterial cultures obtained from adaptation experiment were prepared as described in Section 
3.2.1.5 and seeded over hardened drug-free MH agar Petri dishes using a sterilized cotton swab. 
A volume of 10 µl of ciprofloxacin prepared according to CLSI (2015b) guidelines (ciprofloxacin 
– 5 μg disk-1) was added to the blank disks. Disks with 10 µl of DMSO were used as negative 
control. After incubation each IZD was recorded and antibiotic susceptibility was analysed 
according to CLSI (2015b) guidelines. 
 
 Ethidium bromide accumulation assay by fluorometry 
Ethidium bromide is a substrate for many efflux systems in various MDR microorganisms, 
including S. aureus (Jin et al., 2011), and has been shown to be a particularly suitable probe for 
these studies, since it emits weak fluorescence in aqueous solution (external to the cell) and 
becomes strongly fluorescent when it binds to cellular components (Paixão et al., 2009). EtBr 
accumulation assay was performed in order to assess the putative action of phytochemicals as 
NorA inhibitors. First, the MIC of EtBr (prepared in a stock of 10 g l-1) was determined according 
to CLSI (2015a) guidelines as described in Section 3.2.1.2. The detection of EtBr accumulation 
in S. aureus strains was performed using a fluorometric method according to Rodrigues et al. 
(2013) and Jin et al. (2011). Briefly, bacteria were grown in MH broth at 37°C until mid-log phase 
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(OD600 of 0.6 to 0.7). Bacterial suspensions were centrifuged at 3999 g for 10 min, the supernatant 
was discarded, the pellet was washed in phosphate buffered saline (PBS; pH 7.4), and bacterial 
suspension were adjusted to 108 CFU ml-1 with PBS. Aliquots of 100 µl of bacterial suspensions 
were transferred to wells of a 96-well plate containing serial dilutions of EtBr at concentrations 
ranging from 80 to 0.06 mg l-1. In order to assess the effect of phytochemicals on EtBr 
accumulation, EtBr at ½ MIC (to not compromise the bacterial viability) was applied in the 
absence or presence of each phytochemical: reserpine and quinine at 100 mg l-1; pyrrolidine, 
quercetin and morin at 500 mg l-1. The negative control was performed with DMSO (5% v v-1). 
Also, controls for each phytochemical with EtBr in PBS were performed in order to detect 
possible fluorescence emitted by the products themselves. Fluorescence was acquired every 1 min 
for 60 min at 37°C in a microplate reader (Spectramax M2e) using 530 nm and 590 nm as 
excitation and detection wavelengths, respectively. 
 
 Cytotoxicity tests 
The cytotoxicity of some phytochemicals was evaluated according to ISO/EN 10993 (part 5) 
guidelines with some modifications (ISO, 1992). L929 cells (ATCC CCL 1), derived from an 
immortalized mouse lung fibroblast cell line and routinely used in in vitro cytotoxicity 
assessments, were used. Cells were grown in 175 cm2 culture flasks using Dulbecco’s modified 
eagle medium (DMEM, Sigma-Aldrich, Sintra, Portugal) supplemented with 1% of 
penicillin/streptomycin solution (Sigma-Aldrich, Portugal) and 10% of foetal bovine serum (FBS, 
Biochrom, São Mamede de Infesta, Portugal). The flasks were incubated at 37°C for 72 h in a 
95% air 5% CO2 atmosphere with 100% humidity. Twenty-four hours before the cytotoxicity tests 
starts, cells were trypsinised, seeded in 96-well microtiter plates at a concentration of 1 × 104 cells 
per well and left to adhere at 37°C in a 95% air 5% CO2 atmosphere with 100% humidity. Then, 
the medium in each well was replaced by 200 µl of fresh DMEM with the phytochemicals at 
several concentrations (chosen according to the antimicrobial assays). The phytochemicals did 
not exceed 2% v v-1 of the well final volume. The positive control was performed by adding fresh 
medium without any phytochemical and the negative control by adding DMSO at 2% v v-1. Each 
condition was performed in 5 wells and in triplicate. The plates were incubated for 72 h, at 37°C, 
in a 95% air 5% CO2 atmosphere with 100% humidity. Then, the cell viability was assessed by 
using the Cell Titer 96® One solution Cell Proliferation Assay Kit (Promega, Wisconsin, USA). 
This assay involves the bioreduction of the substrate, (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxyl-methoxy-phenyl)-2(4-sulfophenyl)-2H tetrazolium) (MTS) into a brown formazan 
product by NADPH or NADP produced by dehydrogenase enzymes in metabolically active cells 
(Baran et al., 2004). After incubation, the medium with phytochemicals was removed and 
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replaced by 200 µl of a mixture of DMEM without FBS and MTS (1:5 ratio) and incubated at the 
same conditions for 3 h. The OD490 of each well was measured using a plate reader (Molecular 
Devices, USA). From the dose-response curves obtained, the half maximal inhibitory 
concentration (IC50) values were calculated by probit analysis according to Sebaugh (2011).  
 
 Statistical Analysis 
The results were analysed by Student’s t test using SPSS version 19.0. Statistical calculations 
were based on a confidence level ≥ 95% (P < 0.05) which was considered statistically significant. 
All P values reported were two-tailed.  
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  Task 3. Reexamining plants with a new look into their defense systems: the 
search for antibiotic adjuvants to promote effective treatment of drug-
resistant Staphylococcus aureus 
 
Small description. The current study was designed to assess 29 selected plants from different 
families, some of them with traditional use, for their antibacterial activity, and 
also as adjuvants in antibiotic therapy, against S. aureus, including MRSA. 
Plants have been long scrutinized in the quest for new antibiotics, but no 
strong antibiotic molecule was ever found. It is believed that most 
phytochemicals have a regulatory, adjuvant or potentiating effect of other 
antibacterial compounds, thus promoting an overall greater effect, which can 
have a pronounced effect when applied in clinical therapies. 
Bacterial strains. S. aureus SA1199B, RN4220, XU212, CECT 976, and the MRSA strain 
MJMC001. Information of bacterial strains can be found in Section 3.1.4. 
Antibiotics.  
 
Ampicillin, ciprofloxacin, erythromycin, oxacillin and tetracycline. 
Preparation and specificities of the antibiotics are described in Section 3.1.5. 
Plant material.  
 
Twenty-nine Portuguese medicinal, invasive and fruit plant species were 
mostly collected from the region of Trás-os-Montes and Beira Transmontana 
(Portugal) and characterized by Botanical Garden from Vila Real (Portugal). 
TABLE 3.5 described the plants tested in this study. Relevant information 
about the preparation of the plants can be found in Section 3.1.7. 
 
 
 Extraction of selected plants 
The plant materials (5 g) were freeze-dried and extracted with 50 ml of MeOH at 30ºC, stirring 
at 150 rpm for 60 min. The samples were filtrated and re-extracted with 50 ml MeOH for more 
60 min. The resulting extracts were combined and the solvent was evaporated at low temperature 
(< 40ºC) under reduced pressure. The dried MeOH extracts were prepared in DMSO for 
antibacterial testing.  
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 Antibacterial susceptibility testing  
Before testing, the dried MeOH extracts were prepared in DMSO. The MIC of each plant 
extract was determined by microdilution technique according to CLSI (2015a) guidelines, as 
described in Section 3.2.1.2. Plant extracts did not exceed 5% v v-1 of the well. Three independent 
experiments were performed for each plant extract. 
 
 Antibiotic-potentiation testing by disk diffusion method 
Plant extracts showing no MIC below 4 g l-1 were tested for an antibiotic-potentiating activity 
by disk diffusion method according to CLSI (2015b) guidelines. Samples were applied at several 
concentrations (between 0.125 to 4 g l-1), in order to define the minimal/optimal concentration 
causing antibiotic potentiation. Each extract prepared in DMSO was added to MH agar (after 
autoclaved and cooled) yielding the final concentration desired as described in Section 3.1.8. The 
test was performed as described in Section 3.2.1.5. Disks impregnated with plant extracts at the 
tested concentrations were also applied on simple MH agar plates in order to ensure lack of 
bacterial growth inhibition. The antibiotic-potentiating activity of each plant extract was 
categorized into four classes as explained in TABLE 3.6 in Section 3.2.1.7. 
 
 Statistical analysis 
For statistical analysis, the in vitro results were analysed by Student’s t test using the statistical 
program SPSS version 19.0. Statistical calculations were based on a confidence level ≥ 95% (P < 
0.05) which was considered statistically significant.  
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  Task 4. The potential of Cytisus striatus for antibiotic-potentiating activity: 
isolation and identification of antibiotic adjuvants from this plant 
 
Small description. Disabling resistance mechanisms may restore the activity of old-generation 
antibiotics. With this possibility in mind, it was aimed to identify the active 
potentiating compounds of Cytisus striatus using 1H NMR-based metabolomics. 
This approach, which combines the use of a powerful analytical platform for data 
collection with multivariate data analysis of the information thus collected can 
allow the identification of metabolites that may be involved in synergic activities, 
a major challenge in the discovery of potential drugs derived from natural 
products. Further investigation concerning the activity of the isolated metabolites 
on planktonic and biofilm cells and characterization of their mode of action was 
performed. 
Bacterial strains. S. aureus RWW337, M116, RWW50, M82, RN6390, CECT 976 and SA1199B. 
Information of bacterial strains can be found in Section 3.1.4. 
Antibiotics. Ciprofloxacin and erythromycin. Preparation and specificities of the antibiotics 
are described in Section 3.1.5. 
Phytochemicals. Apigenin, chrysin and luteolin, daidzein and genistein. Preparation and 
specificities of the phytochemicals are described in Section 3.1.6. TABLES 3.3 
and 3.4 show the chemical structures of the flavonoids and isoflavonoids tested, 
respectively. Reserpine (Sigma-Aldrich, Sintra, Portugal), a recognized EPI 
(Gibbons and Udo, 2000; Schmitz et al., 1998), was used as positive control in 
EtBr accumulation assays and prepared in the same way. 
Plant material. Cytisus striatus (Hill) Rothm. (leaves, flowers and twigs). Relevant information 
about the preparation of this plant can be found in Section 3.1.7. 
 
 
 Preparation of plant samples and extracts  
To study the activity of C. striatus leaves, flowers and twigs, 5 g of each of these plant 
materials were extracted with 50 ml of MeOH at 30ºC, stirring at 150 rpm for 60 min. After 
filtration, the extracts were taken to dryness and redissolved in 10 ml methanol (MeOH). This 
extract was partitioned with n-hexane (3 × 10 ml) to eliminate lipophilic compounds. The 
remaining methanolic phase was evaporated using a rotary evaporator and redissolved in 
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H2O/MeOH (95:5). The resulting solution was extracted with 3 × 10 ml portions of ethyl acetate 
(EtOAc) and the extracts were combined and evaporated with a rotary evaporator. These extracts 
were analysed by 1H NMR and tested for both antibacterial and antibiotic-potentiating activities. 
The hexane and remnant H2O/MeOH fractions were also tested in order to ensure that no 
compound of interest had remained in these extracts.  
A multi-extraction strategy was performed for multivariate data analysis. Different 
combinations of C. striatus leaves or flowers with twigs were prepared in order to generate 
metabolic variation. Thus, C. striatus samples were prepared by mixing different percentages of 
leaves or flowers in the twig [0, 25, 50, 70, 85, 100% (wleaf or flower/ wtwig)]. Approximately 1 g of 
each sample was extracted using different conditions of pressure and temperature with a E-916 
speed extractor (Büchi, Flawil, Switzerland). The tested conditions were: temperature (30 or 
90ºC), pressure (50 or 100 bar), solvent (50, 75 and 100% aqueous MeOH). For all conditions, 
the extraction was performed using two 4-minute cycles with a flow of 3 ml of solvent min-1. 
Samples were labelled using a binary numbering system (x,y), where x specifies the extraction 
conditions and y the sample composition (TABLE 3.7). In total, 54 different samples were 
extracted and dried in vacuum (Syncore, Büchi).  
 
TABLE 3.7 | Strategy and conditions used for the multi-extraction of Cytisus striatus.  
Six extractions of different Cytisus striatus samples were performed each time, by 
mixing different percentages of twig in leaves or flowers for 1 g total sample. Nine 
runs were performed with variation of temperature (30 or 90ºC), pressure (50 or 
100 bar) and % MeOH (50-, 75- and 100% in water). Identification of the samples 
was performed by numbering them as (x, y), where x specifies the condition of the 
extraction and y the sample composition 
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y - Sample composition (% (w/w) twig in leaf/flower) 
 MeOH 
(%) 
T 
(ºC) 
P 
(bar) 
 0 % 15% 30 % 50 % 75 % 100 % 
 1 2 3 4 5 6 
1 100 30 50 
L
ea
f 
(1,1) (1,2) (1,3) (1,4) (1,5) (1,6) 
2 90 100 (2,1) (2,2) (2,3) (2,4) (2,5) (2,6) 
3 75 30 50 (3,1) (3,2) (3,3) (3,4) (3,5) (3,6) 
4 90 100 (4,1) (4,2) (4,3) (4,4) (4,5) (4,6) 
5 50 30 50 (5,1) (5,2) (5,3) (5,4) (5,5) (5,6) 
6 90 100 (6,1) (6,2) (6,3) (6,4) (6,5) (6,6) 
7 100 30 50 
F
lo
w
er
 (7,1) (7,2) (7,3) (7,4) (7,5) (7,6) 
8 75 30 50 (8,1) (8,2) (8,3) (8,4) (8,5) (8,6) 
9 50 30 50 (9,1) (9,2) (9,3) (9,4) (9,5) (9,6) 
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All the samples were redissolved in 10 mL methanol and submitted to the fractionation scheme 
described previously. The EtOAc fractions were taken to dryness with a rotary evaporator, 
analysed by 1H NMR and tested for both antibacterial and antibiotic-potentiating activities.  
 
 Antibacterial susceptibility testing 
The MIC was determined by microdilution techniques according to CLSI (2015a) guidelines 
as described in Section 3.2.1.2. The highest concentration of DMSO remaining after dilution 
(5% v v-1) caused no inhibition of bacterial growth. At least three independent experiments were 
performed. 
 
 Antibiotic-potentiation testing by checkerboard 
The checkerboard assay was performed according to CLSI (2015a) guidelines as described in 
Section 3.2.1.3. The antibacterial compounds yielded final concentrations ranging from 2 × MIC 
to 1/64 × MIC. Compounds with no detectable antibacterial activity were tested at several 
concentrations between 120 and 0.06 mg l-1. Drug combinations did not exceed 5% v v-1 of the 
well (200 µl). Antibiotic–phytochemical interactions were classified using the FICI as described 
in TABLE 3.6 in Section 3.2.1.7. When the MIC of the phytochemical alone was not detected in 
the range of tested concentrations, the double of the highest concentration tested was used for 
FICI determination and if FICI value was ≤ 0.5 this interaction was determined to be a potentiation 
(Sopirala et al., 2010). 
 
 Antibiotic-potentiation testing by disk diffusion method 
This method was performed as described in Section 3.2.1.5. The antibiotic-potentiating 
activity C. striatus extracts was categorized according to TABLE 3.6 in Section 3.2.1.7.  
 
 NMR analysis 
Each dried sample was mixed with 500 μl of CD3OD, vortexed for 10 s, sonicated for 20 min 
at 42 kHz, and then centrifuged at 13000 rpm at room temperature for 5 min. The supernatant 
(300 μl) was transferred to a 3 mm micro-NMR tube and analysed. 1H NMR spectra were recorded 
at 25°C on a 600 MHz Bruker DMX-600 spectrometer (Bruker, Karlsruhe, Germany) operating 
at a proton Larmor frequency of 600.13 MHz. Methanol-d4 was used as the internal lock. 1H NMR 
experimental parameters were the following: 128 scans requiring 10 min and 26 s acquisition 
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time, 0.16 Hz point-1, pulse width (PW) = 30° (11.3 μs), and relaxation delay (RD) = 1.5 s. FIDs 
were Fourier transformed with LB = 0.3 Hz. The resulting spectra were manually phased and 
baseline corrected, and calibrated to CD3OD4 at 3.3 ppm, using TOPSPIN 3.2 software (Bruker 
BioSpin GmbH, Rheinstetten, Germany). 2D-NMR techniques (J-resolved, 1H-1H COSY, 1H-13C 
HMBC, and 1H-13C HSQC), were performed when necessary as previously described (Ali et al., 
2012; Kim et al., 2010b).  
 
 Isolation of the bioactive compounds 
NMR-guided isolation was used to isolate the bioactive compounds from C. striatus leaves for 
their identification. For this, 55 g of leaves were extracted with 500 ml of MeOH and fractionated 
with EtOAc as described before. The resulting dry EtOAc fraction (1.2 g) was subjected to 
medium pressure liquid chromatography (MPLC). The sample was introduced as solid using a 
pre-Elut column connected just before the main separation column (200 × 35 mm, i.d, Sepacore® 
Silica 80g, Buchi, Switzerland). Elution was performed using a gradient of chloroform (A) and 
methanol (B) (B:10 %, 15 min; B:10-30%, 5 min; B: 30%, 20 min; B: 30-50%, 5 min; B:50%, 10 
min) at a flow-rate of 20 ml min-1. The eluant was monitored at 220, 254, 280 and 365 nm. Sixty 
fractions were collected and combined in 6 fractions according to Thin Layer Chromatography 
(TLC) profile similarities. The TLC was performed on silica gel TLC plates (Merck, Darmstadt, 
Germany) with CHCl3: MeOH: acetic acid (7.5:2.5:0.2). These six fractions were prepared for 1H 
NMR analysis and for their antibacterial-potentiating analysis as described previously. One of the 
fractions (A3) proved to be active according to the disk diffusion method. This fraction (270 mg) 
was separated on a Sephadex column with methanol at a flow of 3.5 ml min-1 and monitored at 
220, 254, 280, 365 nm. Sixty sub-fractions were collected and combined into 6 fractions (B1-B6) 
according to their TLC profile similarities. These were analysed by 1H NMR analysis and tested 
for their antibacterial-potentiating capacity. Of all these sub-fractions (B), two (B5 and B6) 
showed activity: B5 proved to have an antibiotic-potentiating activity with both ciprofloxacin and 
erythromycin and B6 had antibacterial activity against S. aureus strains. The fraction B5 (13.5 
mg) was purified by semi-preparative reverse-phase high performance liquid chromatography 
(RP-HPLC) (Luna C18 column; 250 × 10 mm, i.d., 5 μm, Phenomex®) and eluted with a gradient 
of solvent (A) 1% aqueous acetic acid and (B) methanol (B:1-42%, 30 minutes; B: t 42-100%, 10 
minutes; B:100%, 2 minutes). The detector was set at 270 nm. Six main fractions were obtained 
and analysed by 1H NMR analysis for the identification of metabolites, and 2D-NMR techniques 
were used when necessary. The B6 fraction (8.3 mg) contained only one compound that was 
identified as luteolin. 
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 EtBr accumulation assay by fluorometry 
The effect of the compounds isolated from C. striatus on EtBr accumulation in S. aureus 
SA1199B and also in MRSA strains was evaluated seeking for efflux pump inhibition. This assay 
was performed as previously explained in Section 3.2.2.4. The MIC of EtBr (prepared in a stock 
of 10 g l-1) was determined for each strain according to CLSI (2015a) guidelines and described in 
Section 3.2.1.2. Reserpine (20 mg l-1) was used as a positive control as it is a recognized EPI 
(Holler et al., 2012). To be able to compare the EtBr accumulation experiments, the relative 
fluorescence (RF) was determined for each assay by applying the equation: RFassay = (MFIassay – 
FIcontrol)/ FIcontrol, where MFIassay was the Maximal Fluorescence Intensity obtained in each 60 min 
assay and FIcontrol was the correspondent Fluorescence Intensity obtained with the DMSO control 
at the same time. High RF values indicated that cells accumulated more EtBr under the tested 
conditions than the control and vice-versa for negative values. The experiments were repeated 
three times, and the RF values presented are the averages of three independent assays. 
 
 Biofilm control assay 
Biofilms of S. aureus CECT 976, a control strain usually assessed for biofilm assays (Borges 
et al., 2012; Saavedra et al., 2010), and SA1199B were developed according to the modified 
microtiter plate test as described in Section 3.2.2.1. Overnight cultures (1 × 108 cells ml-1) were 
added to sterile 96-well polystyrene microtiter plates to form biofilms during 24 h at 37ºC and 
150 rpm. Afterwards, the medium was removed and the biofilms were exposed to the compounds 
isolated from C. striatus (60 g l-1), for 1 h at 37ºC and 150 rpm. Ciprofloxacin and erythromycin 
at MIC were tested as well. The same protocol was repeated for an exposure time of 24 h. After 
incubation, biofilms were washed twice with saline solution (0.85% NaCl), scrapped and diluted 
for CFU counting. The number of CFU cm-2 was assessed on MH agar. The results are also 
presented as CFU reduction (%) from the DMSO control (5% v v-1).  
 
 Data analysis and statistics 
The NMR spectra were bucketed using AMIX 3.9.12 (Bruker BioSpin GmbH, Rheinstetten, 
Germany). Buckets were obtained by integrating 0.04 ppm intervals and scaling the intensity of 
individual peaks to the total intensity recorded in the region δ 0.2– 10.02 ppm. The regions of δ 
4.85–4.95 and δ 3.2–3.4 were excluded from the analysis because of the residual signal of D2O 
and CD3OD, respectively. To correlate metabolites detected in the 1H NMR spectra with the 
bioactivity, OPLS was applied to the data using Y-variable of potentiating activity (IZDs), 
allowing the removal of spectral X-variables unrelated to the sample classes chosen and filtration 
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of the biomarkers from the biological varieties. OPLS based on Pareto scaling were performed 
with the SIMCA-P + software (v. 12.0, Umetrics, Umeå, Sweden). The outliers were not 
considered. The metabolites contributing to the separation were analysed by an S-plot of the 
OPLS modeling. For antibacterial-potentiating, EtBr and biofilm assays means and standard 
deviations were calculated and means comparisons were made with Student’s t-test (two-tailed 
based on a confidence level < 0.05).
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  Task 5. Evaluation of the structure-activity relationship of isoflavonoids as 
antibiotic adjuvants in clinical therapy 
 
Small description. Isoflavonoids isolated from Cytisus striatus were previously found to have 
interesting antibiotic-potentiating activities. For SAR evaluation purposes, 22 
isoflavonoids were assessed as antibiotic adjuvants. The effect of the 
isoflavonoids in NorA inhibition was also assessed by fluorometry and flow 
cytometry. The possible inhibition of Erm methyltransferases was tested. 
Biofilm eradication activity of isoflavonoids was evaluated within exposure 
periods of 1 and 24 hours. 
Bacterial strains. S. aureus RWW337, M116, RWW50, M82, RN6390, CECT 976, SA1199B 
and RN4220. Information of bacterial strains can be found in Section 3.1.4. 
Antibiotics. Ciprofloxacin and erythromycin. Preparation and specificities of the 
antibiotics are described in Section 3.1.5. Erythromycin (15-μg) and 
clindamycin (2-μg) commercial disks were obtained from Oxoid (Hampshire, 
United Kingdom). 
Phytochemicals Biochanin A, calycosin, calycosin-7-O-β-D-glucoside, corylifol A, daidzein, 
daidzin, formonenetin, genistein, genistin, glycitein, glycitin, 3’-
hydroxypuerarin, iridin, irigenin, irisflorentin, 3’-methoxypuerarin, 
neobavaisoflavone, ononin, orobol, puerarin, tectoridin and tectorigenin. 
Preparation and specificities of the isoflavonoids are described in Section 
3.1.6. TABLE 3.4 shows the chemical structures of the tested compounds. 
Reserpine (Sigma-Aldrich, Sintra, Portugal), a recognized EPI (Gibbons and 
Udo, 2000; Schmitz et al., 1998), was used as positive control in EtBr 
accumulation assays and prepared in the same way.  
 
 Antibacterial susceptibility testing 
The MIC of each isoflavonoid was determined by microdilution technique according to CLSI 
(2015a) guidelines described in Section 3.2.1.2. The highest concentration of DMSO remaining 
after dilution (5% v v-1) caused no inhibition of bacterial growth. At least three independent 
experiments were performed. 
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 Antibiotic-potentiation testing by checkerboard 
This method was performed for combinations between antibiotics and isoflavonoids as 
previously described in Section 3.2.4.3. Antibiotic–isoflavonoid interactions were classified using 
the FICI system as described in TABLE 3.6 in Section 3.2.1.7. When the MIC of the 
phytochemical alone was not detected in the range of tested concentrations, the double of the 
highest concentration tested was used for FICI determination and if FICI value was ≤ 0.5 this 
interaction was determined to be a potentiation (Sopirala et al., 2010). 
 
 Antibiotic-potentiation testing by disk diffusion method 
This method was performed as described in Section 3.2.1.5. The antibiotic-potentiating 
activity of isoflavonoids was categorized according to TABLE 3.6 in Section 3.2.1.7.  
 
 EtBr accumulation assay by fluorometry 
This assay was performed as previously explained in Section 3.2.2.4. To be able to compare 
the EtBr accumulation experiments, RF values were calculated as described previously in Section 
3.2.4.7. The experiments were repeated three times, and the RF values presented are the averages 
of three independent assays. 
 
 EtBr accumulation assay by flow cytometry 
Flow cytometry facilitates the analysis of cells in suspension as they pass through a beam of 
light at a high rate in a fluid stream. Data acquisition and analysis were performed using a BD 
Accuri™ C6 Flow Cytometer (Breda, The Netherlands) equipped with three fluorescence 
detectors: FL1 (515 to 565 nm), FL2 (565 to 605 nm), and FL3 (> 605 nm). Absorption maximum 
for EtBr is 518 nm and the fluorescence emission maximum is 605 nm. Preparation of S. aureus 
SA1199B was performed as described in the fluorometric method (Section 3.2.2.4) and bacterial 
cultures were distributed in aliquots of 100 µl. EtBr was added at ½ MIC and the isoflavonoids 
were added at the best concentration defined with the fluorometric method. Positive controls were 
performed with 20 mg l-1 reserpine and negative controls with 1% (v v-1) DMSO. Following 
incubation at 25°C for 60 minutes, the supernatant was removed and the pellet resuspended in 
EtBr-free PBS, adjusting the OD600 to 0.3. Samples were taken for fluorescence measurement in 
the BD Accuri™ C6 Flow Cytometer. Data was collected for at least 10,000 events per sample. 
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 Biofilm control assay 
Biofilms were developed according to the modified microtiter plate test as described in Section 
3.2.2.1. The exposure of isoflavonoids at 60 mg l-1, except orobol that was tested at 30 mg l-1 on 
biofilms for 1 and 24 h was performed as previously described in Section 4.4.7. The number of 
CFU cm-2 was assessed on MH agar and the results are presented as CFU reduction (%) from the 
DMSO control (5% v v-1).  
 
 D-test to detect inducible macrolide antibiotic resistance 
A major form of resistance to the macrolide-lincosamide-streptogramin type B (MLSB) 
antibiotics in pathogenic bacteria results from a base-specific methylation of bacterial 23S 
ribosomal RNA near or within the macrolide binding site (Gaynor and Mankin, 2003). As a result, 
the MLS antibiotics lose their ability to bind to the ribosome and no longer exhibit antibacterial 
activity. RNA methylation occurs through the action of the Erm (erythromycin-resistance 
methylase) family of methyltransferases (Hajduk et al., 1999). Three resistance phenotypes have 
been detected to these antibiotics: strains containing cMLSB (constitutive MLSB) and iMLSB 
(inducible MLSB), which are resistant to macrolide, lincosamide and streptogramin B antibiotics, 
and MS, which is only resistant to macrolide and streptogramin B antibiotics. Inducible resistance 
is obtained following exposure to a macrolide and can be detected by induction tests such as the 
D-test using erythromycin and clindamycin disks (Fiebelkorn et al., 2003). Despite macrolide 
antibiotic resistance in S. aureus is usually due to ribosomal target modification, active efflux 
mechanism encoded by msrA can also occur. This method was performed as described by 
Fiebelkorn et al. (2003). The bacterial suspensions were adjusted to 0.5 McFarland standards and 
seeded over hardened MH agar Petri dishes using a sterilized cotton swab and allowed to set (for 
10 to 15 min). MH agar plates prepared with each isoflavonoid yielding the final concentration 
desired were also prepared, according to Section 3.1.8. Control plates had no isoflavonoids 
incorporated. Erythromycin (15 μg disk-1) and clindamycin (2 μg disk-1) commercial disks were 
placed in adjacent positions (15 or 20 mm). After 24 h, the plates were read and analysed 
according to FIGURE 3.7. The flattening of the clindamycin zone adjacent to the erythromycin 
disk indicates inducible MLSB resistance. The characterization of the strains for their 
susceptibility profiles in D-test was performed according to CLSI (2015b) guidelines.  
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Phenotype 
Inferred 
genotype 
 
 
MS phenotype 
 Erythromycin R 
 Clindamycin S 
(with circular zone 
of inhibition) 
 
msrA 
cMLSB phenotype 
 Erythromycin R 
 Clindamycin R 
(with circular zone 
of inhibition if any) 
 
 
erm 
iMLSB phenotype 
 Erythromycin R 
 Clindamycin S 
(D-shaped zone of 
inhibition) 
erm 
 
FIGURE 3.7 | Detecting staphylococci resistance to macrolides and lincosamides by D-test.  
Disks containing erythromycin (15 μg) and clindamycin (2 μg) are placed 15 to 20 mm 
apart on an agar plate that has been inoculated with the clinical isolate. In the top 
scheme, the lack of a zone of inhibition around the erythromycin disk indicates bacterial 
resistance to macrolides (e.g. perhaps due to MsrA efflux pump); the large clear zone 
of inhibition around the clindamycin disk indicates sensitivity to clindamycin; the 
medium scheme indicates constitutive resistance to both erythromycin and 
clindamycin; the bottom scheme depicts a positive D-test: diffusion of erythromycin 
from the disk towards the clindamycin disk does not kill bacteria due to Staphylococcus 
aureus resistance to macrolides; however, S. aureus contains an erythromycin-inducible 
methylase (iMLSB) that is encoded by a plasmid-borne gene (erm) and when this 
methylase is induced it alters the binding site on the 23S subunit of the 50S ribosome 
that both erythromycin and clindamycin bind to, making both antibiotics ineffective 
(inducing resistance). Resistance phenotypes were identified on the basis of 
erythromycin- and clindamycin-susceptibility tests and on the basis of clinical 
implications (CLSI, 2015b; Leclercq, 2002; Prabhu et al., 2011; Woods, 2009). MSB, 
macrolides and streptogramins B; R, resistant; S, susceptible. 
 
  
Erythromycin 
Clindamycin 
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 Statistical analysis 
For statistical analysis, the in vitro results were analysed by Student’s t test using the statistical 
program SPSS version 19.0. Statistical calculations were based on a confidence level ≥ 95% (P < 
0.05) which was considered statistically significant.  
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  Task 6. The potential of Buxus sempervirens for antibiotic-potentiating 
activity: isolation and identification of antibiotic adjuvants from this plant 
 
Small description. Buxus sempervirens was chosen for its promising antibiotic-potentiating 
activity and evaluated for its ability to control (remove and inactivate) biofilms 
of S. aureus CECT 976 within 1 h of exposure. Further phytochemical 
investigation of B. sempervirens was performed. One possible candidate, 
betulinic acid, along with five similar triterpenoids, were assessed for their 
antibacterial activity, synergic interaction with the antibiotics by checkerboard 
technique and, additionally, were also applied against S. aureus biofilms. 
Bacterial strains. S. aureus CECT 976. Information on this strain can be found in Section 3.1.4. 
Antibiotics.  
 
Ampicillin, ciprofloxacin, erythromycin and tetracycline. Preparation and 
specificities of the antibiotics are described in Section 3.1.5. 
Phytochemicals. Betulinic acid, lupeol, betulin, hederagenin, ursolic acid and oleanolic acid. 
Preparation and specificities of the triterpenoids are described in Section 3.1.6.  
Plant material. Buxus sempervirens L. for. grandiflora (F. Muell.) P. Cout. (leaves). Relevant 
information about the preparation of this plant can be found in Section 3.1.7. 
 
 
 Biofilm control assay 
Biofilms control experiment was developed as described in Section 3.2.2.1. Overnight cultures 
(~106 cells ml-1) were added to sterile 96-well polystyrene microtiter plates to form biofilms at 
37ºC and stirring at 150 rpm for 24 h. Afterwards, the medium was removed and the biofilms 
were exposed to the antibiotics and to the plant extract individually and in combination at 37ºC 
and stirring at 150 rpm for 1 h. Antibiotic solutions were applied at MIC and 50 × MIC against 
biofilms. The MeOH extract of B. sempervirens was applied at concentrations ranging from 0.05 
to 5 g l-1. Drug combinations did not exceed 5% v v-1 of the well (200 µl). After incubation, 
biofilms were washed twice with saline solution (0.85% NaCl), scraped and diluted for CFU 
counting. The numbers of CFU per unit of adhesion area (CFU cm-2) were assessed in MH agar. 
Reduction (%) of the number of CFU cm-2 (compared with DMSO growth control) was also 
assessed. 
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 Fractionation of active extract of Buxus sempervirens 
Buxus sempervirens leaves (160 g) were extracted with 500 ml of MeOH following the process 
described previously (Section 3.2.3.1). The MeOH extract was taken to dryness and redissolved 
in 225 ml of H2O/MeOH (4:1) and successively partitioned with 3 × 112.5 ml of dichloromethane 
(CHCl2) and buthanol (n-BuOH), respectively. All the fractions were analysed by 1H NMR and 
tested for both antibacterial and antibiotic-potentiating activities. Afterwards, the n-BuOH 
fraction (1.2 g) was further submitted to phytochemical investigation. The n-BuOH fraction was 
subjected to medium pressure liquid chromatography (MPLC, Sepacore, Büchi, Switzerland) in 
a silica gel column (80 g, 200 × 35 mm, i.d, Büchi), eluted with a gradient of CHCl3 (A): MeOH 
+ HOAc 2% (B) as follow: 10% B for 15 min; linear increase 10-30% B in 5 min; isocratic elution 
using 30% B for 20 min; linear increase 30-50% B in 5 min, and finally 50% B for 10 min. The 
flow rate was 20 ml min-1 and the analysis was monitored by UV spectrometer at 220, 254, 280 
and 365 nm. Collection was performed by volume where each fraction contained 20 ml, totalizing 
53 fractions. The fractions were analysed by analytical TLC and combined into 8 subfractions. 
TLC was performed using silica gel TLC plates (Merck, Darmstadt, Germany) with 
CHCl3:MeOH:HOAc (7.5:2.5:0.2). These eight fractions were analysed by 1H NMR and for their 
antibacterial-potentiating activity. 
 
 NMR analysis  
Five hundred microliters of CD3OD were added to dried samples, and the resultant mixtures 
were vortexed for 10 s and sonicated for 20 min at 42 kHz, followed by centrifugation at 3999 g 
at room temperature for 5 min. Three hundred microliters of the supernatant were transferred to 
a 3 mm micro-NMR tube and analysed. 1H NMR spectra were recorded at 25 °C on a 600 MHz 
Bruker DMX-600 spectrometer (Bruker, Karlsruhe, Germany) operating at a proton frequency of 
600.13 MHz. MeOD-d4 was used as the internal lock. 1H NMR experimental parameters were 
described in Section 3.2.4.5. The resulting spectra were manually phased and baseline corrected, 
and calibrated to residual CD3OD at 3.3 ppm, using TOPSPIN 3.2 software (Bruker BioSpin 
GmbH, Rheinstetten, Germany).  
 
 Antibacterial susceptibility testing  
The MIC of the tested compounds was determined by microdilution techniques according to 
CLSI (2015a) guidelines as described in Section 3.2.1.2. The highest concentration of DMSO 
remaining after dilution (5% v v-1) caused no inhibition of bacterial growth. At least three 
independent experiments were performed. 
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 Antibiotic-potentiation testing by checkerboard  
The checkerboard assay was performed according to CLSI (2015a) guidelines as described in 
Section 3.2.1.3 between the phytochemical tested (which had a detectable MIC) and antibiotics. 
Both antibacterial compounds to be combined yielded final concentrations ranging from 2 × MIC 
to 1/64 × MIC. Drug combinations did not exceed 5% v v-1 of the well (200 µl). Antibiotic–
phytochemical interactions were classified using the FICI as described in TABLE 3.6 at 
Section 3.2.1.7. 
 
 Statistical analysis 
For statistical analysis, the in vitro results were analysed by Student’s t test using the statistical 
program SPSS version 19.0. Statistical calculations were based on a confidence level ≥ 95% (P < 
0.05), which was considered statistically significant.  
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4. RESULTS AND DISCUSSION 
 
 
 
 
n this section, all the results obtained within this thesis are described, 
analysed and discussed. Comparison with other important studies and 
results from relevant bibliographic sources is performed and the novelty of the 
results obtained is emphasised. A brief conclusion of each task is presented, 
highlighting the main results obtained and suggestions for future work. 
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 TASK 1. EVALUATION OF THE BEST METHOD TO ASSESS ANTIBIOTIC 
POTENTIATION BY PHYTOCHEMICALS AGAINST STAPHYLOCOCCUS 
AUREUS 
 
Abstract 
Selected plant alkaloids and flavonoids were combined with five antibiotics against 
ten S. aureus strains, including those expressing distinct efflux pumps and MRSA. 
The efficacy of each combination was assessed using the microdilution checkerboard, 
time-kill, Etest and disk diffusion methods. The methods were optimized for detecting 
antibiotic-potentiation and the results compared. Reserpine, pyrrolidine, quinine, 
morin and quercetin were highlighted as antibiotic potentiators. Disk-diffusion and 
checkerboard methods were considered the best methods to detect antibiotic-
potentiation. 
 
 
  Characterization of S. aureus strains regarding their resistance profile 
The classifications of the S. aureus strains according to their antibiotic resistance profile were 
done based on the comparison of the MICs/IZDs results and the susceptibility breakpoints of 
CLSI (2015a; 2015b) (TABLE 4.1). Discrepancies between the categorizations were considered 
insignificant when an isolate found intermediate by one method was susceptible according to 
another, and no distinction was made in these cases. For S. aureus SA1199B, RN4220 and 
XU212, only ciprofloxacin, erythromycin and tetracycline were tested, respectively. Also, Etest 
was only done for the antibiotics which achieved good combinatorial results on the checkerboard 
and disk-diffusion method: ciprofloxacin, tetracycline and erythromycin.  
The agreement between the MICs obtained by checkerboard and Etest (within ± 1-log2 
dilutions) was 75% for tetracycline, 88% for erythromycin and only 38% for ciprofloxacin. 
According to the classifications presented by Reynolds et al. (2003), there was good agreement 
for erythromycin and poor agreements for tetracycline and ciprofloxacin. The discrepancy results 
were caused by broth MICs higher than Etest MICs. So, these results demonstrate an apparent 
increased sensitivity of the agar testing method over the microdilution assay. In the majority of 
studies, the agreement between the MICs of these two methods varies since these test systems 
measure different interactions between an antimicrobial agent and a microorganism (Mayrhofer 
et al., 2008; Serrano et al., 2003; Szekely et al., 1999; van der Heijden et al., 2007). Therefore, it 
is expected that there will be some minor differences between the systems (Rennie et al., 2012). 
CHAPTER 4. RESULTS AND DISCUSSION 2016 
 
 
104 
TABLE 4.1 | Minimal inhibitory concentration (MIC, for checkerboard and Etest) and 
inhibition zone diameter (IZD, for disk-diffusion method) of antibiotics against 
Staphylococcus aureus. Strains were classified as susceptible (S), intermediate (I) 
or resistant (R) to antibiotics according to CLSI (2015b) 
S. aureus Antibiotic 
Checkerboard 
MIC (mg l-1) 
Etest MIC 
(mg l-1) 
IZD (mm) Classif. 
CECT 976 CIP 1 0.064 33.3 ± 0.6 S 
TET 0.96 0.38 23.7 ± 0.6 S 
ERY 0.24 0.19 26.3 ± 0.6 S 
AMP 1.5 NP 36.0 ± 1.0 S 
OXA 0.48 NP 39.7 ± 0.6 S 
SA1199B CIP 128 4 13.0 ± 0.0 R 
XU212 TET 128 32 9.3 ± 0.6 R 
RN4220 ERY 256 256 NI R 
MRSA MJMC001 CIP 256 >32 NI R 
TET 0.5 0.38 26.0 ± 0.0 S 
ERY 96 96 12.5 ± 0.6 R 
AMP 64 NP NI R 
OXA 128 NP NI R 
MRSA MJMC002 CIP 256 >32 NI R 
TET 0.5 0.38 26.0 ± 0.0 S 
ERY 96 96 12.0 ± 0.0 R 
AMP 64 NP NI R 
OXA 128 NP NI R 
MRSA MJMC004 CIP 256 >32 NI R 
TET 0.5 0.38 27.0 ± 1.0 S 
ERY 96 96 12.0 ± 0.0 R 
AMP 64 NP NI R 
OXA 15.6 NP NI R 
MSSA MJMC003 CIP 0.5 0.19 36.0 ± 0.0 S 
TET 2 0.38 35.0 ± 1.0 S 
ERY 0.5 0.19 32.3 ± 0.6 S-I* 
AMP 25 NP 10.0 ± 1.0 R 
OXA 1 NP 23.3 ± 0.6 S 
MSSA MJMC009 CIP 1 0.19 36.3 ± 0.6 S 
TET 0.5 0.25 35.0 ± 0.0 S 
ERY 2 2 32.0 ± 0.0 S-I* 
AMP 10 Np 10.0 ± 0.0 R 
OXA 1 NP 23.7 ± 0.6 S 
MSSA MJMC010 CIP 1 0.19 37.0 ± 1.0 S 
TET 0.5 0.38 37.0 ± 0.0 S 
ERY 0.5 0.25 32.0 ± 0.0 S 
AMP 10 NP 10.0 ± 0.0 R 
OXA 1 NP 23.7 ± 0.6 S 
*Discordance between methods; NI, no inhibition; NP, not performed; AMP: ampicillin; OXA: 
oxacillin; CIP: ciprofloxacin; TET: tetracycline; ERY: erythromycin; Time-kill assays were performed 
only for S. aureus SA1199B, RN4220 and XU212; Etest was only directed for CIP, TET and ERY. 
Data are means and SD from at least three independent experiments.  
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According to the analysis of MICs and IZDs by the susceptibility breakpoints of CLSI (2015a) 
guidelines, the MRSA strains were classified as resistant to ampicillin, oxacillin, erythromycin 
and ciprofloxacin and only susceptible to tetracycline. MSSA strains were classified as 
susceptible to all antibiotics, with exception of ampicillin. Broth test, Etest and disk-diffusion 
method showed 95% agreement on these classifications. 
 
  Antibacterial and antibiotic-potentiating activity of alkaloids 
Alkaloids are heterocyclic nitrogen compounds (Cowan, 1999). There is an excellent rationale 
that plant alkaloids should possess antibacterial activity, particularly given the number of 
cytotoxic drugs and templates from this source (Gibbons, 2004).  
All alkaloids were assessed for antibacterial activity using the broth microdilution technique. 
Only quinine had antibacterial activity, with a MIC of 500 mg l-1 against S. aureus CECT 976. 
For the other strains, no MIC was detected for quinine up to 1500 mg l-1. The other alkaloids had 
no activity against the strains tested for the same concentrations. Reserpine added to the MH broth 
generated a precipitate, perhaps because of its low solubility in water, causing a blank turbidity, 
which complicated the detection of its MIC. Therefore, colony counts in MH agar were performed 
in order to evaluate the growth of the bacteria with the increasing concentrations of reserpine. No 
growth reduction was verified. No IZD was obtained when each alkaloid was applied alone to the 
disks at 1500 mg l-1.  
As previously mentioned, for detecting RMAs or antibiotic coadjuvants, it is expected to 
observe a high inactivation of resistant bacteria when the combination of antibiotic/plant 
compound is applied and only minor or no antibacterial activity of the phytochemical. TABLE 
4.2 presents the results of the combinations of antibiotics and alkaloids obtained by checkerboard, 
Etest, disk-diffusion method and time-kill assay. Etest was only directed for CIP, TET and ERY 
which achieved good combinatorial results on the checkerboard and disk-diffusion method. Time-
kill assay was only performed for the strains with known efflux pumps (S. aureus SA1199B, 
XU212, RN4220) to compare the results obtained with the other methods. Only the combinations 
that resulted in a significant modification in comparison to antibiotics alone in, at least, one 
method, have been presented. No increase in the MICs of the antibiotics was obtained in the 
presence of alkaloids (P > 0.05). The IZD of each combination was never smaller than that 
produced by each drug alone (P > 0.05).  
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TABLE 4.2 | Minimal inhibitory concentrations (MIC)-fold reductions (by checkerboard 
and Etest), inhibition zone diameters (IZDs) increases (by disk-diffusion) and log10 
CFU reductions (by time-kill assay) for the combination of antibiotics with alkaloids.  
Classification of the interaction as potentiation (P), additive (A) or indifferent (I) is 
made. Total agreement (T) was obtained when all methods give the same 
classification to the interaction, and minor (m) or major (M) disagreements if one or 
more than one method, respectively, are in disagreement 
S. aureus Antib. Alk. 
Checker-
board 
Etest 
Disk 
diffusion 
Time-
kill 
Final 
classif.* 
CECT 976 ERY PYR 4.0 (P) 4.0 (P) 6.7 (P) NP P (T) 
AMP RES NC (I) NC (I) 9.7 (P) NP I (m) 
QUIN NC (I) NC (I) 6.0 (P) NP I (m) 
SA1199B CIP RES 2.0 (A) 2.0 (A) 5.0 (A) 0.2 (I) A (T) 
PYR 2.0 (A) 2.0 (A) 4.3 (A) 2.4 (P) A (T) 
  QUIN 1.3 (I) 8.0 (P) 12.0 (P) 1.3 (A) P (m) 
XU212 TET RES 4.0 (P) 3.0 (P) 4.0 (A) 2.8 (P) P (m) 
QUIN 1.3 (I) 2.0 (A) 1.7 (I) 2.0 (P) I (T) 
RN4220 ERY PYR 4.0 (P) 8.0 (P) 8.7 (P) 0.4 (I) P (T) 
MJMC001 TET QUIN 2.0 (A) 2.0 (A) 4.7 (A) NP A (T) 
MJMC002 TET RES 2.0 (A) 2.0 (A) NC (I) NP A (m) 
QUIN 2.0 (A) 2.0 (A) NC (I) NP A (m) 
MJMC003 CIP RES 2.0 (A) 2.0 (A) 4.0 (A) NP A (T) 
PYR 2.0 (A) 2.0 (A) NC (I) NP A (m) 
QUIN 2.0 (A) 2.0 (A) NC (I) NP A (m) 
TET PYR 2.0 (I) NC (I) 6.0 (P) NP I (m) 
QUIN 2.0 (A) 2.0 (A) NC (I) NP A (m) 
ERY RES 2.0 (A) 2.0 (A) NC (I) NP A (m) 
PYR 4.0 (P) 4.0 (P) 12.0 (P) NP P (T) 
QUIN 2.0 (I) NC (I) NC (I) NP I (T) 
AMP RES 7.0 (P) NP NC (I) NP ? 
MJMC009 CIP RES 2.0 (A) 2.0 (A) 8.7 (P) NP A (m) 
PYR 8.0 (P) 2.0 (A) 8.0 (P) NP P (m) 
QUIN 4.0 (P) 2.0 (A) 10.0 (P) NP P (m) 
TET RES 8.0 (P) NC (I) 5.0 (A) NP ? (M) 
PYR 2.0 (A) NC (I) 5.0 (A) NP A (m) 
QUIN 8.0 (P) NC (I) 5.0 (A) NP ? (M) 
ERY RES NC (I) 2.0 (A) 9.0 (P) NP ? (M) 
PYR 2.0 (A) 4.0 (P) 8.3 (P) NP P (m) 
QUIN 2.0 (A) NC (I) 5.0 (A) NP A (m) 
AMP RES 7.0 (P) NP NC (I) NP ? 
PYR 14.0 (P) NP NC (I) NP ? 
QUIN 7.0 (P) NP NC (I) NP ? 
MJMC010 CIP RES 8.0 (P) 4.0 (P) 6.0 (P) NP P (T) 
PYR 4.0 (P) 3.0 (P) 6.0 (P) NP P (T) 
TET RES 8.0 (P) 6.0 (P) NC (I) NP P (m) 
QUIN 8.0 (P) 1.5 (I) NC (I) NP I (m) 
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ERY RES NC (I) 2.0 (A) 9.0 (P) NP ? (M) 
PYR 2.0 (A) 4.0 (P) NC (I) NP ? (M) 
QUIN 2.0 (A) 4.0 (P) 4.0 (A) NP A (m) 
NP, not performed; NC, no change; (?) contradictory results. CAF: caffeine; RES: reserpine; PYR: pyrrolidine; 
THEO: theophylline; QUIN: quinine; AMP: ampicillin; OXA: oxacillin; CIP: ciprofloxacin; TET: tetracycline; 
ERY: erythromycin. Only the combinations that were significantly different from the antibiotic control in, at least, 
one method are presented. Additive interactions were distinguished from indifference when two or more methods 
indicated that same categorical result. Time-kill assays were performed for S. aureus SA1199B, RN4220 and 
XU212; Etest was directed for CIP, TET and ERY. *Final classification considers the results of checkerboard, Etest 
and disk diffusion method. Data are means and SD from at least three independent experiments.  
 
FIGURE 4.1 shows the resume of time-kill assay after 24 h of cell incubation with the 
combination of antibiotics with the alkaloids. The log10 CFU increase or decrease obtained for 
each combination over the single activity of the antibiotic alone can be visualised. 
 
 
 
FIGURE 4.1 | Time-kill assay after 24 h incubation of Staphylococcus aureus SA1199B 
(A), XU212 (B) and RN4220 (C) with the alkaloids combined with ciprofloxacin (CIP), 
tetracycline (TET) and erythromycin (ERY), respectively. Bars with (*) are statistically 
different from the antibiotic controls (P < 0.05).  
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No CFU reduction was observed with the alkaloids alone for the concentrations tested (P > 
0.05, data not shown). The effect of the combination between pyrrolidine and ciprofloxacin (½ 
MIC) against S. aureus SA1199B caused 2.4 log10 decrease in CFU ml-1 (with an initial inoculum 
of 6.5 ± 0.53 log10 CFU ml-1 to undetectable levels) after 24 h of incubation when compared with 
ciprofloxacin alone. Also, the combination between quinine and ciprofloxacin (½ MIC) caused a 
1.3 log10 decrease in CFU ml-1 after the same time over antibiotic activity alone. Tetracycline at 
½ MIC combined with reserpine and quinine against S. aureus XU212 achieved log10 reduction 
of 2.8 and 2.0 in CFU ml-1, respectively, comparing with that promoted by tetracycline alone. No 
effect was observed with the combination of alkaloids and erythromycin against S. aureus 
RN4220 (P > 0.05).  
Results from each test were classified based on the interpretation of an interaction as 
negative/indifferent/additive/potentiation and compared between each other (TABLE 4.2). 
Indifference was most common among all three methods, being found in 157 of 190 combinations 
(82.6%), considering the cases showing agreement or minor disagreement. Additive interactions 
were found in 14 of 190 combinations (7.4%). Potentiating activities were found in 11 of 190 
combinations (5.8%), also considering both the total agreement and minor disagreement cases. 
No negative interactions were detected. Relevant potentiation or additive interactions were 
observed with: 
 reserpine (100 mg l-1) when combined with ciprofloxacin against SA1199B, MSSA strains 
(3/3), and with tetracycline against XU212, one MSSA strain (1/3) and one MRSA strain 
(1/3);  
 pyrrolidine (500 mg l-1) when combined with erythromycin against strains CECT 976, 
RN4220, and MSSA strains (2/3), and with ciprofloxacin against MSSA strains (3/3) and 
SA1199B;  
 quinine (100 mg l-1) when combined with ciprofloxacin against SA1199B and two MSSA 
strain (2/3).  
No effect was observed with the combination between β-lactams and alkaloids. Also, caffeine 
and theophylline did not potentiate any antibiotic against any strain. 
 
  Antibacterial and antibiotic-potentiating activity of flavonoids 
Flavonoids are hydroxylated phenolics commonly found in leaves, fruits and flowers. The 
existence, number, position and degree of substitution of hydroxyl or methyl groups on the 
benzene ring provide much of the structural variation found in flavonoids (Bohm, 1998) and they 
consequently have a diverse range of pharmacological properties, including anti-inflammatory, 
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oestrogenic, anti-allergic, antifungal, antimicrobial and antioxidant (Cowan, 1999; Harborne and 
Williams, 2000; Martini et al., 2004). Importantly, several flavonoids were found to potentiate 
some antibiotics due to a possible activity as inhibitors of MDR mechanisms, such as efflux 
pumps (Musumeci et al., 2003). Quercetin, rutin, hesperidin and (+)-catechin were reported to 
have a synergistic activity when combined with oxacillin against VISA (Basri et al., 2008). It was 
aimed to evaluate if these compounds were able to potentiate other antibiotics against other S. 
aureus resistant strains. Morin, an isomer of quercetin, was also included in the tests.  
No MIC was detected for any flavonoid for concentrations lower than 1500 mg l-1. Also, no 
IZD was obtained with the flavonoids for the same amount of compound (22.5 μg disk-1).  
TABLE 4.3 presents the results of the combinations of antibiotics and flavonoids obtained by 
checkerboard, Etest, disk-diffusion method and time-kill assay. Only the combinations that 
resulted in a significant modification in comparison with antibiotics alone in, at least, one method 
have been presented.  
 
TABLE 4.3 | Minimal inhibitory concentrations (MIC)-fold reductions (by checkerboard 
and Etest), inhibition zone diameters (IZDs) increases (by disk-diffusion) and log10 
CFU reductions (by time-kill test) for the combination of antibiotics with flavonoids.  
Classification of the interaction as potentiation (P), additive (A) or indifferent (I) is 
made. Total agreement (T) is obtained when all methods give the same classification 
to the interaction; minor disagreement (m) if one method is in disagreement 
S. aureus Antib. Flav. 
Checker-
board 
Etest 
Disk 
diffusion 
Time-
kill 
Final 
classif.* 
CECT 976 CIP MOR 2.0 (A) NC (I) 4.4 (A) NP A (m) 
QUERC 4.0 (P) 3.0 (P) 20.0 (P) NP P (T) 
TET MOR 4.0 (P) 4.0 (P) 9.3 (P) NP P (T) 
QUERC 4.0 (P) 12.0 (P) 24.0 (P) NP P (T) 
RUT NC (I) 3.0 (P) 7.0 (P) NP P (m) 
ERY MOR 2.0 (I) NC (I) 6.4 (P) NP I (m) 
QUERC 4.0 (P) 2.0 (I) 14.0 (P) NP P (m) 
AMP MOR 1.5 (I) NP 9.7 (P) NP - 
SA1199B CIP MOR NC (I) 3.0 (P) 13.7 (P) -1.6 (I) P (m) 
QUERC 4.0 (P) 3.0 (P) 18.9 (P) -1.2 (I) P (T) 
XU212 TET MOR NC (I) NC (I) NC (I) 1.2 (I) I (T) 
QUERC NC (I) NC (I) NC (I) 2.3 (P) I (T) 
MJMC001 TET MOR 4.0 (P) 3.0 (P) 6.0 (P) NP P (T) 
QUERC 8.0 (P) 8.0 (P) 6.1 (P) NP P (T) 
MJMC002 TET MOR 4.0 (P) 6.0 (P) 9.0 (P) NP P (T) 
QUERC 8.0 (P) 6.0 (P) 18.0 (P) NP P (T) 
RUT NC (I) NC (I) 8.3 (P) NP I (m) 
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MJMC003 CIP MOR 2.0 (I) 6.0 (P) 8.3 (P) NP P (m) 
QUERC 2.0 (I) NC (I) 15.0 (P) NP I (m) 
TET MOR 4.0 (P) 12.0 (P) 10.7 (P) NP P (T) 
QUERC 2.0 (A) 8.0 (P) 4.3 (A) NP A (m) 
ERY MOR 2.0 (A) 2.0 (A) 15.0 (P) NP A (m) 
QUERC NC (I) NC (I) 5.0 (I) NP I (T) 
MJMC004 TET MOR 4.0 (P) 4.0 (P) 9.0 (P) NP P (T) 
QUERC 8.0 (P) 8.0 (P) 6.0 (P) NP P (T) 
MJMC009 CIP MOR NC (I) 6.0 (P) 9.7 (P) NP P (m) 
QUERC NC (I) NC (I) 6.3 (P) NP I (m) 
TET MOR 8.0 (P) 8.0 (P) 6.0 (P) NP P (T) 
QUERC 4.0 (P) 3.0 (P) 11.7 (P) NP P (T) 
ERY MOR 2.0 (I) 16.0 (P) 18.1 (P) NP P (m) 
QUERC NC (I) 3.0 (P) 16.3 (P) NP P (m) 
MJMC010 CIP MOR 2.0 (I) 16.0 (P) 6.0 (P) NP P (m) 
TET MOR 8.0 (P) 8.0 (P) 10.3 (P) NP P (T) 
QUERC 2.0 (I) 8.0 (P) 6.0 (P) NP P (m) 
ERY MOR 2.0 (I) 3.0 (P) 10.1 (P) NP P (m) 
QUERC 2.0 (A) 2.0 (A) 13.0 (P) NP A (m) 
AMP QUERC NC (I) NP 3.2 (I) NP I (-) 
NP, not performed; NC, no change. MOR: morin; QUERC: quercetin; RUT: rutin; HESP: hesperidin; CAT: 
catechin; AMP: ampicillin; OXA: oxacillin; CIP: ciprofloxacin; TET: tetracycline; ERY: erythromycin. Only 
the combinations that were significantly different from the antibiotic control in, at least, one method are 
presented. An additive interaction was only distinguished from indifference when two or more methods 
indicated that same categorical result. Time-Kill assays were only performed for S. aureus SA1199B, RN4220 
and XU212; Etest was only directed for CIP, TET and ERY. *Final classification considers the results of 
checkerboard, Etest and disk diffusion method. Data are means and SD from at least three independent 
experiments.  
 
 
Checkerboard and Etest methods revealed MIC reductions of the antibiotics, especially in the 
presence of morin and quercetin at 500 mg l-1. No increase on the MIC was obtained for antibiotics 
with the addition of flavonoids, which proves there was no antagonism detected in the 
combinations. The same behavior was observed by disk-diffusion method, where the higher IZD 
increases were obtained especially with morin and quercetin. Also, the IZD of each combination 
was never smaller than that produced by each drug alone (P > 0.05). 
Time-kill assays were performed only for S. aureus SA1199B, RN4220 and XU212 since this 
method was done on combinations selected on the basis of their performance, assessed by the 
other three tests. FIGURE 4.2 presents the log10 CFU ml-1 results vs time for each combination. 
No CFU reduction was observed with the flavonoids alone for the concentrations tested 
comparing to the growth control (P > 0.05, data not shown).  
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FIGURE 4.2 | Time-kill assay after 24 h incubation of Staphylococcus aureus SA1199B 
(A), XU212 (B) and RN4220 (C) with flavonoids combined with ciprofloxacin (CIP), 
tetracycline (TET) and erythromycin (ERY), respectively. Bars with (*) are 
statistically different from the antibiotic controls (P < 0.05).  
 
Log10 CFU ml-1 increases were obtained for S. aureus SA1199B when ciprofloxacin (½ MIC) 
was combined with morin and quercetin (500 mg l-1), comparing with ciprofloxacin alone (1.6 
and 1.2 log10 increases of CFU ml-1, respectively). The other methods provided potentiating 
effects for these combinations (TABLE 4.3). For S. aureus XU212, tetracycline combined with 
morin and quercetin caused 1.8 and 1.7 log10 CFU ml-1 reduction, respectively, when compared 
with tetracycline (¼ MIC); and 1.2 and 2.6 log10 CFU ml-1 reduction, respectively, compared with 
tetracycline (½ MIC). However, indifferent results were obtained for these combinations with the 
other three methods (TABLE 4.3). For S. aureus RN4220, time-kill assay and the other methods 
provided indifferent results. 
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The combinations tested with the four methods were classified as potentiation, additive or 
indifferent as previously described (TABLE 4.3). No antagonistic effects were observed. 
Considering the total agreement and minor disagreement cases (for checkerboard, Etest and disk-
diffusion method), potentiation was found for 24 of 190 combinatorial cases (12.6%) and additive 
interactions only for 4 of 190 combinations (2.1%). The majority of the combinations (84.2%) 
were indifferent. Potentiation or an additive effect were obtained for the combination of: 
 Morin (500 mg l-1) with ciprofloxacin against SA1199B, MSSA strains (3/3) and CECT 976, 
tetracycline against CECT 976, MRSA (3/3) and MSSA strains (3/3), and erythromycin 
against MSSA (3/3);  
 Quercetin (500 mg l-1) with ciprofloxacin against CECT 976, SA1199B, and MSSA (1/3), 
tetracycline against CECT 976, MRSA (3/3) and MSSA (3/3) strains, and erythromycin 
against CECT 976 and MSSA (2/3);  
 Rutin (500 mg l-1) with tetracycline against CECT 976.  
No additive or potentiating effects were obtained with catechin or hesperidin. Furthermore, no 
flavonoid potentiated the activity of neither β-lactam (ampicillin and oxacillin).  
 
  Overall agreement between the methods 
As previously explained, total agreement between methods was defined as all methods having 
the same interpretative category, minor disagreement as only one method displaying disagreement 
results and major disagreement was defined when two or more methods display disagreement 
results. Time-kill assay results showed 66.7% of agreement when compared with the other 
methods for SA1199B, XU212, RN4220 (indeed, this method disagrees with the others in 5 out 
of the 6 cases showed in TABLE 4.2) for combinations with alkaloids. For combination with 
flavonoids, the agreement was higher (80%). However, time-kill assay usually failed to agree 
with the other methods for the most promising combinations (with morin and quercetin) against 
S. aureus SA1199B and XU212. Agreement between checkerboard, Etest and disk-diffusion 
method was obtained in 77.5% of combinatorial cases with alkaloids and 85% with flavonoids. 
So, considering the total population, agreement between these three methods was observed for 
195 of 240 cases (81%). Minor disagreements were obtained in 41 of 240 cases (17.0%) and major 
disagreements were found in only 5 of 240 combinations (2.1%) and only for combinations 
involving alkaloids. About 214 of 240 cases (89.2%) showed agreement between checkerboard 
and Etest, 338 of 380 cases (88.9%) between checkerboard and disk-diffusion method and 210 of 
240 cases (87.5%) demonstrated agreement between Etest and disk-diffusion method.  
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  Relevant remarks 
Regarding the alkaloids, despite the minimal antimicrobial activity observed, MIC reductions 
were obtained with reserpine, pyrrolidine or quinine combined with ciprofloxacin, tetracycline or 
erythromycin. Of all 190 combinations performed in this study, only 5.8% and 7.4% corresponded 
to potentiation and additive interactions, respectively, while the remaining were considered 
indifferent. No potentiating activity was obtained against MRSA strains; only additive effects 
were observed between tetracycline and quinine (against 2/3 MRSA strains) and reserpine 
(against 1/3 MRSA). MSSA strains and, less extensively, SA1199B, XU212 and RN4220 strains 
showed to be much more amenable to potentiation with the alkaloids than the MRSA strains. With 
the aim of finding new therapy options in mind, this is not the kind of result one would hope to 
see. The success of a potentiation may depend on the virulence, persistence and resistance profiles 
of the strains. 
Reserpine, originally extracted from Rauwolfia serpentina, was already studied by several 
authors due to its properties as EPI (Aeschlimann et al., 1999; Gibbons and Udo, 2000; Markham 
et al., 1999; Schmitz et al., 1998). In this work, this alkaloid showed a potentiating/additive 
activity when combined with tetracycline against XU212, one MRSA and one MSSA strains and 
with ciprofloxacin against SA1199B, one MRSA and two MSSA strains. In general, this fact 
supports previous studies (Gibbons et al., 2003a; Gibbons and Udo, 2000; Schmitz et al., 1998). 
Reserpine appears to be involved especially in the inhibition of NorA and also TetK efflux pumps 
but other efflux pumps may probably be implicated. While reserpine had effect on some S. aureus 
strains, for others no effect was observed. This can be associated to the fact that strains could vary 
in the extent to which reserpine is able to block NorA or TetK or, also, due to the varying rates of 
transcription or expression of the norA and tetK genes or differences in the stability of its mRNA 
(Schmitz et al., 1998).  
Pyrrolidine, found naturally in the leaves of tobacco and carrot, potentiated or had an additive 
effect on the activity of erythromycin against S. aureus RN4220, CECT 976 and one MSSA strain 
and of ciprofloxacin against all MSSA strains. This compound has never been studied for its 
synergistic activity.  
Quinine occurs naturally in the bark of Cinchona tree and it is a well-known compound with 
a long history of use due to their efficacy as an anti-malaria agent. Despite major toxicity concerns 
and adverse reactions among patients, quinine remains one of the most commonly used 
antimalarial for therapy (van Vuuren and Viljoen, 2011). Moreover, this alkaloid was reported 
for the inhibition of the invasive ability of some bacteria, namely staphylococci, which would 
protect the immunocompromised patients of being infected during the antimalarials treatment 
(Wolf et al., 2002; Wolf et al., 2006). In this study, quinine potentiated or had an additive effect 
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on ciprofloxacin against SA1199B and MSSA 3 and 9. Several additive combinations were also 
observed with quinine combined with tetracycline and erythromycin.  
Concerning the flavonoids, potentiating and additive interactions were found in 24 and 4 out 
of 190 combinatorial cases (12.6 and 2.1%), respectively, and mainly for combinations involving 
morin and quercetin. Both morin and quercetin increased the activity of ciprofloxacin and 
tetracycline against S. aureus CECT 976; of ciprofloxacin against SA1199B and of tetracycline 
against all MRSA and MSSA strains. Also, some potentiation/additive interactions were found 
with morin and quercetin combined with erythromycin. Rutin only caused potentiation when 
combined with tetracycline against S. aureus CECT 976. While some potentiating results were 
found on some S. aureus strains, for others this was not observed. 
 Quercetin is the most abundant flavonol found in the human diet (Duthie and Dobson, 1999). 
Morin is an isomer of quercetin and has also been found to possess antibacterial activity. Rutin is 
the glycosidic form of quercetin (Andlauer et al., 2001). Reports on the antibacterial activity of 
these flavonoids are conflicting, especially regarding their MICs, probably owing to inter and 
intra-assay variation in susceptibility testing or due to the difference in genetic variation of the 
strain (Basri et al., 2008; Cushnie and Lamb, 2005; Hirai et al., 2010; Rattanachaikunsopon and 
Phumkhachorn, 2010; Rauha et al., 2000). Quercetin (15 mg l-1) was found to exert antibacterial 
activity against S. aureus, including MRSA, and to potentiate the activity of erythromycin, 
oxacillin, ampicillin, vancomycin and gentamicin against MRSA (Hirai et al., 2010). Other 
investigation showed that 87.3% of the combinations between eight flavonoids (including 
catechin, hesperidin, quercetin and rutin) and oxacillin were synergistic against VISA (Basri et 
al., 2008). However, in this study, no synergy was obtained with oxacillin against the tested S. 
aureus strains. Eumkeb et al. (2010) also demonstrated that quercetin, galangin and baicalein 
exhibited the potential to reverse bacterial resistance to β-lactam antibiotics against penicillin-
resistant S. aureus (PRSA) apparently due to interaction with penicillinase, cytoplasmic 
membrane damage, inhibition of protein synthesis and changes on the PBP2a.  
Among flavonoid-antibiotic combinations, the only potentiation of an antibiotic against a 
strain resistant to that antibiotic was observed for SA1199B with the combination of morin or 
quercetin with ciprofloxacin. In the other combinations, potentiation occurred only with strains 
that were susceptible to the antibiotics. Therefore, with the exception of the first situation which 
may be due to efflux pump inhibition, these activities are in general probably not related to a 
resistance–modifying activity. In fact, several studies have examined the potential of quercetin to 
inhibit various bacterial enzymes, explaining why this molecule has such a diverse applicability 
(including anti-tumor therapy, neuroprotection, cardiovascular disease prophylaxis, 
inflammation, diabetes mellitus, infection, etc.) (Ferry et al., 1996; Guardia et al., 2001; Scambia 
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et al., 1994). However, it is clear that further research is necessary to understand morin/quercetin 
potentiation of ciprofloxacin, tetracycline and erythromycin. One of the proposed mechanisms of 
action of quercetin was the inhibition of gyrases through two different mechanisms based either 
on interaction with DNA or with ATP binding site of gyrase (Plaper et al., 2003). Since 
ciprofloxacin also functions by inhibiting DNA gyrase, the presence of a second compound with 
the same target could inhibit or potentiate its activity. In fact, in this study, it was found 
potentiation of ciprofloxacin by quercetin.  
In this study, four distinct methods were used to evaluate the potentiating activity of alkaloids 
and flavonoids when combined with common antibiotics. It is not new that experimentation on 
drug interactions can lead to opposite conclusions by different methodologies. The various tests 
used measure quite distinct effects of antibiotic interactions against bacteria and use different 
endpoints (inhibition or killing) and medium state (broth vs agar) (Bonapace et al., 2000; 
Eliopoulos and Eliopoulos, 1988; White et al., 1996). However, with this strategy, it was obtained 
an agreement of 81% between checkerboard, Etest and disk-diffusion method. Also, the 
agreements of 89.2% between checkerboard and Etest, 88.9% between checkerboard and disk-
diffusion method and 87.5% between Etest and disk-diffusion method were also very good. On 
the contrary, the agreement of time-kill assay with the other three methods was lower. In general, 
the agreements obtained in the literature are diverse (Bonapace et al., 2000; Cantón et al., 2005; 
Lewis et al., 2002; Martin, 2010; Orhan et al., 2005; White et al., 1996). However, a variety of 
investigators found disagreement between checkerboard and time-kill results (Cappelletty and 
Rybak, 1996; Chang et al., 2007; Visalli et al., 1988; White et al., 1996). 
Regarding the performance of all methods, Etest represents, apparently, the ideal testing 
methodology for the clinical microbiology laboratory since it is a simple and fast method with 
excellent reproducibility. However, it is somewhat expensive. Disk-diffusion method seems to be 
as an excellent strategy because it is also very easy to perform, has good agreement results with 
the others methods and it is much less expensive. In fact, agar methods showed to be suitable for 
tests with phytochemicals (and plant extracts). Due to their low solubility in broth medium, the 
phytochemicals may precipitate when added to the medium even at low concentrations. When 
one is performing checkerboard, this precipitation will difficult the reading of the endpoint (i.e., 
the complete inhibition of growth). The same does not happen in agar testing since the inhibition 
zones can be read anyway and bacterial growth visualised. However, checkerboard allows to test 
several concentrations and define minimal concentrations causing antibiotic potentiation. Time-
kill assay is very laborious if a high number of combinations are required, and the results are 
greatly influenced by differences on the inoculum size (White et al., 1996). Also, methods for the 
interpretation of kill-kinetic studies vary and synergy has been defined by some authors as at least 
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a 100-fold increase in killing at 24 h (Bonapace et al., 2000; Jung et al., 2004; Kiraz et al., 2009; 
Mayer and Nagy, 1999), while other authors consider a 200-fold increase (Guo et al., 2008; 
Leonard, 2012; Tan et al., 2011). 
Considering the advantages and disadvantages of each method, it can be considered that the 
diffusion method can be easily used to detect antibiotic potentiation promoted by phytochemicals 
or plant extracts, but confirmation of potentiation using checkerboard should be done (also to 
determine ideal concentrations for cotherapy). For combinations between two antibacterial 
compounds, checkerboard is the most preeminent method and synergy is defined taking into 
account FICI calculations.
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 TASK 2. COMBINATORIAL APPROACHES WITH SELECTED 
PHYTOCHEMICALS TO INCREASE ANTIBIOTIC EFFICACY AGAINST 
STAPHYLOCOCCUS AUREUS BIOFILMS 
 
Abstract 
Combinations of selected phytochemicals (reserpine, pyrrolidine, quinine, morin and 
quercetin) with antibiotics (ciprofloxacin, tetracycline and erythromycin) were tested 
on the prevention and control of S. aureus biofilms. The phytochemicals were also 
studied for their ability to avoid antibiotic adaptation and to inhibit antibiotic efflux 
pumps. Morin, pyrrolidine and quercetin at subinhibitory concentrations had 
significant effects in biofilm prevention and/or control when applied alone and 
combined with antibiotics. Synergy between antibiotics and phytochemicals was 
found especially against biofilms of NorA overexpressing strain S. aureus SA1199B. 
This strain growing with subinhibitory concentrations of ciprofloxacin developed 
increased tolerance to this antibiotic. However, this was successfully reversed by 
quinine and morin. Besides reserpine, quercetin also showed significant efflux pump 
inhibition. The overall results demonstrate the role of phytochemicals in co-therapies 
to promote more efficient treatments and decrease bacterial resistance to antibiotics. 
 
 
  Effect of phytochemicals for biofilm control within 1 and 24 h exposure 
Phytochemicals have been extensively studied as antibacterial products and, more recently, as 
potentiators/adjuvants of antibiotics (Markham et al., 1999). However, few data can be found on 
their effects against biofilms, even though most infections are biofilm-related. Biofilms are 
recognized for their insusceptibility to current therapeutic approaches (Römling and Balsalobre, 
2012; Smith, 2005). In biofilms, S. aureus expresses a different set of genes such as ica, bap 
and agr types, with an increased potential to induce and develop recurrent infections (Gogoi-
Tiwari et al., 2015). Therefore, new biofilm control strategies are required. 
The ability of phytochemicals and antibiotics to control 24 h-old biofilms formed in sterile 96-
well polystyrene microtiter plates within 1 and 24 h of exposure was evaluated. Antibiotics were 
first applied alone at MIC, 10 × MIC and 50 × MIC. As no significant differences (P > 0.05) in 
biofilm log10 CFU cm-2 reduction were obtained, the combinations were performed with 
antibiotics at MIC. FIGURE 4.3 presents the number of CFU cm-2 in the biofilm after the 
incubation with antibiotics at their MIC and phytochemicals individually for 1 h.  
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CECT 976 
(%) biofilm 
reduction 
 
SA1199B 
(%) biofilm 
reduction 
  
31.0 ± 0.5   
42.0 ± 0.5   
27.0 ± 0.9  54.0 ± 0.1 
45.0 ± 0.4  76.7 ± 1.5 
77.2 ± 0.5  85.4 ± 0.3 
25.0 ± 1.0  63.0 ± 1.0 
91.9 ± 0.5  93.6 ± 0.6 
40.0 ± 1.0  46.7 ± 0.6 
     
XU212 
(%) biofilm 
reduction 
 
RN4220 
(%) biofilm 
reduction 
 
 
 
44.3 ± 3.0  - 
63.9 ± 2.0  42.8 ± 1.0 
85.3 ± 1.0  93.2 ± 1.4 
41.9 ± 2.0  24.9 ± 1.7 
94.2 ± 0.1  99.3 ± 0.5 
60.8 ± 2.0  8.6 ± 1.5 
FIGURE 4.3 | CFU cm-2 of 24 h-old biofilms of Staphylococcus aureus strains that 
remained active after exposure to selected phytochemicals and antibiotics for 1 h.  
Strains SA1199B, XU212 and RN4220 were only exposed to the antibiotic they are 
resistant to: ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY), 
respectively. Antibiotics were applied at minimal inhibitory concentration (MIC); 
reserpine and quinine at 100 mg l-1; pyrrolidine, morin and quercetin at 500 mg l-1. 
(a) when statistically lower than GC (P < 0.05); (b) when statistically lower than 
GC and the antibiotics (P < 0.05). GC – growth control (5% v v-1 DMSO).  
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The number of CFU cm-2 of the biofilms after the incubation with antibiotics at their MIC and 
phytochemicals individually for 24 h is presented in FIGURE 4.4.  
CECT 976 
(%) biofilm 
reduction 
 
SA1199B 
(%) biofilm 
reduction 
 
 
 
57.0 ± 2.0   
49.2 ± 3.0   
39.4 ± 3.0  90.1 ± 1.1 
44.7 ± 4.0  - 
66.8 ± 0.1  - 
31.2 ± 3.0  - 
27.8 ± 2.0  - 
76.5 ± 0.5  - 
 
XU212 (%) biofilm 
reduction 
 
 
RN4220 (%) biofilm 
reduction 
 
 
 
-  41.6 ± 1.4 
60.4 ± 4.0  - 
40.9 ± 4.0  26.7 ± 2.7 
35.5 ± 2.0  18.2 ± 4.0 
-  41.3 ± 4.0 
65.7 ± 4.0  - 
FIGURE 4.4 | CFU cm-2 of 24 h-old biofilms of Staphylococcus aureus strains that 
remained active after exposure to selected phytochemicals and antibiotics for 24 h.  
Strains SA1199B, XU212 and RN4220 were only exposed to the antibiotic they are 
resistant to: ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY), 
respectively. Antibiotics were applied at minimal inhibitory concentration (MIC); 
reserpine and quinine at 100 mg l-1; pyrrolidine, morin and quercetin at 500 mg l-1. 
(a) when statistically lower than GC (P < 0.05); (b) when statistically lower than 
GC and the antibiotics (P < 0.05). GC – growth control (5% v v-1 DMSO). 
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Morin at 500 mg l-1 applied for 1 h caused the highest CFU reductions (log10 CFU cm-2 
reductions of 1.2 - 2.1 for all strains, which is equivalent to 92 - 99% of biofilm eradication), 
followed by pyrrolidine (500 mg l-1, log10 CFU cm-2 reductions of 0.7 - 1.1; 77 - 93% of biofilm 
eradication). These reductions were higher (P < 0.05) than those obtained with antibiotics applied 
at MIC (log10 CFU cm-2 reductions of 0.08 - 0.4; 23 - 54 % of biofilm eradication). These results 
proposed that the selected phytochemicals caused biofilm disruption as they did not show 
antimicrobial activity by themselves. 
Despite being effective when applied for 1 h, morin and pyrrolidine were not so effective (P 
< 0.05) in disturbing biofilms when exposed for 24 h, for which maximal log10 CFU cm-2 
reductions were 0.3 and 0.5, respectively (biofilm eradication of 41 and 67%, respectively). In 
fact, the decreased susceptibility to prolonged exposure periods was generally observed for almost 
all the strains. This is probably due to the effects of longer incubation periods. The fast growing 
cells will die readily when exposed to the antibiotics but the dormant cells fraction can survive 
and replicate (Shafahi and Vafai, 2010). The exception is verified with strain SA1199B when 
exposed to ciprofloxacin, which log10 CFU cm-2 reduction increased with the longer exposure 
from 0.4 to 1.1 (promoting 90% of biofilm reduction). 
 
  Effect of selected phytochemicals to prevent biofilm formation 
Additionally, in order to assess the ability of the phytochemicals to prevent bacterial adhesion 
and biofilm formation, tests with sessile cells were performed in the presence of the 
phytochemicals for 24 h. FIGURE 4.5 presents the number of CFU cm-2 that was able to adhere 
to polystyrene when grown in the presence of the antibiotics and phytochemicals for 24 h.  
All antibiotics at MIC caused high prevention of biofilm formation - reduced number of CFU 
cm-2 compared to growth control (P < 0.05). Morin was able to reduce biofilm formation of all 
strains (P < 0.05), especially of RN4220 (1.4 log10 CFU cm-2 reductions; 98% of biofilm 
reduction). Additionally, quercetin at 500 mg l-1 also had a considerable effect in preventing 
biofilm formation (P < 0.05), particularly of strains SA1199B and XU212 (approximately 1 log10 
CFU cm-2 reductions; 88% of biofilm reduction). Pyrrolidine was unable to prevent biofilm 
formation, as it did not affect biofilm removal when applied for 24 h, despite showing significant 
effects when applied for 1 h (P > 0.05). No antibiotic or phytochemical caused total biofilm 
control or prevention. This reinforces the higher tolerance of biofilm cells compared to their 
planktonic counterparts. Studies report that even cells that are merely adhered to a surface have 
more resistant phenotypes (Bridier et al., 2011). However, it seems that, among all 
phytochemicals, morin is particularly effective in controlling (within 1 h of incubation) and 
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inhibiting biofilm formation. This provides morin to the reduced list of phytochemicals with 
potential to interfere with the process of biofilm formation and development (Simões et al., 2009).  
CECT 976 
(%) biofilm 
reduction 
 
SA1199B 
(%) biofilm 
reduction 
 
 
 
100.0 ± 0.1   
97.2 ± 0.0   
96.7 ± 0.1  99.9 ± 0.0 
23.5 ± 1.0  - 
37.8 ± 3.0  - 
77.1 ± 2.0  - 
51.8 ± 2.9  61.6 ± 0.6 
59.4 ± 3.0  88.2 ± 0.5 
  
 
  
XU212 
(%) biofilm 
reduction 
 
RN4220 
(%) biofilm 
reduction 
 
 
 
58.3 ± 2.0  94.7 ± 1.1 
24.6 ± 2.0  58.9 ± 3.1 
46.3 ± 1.0  67.0 ± 2.0 
29.8 ± 0.4  67.7 ± 0.0 
73.0 ± 2.4  97.6 ± 0.0 
87.8 ± 0.0  83.7 ± 0.0 
  
 
  
FIGURE 4.5 | CFU cm-2 of biofilms of Staphylococcus aureus strains formed during 24 h 
in 96-well microtiter plates in the presence of selected phytochemicals or antibiotics. 
Strains SA1199B, XU212 and RN4220 were only exposed to the antibiotic they are 
resistant to: ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY), 
respectively. Antibiotics were applied at minimal inhibitory concentration (MIC); 
reserpine and quinine at 100 mg l-1; pyrrolidine, morin and quercetin at 500 mg l-1. (a) 
when statistically lower than GC (P < 0.05); (b) when statistically lower than GC and 
the antibiotics (P < 0.05). GC – growth control (5% v v-1 DMSO). 
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  Effect of combinations antibiotic-phytochemical in biofilm control/prevention 
TABLE 4.4 presents the log10 CFU cm-2 reductions caused by the combinations 
phytochemical-antibiotic towards S. aureus biofilm control and prevention.  
 
TABLE 4.4 | Log10 CFU cm-2 reduction after biofilm exposure to the drugs combinations.  
A – biofilm exposure to antibiotics and phytochemicals for 1 h; B – biofilm exposure 
to antibiotics and phytochemicals for 24 h; C – biofilm grown in the presence of 
antibiotics and phytochemical/biofilm prevention 
Strains Antibiotic Reserpine Pyrrolidine Quinine Morin Quercetin 
A - Biofilm control (1 h) 
CECT 976 CIP 0.29 0.91 0.36 1.29 0.45 
TET 0.49 0.81 0.42 0.99 0.05 (A) 
ERY 0.28 1.44 (S) 0.26 0.64 (A) 0.28 
SA1199B CIP 0.37 1.10 0.53 0.98 (A) 0.57 
XU212 TET 0.33 0.93 0.29 0.92 (A) 0.37 
RN4220 ERY 0.01 1.08 0.24 (S) 1.03 (A) 0.47 (S) 
B - Biofilm control (24 h) 
CECT 976 CIP 0.33 0.52 0.48 0.05 (A) 0.03 (A) 
TET 0.28 0.24 (A) 0.25 0.04 (A) 0.04 (A) 
ERY 0.49 0.47 0.48 0.18 0.28 (A) 
SA1199B CIP 1.30 (S) 1.71 (S) 2.10 (S) 1.05 0.92 
XU212 TET 0.23 0.16 0.22 0.33 (S) 0.11 
RN4220 ERY 0.36 0.39 0.49 0.29 0.05 (A) 
C - Biofilm prevention 
CECT 976 CIP 3.21 3.34 3.51 1.42 (A) 1.13 (A) 
TET 1.43 0.97 (A) 1.41 1.33 1.06 (A) 
ERY 1.51 2.09 (S) 1.50 1.17 1.18 
SA1199B CIP 3.52 (S) 2.7 3.05 3.43 2.11 
XU212 TET 0.70 (S) 1.55 (S) 0.48 1.12 (S) 1.16 
RN4220 ERY 1.08 1.03 1.07 1.26 0.84 
The combination was considered synergic (S) when log10 CFU cm-2 reduction of the combination treatment 
was significantly higher (P < 0.05) than the sum of log10 CFU cm-2 reductions of individual treatments (Monzón 
et al., 2001). An antagonistic (A) combination was obtained when the log10 CFU cm-2 reduction of the 
combination was significantly lower (P < 0.05) than that obtained with the most effective product. Bold values 
represent synergic interactions with log10 CFU cm-2 reduction ≥ 1.0. 
 
The maximum CFU reduction was obtained after 24 h exposure to the synergic combination 
of ciprofloxacin and quinine (log10 CFU cm-2 reduction of 2.1) against SA1199B biofilms. 
Additionally, the combination between ciprofloxacin with reserpine, also considered synergic, 
CHAPTER 4. RESULTS AND DISCUSSION 2016 
 
 
123 
was the most efficient in preventing biofilm formation (log10 CFU cm-2 reduction of 3.5) of strain 
SA1199B. Other synergic antibiotic-phytochemical combinations were found, being highlighted 
the following ones causing ≥ 1 log10 reduction in CFU cm-2: ciprofloxacin combined with 
pyrrolidine and reserpine (log10 CFU cm-2 reduction of 1.7 and 1.3, respectively) to control 
SA1199B biofilms exposed for 24 h; erythromycin combined with pyrrolidine to control biofilms 
of CECT 976 exposed for 1 h (log10 CFU cm-2 reduction of 1.4) and also to prevent their formation 
(log10 CFU cm-2 reduction of 2.1); tetracycline combined with pyrrolidine and morin to prevent 
biofilm formation of XU212 (log10 CFU cm-2 reduction of 1.6 and 1.1, respectively).  
The majority of these synergic results corroborate previous studies with planktonic cells 
(Section 4.1). Some antagonistic interactions were obtained, especially for combinations 
involving the phenolic compounds. It seems that the presence of antibiotics disturbs the activity 
of morin, which was found to be effective when applied individually for 1 h. Indeed, biofilms 
facilitate the spread of antibiotic resistance by promoting horizontal gene transfer and cells can 
switch to more tolerant phenotypes upon environmental stresses (Fux et al., 2005). Antagonistic 
combinations were also found with quercetin when combined with antibiotics mainly against 
CECT 976 biofilms. Other discrepancies in the effects against the diverse strains were found, such 
as the fact that combinations of tetracycline with morin and tetracycline with pyrrolidine were 
synergic against XU212 but antagonist against CECT 976 in biofilm control for 24 h and biofilm 
prevention, respectively. This strain-dependent susceptibility can be related to the impact of 
combined stresses on their susceptibility/resistance patterns and it would need a more integrated 
approach in order to be fully understood. Antibiotic-mediated interactions may trigger 
multicellular behaviors in bacteria, which turns impossible the prediction of cell responses. The 
rest of the combinations tested had indifferent effects in biofilm prevention and control. 
 
  Effect of phytochemicals on preventing Staphylococcus aureus SA1199B 
adaptation to ciprofloxacin 
Since most synergic interactions were obtained against strain SA1199B (the NorA 
overexpressing strain), a further experiment was conducted to force adaptation of SA1199B cells 
to ciprofloxacin. The phytochemicals were also added to understand their effects in reversing 
bacterial adaptation to this antibiotic ciprofloxacin after long exposure times. 
FIGURE 4.6 shows the results obtained in the adaptation assay with SA1199B to ciprofloxacin 
(the treatment was performed as previously indicated in Section 3.2.2.2 in FIGURE 3.6).  
CHAPTER 4. RESULTS AND DISCUSSION 2016 
 
 
124 
 
FIGURE 4.6 | Inhibition zone diameters (IZDs) promoted by ciprofloxacin (CIP) 
against Staphylococcus aureus SA1199B growing during 15 days in the presence 
of sub-inhibitory doses of this antibiotic and/or the five selected phytochemicals.  
Results are given for the five different phases of this assay by increasing 
ciprofloxacin doses every three days (from 1/32 MIC to 1/2 MIC) in a total of 15 
days, according to FIGURE 3.6 shown in Section 3.2.2.2. Reserpine and quinine 
were applied at 100 mg l-1; pyrrolidine, morin and quercetin at 500 mg l-1. Bars 
with (*) presented significantly higher inhibition zone diameter (P < 0.05) 
comparing to ciprofloxacin control population for each phase. 
 
By growing this strain with sub-inhibitory concentrations of ciprofloxacin (control assay), it 
was possible to observe reduction in the IZDs until day 9 (phase 3), and then no growth inhibition 
was detected (phases 4 and 5), proposing that bacteria became more resistant to ciprofloxacin. In 
fact, biological responses induced in bacteria when antibiotics are applied at sub-inhibitory 
concentrations can affect various cellular responses or alter gene expression leading to different 
adaptive responses impacting antibiotic resistance/tolerance (Bernier and Surette, 2013; Kaplan 
et al., 2012). A potential increased NorA overexpression could explain the improved tolerance to 
ciprofloxacin observed by strain SA1199B. 
In phases 2 and 3, it is possible to observe that the populations growing in the presence of all 
phytochemicals were more susceptible, since IZDs promoted by ciprofloxacin against these 
populations were significantly higher (P < 0.05) than IZDs obtained when bacteria were growing 
only in the presence of ciprofloxacin. In fact, IZDs obtained in phase 3 allowed to characterize 
bacterial cultures as susceptible to ciprofloxacin and not resistant anymore, according to CLSI 
(2015b) guidelines. This susceptibility was observed earlier for quercetin growing-population (in 
phase 1). This means that until day 9, all the phytochemicals were able to reverse the bacterial 
0
5
10
15
20
25
CIP  + Reserpine  + Pyrrolidine  + Quinine  + Morin  + Quercetin
IZ
D
 (
m
m
)
0 1 2 3 4 5
* 
* * 
* 
* * 
* 
* 
* 
* 
* 
CHAPTER 4. RESULTS AND DISCUSSION 2016 
 
 
125 
resistance mechanisms. However, by increasing ciprofloxacin concentrations to ¼ and ½ MIC 
(phases 4 and 5, respectively), all populations were resistant to ciprofloxacin similarly to the 
control (no IZD detected), with the exception of bacteria growing in the presence of quinine (100 
mg l-1) and morin (500 mg l-1). The results propose that both phytochemicals were successful in 
preventing higher tolerance of SA1199B to ciprofloxacin (P < 0.05).  
 
  Effect of selected phytochemicals on EtBr accumulation 
A variety of methods have been used to identify active efflux systems in bacteria, such as the 
use of radiolabeled substrates, fluorometric assays or the determination of the MIC for different 
substrates in the presence of compounds known to modulate the activity of efflux pumps (EPIs) 
(Costa et al., 2011). The potential of the phytochemicals to inhibit NorA was tested using EtBr, a 
substrate widely applied for detecting efflux activity in S. aureus strains (Costa et al., 2013). EtBr 
form complexes with double stranded DNA and RNA by intercalating between base pairs 
(Walberg et al., 1999). The accumulation of EtBr has been observed to increase in bacterial cells 
in the presence of an EPI, such as reserpine that inhibits EtBr efflux activity of Gram-positive 
bacteria (Holler et al., 2012; Mullin et al., 2004). This accumulation can be measured 
fluorometrically in strain SA1199B cells due to the retention of fluorescence over time. Also, in 
order to understand if overexpression of NorA is the reason for the increased tolerance of bacterial 
cells growing with ciprofloxacin for 15 days, this population, named SA1199B(r) (recovered as 
described in Section 3.2.2.2), was included in the experiments. The susceptible strain CECT 976 
was also tested as negative control.  
The MIC of EtBr was first determined for each strain according to CLSI (2015a) guidelines as 
described in Section 3.2.1.2: 5 mg l-1 for CECT 976 and 40 mg l-1 for SA1199B and SA1199B(r). 
Due to the good sensitivity of the fluorometric method, the demonstration of the effects of 
reserpine on the accumulation of EtBr in strain SA1199B over time was readily made. FIGURE 
4.7 shows the EtBr accumulation results in SA1199B. FIGURE 4.7-A shows the comparison 
between EtBr accumulation in strains CECT 976, SA1199B and SA1199B(r). CECT 976 can 
accumulate more EtBr (P < 0.05) contrarily to SA1199B and SA1199B(r), both overexpressing 
NorA. There were no significant differences between EtBr accumulation in SA1199B and 
SA1199B(r) (P > 0.05), proposing that the higher resistance of this strain to ciprofloxacin may be 
due to the expression of resistance mechanisms other than overexpression NorA efflux pump. 
FIGURE 4.7-B shows the effect of several concentrations of reserpine in EtBr accumulation. 
Reserpine at 20 mg l-1 is usually used as reference by diverse authors (Couto et al., 2008; Schmitz 
et al., 1998).  
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FIGURE 4.7 | Detection of the effect of the selected phytochemicals on ethidium 
bromide accumulation for 60 min in Staphylococcus aureus strains by fluorometry.  
(A) Fluorescence as a measure of EtBr accumulation in Staphylococcus aureus 
CECT 976, SA1199B and SA1199B(r) for 60 min; (B) effects of reserpine at 20, 40 
and 100 mg l-1 and (C) of the other phytochemicals on EtBr accumulation in S. 
aureus SA1199B. The bacteria were loaded with EtBr at ½ MIC in the presence of 
different phytochemicals for a period of 60 minutes at 37°C. Mean values of three 
replicates are shown. 
 
FIGURE 4.7-C shows the accumulation of EtBr in SA1199B in the presence of the 
phytochemicals. Quercetin (500 mg l-1) showed the highest EtBr accumulation in SA1199B (P < 
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0.05). Quinine (100 mg l-1) also improved EtBr accumulation (P < 0.05) proposing that this 
compound is inhibiting NorA efflux pump, which could have helped preventing SA1199B to 
become more tolerant to ciprofloxacin. Contrarily, morin (500 mg l-1) had no effect on EtBr 
accumulation, but it was also able to prevent bacterial adaptation to ciprofloxacin, suggesting that 
this product is apparently involved in the inhibition of other mechanism, excluding NorA efflux 
pump, or that this effect may be related to its ability to control biofilms (within 1 h) and to prevent 
their formation. Pyrrolidine did not improve EtBr accumulation neither was able to prevent higher 
tolerance of SA1199B to ciprofloxacin (P > 0.05). However, it caused biofilm removal when 
applied for 1 h. 
 
  Cytotoxicity results of the selected phytochemicals 
To assess the suitability of the tested phytochemicals for antimicrobial therapy, cytotoxicity 
tests were carried out by MTS tests with L929 cells. The positive growth control produced large 
amounts of a brown formazan product after incubation, which is an indicator of normal 
metabolism and that cells were able to metabolize MTS. The DMSO control presented a similar 
viability to the growth control (P < 0.05) indicating that this compound (at 2% v v-1) was not toxic 
for the cells. From the dose-response curves obtained, IC50 values were calculated by probit 
analysis. Quinine demonstrates a high toxicity to mammalian cells, being the most toxic alkaloid 
(IC50 = 25 ± 2.2 mg l-1). The concentration of reserpine used to potentiate antibiotics, 100 mg l-1, 
was inferior to its IC50 (627 ± 57 mg l-1). The other alkaloids were used at concentrations above 
their IC50, which was 352 ± 28, 274 ± 18, and 100 ± 4.7 mg l-1 for caffeine, pyrrolidine and 
theophylline, respectively. The flavonoids quercetin, morin and hesperidin presented low values 
of IC50 (41.8, 67.5, and 50.4 mg l-1, respectively) after 72 h incubation with L929 cells. Catechin 
had a IC50 of 302.5 mg l-1 and rutin showed the highest value (1267.5 mg l-1). 
 
  Relevant remarks 
With this study, known phytochemicals are highlighted for their important activities in 
cotherapies with known antibiotics against S. aureus biofilms. Despite being structurally different 
and presenting diverse activities, all phytochemicals showed interesting results, highlighting the 
use of phytochemicals as adjuvants of antimicrobial therapy against planktonic and sessile 
S. aureus.  
Several significant synergic combinations of antibiotics with the phytochemicals were 
obtained being highlighted the combinations between ciprofloxacin and quinine to control 
SA1199B biofilms (24 h exposure with log10 CFU cm-2 reduction of 2.1) and between 
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ciprofloxacin with reserpine to prevent SA1199B biofilm formation (log10 CFU cm-2 reduction of 
3.5). These effects depend on the incubation time as with longer incubation and at non-lethal 
antibiotic doses, bacteria showed increased antibiotic tolerance. Unfortunately, reserpine cannot 
be used to potentiate the activities of fluoroquinolones because of its neurotoxicity at the 
concentrations required for NorA inhibition (Markham et al., 1999).  
Morin applied for 1 h showed the best biofilm reduction and significantly inhibited biofilm 
formation for all strains. Interestingly, morin has been studied in other fields as an inhibitor of 
amyloid β-peptide aggregation, whereas other hydroxyflavones such as quercetin failed to be 
effective (Lemkul and Bevan, 2012; Noor et al., 2012). Pyrrolidine had a significant effect when 
exposed for 1 h against biofilms, while quercetin was highlighted for preventing biofilm 
formation. Quercetin promoted the highest EPI activity in strain SA1199B.  
Interestingly, the difference in the structures between morin and quercetin is that the first is 
2’,4’-dihydroxylated in B ring while the second is 3’,4’-dyhydroxylated (as can be visualised in 
TABLE 3.3 in Section 3.1.6). However, it is already known that different substitutions on phenolic 
rings can promote significantly different activities (Cushnie and Lamb, 2005; Kumar and Pandey, 
2013). Indeed, Tsuchiya et al. (1996) indicated that 2′,4′- or 2′,6′-dihydroxylation of the B ring 
and 5,7-dihydroxylation of the A ring in the flavanone structure was important for anti-MRSA 
activity. Previous findings of flavonols, such as fisetin, quercetin, and kaempferol state an anti-
biofilm activity against S. aureus (Lee et al., 2013). In addition, it was found previously that 
several flavonoids, such as quercetin, reduce hemolysis by S. aureus, which would reduce the 
virulence of S. aureus and the ability of the bacterium to form biofilms (Caiazza and O'Toole, 
2003). Moreover, due to their extensive functional group chemistry and chirality those products 
are potentially interesting scaffolds for the discovery and development of antibacterial therapeutic 
approaches. 
It has been suggested that flavonoids are likely to have limited toxicity because they are widely 
distributed in edible plants and beverages and have previously been used in traditional medicine 
(Bylka et al., 2004). Indeed, in the U.S., the daily dietary intake of mixed flavonoids is estimated 
to be in the range of 500-1000 mg (Skibola and Smith, 2000). Quercetin has also been used as a 
dietary supplement (250-500 mg three times per day) for therapeutic purposes. However, in this 
study, quercetin presented low values of IC50 after 72 h incubation with L929 cells (41.8 mg l-1). 
This value is in accordance with some other reports. Ngomuo and Jones (1996) carried out the 
cytotoxic effects of quercetin and other compounds and they reported inhibition of cell growth by 
50% after 48 h of incubation for quercetin at 24 mg l-1 for Chinese hamster ovary cells, 36 mg l-1 
for mouse fibroblast cells (3T3) and 21 mg l-1 for normal rat kidney cells. Pawlikowska-Pawlega 
and Gawron (1995) reported that quercetin caused partial growth inhibition of mouse fibroblast 
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cells when used at 10 mg l-1, and almost complete growth inhibition when applied at 50 mg l-1. 
However, based on the information provided by Quercegen Pharmaceutics concerning 
toxicological safety studies (personal communication), human clinical studies corroborating 
epidemiological studies, human pharmacokinetic studies, as well as other information available 
to FDA, quercetin received GRAS status for its intended use as ingredient in beverages, grain 
products and pastas, processed fruits and fruit juices, and soft candies at levels up to 500 
milligrams per serving. FDA has not, however, made its own determination regarding the GRAS 
status of the subject use of quercetin. 
There are tens of reports in the literature concerning the potential benefits of quercetin for 
various applications, with various purported modes of action, while others refer to toxicity issues 
(Ferry et al., 1996; Guardia et al., 2001; Scambia et al., 1994). Although quercetin has tested 
positive for mutagenicity and genotoxicity in vitro in some reports, other in vitro studies suggest 
that quercetin is protective against genotoxicants, and regarded as antimutagenic (Okamoto, 
2005). The implications of these conflicting findings in an assessment of human safety have not 
been established (Harwood et al., 2007). Therefore, the mechanisms underlying its biological 
effects remain obscure and understanding how quercetin causes either protection or cell death in 
the same model is a research priority (Ossola et al., 2008). Considering the considerable number 
of studies reporting the potentially beneficial effects of quercetin on health, little is known about 
its bioavailability (Erlund et al., 2000). At present, a number of studies have been carried out both 
in animals and humans. However, in vivo data on the disposition, absorption, bioavailability, and 
metabolism of quercetin are scarce and contradictory. The low bioavailability of flavonoids has 
been a concern. However, it can be improved by using food matrix components or particular 
delivery forms (Bischoff, 2008).  
  
 
 
 
CHAPTER 4. RESULTS AND DISCUSSION 2016 
 
131 
 TASK 3. REEXAMINING PLANTS WITH A NEW LOOK INTO THEIR 
DEFENSE SYSTEMS - THE SEARCH FOR ANTIBIOTIC ADJUVANTS TO 
PROMOTE EFFECTIVE TREATMENT OF DRUG-RESISTANT 
STAPHYLOCOCCUS AUREUS 
 
Abstract 
It becomes apparent that plants adopt a different paradigm – synergy – to combat 
infections. The current study assessed 29 plants from different families for their 
antibacterial activity, and also as adjuvants in antibiotic therapy, against S. aureus, 
including one MRSA strain. Eucalyptus globulus, Castanea sativa, Agrimonia 
eupatoria and Fraxinus excelsior methanolic extracts showed antibacterial activity 
with MICs of 0.125-0.5, 0.5-1.0, 1.0-2.0, and 2.0-4.0 g l-1, respectively. Non-
antibacterial plants were assessed in combination with ampicillin, oxacillin, 
ciprofloxacin, erythromycin and tetracycline by disk diffusion test. Methanolic 
extracts of Acacia dealbata, Prunus spp. plants, Centaurea nigra, Eupatorium 
cannabium and Buxus sempervirens showed a potentiating effect mostly of 
ciprofloxacin, erythromycin and tetracycline. 
 
 
 
  Determination of antibacterial properties of selected plants 
During the last few years, the increasing incidence of drug-resistant pathogens has drawn the 
attention of the pharmaceutical and scientific communities towards studies on the potential 
antimicrobial activity of plant-derived substances. This allowed a resurgence in the use of herbal 
medicines worldwide (Yap et al., 2014). Plant-based systems continue to play an essential role in 
healthcare, and their use by different cultures has been extensively documented (Cragg and 
Newman, 2013). 
Regardless of their medicinal uses, all plants have their own defense mechanisms from 
pathogens, producing a wide range of different chemicals for that purpose. In this study, 29 plants 
were selected, among different families, mainly from Rosaceae (9 plants), Fabaceae (3 plants), 
Asteraceae, Solanaceae and Apocynacea (with 2 plants of each family), in order to be able to test 
a large variety of extracts and metabolites. Even common and well-studied plants need to be 
continuously investigated from different perspectives to achieve a deeper understanding of their 
defense mechanisms and to ascertain their potential biotechnological applications. The plants 
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selected include some typical invasive species existent in Portugal, common fruit plants and 
others considered medicinal for their wide range of therapeutic applications. TABLE 3.5 in the 
Section 3.1.7 described the plants tested in this study and TABLE A.2 in Appendix A2 described 
their ethnopharmacological relevance according to the Plants For A Future (PFAF, 2016) online 
database. The selected plants were assessed for their antibacterial activities against diverse S. 
aureus strains. The MIC for all methanolic extracts was determined for concentrations below 
4 g l-1. Only four plant extracts showed a detectable MIC, as shown in TABLE 4.5.  
 
TABLE 4.5 | Ranges of minimal inhibitory concentrations (MIC, g l-1) for the plant 
methanolic extracts that exhibited antibacterial activity for concentrations lower than 
4 g l-1 against four Staphylococcus aureus strains (CECT 976, SA1199B, XU212, 
RN4220 and one MRSA strain MJMC001) 
Plant  MIC (g l-1) 
E. globulus 0.125 - 0.5 
C. sativa 0.5 - 1.0 
A. eupatoria 1.0 - 2.0 
F. excelsior 2.0 - 4.0 
 
Eucalyptus globulus presented the highest antibacterial activity with MIC between 0.125 and 
0.25 g l-1 against the diverse S. aureus strains (CECT 976, SA1199B, XU212, RN4220 and one 
MRSA strain MJMC001). This activity is in accordance with its therapeutic use (PFAF, 2016). 
Other studies reported that the essential oils from the leaves and the flowers of E. globulus 
inhibited the growth of E. coli, S. aureus (Bachir and Benali, 2012), MRSA and the VRE 
Enterococcus faecalis (Srinivasan et al., 2001). Aromadendrene was described as the major 
constituent causing antimicrobial activity (Srinivasan et al., 2001). The aqueous extract of E. 
globulus leaves was also found to inhibit a wide range of bacteria and fungi (Mulyaningsih et al., 
2010). 
Concerning the other antibacterial plants, other studies were in agreement with the results 
obtained. Basile et al. (2000) found a MIC in the range of 64–256 mg l-1 of the aqueous extract of 
Castanea sativa (pH 3.0) against several bacteria including S. aureus. Rutin, hesperidin, 
quercetin, apigenin, morin, naringin, galangin and kaempferol were already identified in this plant 
extract (Basile et al., 2000). Agrimonia eupatoria was reported for its inhibitory effects against S. 
aureus (Copland et al., 2003; Dulgerm and Gonuz, 2004; Watkins et al., 2012). Several 
constituents were described for A. eupatorium: apigenin, luteolin, quercetin, kaempferol, 
tiliroside, triterpene glycosides, such as euscapic acid and tormentic acid, phenolic acids and 
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tannins (Watkins et al., 2012). Middleton et al. (2005) reported antibacterial activity of n-hexane 
and CHCl2 extracts of Fraxinus excelsior against S. aureus (MIC of 0.125 and 0.25 g l-1, 
respectively) and MRSA strains (MIC of 0.5 and 1.0 g l-1, respectively). To date, various classes 
of compounds, including coumarins, benzoquinones, flavonoids, phenylethanoids, secoiridoid 
glucosides, indole derivatives and simple phenolics have been reported from F. excelsior 
(Middleton et al., 2005), and isolated compounds included 7-β-1-D-glucopyranosyl 11-
methyloleoside, oleoside dimethyl ester, excelsioside and ligustroside (Soler-Rivas et al., 2000). 
 
  Evaluation of antibiotic-potentiating effect by plant extracts 
The plant extracts that did not show any detectable antibacterial activity were further evaluated 
for antibiotic-potentiating activity with five antibiotics by disk diffusion method. First, the 
classification of S. aureus strains according to their resistance profile was performed based on the 
comparison of the MICs/IZDs results and the susceptibility breakpoints of CLSI (2015b) 
guidelines, as shown previously in TABLE 4.1 (Section 4.1.1): CECT 976 is susceptible to all 
antibiotics, while S. aureus SA1199B, RN4220 and XU212 are resistant to ciprofloxacin, 
erythromycin and tetracycline, respectively, and the MRSA MJMC001 is resistant to all 
antibiotics, excepting tetracycline. TABLE 4.6 shows the antibiotic-potentiation results obtained 
for the plant extracts. Only extracts showing potentiation of at least one antibiotic were included.  
 
TABLE 4.6 | Classification of the combination between the antibiotics and the plant 
methanolic extracts against Staphylococcus aureus strains by disk diffusion method 
as indifferent (+), additive (++) and potentiation (+++) 
  CECT 976 SA1199B XU212 RN4220 MJMC001 
Plant g l-1 AMP OXA CIP TET ERY CIP TET ERY AMP OXA CIP TET ERY 
C. striatus 0.5 + + +++ ++ +++ +++ + +++ + + +++ + +++ 
A. dealbata 2.0 + + +++ + +++ +++ + ++ + + + + ++ 
P. communis 4.0 + + + +++ +++ + ++ + + + + + + 
P. avium 4.0 + + + +++ +++ +++ ++ +++ + + + + ++ 
P. domestica 4.0 + + + +++ +++ +++ ++ +++ + + + + ++ 
P. persica 4.0 + + ++ +++ ++ +++ ++ +++ + + ++ + ++ 
C. nigra 1.0 + + +++ + +++ +++ + + + + + + + 
E. cannabinum 1.0 + + + +++ +++ + + +++ + + + + +++ 
F. carica 2.0 + + + ++ + +++ + + + + + + + 
B. sempervirens 1.0 ++ ++ +++ +++ +++ +++ + +++ + + + + +++ 
The concentrations described for each plant extract are the minimal/optimal concentrations causing potentiation of the 
antibiotics. Only the plant extracts that potentiate at least one antibiotic are presented. No antagonistic interactions 
between antibiotics and plant extracts were obtained. 
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No IZD originated by the combinations between plant extracts and antibiotics was ever inferior 
to that promoted by the antibiotic alone (P > 0.05). Potentiating results were obtained with plants 
from Fabaceae family, especially Cytisus striatus and Acacia dealbata, and Rosaceae family, 
including all Prunus spp. and Pyrus communis. Also, both plants from Asteraceae family, 
Centaurea nigra and Eupatorium cannabium, showed good potentiating results. Buxus 
sempervirens was also highlighted for its high antibiotic-potentiating activity. No plant extract 
significantly potentiated β-lactam antibiotics (ampicillin and oxacillin), but additive effects were 
found with B. sempervirens.  
The MeOH leaf extracts from both invasive Fabaceae plants, C. striatus (0.5 g l-1) and A. 
dealbata (2 g l-1), showed similar potentiating effects. Both extracts potentiated ciprofloxacin 
against S. aureus CECT 976 and SA1199B and erythromycin against CECT 976, RN4220 and 
MJMC001 (A. dealbata only showed additive interactions against these last two strains). C. 
striatus leaves extract also potentiated ciprofloxacin against MJMC001, being thus highlighted 
from the other extracts. More studies should be performed in order to understand what metabolites 
exist in common between these two plants that could cause similar antibiotic-potentiating 
activities. The presence of isoflavonoids is common among Fabaceae family. Taguri et al. (2006) 
found generally weak activity of A. dealbata extract against many different bacteria. Olajuyigbe 
and Afolayan (2012) found synergistic interactions between one Acacia sp. plant, Acacia 
mearnsii, and erythromycin, metronidazole, amoxicillin, chloramphenicol and kanamycin against 
S. aureus. No reports of antibiotic potentiation were found for C. striatus. 
Prunus spp. MeOH extracts showed interesting potentiating results though only at high 
concentrations (4 g l-1). Results were very similar between the three plant extracts. 
Potentiation/additive effects were mainly found with ciprofloxacin against SA1199B, tetracycline 
against CECT 976 and erythromycin against CECT 976, RN4220 and MJMC001. No study about 
antibiotic-potentiating activity of these Prunus spp. was previously reported. Yet, some main 
compounds from these plants were reported: hentricontane, ethyl hexadecanoate and linoleic acid 
were found from P. domestica oil (Mahmood et al., 2009); tectochrysin and (-)-sakuranetin were 
isolated from CHCl3 extract of P. avium, while from the MeOH extract (+)-catechin, (+)-
naringenin [which has antibacterial activity according to Alzoreky and Nakahara (2003)] (−)-
dihydrowogonin and (+)-dihydrokaempferol were identified (McNulty et al., 2009).  
B. sempervirens (1 g l-1) is also highlighted since its methanolic extract promoted several 
additive and potentiating effects when combined with all antibiotics against CECT 976, with 
ciprofloxacin against SA1199B and erythromycin against RN4220 and MJMC001. So, these 
extracts seem to act in a more “general” way to potentiate the antibiotics tested. No other similar 
reports about antibiotic-potentiating activity promoted by this plant were found in bibliography. 
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Other MeOH extracts showed in TABLE 4.6 presented promising results, being highlighted 
the following combinations: C. nigra (1 g l-1) potentiated ciprofloxacin against CECT 976 and 
SA1199B and erythromycin against CECT 976; E. cannabium (1 g l-1) had a potentiating effect 
on tetracycline against CECT 976, and on erythromycin against CECT 976, RN4220 and 
MJMC001; P. communis (4 g l-1) potentiated tetracycline and erythromycin against CECT 976; 
and F. carica (2 g l-1) potentiated ciprofloxacin against SA1199B.  
 
  Relevant remarks 
This study allowed to assess the potential of 29 different plant species to be used in co-
therapies against S. aureus, a major cause of HAIs. From the 29 tested plants, four (E. globulus, 
C. sativa, A. eupatoria and F. excelsior) were found to have antibacterial activity, being in 
agreement with their traditional uses (PFAF, 2016), and ten (A. dealbata, C. striatus, P. 
communis, P. avium, P. domestica, P. persica, C. nigra, E. cannabinum, F. carica, B. 
sempervirens) were able to potentiate antibiotic activity, especially ciprofloxacin, tetracycline and 
erythromycin. Further studies with these plants would be necessary in order to conclude about the 
responsible metabolites promoting these antibiotic-potentiating activities.  
Resistance to the antibiotics tested can be easily achieved with the expression of efflux pumps 
from pathogens (Fernández and Hancock, 2012). So, most of these plant extracts may be causing 
efflux pump inhibition on S. aureus, thus explaining the potentiation of ciprofloxacin, tetracycline 
and erythromycin. Indeed, the number of plant extracts producing efflux pump inhibitors seems 
to be considerable, as it is being extensively reported (Gibbons et al., 2003a; Smith et al., 2007b; 
Stavri et al., 2007). C. striatus was highlighted in this initial screening and further studies focusing 
on the isolation and characterization of the main metabolites responsible for this antibiotic-
potentiating activity were performed and will be further described in Sections 4.4 and 4.5. 
No plant extract significantly potentiated β-lactam antibiotics, but additive effects were found 
with B. sempervirens. Thus, B. sempervirens seems to act as a general potentiator for the several 
antibiotics, not being dependent of the antibiotic-class. Thus, other interesting possibilities to 
explain this potentiation that not an efflux pump activity emerge. Antibiotic potentiation can be 
reached by compounds that are interfering with other mechanisms of the bacterial cell that not 
involve drug resistance mechanisms, such as quorum-sensing, virulence activation, biofilm 
formation, adherence to the host tissues (Chatterjee et al., 2016), etc. For this reason, B. 
sempervirens was also selected for further investigation and phytochemical elucidation, which 
results will be further presented and discussed in Section 4.6.
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 TASK 4. THE POTENTIAL OF CYTISUS STRIATUS FOR ANTIBIOTIC-
POTENTIATING ACTIVITY: ISOLATION AND IDENTIFICATION OF 
ANTIBIOTIC ADJUVANTS  
 
Abstract 
Antibacterial therapy is perhaps the only field of medicine in which therapeutic 
options have declined over time. The spread of multidrug resistant S. aureus strains, 
including MRSA, has shortened the useful life of anti-staphylococcal drugs 
extremely. Disabling resistance mechanisms may restore the activity of old-
generation antibiotics. Herein, the use of 1H NMR-based metabolomics to identify the 
antimicrobial and antibiotic potentiating compounds of C. striatus is described. 
Luteolin was isolated from the plant and showed antibacterial activity (MIC = 30-120 
mg l-1). Genistein, 2’-hydroxygenistein and apigenin are potentially implicated in the 
potentiation of ciprofloxacin and erythromycin against MRSA strains belonging to 
CC8 (ST239 and USA300). Interesting activities were also shown by the isolated 
compounds from C. striatus, namely EPI activity and S. aureus biofilm control. 
 
 
 
  Antibacterial and antibiotic-synergistic activities of Cytisus striatus leaf, 
flower and twig methanolic extracts  
Previously, the methanolic extract of C. striatus leaves were assessed for antibacterial and 
antibiotic-potentiating activities. To determine if other parts of the plant have the same activity, 
methanolic extracts of flowers and twigs of this plant were assessed as well. The MICs of the 
EtOAc fractions of the methanolic extracts of C. striatus leaves, flowers and twigs were 
determined by microdilution techniques according to CLSI (2015a) guidelines against seven S. 
aureus strains including USA300 and ST239 MRSA strains. Characterization of these strains 
concerning the origin was detailed previously in TABLE 3.1 in Section 3.1.4. None of the extracts 
exhibited a MIC below 1 g l-1 against the S. aureus strains. In TABLE 4.7, MICs of ciprofloxacin 
and erythromycin are presented for each strain.  
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TABLE 4.7 | Minimal inhibitory concentrations (MIC, mg l-1) were determined for each 
strain according to CLSI (2015a) guidelines and classified as resistant (R), 
intermediate (I) or susceptible (S) to ciprofloxacin (CIP) and erythromycin (ERY) 
S. aureus CIP ERY 
M116 32 (R) 32 (R) 
RWW337 16 (R) > 10 000 (R) 
RWW50 2 (I) 64 (R) 
M82 0.25 (S) 0.5 (S) 
RN6390 0.25 (S) 0.5 (S) 
CECT 976 1.0 (S) 0.25 (S) 
SA1199B 4 (R) n.p. 
n.p. not performed 
 
The EtOAc fractions of methanolic extracts of leaves, flowers and twigs of C. striatus 
(0.5 g l.1) were assessed for their potentiating effect of ciprofloxacin and erythromycin activity 
against the seven S. aureus strains, using the disk-diffusion method (TABLE 4.8).  
 
TABLE 4.8 | Antibiotic-potentiating activity of the methanolic extracts of Cytisus striatus 
leaf, flower and twig (0.5 g l-1). The activity is expressed as the increase on inhibition 
zone diameters (IZDs, mm) promoted by ciprofloxacin (CIP) or erythromycin (ERY) 
in the presence of the plant extracts 
 Increased IZD (IZDc – IZDa) (mm) 
S. aureus  
Leaf Flower Twig 
CIP ERY CIP ERY CIP ERY 
M116 7.0 ± 1.0 (P) 10.0 ± 0.0 (P) - - - - 
RWW337 8.3 ± 0.6 (P) - - - - - 
RWW50 7.0 ± 0.0 (P) 5.0 ± 1.0 (A) - - - - 
M82 4.0 ± 0.0 (A) 4.5 ± 0.0 (A) - - - - 
RN6390 - 5.0 ± 0.3 (A) - - - - 
CECT 976 6.3 ± 1.0 (P) 9.1 ± 0.6 (P) 5.4 ± 1.2 (A) 4.5 ± 1.0 (A) - - 
SA1199B 14.0 ± 2.5 (P) n.p. 17.3 ± 0.3 (P) n.p. - n.p. 
Inhibition zones obtained with the combinations (IZDc) over antibiotic-single activity (IZDa) are given and classified 
as: (-) indifferent (IZDc – IZDa < 4 mm); (A) additive (4 ≤ IZDc – IZDa < 6 mm); and (P) potentiation (IZDc – IZDa ≥ 
6 mm, in bold). Data are means and SD from at least three independent experiments; n.p. not performed. 
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The different parts of the plant showed different antibiotic-potentiating activities. The leaf 
extract showed the best potentiating effect on both ciprofloxacin and erythromycin against several 
strains. The flower extract showed additive effects with the antibiotics only against S. aureus 
strains CECT 976 and SA1199B. The twig extract showed no antibiotic-potentiating activity at 
all against the seven S. aureus strains tested. The IZD of each combination was never lower than 
that produced by each antibiotic alone (P > 0.05), which proves there was no antagonism detected 
in the combinations. 
Antibiotic potentiation caused by the methanolic extract of C. striatus leaf was also confirmed 
by checkerboard method (TABLE 4.9). 
 
TABLE 4.9 | Minimal inhibitory concentrations (MIC, g l-1) of Cytisus striatus leaf 
methanolic extract against Staphylococcus aureus, when applied alone (MICa) and in 
combination (MICb) with ciprofloxacin (CIP) or erythromycin (ERY). Fold-
reductions of antibiotic MICs (R) and fractional inhibitory concentration index (FICI) 
values are shown 
   CIP  ERY 
S. aureus MICa  MICb R FICI  MICb R FICI 
M116 > 1.0  0.25 4 ≤ 0.38 (P)  0.5 4 ≤ 0.5 (P) 
RWW337 > 1.0  0.25 4 ≤ 0.38 (P)  - - I 
RWW50 > 1.0  0.125 4 ≤ 0.31 (P)  0.5 2 > 0.5 (I) 
M82 > 1.0  0.5 2 > 0.5 (I)  - - I 
RN6390 > 1.0  - - I  - - I 
CECT 976 > 1.0  0.25 4 ≤ 0.38 (P)  0.25 4 ≤ 0.38 (P) 
SA1199B > 1.0  0.125 4 ≤ 0.31 (P)  n.p. 
- = no decrease or increase in the MIC was observed; n.p. not performed; plant extracts (EtOAc 
fractions) were tested in a range of concentrations from 0.06 to 1.0 g l-1. When FICI ≤ 0.5 (in bold), 
the effect is considered potentiation (P); if FICI > 0.5, the interaction is considered indifferent (I). 
ERY was not tested against SA1199B. The experiments were repeated three times, and the values 
presented are the averages of three independent assays.  
 
  1H NMR measurement of the extracts of different parts of Cytisus striatus 
1H NMR was applied to obtain metabolic profiles of all samples (Ali et al., 2012). 1H NMR is 
widely used in combination with different multivariate data analyses methods to obtain metabolic 
profiles of all types of samples (Ali et al., 2012). An 1H NMR spectrum can be roughly divided 
into three distinct regions: δ 0.80–4.00 corresponds to signals from amino acids and organic acids, 
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δ 4.00-5.50 is known as the carbohydrates region and δ 5.50–8.60 is considered to be the phenolic 
region. Visual inspection of the 1H NMR spectra of the EtOAc fractions of the methanolic extracts 
of leaf, flower and twig revealed some differences in their chemical profiles (FIGURE 4.8), 
especially in the phenolic region, which could be responsible for differences in antibiotic-
potentiating activity: leaves (most active) > flower > twig (non-active).  
 
FIGURE 4.8 | Representative 1H NMR spectra of Cytisus striatus extracts. 1H NMR 
spectra (600 MHz, in CD3OD, phenolic region) of the ethyl acetate fractions of the 
methanolic extracts of (A) leaf, (B) flower and (C) twig. 
 
  Multivariate data analysis for identification of the biomarkers 
A number of different extracts was made to enable the use of multivariate data analysis to 
identify the markers of activity. The experimental diagram performed to find the biomarkers can 
be found in FIGURE 4.9. For the correlation between activity and chemical data, high chemical 
variation is essential. Therefore, leaves or flowers (active parts) were mixed with twig (non-active 
parts) by various % ratio in order to give more variation. Then, mixed parts of C. striatus plants 
were extracted using different solvents, temperature and pressure conditions. TABLE 3.7 in 
Section 3.2.4.1 showed the rationale of the extractions performed.  
 
A 
B 
C 
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FIGURE 4.9 | Elucidating diagram describing the steps performed during this study.  
1st step (A) - identification of the biomarkers correlated with antibiotic-potentiating 
activity through a multivariate data analysis applied to 1H NMR data; 2nd step (B) - 
isolation and identification of active compounds. 
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The resulting 54 EtOAc fractions of the methanolic extracts were assayed for their potentiation 
of the activity of ciprofloxacin and erythromycin against S. aureus CECT 976 using the disk 
diffusion method (FIGURE 4.10). This strain was chosen for this screening since a clearly distinct 
response was obtained with the different parts of C. striatus (previsouly shown in TABLE 4.8). 
In general, extracts obtained with 100% methanol showed a higher potentiating activity than those 
prepared with 75- and 50% MeOH in water (P < 0.05); temperature and pressure did not 
significantly affect the activity (P < 0.05).  
 
 
FIGURE 4.10 | Potentiating results obtained for the 54 methanolic extracts of Cytisus 
striatus when combined with antibiotics against Staphylococcus aureus CECT 976.  
The activity is expressed as the increase in the inhibition zone diameters (IZDs, 
mm) promoted by (A) ciprofloxacin (CIP) or (B) erythromycin (ERY) in the 
presence of the extracts dissolved in Mueller-Hinton agar medium, compared with 
reference conditions (without the extracts). Bars above the line y = 6 mm show 
potentiation of antibiotic. Bars represent means and SD from at least three 
independent experiments. Classification of the samples was performed as (x,y) and 
shown in TABLE 3.7.  
 
The 1H NMR data obtained for the 54 samples were reduced by OPLS modeling to investigate 
the grouping of the samples according to the potentiating activity of ciprofloxacin (FIGURE 4.11-
A) and erythromycin (FIGURE 4.11-B). The aromatic region ( 6.0 - 8.6) was considered since 
phenolic compounds were expected to have better therapeutic potential.  
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FIGURE 4.11 | Orthogonal partial least squaring model applied to Cytisus striatus 1H NMR data.  
OPLS score- and S-plots obtained from the potentiating activity (1: no activity , 2: additive 
activity , 3: potentiating activity ) of ciprofloxacin (A) and erythromycin (B) and 1H NMR 
data in the range of the region between δ 6.00 – 8.60 of the different extracts of C. striatus. 
The sample preparation and extraction conditions were performed as shown in TABLE 3.7. 
 
Both OPLS score plots of ciprofloxacin and erythromycin showed that the phenolic ingredients 
correlated well with the potentiating activity, which was confirmed by permutation test. For 
identification of the contributing metabolites to the activity, S-plot was employed. The signals in 
the range of 7.9 - 8.2, e.g. H-2 of isoflavonoids or H-2’ and H-6’ of flavonoids having a 4’-
monohydroxy group in B-ring were found to strongly correlate with the potentiating activity.  
 
  Identification of compounds correlated with the antibiotic-potentiation 
To confirm the chemical structures associated with the activities, the C. striatus leaf 
methanolic extract was separated by column chromatography using silica gel and followed by a 
Sephadex LH-20 column yielding two fractions, B5 and B6 that exhibited distinct activities: B5 
A 
B 
 7.96  8.08 
 8.08 
 7.96 
OPLS score plot OPLS S-plot 
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potentiated the activity of ciprofloxacin and erythromycin (similarly to C. striatus extract) and 
B6 showed antibacterial activity against S. aureus CECT 976. The B6 fraction was identified as 
luteolin. Semi-preparative RP-HPLC of fraction B5 allowed the separation of a number of 
compounds that were identified by 1H NMR as apigenin, chrysin, daidzein, genistein, 2’-
hydroxygenistein and 3’-hydroxydaidzein (TABLE 4.10). The identification was carried out 
using the in-house library of NMR data of common metabolites. When necessary, 2D-NMR 
techniques were used to confirm the identity (J-resolved, 1H-1H COSY, 1H-13C HMBC, 1H-13C 
HSQC).  
 
TABLE 4.10 | Main metabolites detected in active fraction of Cytisus striatus leaves  
 
Chemical 
formula 
1H NMR [CD3OD-d4; δ (ppm)] 
Apigenin C15H9O5 6.19 (H-6, d, J = 1.9), 6.43 (H-8, d, J = 1.9), 6.57 (H-3, s), 6.92 (H-3’/H-
5’, d, J = 8.8), 7.84 (H-2’/H-6’, d, J = 8.8) 
Chrysin C15H10O4 6.18 (H-6, d, J = 1.9), 6.42 (H-8, d, J = 1.9), 6.70 (H-3, s), 7.56 (H-3’/H-
4’/H-5’, m); 7.97 (H-2’/H-6’, d, J = 7.8) 
Luteolin C15H9O6 6.19 (H-6, d, J = 1.9), 6.42 (H-8, d, J = 1.9), 6.53 (H-3, s), 6.89 (H-5’, d, 
J = 8.4), 7.37 (H-6’, dd, J = 8.4, 1.9), 7.37 (H-2’, d, J = 1.9) 
Daidzein C15H10O4 6.83 (H-3’/H-5’, d, J = 8.4), 6.84 (H-8, d, J = 1.8), 6.92 (H-6, dd, J = 9.0, 
2.4), 7.36 (H-2’/H-6’, d, J = 8.4), 8.04 (H-5, d, J = 8.4), 8.12 (H-2, s) 
3’-Hydroxydaidzein C15H9O5 6.79 (H-8, d, J = 1.8), 6.82 (H-5’/H-6’, m), 6.90 (H-6, dd, J = 9.0, 
2.4),7.00 (H-2’, d, J = 1.8), 8.02 (H-5, d, J = 8.4), 8.08 (H-2, s), 
Genistein C15H9O5 6.20 (H-6, d, J = 2.1), 6.32 (H-8, d, J = 2.1), 6.84 (H-3’/H-5’, d, J = 8.4), 
7.36 (H-2’/H-6’, d, J = 8.4), 8.04 (H-2, s) 
2’-Hydroxygenistein C15H10O6 6.15 (H-6, d, J = 1.8), 6.26 (H-8, d, J = 1.8), 6.37 (H-5’, dd, J = 7.8, 2.4), 
6.39 (H-3’, d, J = 1.8), 7.03 (H-6’, d, J = 8.4), 7.95 (H-2, s) 
1H NMR data are measured in ppm and coupling constants (J) in Hertz. 
 
  Antibacterial evaluation of the compounds isolated from Cytisus striatus 
The MICs of luteolin, apigenin, chrysin, genistein and daidzein against S. aureus strains were 
determined (TABLE 4.11). Unfortunately, it was not possible to isolate enough 2’-
hydroxygenistein and 3’-hydroxydaidzein for biological assays. Luteolin was the only compound 
that showed antibacterial activity against S. aureus with mild MIC between 30 and 120 mg l-1. 
The potentiating effect of the five isolated compounds on the activity of ciprofloxacin and 
erythromycin was tested by checkerboard (TABLE 4.11) and the FICIs were calculated. The 
minimal concentration of compounds that exhibited antibiotic potentiation is shown for each 
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strain. Synergy (for luteolin) or potentiation (for the non-antibacterial phytochemicals) was 
considered for FICI ≤ 0.5. 
 
TABLE 4.11 | Minimal inhibitory concentrations (MIC, mg l-1) of the isolated compounds 
from Cytisus striatus against Staphylococcus aureus strains applied alone (MICa) and in 
combination (MICb) with ciprofloxacin (CIP) or erythromycin (ERY). Antibiotic MICs 
fold-reductions (R) and fractional inhibitory concentration index (FICI) values are shown 
- = no decrease or increase in the MIC was observed; n.p. not performed; *no MIC was detected for erythromycin alone 
against RWW337, but when combined with apigenin and genistein. MIC for erythromycin was found to be at least ½ 
(not conclusive) and ¼ of the maximal concentration tested, respectively. When FICI ≤ 0.5 (in bold), if the 
phytochemical has a determinable MIC value the effect is considered as synergy (S); if the phytochemical has no 
detectable MIC the effect is called potentiation (P). If FICI > 0.5, the interaction is indifferent (I). Erythromycin was 
not tested against SA1199B strain. The experiments were repeated three times and the values presented are the averages 
of at least three independent assays. Lut: luteolin; Apig: apigenin; Chry: chrysin; Gen: genistein. 
 
 CIP   ERY  
 Lut Apig Chry Gen Daid  Lut Apig Chry Gen Daid 
M
1
1
6
 
MICa 30 >120 >120 >120 >120  30 >120 >120 >120 >120 
MICb - 30 - 60 15  3.5 30 - 30 - 
R - 4 - 4 2  2 4 - 4 - 
FICI I ≤0.38 (P) I ≤0.50 (P) >0.5 (I)  0.63 (I) ≤0.38 (P) I ≤0.38 (P) I 
R
W
W
3
3
7
 
MICa 30 >120 >120 >120 >120  30 >120 >120 >120 >120 
MICb - 60 - 60 -  - 30 - 60 - 
R - 8 - 8 -  - ≥2 - ≥4 - 
FICI I ≤0.38 (P) I ≤0.38 (P) I  I* (*) I* ≤0.50 (P)* I* 
R
W
W
5
0
 MICa 60 >120 >120 >120 >120  30 >120 >120 >120 >120 
MICb - 15 - 30 -  - - - 60 - 
R - 2 - 2 -  - - - 4 - 
FICI I >0.5 (I) I >0.5 (I) I  I I I ≤0.50 (P) I 
M
8
2
 
MICa 120 >120 >120 >120 >120  60 >120 >120 >120 >120 
MICb 60 30 - 30 -  60 - - 30 - 
R 4 2 - 2 -  4 - - 2 - 
FICI 0.75 (I) >0.5 (I) I >0.5 (I) I  0.75 (I) I I >0.5 (I) I 
R
N
6
3
9
0
 MICa 120 >120 >120 >120 >120  120 >120 >120 >120 >120 
MICb - - - - -  - - - - - 
R - - - - -  - - - - - 
FICI I I I I I  I I I I I 
C
E
C
T
 9
7
6
 
MICa 120 >120 >120 >120 >120  120 >120 >120 >120 >120 
MICb - - - 30 30  - - - 30 - 
R - - - 4 2  - - - 4 - 
FICI I I I ≤0.38 (P) >0.5 (I)  I I I ≤0.38 (P) I 
S
A
1
1
9
9
B
 MICa 120 >120 >120 >120 >120 
 
n.p. MICb - 10 - 60 60  
R - 2 - 8 4  
FICI I >0.5 (I) I ≤0.38 (P) ≤0.25 (P)  
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No synergistic effects were obtained with luteolin when combined with ciprofloxacin or 
erythromycin (FICI > 0.5). The MIC of ciprofloxacin against ST239 was reduced 4- and 8-fold 
by apigenin (15 – 60 mg l-1) and its isoflavone analogue genistein (30 – 60 mg l-1), respectively. 
Genistein also reduced by 8-fold the MIC of ciprofloxacin against SA1199B (reversing the 
resistance of this strain) but not apigenin. Daidzein (60 mg l-1) only potentiated ciprofloxacin 
against SA1199B (4-fold reduction of the MIC of this antibiotic). Genistein produced a 4-fold 
reduction of the MIC of erythromycin against ST239 and USA300 strains. No potentiating effect 
was obtained with chrysin. No potentiation effect was observed with any of the compounds 
against the susceptible strains CECT 976, M82 and RN6390, excepting for genistein against 
CECT 976 (4-fold reduction of the MIC of ciprofloxacin and erythromycin). Ciprofloxacin-
potentiation promoted by the compounds isolated from C. striatus was confirmed by disk 
diffusion method (TABLE 4.12), but erythromycin potentiation was more difficult to detect for 
MRSA strains, maybe because no inhibition halo was observed for erythromycin against some of 
these strains.  
  
TABLE 4.12 | Antibiotic-potentiating activity promoted by four phytochemicals found in 
Cytisus striatus against Staphylococcus aureus detected by disk diffusion method. 
 The activity is expressed as the increase in the diameter of growth inhibition zones 
(mm) promoted by ciprofloxacin (CIP) and erythromycin (ERY) in the presence of 
the isoflavonoids (60 mg l-1) dissolved in Mueller-Hinton agar medium 
  Increased IZD (IZDc – IZDa) (mm) 
  Apigenin Chrysin Genistein Daidzein 
CECT 976 CIP - - 10.0 ± 0.0 (P) 4.0 ± 0.0 (A) 
ERY - - 6.0 ± 0.0 (P) - 
M116 CIP 8.0 ± 1.0 (P) - 9.0 ± 0.0 (P) - 
 ERY - - 4.3 ± 0.6 (A) - 
RWW337 CIP 8.0 ± 1.0 (P) 4.5 ± 1.0 (A) 7.0 ± 1.0 (P) - 
 ERY - - - - 
RWW50 CIP 10.0 ± 0.0 (P) 5.0 ± 0.0 (A) 8.3 ± 0.6 (P) - 
 ERY - - - - 
M82 CIP 5.3 ± 0.6 (A) - 4.0 ± 1.0 (A) - 
 ERY - - 4.0 ± 0.0 (A) - 
RN6390 CIP - - - - 
 ERY - - - - 
SA1199B CIP 4.6 ± 0.3 (A) 4.0 ± 0.0 (A) 10.0 ± 0.0 (P) 13.0 ± 1.0 (P) 
 ERY n.p. n.p. n.p. n.p. 
n.p.: not performed; - no significant increase over antibiotic activity (P > 0.05). Inhibition zones obtained with the 
combinations (IZDc) over antibiotic-single activity (IZDa) are given and classified as: (-) indifferent (IZDc – IZDa < 4 
mm); (A) additive (4 ≤ IZDc – IZDa < 6 mm); and (P) potentiation (IZDc – IZDa ≥ 6 mm, in bold). Data are means and 
SD from at least three independent experiments. 
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Dual combinations between luteolin and the other flavonoids/isoflavonoids found in C. 
striatus were performed to understand if luteolin, the main antibacterial compound produced by 
C. striatus, would benefit from the presence of the other compounds. Luteolin MIC was not 
reduced by the presence of any compound applied alone (120 mg l-1). It would be interesting to 
test multiple combinations of the compounds. However, detecting the high number of possible 
dual and multiple interactions of the compounds as well as their optimal doses is extremely 
challenging. To assess and predict real interactions of the compounds, it would be valuable to test 
the effects of such combinations against plant pathogens. This would allow a better perception of 
the defense system of this plant.  
Apigenin and genistein presented the best potentiating results, and this in agreement with the 
analysis of the S-plot in FIGURE 4.11. However, genistein and daidzein were able to potentiate 
ciprofloxacin (4-8 fold) against the NorA overexpressing SA1199B, indicating that these 
isoflavonoids may be efflux pump inhibitors. To confirm this hypothesis, EtBr accumulation in 
SA1199B and on MRSA strains was assessed in the presence of these compounds by fluorometry. 
 
  Effect of the compounds isolated from Cytisus striatus on EtBr accumulation 
Fluoroquinolone resistance in S. aureus has been mainly attributed to mutations occurring in 
the cellular targets GrlA/GrlB (topoisomerase IV, encoded by genes grlA/grlB) and GyrA/GyrB 
(DNA gyrase, encoded by genes gyrA/gyrB). However, reports of antibiotic resistance mediated 
by efflux pumps in S. aureus is also greatly observed for fluoroquinolones, as well as for 
tetracyclines and macrolides (Costa et al., 2013). S. aureus encodes several MDR efﬂux pumps 
among which NorA has been extensively examined.  
The potential of the non-antibacterial compounds isolated from C. striatus to inhibit efflux 
pumps was assessed on S. aureus SA1199B. The MIC of EtBr for SA1199B cells was previously 
determined according to CLSI (2015a) guidelines as described in Section 3.2.1.2. Accumulation 
of EtBr applied at ½ MIC, to avoid compromising the cellular viability, was measured 
fluorometrically. The real-time setup and sensitivity of the fluorometric method allowed the 
observation of the effect of the phytochemicals (60 mg l-1) on the overtime accumulation of EtBr 
(20 mg l-1) in S. aureus SA1199B (FIGURE 4.12).  
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FIGURE 4.12 | Detection of the effect of the compounds isolated from the active fraction of 
Cytisus striatus on ethidium bromide accumulation in Staphylococcus aureus SA1199B.  
The bacteria were loaded with EtBr at 20 mg l-1 in the presence of the phytochemicals (60 
mg l-1) for 60 min at 37°C and fluorescence measured. Mean values of at least three 
independent experiments are shown. Reserpine at 20 mg l-1 was used as a positive control. 
 
Reserpine control (20 mg l-1) showed the best EtBr accumulation, confirming the EPI activity. 
Genistein and, in less extension, apigenin increased the accumulation of EtBr in SA1199B until 
approximately 20 min, after which either the signal levels slightly reduced (for apigenin, to values 
lower than the control, P < 0.05). Daidzein also showed high EtBr accumulation over time (P < 
0.05). This increased EtBr accumulation obtained with daidzein and genistein may be due to a 
NorA inhibition, which could explain the ciprofloxacin-potentiation by 4- and 8-fold, 
respectively, verified against SA1199B (TABLE 4.13). In line with these observations, apigenin 
only achieved a 2-fold potentiation of ciprofloxacin against SA1199B and no effect was observed 
with chrysin (P < 0.05).  
The effect of the phytochemicals on the accumulation of EtBr was also tested by fluorometry 
for strains M116, RWW337 and RWW50. The MIC of EtBr was determined for each strain using 
the microdilution technique, resulting in 5 mg l-1 for M116 and RWW50 and 40 mg l-1 for 
RWW337. The three MRSA strains also showed a poor accumulation of EtBr, suggesting that, 
contrarily to the other strains, there is overexpression of NorA or other related MDR efflux pumps 
in these strains. Relative fluorescence (RF) values were calculated using the maximal 
fluorescence intensities (MFI) of each assay (FIGURE 4.13).  
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FIGURE 4.13 | Detection of the effect of the compounds isolated from the active fraction 
of Cytisus striatus on ethidium bromide accumulation in ST239 and USA300 strains.  
Relative fluorescence (RF) values were calculated for the isolated compounds from 
C. striatus by fluorometry in SA1199B and MRSA strains: RFassay = (MFIassay – 
FIcontrol)/ FIcontrol, where MFIassay was the Maximal Fluorescence Intensity obtained in 
each 60 min assay and FIcontrol was the correspondent Fluorescence Intensity obtained 
with the DMSO control at the same time. Reserpine (20 mg l-1) was used as positive 
EPI control. Bars with (*) accumulated more EtBr than the control (P < 0.05). RFs 
are averages and standard deviations of three independent assays. 
 
High RF values indicated that cells accumulated more EtBr under the tested conditions than 
the control and vice-versa for negative values. Reserpine showed high RF values for all the MRSA 
strains, confirming that this compound is inhibiting MDR efflux pumps. Despite being an EPI 
universally used for Gram-positive bacteria in predicting pump gene overexpression, it seems that 
the use of reserpine to predict the contribution of efflux to the reduced susceptibility in clinical S. 
aureus isolates is not reliable and reserpine may fail to identify overexpression of staphylococcal 
MDR pump genes using microdilution susceptibility testing (Frempong-Manso et al., 2008).  
Genistein also showed significant RF values for all MRSA strains (P < 0.05). The fact that 
genistein potentiated ciprofloxacin against these MRSA strains is in line with these observations. 
Daidzein only showed significant RF values (P < 0.05) for SA1199B and, likewise, this 
compound only caused ciprofloxacin potentiation on SA1199B strain. Apigenin achieved inferior 
RF values for MRSA strain even though this flavonoid was able to potentiate ciprofloxacin 
against MRSA strains. Other mechanisms may be involved in the potentiation observed with this 
compound. Chrysin, as expected, showed inferior RF values than the other compounds. 
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  Effect of the compounds isolated from Cytisus striatus on biofilm control 
As mentioned before, eradication of biofilms has been a challenging task due to the biological 
complexity of the biofilm structure (Kishen et al., 2010). Combination of one antibiotic with a 
biofilm inhibitor could eventually improve the treatment of biofilm-related infections.  
The effect of the five compounds isolated from C. striatus was evaluated for their activity on 
biofilms. The exposure of the compounds for 1 and 24 h was first evaluated against biofilms of 
S. aureus CECT 976, which is the reference strain for biofilm assays. The number of CFU cm-2 
of the biofilms obtained is shown in FIGURE 4.14, as well as the percentages of biofilm reduction. 
Ciprofloxacin and erythromycin were also applied at MIC, for comparison. Previously (in Section 
4.2.1), it was found that no differences were obtained among application of these antibiotics at 
MIC, 10 × MIC or 50 × MIC.  
 
1 h 
% biofilm 
reduction 
24 h 
% biofilm 
reduction 
  
22.2 ± 2.0 48.2 ± 1.7 
18.4 ± 1.4 41.5 ± 2.0 
16.6 ± 3.0 - 
- - 
8.4 ± 2.9 20.0 ± 3.0 
- 11.8 ± 2.4 
- 20.0 ± 1.2 
FIGURE 4.14 | CFU cm-2 of biofilms of Staphylococcus aureus CECT 976 after exposure 
to the five phytochemicals isolated from Cytisus striatus at 60 mg l-1 for 1 and 24 h.  
Biofilm reductions (%) are shown. (*) when statistically higher than GC (P < 0.05), 
(a) when statistically lower than GC (P < 0.05). GC – growth control (5% v v-1 
DMSO). 
 
Despite having antibacterial activity, luteolin at 60 mg l-1 did not cause any significant 
reduction of CECT 976 biofilms when applied for 1 h (only 17%), and even increased the amount 
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of biofilm formed comparing to the control, when applied for 24 h (P > 0.05). Similarly, apigenin 
and chrysin applied at 60 mg l-1, either for 1 h or 24 h, did not promote any significant reduction 
of CECT 976 biofilms. The isoflavonoids genistein and daidzein only significantly removed 
CECT 976 biofilms when applied for 24 h, but only by 12 and 20%, respectively.  
The effects of the compounds were also assessed on SA1199B biofilms after 1 and 24 h 
exposure. The interest of testing this strain was to understand if the phytochemicals acting as 
EPIs, mostly daidzein and also genistein, could promote better biofilm control activities. The 
number of CFU cm-2 of biofilms obtained is presented in FIGURE 4.15 along with the percentages 
of biofilm reduction. 
 
1 h 
% biofilm 
reduction 
24 h 
% biofilm 
reduction 
  
41.8 ± 3.7 93.9 ± 2.3 
  
- 17.8 ± 2.7 
13.8 ± 2.2 99.6 ± 0.6 
  
40.6 ± 3.0 39.7 ± 4.5 
56.7 ± 2.3 99.2 ± 0.8 
  
42.4 ± 3.2 41.5 ± 2.4 
45.5 ± 2.5 99.3 ± 1.0 
  
23.8 ± 1.4 9.9 ± 6.5 
58.4 ± 1.2 85.6 ± 3.0 
  
61.8 ± 2.2 63.0 ± 1.6 
45.2 ± 1.2 99.2 ± 1.5 
  
  
FIGURE 4.15 | CFU cm-2 of biofilms of Staphylococcus aureus SA1199B after exposure 
to the five phytochemicals isolated from Cytisus striatus at 60 mg l-1 for 1 and 24 h.  
Biofilm reductions (%) are shown. (a) when statistically lower than GC (P < 0.05), 
and (b) than both GC and ciprofloxacin applied alone (P < 0.05). GC – growth control 
(5% v v-1 DMSO). 
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Similarly, luteolin applied alone at 60 mg l-1 caused no considerable reduction on SA1199B 
biofilms (only of 18% when applied for 24 h, P < 0.05) and neither caused genistein (24 and 10% 
for 1 and 24 of exposure, respectively). Apigenin and chrysin caused approximately 40% of 
biofilm reduction for both 1 and 24 h of exposure. Daidzein showed the best removal activity 
when applied alone, achieving 62% of biofilm reduction when exposed for 1 h and 63% for 24 h. 
This activity may be related to its EPI activity on SA1199B strain.  
Combinations between the phytochemicals with ciprofloxacin were not always advantageous 
for exposures of 1 h, excepting for combination with apigenin and genistein (P < 0.05). For 
exposures of 24 h, combinations ciprofloxacin-phytochemicals achieved better results (around 
99% of biofilm reduction) than when the compounds were applied alone (P < 0.05), excepting for 
the combination with genistein that caused worst results comparing to when ciprofloxacin was 
applied individually (P < 0.05). Still, these combinations are not considered synergic according 
to Monzón et al. (2001). 
 
  Relevant remarks 
The chemical novelty and diversity of natural products, especially those derived from plants, 
is higher than that of synthetic sources. Moreover, through evolution they have been selected as 
effective compounds in various survival strategies of different organisms. In plants this has 
resulted for example, in resistance against most microorganisms. The antimicrobial properties 
displayed by a number of plants can be attributed, generally, to mixtures of active constituents 
(Mukne et al., 2011). It is also known that plants can produce inhibitors as a protection against 
multidrug resistant pathogens ensuring the efficient delivery of the antimicrobial compounds. A 
good example of this is provided by Tegos et al. (2002). The role of phytochemistry in the search 
for S. aureus NorA inhibitors is significant, having led to the discovery of several chemically 
diverse plant-derived EPIs, including flavones, isoflavones, acylated glycosides, porphyrin 
phaeophorbide A or kaempferol rhamnoside (Handzlik et al., 2013), among others. 
As a bioassay-guided fractionation does not generally detect synergy, metabolomics was used 
as an alternative strategy. Whether using LC-MS or NMR as an analytical platform, it is necessary 
to have a larger number of samples with different levels of the different plant metabolites to be 
able to detect signals or peaks related to activity. These could be samples of different plants, or 
different extracts from the same plant and/or their fractions. An example of the use of fractions 
was reported by Yuliana et al. (2011). When fractionation is used there is, of course, the risk that 
interacting molecules have been separated. In this strategy, this could be circumvented by using 
different extracts for fractionation. With this approach, it was proven that even using one single 
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plant, it was possible to obtain a variety of different extracts by mixing the different plant parts in 
different rations and extracting them under different conditions. Applying multivariate data 
analysis to the resulting NMR spectra then allowed the identification of signals that were 
correlated to activity. 
The present study resulted in the identification of one main antibacterial compound in C. 
striatus leaf extract - luteolin - with MICs between 30 and 120 mg l-1 against various S. aureus 
strains. Surprisingly, luteolin had lower MICs for ST239-MRSA strains when compared to 
antibiotic-susceptible strains. The multivariate data analysis also revealed correlations of the 
activity with a number of other phenolics. These were isolated and identified as apigenin, 
daidzein, genistein, 2’-hydroxygenistein and 3’-hydroxydaidzein. Among these, apigenin and 
genistein clearly showed potentiation of the antibiotics against ST239 and USA300-MRSA 
strains but not against the susceptible strains M82 and RN6390. Daidzein showed some weaker 
potentiating activity against cell line M116 and against the resistant line SA1199B (4-fold 
increase). 
Sato et al. (2000) also reported an antibacterial activity for luteolin with MICs between 62.5 – 
125 mg l-1 against MRSA and MSSA strains. Apigenin showed no MIC for concentrations below 
120 mg l-1, in agreement with other studies that reported values of up to 128 mg l-1 (Basile et al., 
2000). Other authors, however, report a MIC in the range of 3.9 to 15.6 mg l-1 for 15 MRSA and 
5 MSSA strains (Sato et al., 2000). Genistein also showed no detectable MIC until 120 mg l-1. In 
agreement, Albert Dhayakaran et al. (2015) reported that MRSA strains and their biofilms were 
not inhibited by soy isoflavones, including genistein and daidzein (until 100 mg l-1), and Morán 
et al. (2014) reported no MIC for genistein until 2 g l-1 against S. aureus CECT 59. Contrarily, 
other group found growth inhibition of an enteroisolate of S. aureus of more than 90% by either 
genistein or daidzein at 125 mg l-1 (Parkar et al., 2008). Hong et al. (2006) revealed that CFU 
determination results at 8 h of incubation showed the inhibitory effects of genistein (270 mg l-1) 
on S. aureus and MRSA strains but not at 15 and 24 hours, probably due to the degradation of 
genistein in culture or outgrowth of bacteria. It is known and it was mentioned before that results 
of antibacterial activity of phenolic compounds can be widely inconsistent as reported by Cushnie 
and Lamb (2005), probably owing to variations in their susceptibility testing and differences in 
genetic determinants of the strains, culture conditions, antimicrobial tests, etc. Wang et al. (2014) 
reported that genistein reduced the MIC of norfloxacin against SA1199B by four times and had a 
moderate efflux pump inhibitory effect against the same strain.  
Flavonoids have been reported to exert a number of biological activities. These activities have 
been attributed to many molecular mechanisms, including the modulation of the activities of 
phase I and II detoxification enzymes, direct and indirect antioxidant activities, inhibition of 
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protein kinases, effects on cell cycle, modulation of gene transcription, and epigenetic activities 
(Busch et al., 2015). The B ring of flavonoids can intercalate or form hydrogen bonds with the 
stacking of nucleic acid bases and further lead to inhibition of DNA and RNA synthesis in bacteria 
and influence DNA gyrase activity (Mierziak et al., 2014). Genistein has been described as a 
tyrosine kinase and topoisomerase II inhibitor (Verdrengh et al., 2004) and for its antioxidant, 
estrogenic and antiangiogenic properties. Other study also refers that genistein, apigenin and other 
isoflavone, biochanin A, inhibited topoisomerase II to the same extent as etoposide, a specific 
inhibitor of the enzyme (Azuma et al., 1995). This inhibition could explain the potentiation 
observed with genistein and apigenin with ciprofloxacin. Since ciprofloxacin also functions by 
inhibiting DNA gyrase, the presence of a second compound with the same target could inhibit or 
potentiate its activity. It was also observed the same effect with quercetin (in Sections 4.1 and 
4.2). However, more conclusive studies are necessary to verify such effect. 
Ethidium bromide accumulation assays allowed to conclude that genistein and daidzein 
increased EtBr accumulation in SA1199B cells, thus presenting a EPI activity on NorA efflux 
pump. This result could explain the potentiation of ciprofloxacin against the same strain. Daidzein 
failed to show the same effect for the other MRSA strains, while genistein showed significant 
results, being in line with the fact that genistein potentiated ciprofloxacin also against the MRSA 
strains.  
When studying efflux activity in clinical isolates instead of well-defined collection strains, the 
myriad of bacterial responses can complicate the clear interpretation of data. The role played by 
each individual efflux system is difficult to determine. Each efflux system is regulated by several 
specific and/or global regulators that act in an intricate network of regulatory/sensory pathways. 
Bacterial response to ciprofloxacin is mediated, in most of the cases, not by one single efflux 
pump but by several (such as SdrM, MdeA, MepA, NorB or NorC) (Costa et al., 2013) hampering 
the perception of the role played by each individual pump on the overall efflux activity/resistance 
phenotype. For example, even if the isoflavonoids are successful in inhibiting NorA, which could 
be detected by an increase EtBr accumulation in SA1199B strain, when testing other clinical 
isolates, efflux pumps others than NorA can be overexpressed and can still extrude ciprofloxacin 
out of the cell. Frempong-Manso et al. (2008) revealed that nearly one-half of clinical isolates 
with an efflux phenotype were overexpressing norA-B-C, mepA or mdeA. Costa et al. (2011) 
described the predominance of norB overexpression among a collection of S. aureus bloodstream 
isolates, while norA was the only for which no overexpression was detected. Thus, it is suggested 
that other efflux pumps than NorA can have a more relevant role in the resistance to 
fluoroquinolones and EtBr in S. aureus. The same substrate can also promote the expression of 
different efflux pump genes depending on its concentration and/or time of exposure (Costa et al., 
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2011). Even isolates belonging to the same clonal type can have distinct levels of efflux activity 
and respond to the same agent through the activation of different efflux pumps (Costa et al., 2011). 
More studies are necessary to clearly define the molecular, functional and genetic bases of the 
efflux pumps being expressed by these S. aureus strains. Detection of MDR efflux pumps gene 
expression analysis using quantitative real-time reverse transcription polymerase chain reaction 
(qRT-PCR) would be valuable for a deeper study of this phenomenon.  
Among the five phytochemicals tested, daidzein showed the best eradication of SA1199B 
biofilms: 62 and 63 % of biofilm reduction when exposed for 1 and 24 h, respectively. However, 
against CECT 976 biofilms, the maximal biofilm reduction was only 20%, obtained after 24 h 
exposure. The apparently opposite effect observed with the same metabolite on biofilms formed 
by different strains can be a consequence of the multiple molecules and factors that characterize 
a biofilm (adhesion factors, quorum sensing, extracellular polymers in the matrix, etc.) and that 
indeed can differ between bacterial species (Morán et al., 2014). Also, it is suggestive that the 
anti-biofilm effect of daidzein may be related to its EPI activity. Kvist et al. (2008) refers that 
some EPIs reduced biofilm formation and, when in combination, they could abolish biofilm 
formation completely. Any relevant study was found about the activity of daidzein on biofilms. 
Nevertheless, an anti-biofilm activity against S. aureus was demonstrated for genistein at 
500 mg l-1, which inhibited S. aureus biofilm formation by 45% (Morán et al., 2014).  
This study aimed to identify active antibiotic adjuvants from a promising plant, Cytisus 
striatus, by a metabolomics approach, which proved to be very efficient on the detection of 
synergistic activities among plant metabolites. These results reveal very clear potentiation effects 
between plant secondary metabolites (belonging to flavonoid and isoflavonoid class) and two 
antibiotics, showing a promising potential for the application of these systems in the treatment of 
infectious diseases caused by MRSA in clinical settings. 
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 TASK 5. EVALUATION OF THE STRUCTURE-ACTIVITY RELATIONSHIP 
OF ISOFLAVONOIDS AS ANTIBIOTIC ADJUVANTS IN CLINICAL THERAPY 
 
Abstract 
For SAR evaluation purposes, 22 isoflavonoids were assessed as antibiotic adjuvants 
against S. aureus and MRSA strains. Genistein, tectorigenin and biochanin A were 
highlighted being able to potentiate ciprofloxacin and erythromycin by 2-8 fold, 
especially against ST239 and USA300 MRSA strains. The NorA efflux pump 
inhibitory activity of the isoflavonoids was also tested as a possible mechanism for 
this coadjuvant activity and, besides genistein and daidzein, biochanin A, calycosin, 
irigenin, irisflorentin and tectorigenin were found to be active. The possible inhibition 
of Erm methyltransferases was tested but no effect was found. The effect of the 
isoflavonoids on the eradication of biofilms was also assessed, being highlighted 
daidzein and irisflorentin. This study reveals the great potential for the application of 
isoflavonoids in clinical therapy of MRSA infection. 
 
 
  Antibacterial evaluation of isoflavonoids 
The antimicrobial activity of isoflavonoids (low or moderate activity in most cases) has been 
reported (Chacha et al., 2005; Dastidar et al., 2004; Osawa et al., 1992), and they are seemingly 
involved in the inducible defense response of Leguminosae plants. However, their mechanism of 
action remains largely unexplained. Similarly, the potentiating activity of ciprofloxacin against S. 
aureus described for some isoflavonoids (Belofsky et al., 2006; Morel et al., 2003; Tanaka et al., 
2002; Wang et al., 2014), has yet to be understood.  
For SAR purposes, twenty-two structurally different isoflavonoids were analysed for their 
antibacterial and antibiotic-potentiating properties. The chemical structures of the compounds 
tested were previously shown in TABLE 3.4, Section 3.1.6. TABLE 4.13 shows the MICs 
obtained for the active isoflavonoids alone and combined with ciprofloxacin and erythromycin.  
From the 22 isoflavonoids tested, only three showed antibacterial activity below 120 mg l-1: 
neobavaisoflavone, corylifol A and orobol. Synergy was obtained with neobavaisoflavone 
combined with ciprofloxacin against SA1199B (FICI of 0.5) and corylifol A combined with both 
ciprofloxacin and erythromycin against RWW337 (FICIs of 0.38).  
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TABLE 4.13 | Minimal inhibitory concentrations (MICs) of the isoflavonoids against 
Staphylococcus aureus when applied alone (MICa) and in combination (MICb) with 
ciprofloxacin (CIP) or erythromycin (ERY). Fold-reductions of antibiotic MICs (R) 
and fractional inhibitory concentration index (FICIs) values are shown 
 
 CIP 
 
 Neob CorA Orob Gen Tect BiochA Calyc Irig Gly Daid Irisfl 
M
1
1
6
 
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 5 - 60 60 60 30 - - - 15 - 
R 2 - 8 4 2 4 - - - 2 - 
FICI 0.75 (I) I 0.63 (I) ≤0.50 (P) >0.5 (I) ≤0.38 (P) I I I >0.5 (I) I 
R
W
W
3
3
7
 
MICa 20 20 120 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 5 5 60 60 60 30 30 60 - - - 
R 2 8 4 8 4 4 2 2 - - - 
FICI 0.75 (I) 0.38 (S) 0.63 (I) ≤0.38 (P) ≤0.50 (P) ≤0.38 (P) >0.5 (I) >0.5 (I) I I I 
R
W
W
5
0
 
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 10 - - 30 60 15 30 30 - - - 
R 4 - - 2 2 2 2 2 - - - 
FICI 0.75 (I) I I >0.5 (I) >0.5 (I) >0.5 (I) >0.5 (I) >0.5 (I) I I I 
M
8
2
 
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 10 1.25 - 30 30 30 - 60 - - - 
R 4 2 - 2 2 2 - 2 - - - 
FICI 0.75 (I) 1 (I) I >0.5 (I) >0.5 (I) >0.5 (I) I I I I I 
R
N
6
3
9
0
 
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 10 - - - - - - - - - - 
R 4 - - - - - - - - - - 
FICI 0.75 (I) I I I I I I I I I I 
C
E
C
T
 9
7
6
 
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 10 - - 30 60 60 60 60 - 30 60 
R 2 - - 4 2 2 2 2 - 2 2 
FICI 1.0 (I) I I ≤0.38 (P) >0.5 (I) >0.5 (I) >0.5 (I) >0.5 (I) I >0.5 (I) >0.5 (I) 
S
A
1
1
9
9
B
 MICa 20 0.06 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 5 - 15 60 60 30 60 60 60 60 60 
R 4 - 2 8 4 8 4 4 2 4 4 
FICI 0.50 (S) I >0.5 (I) ≤0.38 (P) ≤0.50 (P) ≤0.38 (P) ≤0.50 (P) ≤0.50 (P) >0.5 (I) ≤0.25 (P) ≤0.50 (P) 
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 ERY 
 
 Neob. Cor.A Orob Gen Tect Bioch.A Calyc Irig Gly Daid Irisfl 
M
1
1
6
 
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120 
MICb - 1.25 - 30 60 15 30 60 - - - 
R - 2 - 4 4 4 2 2 - - - 
FICI I 1 (I) I ≤0.38 (P) ≤0.38 (P) ≤0.28 (P) >0.5 (I) >0.5 (I) I I I 
R
W
W
3
3
7
 
MICa 20 20 120 240 >240 >240 >240 >240 >120 >120 >120 
MICb - 5 60 60 120 60 - - - - - 
R - ≥8 ≥4 ≥4 ≥2 ≥4 - - - - - 
FICI I* ≤0.38 (S)* >0.50 
(I)* 
≤0.50 (P)* (*) ≤0.50 (P)* I* I* I I I 
R
W
W
5
0
 
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 10 - - 60 60 60 30 60 - - - 
R 8 - - 4 4 4 2 2 - - - 
FICI 0.63 (I) I* I* ≤0.50 (P) ≤0.50 (P) ≤0.50 (P) >0.5 (I) >0.5 (I) I I I 
M
8
2
 
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 5 1.25 - 30 60 30 120 60 - - - 
R 2 2 - 2 2 2 2 2 - - - 
FICI 0.75 (I) 1 (I) I ≥0.56 (I) ≥0.63 (I) ≥0.56 (I) >0.5 (I) >0.5 (I) I I I 
R
N
6
3
9
0
 
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb 10 - - - - - - - - - - 
R 4 - - - - - - - - - - 
FICI 0.75 (I) I I I I I I I I I I 
C
E
C
T
 9
7
6
 MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120 
MICb - 1.25 - 30 60 - 60 60 - - - 
R - 2 - 4 2 - 2 2 - - - 
FICI I 1 (I) I ≤0.38 (P) >0.5 (I) I >0.5 (I) >0.5 (I) I I I 
- = no decrease or increase in the MIC was observed; n.p. not performed; *no MIC was detected for erythromycin alone 
against RWW337, but when combined with genistein and biochanin A, erythromycin MIC was found to be at least ¼ 
of the maximal concentration tested, and at least ½ for tectorigenin. When FICI ≤ 0.5 (in bold), if the isoflavonoid has 
a determinable MIC value, the effect is considered as synergy (S); if the isoflavonoid has no detectable MIC, the effect 
is called potentiation (P). If FICI > 0.5, the interaction is considered indifferent (I). Isoflavonoids showing only 
indifferent effects were not included. ERY was not tested against SA1199B. The experiments were repeated three 
times, and the values presented are the averages of three independent assays. Neob: neobavaisoflavone; CoryA: 
corylifol A; Orob: orobol; Gen: genistein; Tect: tectorigenin; BiochA: biochanin A; Calyc: calycosin; Irig: irigenin; 
Gly: glycitein; Daid: daidzein; Irisfl: irisflorentin. 
 
Concerning the non-antibacterial isoflavonoids, biochanin A (15 – 60 mg l-1) and tectorigenin 
(60 – 120 mg l-1) have a similar activity to genistein (30 – 60 mg l-1) when combined with 
ciprofloxacin and erythromycin against all cell lines except for the susceptible strains CECT 976, 
M82 and RN6390, for which no activity was found. Additionally, calycosin, irisflorentin, irigenin 
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and daidzein (60 mg l-1) were also able to reduce the MIC of ciprofloxacin by 4-fold against the 
NorA overexpressing strain SA1199B.  
The disk diffusion method was also performed to confirm these antibiotic-potentiating results 
promoted by the non-antibacterial isoflavonoids, which were dissolved in MH agar at 60 mg l-1. 
The increase on IZDs in the presence of isoflavonoids over antibiotic single activity is shown in 
TABLE 4.14.  
 
TABLE 4.14 | Antibiotic-potentiating activity of isoflavonoids by disk diffusion method. 
The activity is expressed as the increase in the diameter of growth inhibition zones 
(mm) promoted by the antibiotics with ciprofloxacin (CIP) and erythromycin (ERY) 
in the presence of the isoflavonoids in MH agar medium and applied at 60 mg l-1 
Increased IZD (IZDc – IZDa) (mm) 
S. aureus  Gen Bioch A Tecto Irig Calyc Daid Glyc Irisfl 
M116 CIP 9.0 ± 0.0 
(P) 
7.0 ± 0.0 
(P) 
5.0 ± 0.0 
(A) 
4.3 ± 0.6 
(P) 
4.0 ± 0.0 
(P) 
- - - 
 ERY 4.3 ± 0.6 
(A) 
- 0 - - - - - 
RWW337 CIP 7.0 ± 1.0 
(P) 
6.5 ± 1.0 
(P) 
6.0 ± 0.0 
(P) 
- - - - - 
 ERY - - - - - - - - 
RWW50 CIP 8.3 ± 0.6 
(P) 
6.0 ± 1.0 
(P) 
6.5 ± 1.0 
(P) 
4.6 ± 0.3 
(A) 
5.0 ± 1.0 
(A) 
- - - 
 ERY - - - - - - - - 
M82 CIP 4.0 ± 1.0 
(A) 
5.0 ± 0.0 
(A) 
4.0 ± 0.0 
(A) 
- - - - - 
 ERY 4.0 ± 0.0 
(A) 
- 5.0 ± 0.0 
(A) 
- - - - - 
RN6390 CIP - - - - - - - - 
 ERY - - - - - - - - 
CECT 976 CIP 10.0 ± 0.0 
(P) 
- 4.0 ± 0.0 
(A) 
5.0 ± 0.0 
(A) 
5.0 ± 0.0 
(A) 
4.0 ± 0.0 
(A) 
- 5.0 ± 0.0 
(A) 
 ERY 6.0 ± 0.0 
(P) 
- 5.0 ± 0.0 
(A) 
5.0 ± 0.0 
(A) 
4.0 ± 0.0 
(A) 
- - - 
SA1199B CIP 10.0 ± 0.0 
(P) 
12.0 ± 2.0 
(P) 
10.0 ± 0.0 
(P) 
11.0 ± 1.0 
(P) 
8.0 ± 0.0 
(P) 
13.0 ± 1.0 
(P)  
5.0 ± 1.0 
(A) 
6.0 ± 0.0 
(P) 
ERY n.p. n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
n.p.: not performed; - no significant increased over antibiotic activity (P > 0.05); Inhibition zones obtained with the 
combinations (IZDc) over antibiotic-single activity (IZDa) are given and classified as: (-) indifferent (IZDc – IZDa < 4 
mm); (A) additive (4 ≤ IZDc – IZDa < 6 mm); and (P) potentiation (IZDc – IZDa ≥ 6 mm, in bold). Data are means and 
SD from at least three independent experiments. 
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As previously observed, potentiation of erythromycin by any isoflavonoid was poorly detected 
for MRSA strains using the disk diffusion method. Despite that, several potentiation effects of 
ciprofloxacin obtained by this method were in agreement with the checkerboard results. Besides 
genistein and daidzein, as previously reported, many isoflavonoids showed to potentiate 
ciprofloxacin against SA1199B, which is resistant to ciprofloxacin due to the overexpression of 
NorA. Thus, the possibility of inhibition of this efflux pump was also investigated for all the 
isoflavonoids. 
 
  Effect of isoflavonoids on EtBr accumulation 
The potential of the isoflavonoids to inhibit efflux pumps was assessed fluorometrically with 
an efflux accumulation assay of EtBr at ½ MIC to avoid compromising the cellular viability. The 
fluorometric method allowed the observation of the effect of the isoflavonoids on the overtime 
accumulation of EtBr (20 mg l-1) in S. aureus SA1199B (FIGURE 4.16), using reserpine at 
20 mg l-1 as positive control. 
 
 
FIGURE 4.16 | Detection of the effect of the isoflavonoids on ethidium bromide 
accumulation for 60 min in Staphylococcus aureus SA1199B cells by fluorometry. 
Bacteria were loaded with EtBr at 20 mg l-1 in the presence of isoflavonoids (60 
mg l-1, except orobol at 30 mg l-1) for 60 min at 37°C and fluorescence was 
measured. Mean values of least three independent experiments are shown. Reserpine 
at 20 mg l-1 was used as a positive control. (A) the isoflavonoids increasing the 
accumulation over control over time (P < 0.05) are presented; (B) Genistein, 
tectorigenin and orobol increased EtBr accumulation in the first 20-30 min, but then 
this accumulation was reverted for values similar or lower than the control. 
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As can be observed in FIGURE 4.16-A, isoflavonoids increased the accumulation of EtBr in 
SA1199B until approximately 40 min, after which either the signal levels stabilized or were 
slightly reduced again. As previously observed with genistein, tectorigenin and orobol showed a 
different pattern (FIGURE 4.16-B), producing a significant increase on the accumulation of EtBr 
in the first 20-30 min (P < 0.05) after which values reverted to levels that were similar (for 
genistein, P > 0.05) or lower (for orobol and tectorigenin, P < 0.05) than the control. If these 
results are related to the ciprofloxacin-potentiating activity data shown in TABLE 4.13, it can be 
observed that the isoflavonoids that most increased the accumulation of EtBr in SA1199B were 
also those that potentiated ciprofloxacin against the same strain.  
There is a lack of consensual methodological approaches that guarantee appropriate address 
of all the issues related to efflux pump expression and inhibition. So, the positive effect of some 
isoflavonoids on the accumulation of EtBr in SA1199B cells was also shown and confirmed by 
flow cytometry by the acquisition of mean fluorescence intensities (FL3-A) after incubation of 
SA1199B cells with EtBr (1/2 MIC), reserpine (20 mg l-1) and each isoflavonoid. Mean 
fluorescence intensities are shown in FIGURE 4.17.  
 
 
FIGURE 4.17 | Detection of the effect of the isoflavonoids on ethidium bromide 
accumulation for 60 min in Staphylococcus aureus SA1199B cells by flow cytometry.  
(A) Median fluorescence values obtained by flow cytometry for SA1199B after 60 
min of exposure to EtBr (20 mg l-1) at 37°C with reserpine (20 mg l-1) and 
isoflavonoids (60 mg l-1, except orobol at 30 mg l-1); only the efflux pump inhibitors 
(EPI) which fluorescence values statistically differ from the control (no EPI, P < 0.05) 
are presented. Bars represent means and SD from at least three independent 
experiments. The effect of EPIs on the accumulation of EtBr in SA1199B is observed 
with a histogram shift: (B) without EPI, (C) with genistein and (D) biochanin A.  
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FIGURE 4.17-A shows that the highest accumulation of EtBr was obtained in the presence of 
genistein (similar to reserpine, P > 0.05) and biochanin A. Tectorigenin, calycosin and irigenin 
also promoted higher EtBr accumulation than control (P < 0.05) but the results were not so 
satisfactory. In this assay, the fluorescence values were only recorded after 60 min of incubation, 
and since it was observed that the final fluorescence values are not necessarily the ones that best 
reflect EtBr accumulation for all isoflavonoids, the results could be unreliable. Usually, the 
distribution of fluorescence was well defined by the population and the intensity distributed 
around one peak. FIGURE 4.17 (B-D) show the histogram peak shifts promoted by genistein and 
biochanin A. 
The effect of the isoflavonoids on the accumulation of EtBr was also tested by fluorometry for 
strains M116, RWW337 and RWW50. RF values were calculated using the MFI values of each 
assay (FIGURE 4.18) as previously described. Reserpine showed high values of RF for all the 
MRSA strains. Among the isoflavonoids, biochanin A and tectorigenin caused the highest EtBr 
accumulation in MRSA strains. Calycosin and irigenin also showed high RF values (P < 0.05) for 
all MRSA strains, followed by genistein.  
 
 
FIGURE 4.18 | Detection of the effect of isoflavonoids on ethidium bromide 
accumulation for 60 min in SA1199B, ST239 and USA300 strains by fluorometry. 
Relative fluorescence (RF) values were calculated for the isoflavonoids by 
fluorometry in SA1199B and MRSA strains: RFassay = (MFIassay – FIcontrol)/ FIcontrol, 
where MFIassay was the Maximal Fluorescence Intensity obtained in each 60 min 
assay and FIcontrol was the correspondent Fluorescence Intensity obtained with the 
DMSO control at the same time. Reserpine (20 mg l-1) was used as positive EPI 
control. Bars with (*) accumulated more EtBr than the DMSO control (P < 0.05). 
RFs are averages and standard deviations of three independent assays. 
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  Effect of isoflavonoids on preventing inducible resistance to clindamycin 
The inhibition of NorA or other related MDR efflux pumps may explain the potentiation of 
ciprofloxacin by some isoflavonoids against MRSA and SA1199B strains. However, the 
potentiation of erythromycin, which was mainly observed against MRSA strains, is still not 
understood. Staphylococci resist macrolide and lincosamide antibiotics in 2 ways: (1) ribosomal 
target modification - Erm family of methyltransferases confers resistance to the macrolide-
lincosamide-streptogramin type B (MLSB) antibiotics through the methylation of 23S ribosomal 
RNA (Fiebelkorn et al., 2003); (2) an active efflux mechanism encoded by msrA (Leclercq, 2002). 
Modification of the ribosomal target confers broad-spectrum resistance to macrolides and 
lincosamides, whereas efflux or inactivation affect only some of these molecules.  
MLSB resistance is either constitutive or inducible following exposure to a macrolide and can 
be detected by induction tests (“D-test”) using erythromycin and clindamycin disks as shown in 
FIGURE 4.19. The MRSA strain M116 expressed an erythromycin-inducible methylase (iMLSB 
phenotype), as it can be concluded by a positive D-test (FIGURE 4.19-A), RWW50 was resistant 
to erythromycin but susceptible to clindamycin (MS phenotype, FIGURE 4.19-B); and RWW337 
was constitutively resistant to clindamycin (cMLSB phenotype, FIGURE 4.19-C).  
 
 
   
   
FIGURE 4.19 | D-test for detecting if resistance to the macrolide-lincosamide-
streptogramin type B (MLSB) antibiotics in staphylocci is constitutive or inducible. 
(A) D-test positive: inducible resistance to clindamycin (iMLSB phenotype); D-test 
negative: isolate resistant to erythromycin and susceptible to clindamycin (MS 
phenotype); (C) constitutive resistance to clindamycin (cMLSB phenotype). 
 
Thus, macrolide resistance in M116 and RWW337 (ST239) strains is caused by erm genes, 
while in RWW50 it is caused most probably by ABC transporters encoded by msrA genes. 
However, it was previously observed that genistein, biochanin A and tectorigenin can potentiate 
erythromycin in the three strains; thus one would expect that they are affecting a common trait in 
the three strains. Nevertheless, the D-test was also performed in MH plates containing the 
isoflavonoids at 60 mg l-1. The aim was to check if isoflavonoids would be able to inhibit Erm 
methyltransferases, thus avoiding the methylation of the 23S rRNA, and preventing bacteria to 
A B C 
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become resistant to macrolides. Genistein and other dietary polyphenols, such as (-)-
epigallocatechin 3-gallate, have been demonstrated to inhibit DNA methyltransferases in vitro 
(Fang et al., 2007). No phenotype changes were observed from control to isoflavonoids plates.  
To understand if the isoflavonoids are inhibiting MsrA efflux pump, the activity of 
erythromycin in the presence of the isoflavonoids was evaluated on the overexpressing MsrA 
efflux pump S. aureus RN4220 strain. Interestingly, genistein and tectorigenin effectively 
potentiated erythromycin (causing 4-fold reduction of the MIC), while biochanin A promoted 
only a 2-fold reduction. Additional genetic tests are necessary to characterize the ST239 strains 
regarding the presence of msrA genes.  
 
 
  Effect of isoflavonoids on biofilm control 
In this section, it is aimed to assess the effect of isoflavonoids for their activity on biofilm 
control. Besides genistein and daidzein that were previously tested in Section 4.4.7, only the 
isoflavonoids showing antibiotic potentiation and/or EPI activity were selected (tectorigenin, 
biochanin A, calycosin, irigenin and irisflorentin). The exposure of biofilms of S. aureus CECT 
976 to isoflavonoids and antibiotics for 1 and 24 h was evaluated (FIGURE 4.20).  
 
1 h % biofilm 
reduction 
 24 h % biofilm 
reduction 
 
 
 
22.2 ± 2.0  48.2 ± 1.7 
18.4 ± 1.4  42.5 ± 2.0 
-  11.8 ± 2.4 
-  20.0 ± 3.4 
63.1 ± 0.9  60.9 ± 0.3 
-  30.9 ± 2.4 
42.5 ± 3.5  40.0 ± 1.7 
53.8 ± 0.5  60.9 ± 0.7 
-  20.0 ± 1.2 
 
FIGURE 4.20 | CFU cm-2 of biofilms of Staphylococcus aureus CECT 976 after 1 or 24 h 
exposure to isoflavonoids (60 mg l-1), ciprofloxacin (CIP) and erythromycin (ERY) at MIC. 
Percentages of biofilm reduction are shown. (*) when statistically higher than GC, or (a) 
lower than GC (P < 0.05); GC – growth control (5% v v-1 DMSO). 
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Among the seven isoflavonoids tested, biochanin A promoted the highest reductions of S. 
aureus CECT 976 biofilms for both exposure times of 1 and 24 h (63 and 61%, respectively). 
Irisflorentin was also highlighted, being able to reduce biofilms of CECT 976 strain by 54 and 
61%, for 1 and 24 h of exposure, respectively. These biofilm reductions were higher than those 
obtained with the individual exposure of ciprofloxacin (22 and 48%) and erythromycin (18 and 
43%), for exposure times of 1 and 24 h, respectively (P < 0.05).  
The effect of the isoflavonoids was also assessed against biofilms of SA1199B strain for 1 and 
24 h exposure. Additionally, ciprofloxacin at MIC was applied either alone or combined with the 
isoflavonoids at 60 mg l-1 searching for potentiation effects, as obtained against planktonic cells. 
CFU cm-2 of biofilms after exposure to isoflavonoids and/or ciprofloxacin for 1 and 24 h are 
shown in FIGURE 4.21. Percentages of biofilm reduction after drug treatment are also shown.  
Within 1 h of exposure, ciprofloxacin caused 42% reduction on SA1199B biofilms. The 
highest biofilm reduction was obtained with irisflorentin applied alone at 60 mg l-1 (83%). Besides 
daidzein, which as mentioned before promoted reduction of SA1199B biofilm of 62%, interesting 
activities were also obtained with irigenin, daidzein and biochanin A at 60 mg l-1 (83, 70 and 59%, 
respectively) applied individually. 
Generally, the combination of ciprofloxacin with isoflavonoids was unfavorable, disturbing 
the anti-biofilm activity of isoflavonoids, excepting for combinations between ciprofloxacin with 
reserpine and calycosin (biofilm reduction increased from 24- to 58% and from 38- to 51%, 
respectively). Still, these combinations are not considered synergic according to Monzón et al. 
(2001). 
Within 24 h exposure, ciprofloxacin applied at MIC reduced the amount of biofilm by 94% 
regardless of the presence of isoflavonoids. Some isoflavonoids applied alone promoted relevant 
biofilm reduction (P < 0.05), being highlighted daidzein, irisflorentin and biochanin A (with 63, 
54 and 51 % of biofilm reduction, respectively), which were also quite active when exposed for 
1 h. Despite irisflorentin achieved lower biofilm reduction when applied for 24 h (P < 0.05) than 
when exposed for 1 h, daidzein still promoted a similar biofilm reduction in both exposure times 
(P > 0.05). On the contrary, the exposure of biochanin A and irigenin to SA1199B biofilms for 
24 h did not achieve so interesting as when they were applied for 1 h. The decreased susceptibility 
to phytochemicals after a prolonged exposure period (24 h) was generally observed in this study. 
As previously mentioned, longer incubation periods can allow bacteria to adopt more resistant 
profiles or a dormant behavior, being thus able to survive (Shafahi and Vafai, 2010). 
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1 h % biofilm 
reduction 
24 h % biofilm 
reduction 
 
 
 
 
 
 
41.8 ± 1.2 93.8 ± 2.3 
  
23.8 ± 1.4 9.9 ± 6.5 
58.4 ± 1.2 85.6 ± 3.0 
  
34.4 ± 1.0 43.7 ± 3.8 
40.3 ± 0.2 96.1 ± 2.2 
  
58.8 ± 2.8 50.8 ± 7.0 
53.3 ± 2.3 91.1 ± 4.1 
  
37.6 ± 2.8 36.0 ± 7.4 
51.1 ± 1.6 91.6 ± 3.5 
  
69.6 ± 2.1 27.2 ± 5.7 
59.5 ± 0.6 88.8 ± 2.6 
  
82.8 ± 1.0 54.1 ± 7.1 
68.8 ± 2.7 98.9 ± 3.0 
  
61.8 ± 2.2 63.0 ± 1.6 
45.2 ± 1.3 99.2 ± 1.5 
 
 
FIGURE 4.21 | CFU cm-2 of Staphylococcus aureus SA1199B biofilms after 1 h or 24 h 
exposure to isoflavonoids (60 mg l-1), ciprofloxacin (CIP, MIC), and their combinations.  
Percentages of biofilm reduction are shown. Only isoflavonoids active as EPIs were 
tested and were applied at 60 mg l-1. All assays are statistically lower than GC (P < 
0.05); (a) when statistically lower than ciprofloxacin applied alone (P < 0.05); and (b) 
than ciprofloxacin and the respective isoflavonoid applied alone (P < 0.05). GC – 
growth control (5% v v-1 DMSO).  
 
Additionally, the combinations between ciprofloxacin and daidzein or irisflorentin allowed a 
higher biofilm reduction than when ciprofloxacin applied alone (P < 0.05), causing 99% reduction 
on CFU cm-2. Likewise, these combinations are not synergic according to Monzón et al. (2001) 
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  Relevant remarks 
Isoflavones are well known for their therapeutic properties having anti-inflammatory, 
estrogenic, anti-estrogenic, anticancer, antibiotic as well as radical scavenging activities (Dixon 
and Steele, 1999; Hummelova et al., 2015; Pandey and Rizvi, 2009; Russo et al., 2012). They 
have also long been thought to play a role in plant–microbial interactions as part of the defensive 
arsenal of the host plant but neither this (Dixon and Steele, 1999) nor the exact relationship 
between chemical structure and activity are fully understood (Osawa et al., 1992; Pandey and 
Rizvi, 2009; Wu et al., 2013). 
Only three compounds revealed antimicrobial activity against all S. aureus strains, 
neobavaisoflavone (MIC of 20 mg l-1), corylifol A (MIC between 0.06 - 2.5 mg l-1), which both 
have a lipophilic prenyl group attached to the B-ring, and orobol (MIC between 60 - 120 mg l-1).  
Besides genistein, biochanin A (a structurally similar isoflavonoid) and tectorigenin were able 
to potentiate ciprofloxacin and erythromycin (2 to 8-fold MIC reduction) against MRSA strains. 
Besides studies previously described about genistein potentiating effects, a range of MIC values 
between 64-512 mg l-1 against 12 S. aureus strains have been reported for biochanin A, which 
also showed synergism with ciprofloxacin (Liu et al., 2011). A MIC of 125 mg l-1 against MRSA 
strains has been reported for tectorigenin (Joung et al., 2014). The possible mode of action may 
be based either on DNA topoisomerases inhibition, as reported for genistein and biochanin A 
(Azuma et al., 1995). Considering their structural similarity, it can be assumed that tectorigenin 
could also have a similar effect. Also, tectorigenin seems to affect membrane permeability and 
ABC transporters (Joung et al., 2014). As previously mentioned, the inhibition of DNA 
topoisomerases could explain both potentiation effects with ciprofloxacin (having the same target 
it could either benefit as detected in this study, or disturb the activity of ciprofloxacin) and 
erythromycin (by a multi-target effect). However, it does not explain why the potentiation is 
notorious against MRSA strains and not against susceptible strains. Thus, it is expected that other 
targets may be involved, also considering the reactivity of these phenolic compounds and their 
ability to complex with several extracellular and soluble proteins. In line with this idea, it has 
been suggested that the mechanism of flavonoid antibacterial activity can based on their ability 
to inactivate cell envelope transport proteins (Mierziak et al., 2014).  
In our study, seven of the tested non-antimicrobial active isoflavonoids were able to potentiate 
ciprofloxacin activity (with 4- to 8-fold reductions of the MIC value) against the resistant 
SA1199B, in decreasing order of activity these were: genistein, biochanin A, tectorigenin, 
daidzein, calycosin, irigenin and irisflorentin. Also the active antimicrobial neobavaisoflavone, 
showed synergism, with a FICI of 0.5 with ciprofloxacin against SA1199B.  
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Genistein and biochanin A were the most active of all the tested isoflavonoids, potentiating 
ciprofloxacin and erythromycin against resistant S. aureus strains. A comparison of their 
structures suggests that the two meta-hydroxyl groups in the A-ring present in these compounds, 
are a key feature for this antibiotic-potentiation. Biochanin A has the same substitution pattern on 
the A-ring, but the hydroxyl groups in the B-ring is replaced by a methoxy group. Orobol which 
also has the same A-ring substitution but two ortho-hydroxyl groups in the B-ring, shows 
antibacterial activity. Daidzein which lacks the 5-hydroxyl group but is otherwise identical to 
genistein is also less active. It seems that synergistic properties might parallel the estrogenic 
activity (Miyazaki, 2004). Furthermore, all compounds in which the C-7 hydroxyl group was 
glycosylated were inactive. Hummelova et al. (2015) coincides partially with our observations, 
concluding that the isoflavonoids with strongest S. aureus inhibitory effect were ortho-
dihydroxyisoflavones. Other studies showed that 5,7-dihydroxylation of the flavonoid A ring was 
important for anti-MRSA activity (Alcaráz et al., 2000; Hummelova et al., 2015; Tsuchiya et al., 
1996) and monomethoxy B-ring derivatives were generally found to be more active (antibiotic 
synergy) than the disubstituted B-ring derivatives (Wang et al., 2014). 
The next question to answer is the possible mode of action of the synergistic activity. The 
uptake and efflux of the antibiotics are decisive for this activity. To measure the effect on the 
uptake and efflux, the accumulation of the highly fluorescent EtBr in the bacteria was measured 
in the presence of the isoflavonoids. The seven isoflavonoids that potentiated ciprofloxacin 
against SA1199B were the ones that most increased the accumulation of EtBr. Against the MRSA 
strains, biochanin A, genistein and tectorigenin were the most active EPIs, similarly to reserpine. 
Calycosin and irigenin had lower RFs, but still improved EtBr accumulation as compared to the 
control in all MRSA strains. The effects obtained with these five isoflavonoids active as EPIs 
were successfully confirmed by flow cytometry against SA1199B. There is clear evidence that 
inhibition of MDR transporters, and in particular NorA, do play a role in resistance. 
Accumulation is the net result of uptake and efflux. Transport in cells occurs in diverse ways, 
including non-selective diffusion, and more or less selective transporters for uptake or efflux. A 
higher uptake can thus be related to each of the three processes. Only in the case of efflux there 
is clear evidence of the role of MDR-like transporters, and in particular NorA, in resistance. Cell 
membrane damage has also been reported in connection with the isoflavonoids (Joung et al., 2014; 
Mierziak et al., 2014). Considering the results obtained, isoflavonoids seem to induce a fast 
uptake, but over time the levels in the cell reverted to those of the controls, meaning that an 
equilibrium was reached after a certain time. This means that the synergistic effect may have other 
modes of action as well.  
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Additional experiments were conducted in order to understand the potentiation of 
erythromycin by genistein, tectorigenin and biochanin A against ST239 and USA300 strains. The 
resistance to macrolide can be mediated by msrA gene coding for efflux mechanism or 
via erm gene encoding for enzymes that confer inducible or constitutive resistance to MLSB 
antibiotics. There are reports of some compounds that bind weakly to ErmAM (Hajduk et al., 
1999) and ErmC (Clancy et al., 1995) methyltransferases, thus inhibiting the Erm-mediated 
methylation of rRNA. These studies suggest that Erm inhibitors used in combination with a broad-
spectrum macrolide antibiotic could be useful for the treatment of infections caused by MLS-
resistant pathogenic bacteria. Despite genistein has been demonstrated to inhibit DNA 
methyltransferases in vitro (Fang et al., 2007), inhibition of Erm methyltransferases by 
isoflavonoids, which were causing macrolide resistance on ST239 strains, was not detected by D-
test. So, inhibition of MsrA efflux pump could be a reasonable explanation if ST239 is also 
expressing these efflux pumps. By testing the MrsA overexpressing strain RN4220 it was possible 
to observe a potentiating/additive effect of genistein, tectorigenin and biochanin A with 
erythromycin. However, it seems that while the prevalence of erm-mediated macrolide resistance 
is notorious among MRSA strains, msrA genes are not so predominant: Moosavian et al. (2014) 
reported that ermA and ermC are the most common among 124 S. aureus isolates, but ermB and 
msrA were never detected; Schmitz et al. (2000) showed that the most prevalent resistance gene 
in 851 S. aureus isolates was ermA (67%), followed by ermC (23%) and msrA/B (6%). Yet, further 
studies would be necessary to fully understand this phenomenon.  
The mechanism behind transport inhibition is unknown. Inhibition of several MDR efflux 
pumps may be the explanation to these effects promoted by the isoflavonoids. In fact, there are 
reports of compounds that can inhibit more than one efflux pump, such as reserpine. For example, 
Gibbons et al. (2003a) reported that GG918 (drug specifically developed for overcoming MDR 
phenotype) and reserpine potentiated norfloxacin and ciprofloxacin in a fluoroquinolone-
susceptible S. aureus strain and in strains expressing the MsrA and TetK proteins, which mediate 
efflux-related resistance to macrolides and tetracyclines, respectively. NorA appears to export a 
surprisingly large variety of structurally unrelated drugs, such as ﬂuoroquinolones, EtBr, 
cetrimide, benzalkonium chloride, tetraphenylphosphonium bromide and acriﬂavine (Deng et al., 
2012). So, the explanation may lie in the low substrate speciﬁcity of these systems (Markham et 
al., 1999). Nevertheless, it seems that the most active agents belong to the families of compounds 
possessing conjugated double bonds (Handzlik et al., 2013). Finally, there is still a lack of 
consensual methodological approaches that guarantee appropriate address of all these issues 
(Costa et al., 2013). The use of molecular approaches would be necessary to fully understand the 
function that each individual efflux pump undertakes in the bacterial cell response to antimicrobial 
compounds and how they are being affected by the presence of EPIs.  
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Currently, increasing evidence has elucidated that efflux pump systems are not merely pumps 
involved in the transport of drugs or other toxic substances out of the cells but they have been 
also implicated in quorum-sensing regulation and the subsequent expression of genes responsible 
for virulence and biofilm formation (Beceiro et al., 2013; Sun et al., 2014). For example, mutants 
of Salmonella typhimurium that lack TolC or AcrB were compromised in their ability to form 
biofilms, but not in the presence of efflux pump inhibitors (Baugh et al., 2014).  
From this study, irisflorentin is highlighted for its anti-biofilm activity being able to reduce 
biofilms of S. aureus CECT 976 and SA1199B by 54 and 83% when applied for 1 h, and by 61 
and 54%, when applied for 24 h, respectively. Daidzein was able to cause biofilm reductions of 
62 and 63% when applied for 1 and 24 h, respectively against S. aureus SA1199B, but no 
significant effects were obtained against CECT 976 strain. Biochanin A also promoted interesting 
effects on biofilms, being able to reduce CECT 976 biofilms by 63 and 61%, and SA1199B 
biofilms by 59 and 51%, when applied for 1 and 24 h, respectively. 
Testing twenty-two structurally different isoflavonoids allowed to detect a relationship 
between the potentiation of ciprofloxacin and inhibition of NorA efflux pump. Also, it was shown 
that antimicrobial and antibiotic-potentiation properties of isoflavonoids are highly structure-
dependent. Further questions arise, namely whether the refereed isoflavonoids could also inhibit 
other similar efflux pumps, also possibly in other organisms. Additionally, inhibition of NorA 
does not explain the potentiation observed for erythromycin; thus interference with other cellular 
efflux pumps, mechanisms and/or targets is most probably occurring and should be subject of 
further research. The concept of restoring and enhancing the therapeutic value of antimicrobials 
by employing EPIs is a formidable challenge. The development of combinations of 
ﬂuoroquinolone antibiotics with a transporter inhibitor appears to be a feasible alternative to the 
discovery of “rare” compounds that are poorly recognized by multidrug transporters. However, 
this is not yet at a therapeutic stage and a number of methodological gaps should be overcome for 
the clinical implementation of EPIs.  
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 TASK 6. THE POTENTIAL OF BUXUS SEMPERVIRENS FOR ANTIBIOTIC-
POTENTIATING ACTIVITY: ISOLATION AND IDENTIFICATION OF 
ANTIBIOTIC ADJUVANTS  
 
Abstract 
Among the tested plants, Buxus sempervirens showed to potentiate mostly 
ciprofloxacin, erythromycin and tetracycline but also showed an additive effect when 
combined with β-lactams. In this study, B. sempervirens (1 g l-1) was able to cause 
88% reduction of 24 h-old biofilms of S. aureus CECT 976 within 1 h of exposure. 
Further phytochemical investigation of B. sempervirens allowed to identify one 
candidate, betulinic acid. This and other similar terpernoids, lupeol, betulin, 
hederagenin, ursolic acid and oleanolic acid, were tested for antibacterial and 
antibiotic-potentiating activities. Among the compounds tested, oleanolic acid and 
ursolic acid were highlighted, showing MIC of 62.5 and 15.6 mg l-1, respectively, 
against S. aureus. Additionally, oleanolic acid showed synergism when combined 
with tetracycline and erythromycin and biofilm reductions of 70, 81 and 85% when 
applied at ½ MIC, MIC and 2 × MIC, respectively. 
 
 
 
  Effect of Buxus sempervirens methanolic extract on biofilm control 
Any effective strategy able to impair biofilm formation or disturb, weaken or disperse its 
structure is urgently needed and for long desired. In this study, the MeOH extract of Buxus 
sempervirens was analysed for its ability to control biofilms within 1 h of contact of the 
susceptible strain S. aureus CECT 976, against which the combinations with B. sempervirens 
were generally more effective (as previously shown in Section 4.3.2, TABLE 4.6). 
The MeOH extract of B. sempervirens was evaluated against CECT 976 24 h-old biofilms at 
several concentrations (FIGURE 4.22). It was possible to observe an overall concentration-
dependent effect, and increasing concentrations of B. sempervirens extract caused higher biofilm 
removal percentages (P < 0.05), except for applications at 0.25 g l-1 and 5 g l-1, which did not 
show improvement over the preceding concentrations of 0.1 and 1 g l-1, respectively (P > 0.05). 
The minimal concentration causing potentiation with planktonic cells (1 g l-1) was the one causing 
the highest biofilm reduction (88%). 
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(%) biofilm 
reduction  
 
9.0 ± 1.0 
34.7 ± 1.1 
31.4 ± 0.3 
87.5 ± 1.6 
86.1 ± 0.7 
 
FIGURE 4.22 | CFU cm-2 of Staphylococcus aureus CECT 976 biofilms after 1 h 
exposure to methanolic extract of Buxus sempervirens (0.05, 0.1, 0.25, 1 and 5 g l-1). 
Biofilm reductions (%) are shown for each assay. (*) when statistically lower than GC 
and (**) than the preceding concentration (P < 0.05). GC – growth control (5% v v-1 
DMSO); BS – B. sempervirens. 
 
Additionally, combinations between B. sempervirens MeOH extract with ciprofloxacin, 
tetracycline and erythromycin against 24 h-old biofilms were assessed (FIGURE 4.23). 
Antibiotics were applied at MIC and 50 × MIC and the extract of B. sempervirens was applied at 
the concentration causing highest biofilm reduction (1 g l-1).  
Concerning the single activity of the antibiotics at MIC, ciprofloxacin, tetracycline and 
erythromycin promoted biofilm reductions of 38, 31 and 21%, respectively. Both ciprofloxacin 
and erythromycin applied at 50 × MIC did not show any improvement over application at MIC 
(P > 0.05). Tetracycline at 50 × MIC did not cause ant biofilm reduction at all (similar CFU cm-2 
values to the growth control, P > 0.05). This supports the concept of how bacteria are much more 
protected within a biofilm. 
Comparing individual activities, B. sempervirens MeOH extract surprisingly achieved the best 
ability to control S. aureus CECT 976 biofilms within 1 h of application, even not showing 
antibacterial activity at this concentration. According to Monzón et al. (2001), it is possible to 
classify a combination between a plant extract/phytochemical and an antibiotic as synergic if the 
log10 reduction CFU cm-2 caused by the combination is significantly higher (P < 0.05) than the 
sum of reductions of individual treatments. In this case, the application of antibiotics at MIC did 
not promote any significant improvement over the activity of the plant extract alone (P > 0.05).  
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(%) biofilm 
reduction 
87.5 ± 1.6 
38.0 ± 2.2 
36.9 ± 3.5 
81.4 ± 1.1 
31.1 ± 1.7 
-1.7 ± 2.0 
78.8 ± 1.36 
21.1 ± 0.0 
22.6 ± 3.0 
87.9 ± 0.4 
 
FIGURE 4.23 | CFU cm-2 of Staphylococcus aureus CECT 976 biofilms after 1 h exposure 
to ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY) at MIC and 50 × 
MIC, and combined with the methanolic extract of Buxus sempervirens (BS) at 1 g l-1. 
Biofilm reductions (%) are shown. (*) when statistically different from GC (P < 0.05). 
GC – growth control (5% v v-1 DMSO). 
 
  Isolation of bioactive compounds from Buxus sempervirens 
Afterwards, B. sempervirens MeOH extract was submitted to fractionation for the 
identification of the bioactive compounds. Among the subfractions obtained from the n-BuOH 
fraction of B. sempervirens, through silica gel column, F1 and F2 were differentiated, showing 
antibiotic-potentiating activity (0.5 g l-1). Analysing the 1H NMR for all the eight fractions 
obtained, it was possible to compare the spectra of the active fractions F1 and F2 with the non-
active ones. Bearing in mind the similar activity, some signals were found in both fractions 
(FIGURE 4.24-A), which were not found in the non-active ones. The identification was carried 
out using an in-house library of NMR data of common metabolites and based on characteristic 
methyl and olefinic signals it was possible to identify betulinic acid (FIGURE 4.24-B) as a major 
component together with oleanane and ursane type terpenoids. 
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FIGURE 4.24 | 1H NMR spectra (0.4 – 5.0 ppm) of the subfractions obtained from n-
BuOH fraction of B. sempervirens (A); the numbering in the fractions is related to the 
1H assignments of betulinic acid (B), which is only observed in the active fractions F1 
and F2. 
 
  Evaluation of triterpenoids as antibiotic potentiators 
Betulinic acid and other similar terpenoids,  lupeol, betulin, hederagenin, ursolic acid and 
oleanolic acid  were tested for their antibacterial activity by microdilution technique as 
previously explained. Pentacyclic triterpenoids α-amyrin, betulinic acid and betulinaldehyde, and 
other related triterpenes such as imberbic acid, oleanolic acid, ursolic acid, ulsolic acid, rotundic 
acid and zeylasteral have been reported to possess antimicrobial activity against many bacterial 
species, especially Gram-positive, but also against Gram-negative (Chung et al., 2011; Kurek et 
al., 2009). In this study, only oleanolic acid and ursolic acid showed a MIC up to 120 mg l-1, 
which was 62.5 and 15.6 mg l-1, respectively, against S. aureus CECT976.  
After MIC determination, these terpenoids were evaluated in combination with antibiotics 
searching for a synergistic activity through checkerboard method (TABLE 4.15).  
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TABLE 4.15 | Minimal inhibitory concentrations (MIC)-fold reductions obtained with 
the combination between oleanolic acid and ursolic acid and the antibiotics. Fractional 
inhibitory concentration index (FICI) values were determined for each combination. 
Classification of the combinations is given as synergy (S) or indifference (I) 
 Antibiotic - Oleanolic acid Antibiotic - Ursolic acid 
  MIC fold 
reduction 
MIC fold 
reduction 
FICI* 
 MIC fold 
reduction 
MIC fold 
reduction 
FICI* 
AMP  2 2 1.0 (I)  2 2 1.0 (I) 
CIP  4 2 0.75 (I)  8 2 0.63 (I) 
TET  4 4 0.5 (S)  4 16 0.31 (S) 
ERY  8 4 0.38 (S)  2 2 1.0 (I) 
A FICI value of ≤ 0.5 (in bold) was interpreted as synergy, > 4 as antagonism and > 0.5 – 4 as indifferent. FIC: 
fractional inhibitory concentration; FICI: FIC index. AMP: ampicillin; CIP: ciprofloxacin, TET: tetracycline; 
ERY: erythromycin 
 
Analysing the FICI values, it is possible to detect synergism only between oleanolic acid with 
erythromycin and tetracycline (FICI ≤ 0.5) and between ursolic acid and tetracycline (FICI = 
0.31) against S. aureus CECT 976. Similarly, Fontanay et al. (2008) found a MIC for ursolic acid 
and oleanolic acid of 8 and 32-64 mg l-1 against S. aureus ATCC25923 and ATCC29213 but not 
for betulinic acid. No MIC was found against one MRSA strain (Fontanay et al., 2008). Contrarily, 
in other study, oleanolic acid was reported to inhibit MRSA with a MIC between 16 and 128 mg 
l-1 (Kim et al., 2012) and to synergize with ampicillin against S. aureus (Kurek et al., 2012). Chung 
et al. (2011) showed that betulinic acid and similar compounds, α-amyrin and betulinaldehyde, 
inhibited MSSA and MRSA (MIC between 64 and 512 mg l-1), and synergized with methicillin 
and vancomycin against the same strains. Therefore, it seems that the antibacterial and synergistic 
activities of triterpenoids vary widely, not only between susceptibility methods, but also between 
strains belonging to the same species. Considering the low activity displayed by betulinic acid, 
which was found in the active fractions of B. sempervirens, other triterpenoids also existing in 
this plant, as oleanane and ursane type terpenoids may contribute to the antibiotic-potentiation 
and anti-biofilm effects displayed by this plant.  
 
  Evaluation of triterpenoids on biofilm control 
Plenty studies were initiated to identify the cellular targets and molecular mechanisms of 
triterpenoids. Besides their influence on bacterial gene expression (Shin and Park, 2015), cell 
autolysis and peptidoglycan turnover (Kurek et al., 2009), oleanolic acid and related compounds 
also seem to affect the formation and maintenance of biofilms (Wolska et al., 2010). Indeed, 
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terpenes are believed to influence the fatty acid composition of the cell membrane, and thus cell 
hydrophobicity, which can lead to biofilm eradication (Perumal and Mahmud, 2013). To confirm 
this, oleanolic acid, which caused the best antibiotic-potentiation in this study, was evaluated for 
its anti-biofilm activity against S. aureus CECT 976 biofilms. FIGURE 4.25 shows the number 
of CFU cm-2 of biofilms obtained after 1 h exposure to oleanolic acid at ½ MIC, MIC and 2 × 
MIC as well as with antibiotics at MIC, individually and in combination.  
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61.8 ± 2.5 
 
 
FIGURE 4.25 | CFU cm-2 of Staphylococcus aureus CECT 976 biofilms after 1 h exposure 
to oleanolic acid (OA) applied at ½ MIC, MIC or 2 × MIC, individually and combined 
with ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY) at their MICs.  
Biofilm reductions (%) are shown. (a) when statistically different from GC (P < 0.05); 
(b) when statistically different from the respective antibiotic applied individually. GC 
– growth control (5% v v-1 DMSO). 
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Oleanolic acid applied at ½ MIC, MIC and 2 × MIC caused high biofilm CFU reduction, 70, 
81 and 85%, respectively. The combination between the antibiotics and oleanolic acid never 
promoted higher biofilm reductions than those obtained with oleanolic acid alone. The exception 
was the combination of ciprofloxacin (MIC) with oleanolic acid (½ MIC), that showed to be 
significantly than oleanolic acid alone at the same concentration (82%, P < 0.05). However, 
diverse combinations achieved worst biofilm reductions than those obtained with oleanolic acid 
alone (P < 0.05): between oleanolic acid and erythromycin, between oleanolic acid (MIC) and 
tetracycline (MIC) and between oleanolic acid (2 × MIC) and ciprofloxacin (MIC). 
One could expect that by combining antibiotics with a possible biofilm inhibitor, the outcome 
would be an improved therapeutic benefit. Nevertheless, probably by applying the combination 
in a preliminary stage of bacteria adhesion/biofilm formation, the combinations would be more 
effective, which would explain the potentiation observed. 
 
  Relevant remarks 
Although it has been used medicinally in the past as a sedative and to treat syphilis, box (B. 
sempervirens) is very rarely used in modern herbalism. Still, the leaves possess a serious of 
therapeutic properties, and were inclusive used as a quinine substitute in the treatment of malaria 
(PFAF, 2016). In this study, it was observed that the methanolic extract of B. sempervirens (1 g 
l-1) showed an 88% of S. aureus CECT 976 biofilm reduction when applied for 1 h. This effect 
on S. aureus biofilms may be the reason for the antibiotic-potentiation previously observed for 
this plant extract (Section 4.3.2, TABLE 4.6). 
Further fractionation of B. sempervirens allowed to suggest that betulinic acid together with 
oleanane and ursane type terpenoids may be responsible for the activity of the plant. Triterpenoids 
are widely distributed in the plant kingdom and their therapeutic activities (such as antibacterial, 
antiviral, antiulcer, anti-inflammatory and anticancer) have been described in numerous reports. 
Betulinic acid showed weak antibacterial and antibiotic-potentiation activities. Considering this, 
other triterpenoids also existing in this plant, as reported for example by Abramson et al. (1973), 
or other sterols, alkaloids and anthocyanins that are typical of Buxus spp. (Orhan et al., 2012), 
might synergistically contribute to the antibiotic-potentiation and anti-biofilm effects displayed 
by this plant. Further isolation of the active fractions of the plant towards the identification of all 
the involved metabolites is apparently necessary.  
Meanwhile, six structurally similar triterpenoids were studied for antibacterial and antibiotic-
potentiation activities. Among them, oleanolic acid and ursolic acid were highlighted for showing 
a MIC of 62.5 and 15.6 mg l-1, respectively against S. aureus CECT976 and synergism when 
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combined with erythromycin (for both) and tetracycline (only for oleanolic acid) against the same 
strain. Additionally, oleanolic acid was found to remove biofilm CFU by 70, 81 and 85%, when 
applied at ½ MIC, MIC and 2 × MIC, respectively. Kurek et al. (2012) also found synergistic 
antibacterial effects of oleanolic acid in combination with ampicillin against biofilms of S. 
aureus and S. epidermidis, and with oxacillin against biofilms of L. monocytogenes, S. epidermis 
and S. aureus. Ursolic acid was found to inhibit biofilm formation of MRSA by reducing amino-
acids metabolism and expression of adhesins (Qin et al., 2014), to induce genes related to 
chemotaxis, mobility and heat shock response, and to repress genes that have functions in cysteine 
synthesis and sulfur metabolism (Ren et al., 2005). 
Restoring the activity of antibiotics that were already accepted and approved for clinical safety 
aspects, minimal toxicity and side effects, could thereby potentially reduce the costs associated to 
drug preclinical and clinical development. This strategy is possible by combining antibiotic with 
adjuvants that are able to inhibit drug-resistance mechanisms expressed by the pathogens. This 
study highlights the potential of B. sempervirens extract, and particularly of triterpenoids for their 
relevant ability to act against S. aureus biofilms and opens new perspectives for further research.  
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FOR FURTHER RESEARCH 
 
 
 
 
n this section, the main conclusions obtained with this thesis are 
highlighted and summarized. An overview of all the work developed 
is discussed. Some main difficulties and challenges that arised during this 
project are described. Perspectives and suggestions for further research are 
also identified and provided.  
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 GENERAL CONCLUSIONS 
Over the last decade there has been a resurgence of interest in the search for products that will 
restore the activity of licensed antimicrobial agents. It is known by now that plants do not produce 
individual compounds as their defense mechanisms, but they generate complex defense systems 
involving a myriad of metabolites. Indeed, plants have been fighting against the resistance 
mechanisms developed by their attackers for millions of years ago and one could make use of 
their potential.  
The present thesis showed that the prospects of finding useful plant-derived products are 
enormous. Products that interfere with efflux of antibiotics from the cell or other resistance 
mechanisms may be easily found in nature. Within this project, 29 plants and 41 phytochemicals 
were assessed for their antibiotic-potentiating effects. Some were highlighted and selected for 
further investigation and open new perspectives for an antibiotic-combined therapy. Such 
phytochemicals can serve as scaffolds for the design of new and more attractive compounds that 
could be applied in clinical setting towards the treatment of S. aureus and MRSA. Some main 
achievements reached within this thesis will be highlighted in this section. 
 The use of two or more methods to assess antibiotic-potentiation allowed to overcome and 
circumvent the limitations of each method and to characterize drug potentiation with more 
confidence. Disk-diffusion method raised as an excellent strategy and showed good 
agreement with checkerboard and Etest methods in detecting potentiation for ciprofloxacin, 
tetracycline and erythromycin. This method is suitable especially when dealing with plant 
extracts and non-purified fractions. Checkerboard can be easily performed and allow to test 
several concentrations at the same time. Furthermore, characterization of synergy by this 
method is well established among the scientific community. 
 From the initial screening of several plant alkaloids and flavonoids, reserpine, pyrrolidine, 
quinine, morin and quercetin were highlighted as adjuvants of antimicrobial therapy against 
planktonic S. aureus. Reserpine is already known as an EPI for the NorA and TetK efflux 
pumps. This study supports the results already obtained by other authors. Pyrrolidine showed 
a capacity for potentiating erythromycin and ciprofloxacin against some S. aureus strains. 
Quinine would be a viable option if not for the high toxicity of this compound. Nevertheless, 
it had a significant effect on ciprofloxacin against SA1199B and MSSA strains. Morin and 
quercetin increased the activity of ciprofloxacin against S. aureus CECT 976 and SA1199B 
and tetracycline against S. aureus CECT 976 and all MRSA and MSSA strains.  
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 Regarding the effects of these phytochemicals against sessile S. aureus, morin caused the 
highest biofilm reduction when applied for 1 h and also inhibited biofilm formation. 
Pyrrolidine had a significant effect against biofilms for 1 h exposure, while quercetin was 
highlighted for preventing biofilm formation. Several significant synergic combinations of 
antibiotics with the phytochemicals were obtained being highlighted the combinations 
between ciprofloxacin and quinine to control SA1199B biofilms (within 24 h exposure with 
log10 CFU cm-2 reduction of 2.1) and between ciprofloxacin with reserpine to prevent 
SA1199B biofilm formation (log10 CFU cm-2 reduction of 3.2). These effects depend on the 
incubation time. Additionally, quinine and morin were successful in reducing antibiotic 
tolerance of SA1199B strain to ciprofloxacin within 15 days of exposure, the first probably 
due to an EPI effect (it increased accumulation of EtBr) and the second for acting as a biofilm 
inhibitor. In this study, it was also showed that quercetin had EPI activity on strain SA1199B. 
 Among twenty-nine different plant species, four were found to have antibacterial activity, 
(E. globulus, C. sativa, A. eupatoria and F. excelsior with MICs of 0.125-0.5, 0.5-1.0, 1.0-
2.0, and 2.0-4.0 g l-1, respectively) being in agreement with their traditional uses, and nine 
(A. dealbata, P. communis, P. avium, P. domestica, P. persica, C. nigra, E. cannabinum, F. 
carica, B. sempervirens) were able to potentiate antibiotic activity, especially ciprofloxacin, 
tetracycline and erythromycin. C. striatus was highlighted in this initial screening for 
promoting potentiation of ciprofloxacin and erythromycin even against one MRSA strain 
(MJMC001). B. sempervirens seems to act as a general potentiator for several antibiotics. 
For these reasons, both plants were selected for further study focusing on the isolation and 
characterization of the main metabolites responsible for these antibiotic-potentiating 
activities. 
 NMR-based metabolomics was proven to be a powerful tool to identify compounds that are 
related to an activity. With this approach, it was proven that even using one single plant, it 
was possible to obtain a variety of different extracts and activities. Submitting all this data 
to multivariate data analysis allowed the identification of all signals related to the activity. 
Three non-antibacterial compounds (up to 120 mg l-1) were positively correlated with an 
antibacterial-potentiating activity - apigenin, genistein and 2’-hydroxygenistein. Both 
apigenin and its analogue genistein caused 2-8 fold reductions of ciprofloxacin and 
erythromycin MICs against ST239 and USA300-MRSA strains. Suggestions were made that 
this activity could be associated to inhibition of DNA and RNA synthesis in bacteria and 
influence DNA gyrase activity (Mierziak et al., 2014), inhibition of tyrosine kinase 
(Verdrengh et al., 2004) or topoisomerase II (Azuma et al., 1995). However, further studies 
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would be necessary to demonstrate such inhibition. One antibacterial compound was also 
found from C. striatus leaf extract - luteolin - with MICs between 30 and 120 mg l-1 against 
7 S. aureus strains, including the ST239 and USA300 MRSA strains. Other isoflavonoid, 
daidzein, was found to potentiate ciprofloxacin against SA1199B possibly due to EPI 
activity. The same EPI effect was also confirmed for genistein, including for the other MRSA 
strains. Additionally, daidzein showed to reduce SA1199B biofilms by 62 and 63 % when 
exposed for 1 and 24 h, respectively, probably due to its EPI activity.  
 Testing twenty-two structurally showed that antimicrobial and antibiotic-potentiation 
properties of isoflavonoids are highly structure-dependent. Besides genistein, tectorigenin 
and biochanin A were highlighted being able to potentiate ciprofloxacin and erythromycin 
by 2-8 fold, especially against ST239 and USA300 MRSA strains. The hydroxyl group in 
position 5` seems to be correlated with the activity. A relationship between the potentiation 
of ciprofloxacin and inhibition of NorA efflux pump was also detected. Further experiments 
are required to understand the possible interactions of isoflavonoids namely whether these 
compounds can also interact with other efflux pumps, even in other organisms. Additionally, 
irisflorentin and biochanin A showed significant effects on S. aureus biofilm control.  
 Buxus sempervirens leaf methanolic extract showed to potentiate mostly ciprofloxacin, 
erythromycin, but also tetracycline, and caused an additive effect on β-lactam antibiotics 
activity. B. sempervirens (1 g l-1) was able to cause an 88% reduction of 24 h-old biofilms of 
S. aureus CECT 976 within 1 h of exposure. Further phytochemical investigation of B. 
sempervirens active fractions allowed to identify one major compound, betulinic acid. 
Among this and other five similar triterpenoids, only oleanolic acid and ursolic acid showed 
antibacterial activity (MIC of 62.5 and 15.6 mg l-1, respectively) against S. aureus CECT 976 
and synergy when combined with tetracycline (for both) and erythromycin (only for 
oleanolic acid). Additionally, oleanolic acid promoted biofilm reductions of 70, 81 and 85% 
when applied at ½ MIC, MIC and 2 × MIC, respectively.  
The continued evolution and spread of multiple antibiotic resistance in human pathogens is an 
alarming clinical challenge. It is clear from the past two decades of effort that antibiotics that are 
highly effective, safe and broad spectrum are incredibly difficult to find. Consequently, one must 
ask whether the current medical practices and ideas about infection control are appropriate in the 
resistance era. It is important to highlight that researchers should continue investigating the 
synergistic capacity of plant extracts or other natural products, independently of the antimicrobial 
activity they might have alone. Thus, a more integrated approach is necessary to fully and deeply 
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evaluate the defense features of each plant. A NMR-based metabolomics strategy, as it was 
applied in this study, proved to be a valuable and strong tool to reveal synergistic activities 
between phytochemicals from the same plant and allowed the identification of interesting 
metabolites to be applied in the flight of MRSA strains.  
The presence of MDR pumps in bacteria is certainly not just for drug resistance. However, 
understanding the physiological roles of the MDR pumps may continue to be rather difficult as 
the functions of these pumps are often involved in a complex, and overlapping network of 
reactions in the bacterial cell (Li and Nikaido, 2009). Understanding how EPIs block the transport 
of antibacterials is critical for designing and optimizing EPIs. The effect of efflux pumps needs 
to be considered in the design of future antibiotics and the role of inhibitors assessed in order to 
maximize the efficacy of current and future antibiotics. Also, efflux inhibition can be a promising 
anti-biofilm strategy.  
This study reveals the great potential for the application of several phytochemical, especially 
of isoflavonoids, in clinical therapy of MRSA infection. The results of this thesis might contribute 
to pave the way for new treatments for S. aureus, MRSA and biofilm-related infections. 
Additionally, they may open new perspectives for future work on efflux pumps, which may 
include a new therapeutic concept on the usefulness of EPI as adjuvants of the conventional 
antibiotic therapy to overcome the scarcity of therapeutic approaches for these MDR infections.  
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 SUGGESTIONS FOR FUTURE WORK 
Although different assays were performed to study the mode of action of the several 
phytochemicals tested along this project, more tests are needed to understand the interaction of 
phytochemicals with bacterial cells and their possible targets. A lot of mechanistic details still 
remains to be explained. A confirmation of the achieved conclusions on the mode of action of 
these phytochemicals on all bacteria tested should be taken through the study of the expression of 
membrane proteins by proteomic analysis and morphological changes of the bacterial cells by 
transmission electron microscopy (TEM). The use of molecular approaches would be necessary 
to fully understand the role of each efflux pump and how the bacterial cell responds to the 
presence of isoflavonoids.  
All strains used in studies designed to assess MDR efflux pump gene expression in clinical 
isolates should also be evaluated by a method independent of in vitro susceptibility testing.  
Among the 29 plants screened, only two were subject to further research. However, it would 
be interesting to study in more detail other promising plants displaying antibiotic-potentiation 
effect and proceed with the identification of the bioactive compounds. 
It would also be desirable to test the ability of antibiotic-potentiators found in this study in a 
different cell culture system (e.g., a different strain of the same bacterial species or in different 
bacterial species). Additionally, it would be interesting to evaluate the specificity of the candidate 
compound by testing its ability to potentiate the activity of other members of the same class of 
antibiotics. Moreover, the potential for the emergence of resistance in long term, unexpected 
drug–drug interactions, side effects and toxicity issues that might arise from drug combination 
must also be examined thoroughly.  
The apparently opposite effect observed with the same metabolite on biofilm formed by 
different strains can be a consequence of the multiple molecules and factors that characterize a 
biofilm (adhesion factors, quorum sensing, capsular polymers, among others) and that indeed can 
differ between bacterial species (Morán et al., 2014). So, it would be important to evaluate the 
interference of phytochemicals with certain components of the extracellular polymeric matrix of 
the biofilms, which could provide relevant information on the biofilm aspects that confer 
resistance. Additionally, it would be interesting to test these effects on MRSA biofilms, which 
were not included in the biofilm experiments. Efflux pumps seem to be highly active in bacterial 
biofilms, so the use of EPIs could be an attractive measure to control biofilm formation and/or 
reduce biofilm tolerance to antibiotics (Borges et al., 2016). Also, instead of applying the 
antibiotic and the potentiating compound concurrently, it would be interesting to test their 
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administration sequentially, by applying first the RMA/EPI compound, and only after, the 
antibiotic. These questions need to be properly addressed. 
The clinical benefits and the effective synergy of these combinations have to be determined in 
vivo through carefully designed pharmacokinetic studies in animals. Determination of synergy or 
potentiation in vitro might not be reflected in vivo because of the potential failure to achieve 
synergistic levels of drugs in the desired tissue, for the differences in plasma protein binding and 
the drug metabolism (Kalan and Wright, 2011). Suitable animal models and models of bacterial 
infection (e.g. implant/pulmonary infection mouse model) could provide new important data. The 
data obtained from cell culture assays and animal studies could be used to formulate a range of 
dosage to ascertain the potential clinical success of the most promising compounds. Additionally, 
the application of such compounds on implants and other medical surfaces would be interesting 
to test. Their possible use in combination for surface coating could also be a potential immediate 
application. 
Moreover, due to their extensive functional group chemistry and chirality those products are 
potentially interesting scaffolds for the discovery and development of antibacterial therapeutic 
approaches. Knowing the core structure that characterizes a compound shown to display 
potentiating activity for a particular antibiotic agent, subsequent libraries may be generated with 
the features shown to have potentiating activity, until a group of compounds with high 
potentiating activity and, optionally, one or more additional desirable properties (e.g., cell 
permeability) can be found. The modification and optimization of the compounds based on SAR, 
in a way that the intrinsic pharmacological effect of each one is completely suppressed and only 
the potentiating effect with the antibiotics is present, is also a further step of research.  
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A-I 
7. APPENDIX 
  
A1: CHEMICAL STRUCTURES OF IMPORTANT PHYTOCHEMICALS 
REPORTED FOR AN ANTIBIOTIC-POTENTIATING ACTIVITY 
 
TABLE A.1 | Chemical structures of the several adjuvant molecules promoting antibiotic 
potentiation due to a resistance-modifying effect (described in Section 2.6.2) 
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A2: ETHNOPHARMACOLOGICAL RELEVANCE OF THE PLANTS TESTED 
 
TABLE A.2 | Classification and description of the plants tested for their 
ethnopharmacological relevance 
Plant name Class* Ethnopharmacological relevance 
Acacia dealbata - - 
Cytisus striatus - - 
Genista tridentata - - 
Prunus domestica 2 Febrifuge, laxative, stomachic 
Prunus avium 2 Antitussive, astringent, diuretic, tonic 
Prunus persica 3 Astringent, demulcent, diuretic, expectorant, febrifuge, laxative, 
parasiticide and mildly sedative; used to treat gastritis, whooping 
cough, coughs and bronchitis and to help heal sores and wounds 
Pyrus communis 1 - 
Agrimonia eupatoria 3 Popular domestic remedy for diarrhea and to treat wounds and skin 
problems; antiaphonic, astringent, blood purifier, cholagogue, 
diuretic, tonic, vulnerary 
Eriobotrya japonica 3 Analgesic, antibacterial, antiemetic, antitussive, antiviral, astringent, 
diuretic 
Crataegus monogyna 5 Well-known in herbal folk medicine as heart tonic; astispasmidisc, 
astringent, cardiotonic, diuretic, hypotensive, 
sedative, tonic, vasodilator 
Rubus idaeus 3 Anti-inflammatory, astringent, decongestant, ophthalmic, oxytocic 
and stimulant 
Malus communis 2 Antibacterial; antidiarrhoeal; astringent; laxative; odontalgic; stoma
chic 
Eupatorium cannabinum 3 Detoxifying herb for fevers, colds, flu and other viral conditions; 
alterative, cholagogue, depurative, diuretic, emetic, expectorant, 
febrifuge, purgative, tonic 
Centaurea nigra 2 Diaphoretic, diuretic, tonic, once had reputation as healer of wounds 
Physalis angulata 1 Diuretic, expectorant, febrifuge 
Cyphomandra betacea - - 
Nerium oleander 2 Cardiotonic, diaphoretic, diuretic, emetic, expectorant and 
sternutatory 
Trachelospermum 
jasminoides 
2 Estorative and tonic 
Eucalyptus globulus 4 Traditional Aboriginal herbal remedy used for coughs and colds, 
sore throats and other infections; antiperiodic, antiseptic, aromatic, 
deodorant, expectorant, febrifuge, hypoglycaemic and stimulant 
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A-IV 
Calluna vulgaris 2 Medicinal use in folk medicine as good urinary antiseptic and 
diuretic 
Ficus carica 2 Stomachic 
Castanea sativa 2 Treatment of fevers and ague, convulsive coughs such as whooping 
cough, anti-inflammatory, astringent, expectorant and tonic 
Juglans regia 3 To treat constipation, chronic coughs, asthma, diarrhoea, dyspepsia, 
skin ailments and purify the blood; alterative, anthelmintic, anti-
inflammatory, astringent and depurative;  
Diospyros kaki 3 - 
Vitis vinifera 2 Anti-inflammatory, astringent 
Fraxinus excelsior 2 Cathartic, diaphoretic, mildly diuretic, laxative, purgative, treatment 
of fever and rheumatism 
Actinidia chinensis 2 - 
Buxus sempervirens 2 Sedative, alterative, antirheumatic, cathartic, cholagogue, 
diaphoretic, febrifuge, oxytocic and vermifuge; to treat syphilis, and 
also used as quinine substitute in the treatment of malaria 
Pteridium aquilinum 2 Treatment for arthritis 
(-) medicinal use not known (for the plant leaves); (*) classification according to the ethnopharmacological relevance 
described by the database PFAF (2016) as: 1 = very minor uses, 2 = reasonably useful plants, 3 = could be grown as 
standard crops, 4= very useful plants, 5 = great value.  
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A3: PHOTO-GALLERY 
   
Cytisus striatus flower Plant extracts Fractionation of extracts (with 
water and ethyl acetate) 
   
   
Rotaevaporation of plant 
extracts 
Multi-extractor Vials after one extraction cycle 
   
   
MPLC – medium pressure liquid chromatography (with different columns) 
   
   
   
TLC plate Plant-incorporated MH agar 
Disc diffusion method  
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A-VI 
   
Etest 96-well microtiter plates for MIC 
determination or biofilm 
formation 
Cytotoxicity assay with MTS 
MI   
   
Growing mouse lung 
fibroblast cell culture 
Flow cytometry 
   
FIGURE A.1 | Photo-gallery of diverse methodologies performed along this project. 
 
 
  
 
 
 
 
     
